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Abstract
The United States (U.S.) is in the midst of an opioid overdose epidemic. In the
U.S., overdose deaths related to opioid exposure are the leading cause of accidental
death, yet life-saving treatments, such as methadone or buprenorphine (opioid agonist
therapy [OAT]), are underused. OAT underuse is due, in part, to complex regulatory and
health services delivery environments. Public health officials and policymakers have
focused on expanding OAT access in the community (e.g. office-based buprenorphine
treatment, and opioid treatment programs); however, an often-overlooked component
of the treatment pathway is the acute care delivery setting, in particular hospitals.
Opioid use disorder (OUD)-related hospitalizations are increasing, and incurring
significant costs; care delivered in this setting is likely sub-optimal. This study examined
hospital-based services for OUD using a conceptual framework based on an
interdisciplinary review of policy, organizational behavior, systems science, economics,
and health services delivery scholarship. The study’s primary research question was:
How do supply-side attributes influence hospital OAT delivery, health outcomes, and
health services utilization for persons hospitalized with OUD? Supply-side attributes
refer to the contextual elements inside and outside of a hospital that may be associated
with hospital OAT delivery performance, such as social structures (e.g., hospital
standards of care, societal values) and resources and technologies (e.g., hospital
staffing, federal treatment policies).

i

A mixed methods study described, explored, and identified how patients with
OUD are cared for in the hospital and the barriers and facilitators to delivering OAT
during hospitalization. The sequential mixed methods approach (i.e., qualitative
followed by quantitative analyses) included analysis of 17 key informant interviews with
addiction medicine physicians from 16 non-federal U.S. hospitals, 25 hospital guidance
documents from 10 non-federal U.S. hospitals, and administrative data from 12,407
OUD-related hospital admissions from the Veterans Health Administration (VHA) health
system.
The findings from the study’s three aims and 16 research sub-questions were
integrated to reach seven conclusions: 1) OAT is underused in the hospital; 2) OAT
delivery varies within and across hospitals; 3) OAT is used ineffectively; 4) non-OAT
modalities are inappropriately used during and after hospitalization; 5) supply-side
attributes inside and outside the hospital facilitate and impede hospital OAT delivery; 6)
demand-side attributes facilitate and impede hospital OAT delivery; and 7) the hospital
is an important service delivery mechanism in the OUD care continuum.
The study’s findings could be extrapolated to improve policy and practice by
implementing education and health service delivery interventions through regulatory
and allocative policy mechanisms focused on physicians, medical trainees, and hospital
and health system administrators. Understanding how OAT delivery may be improved
within the acute care delivery system is an important element to support efforts to curb
the ongoing drug poisoning crisis.
ii
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Chapter 1: Introduction
This dissertation explores the influence of supply-side attributes (e.g., social,
financial, and policy-related) contributing to opioid agonist therapy (OAT) delivery for
hospitalized patients with opioid use disorder (OUD). This chapter provides a broad
overview of the foundational issues related to OAT delivery that guided the rationale
and design of this dissertation study, presented in six sections:
1. Section 1.1 introduces the contemporary issues and action related to the
opioid overdose epidemic.
2. Section 1.2 provides background for the dissertation including defining and
describing opioids, OUD, and OUD treatments.
3. Section 1.3 outlines the study’s problem statement.
4. Section 1.4 states the study’s research question and three aims.
5. Section 1.5 describes the study’s purpose and significance.
6. Section 1.6 articulates this chapter’s conclusion.
Following Chapter 1, Chapter 2 provides an interdisciplinary literature review
and describes the conceptual framework proposed for the study. Study methods are
detailed in Chapter 3 and results are presented in Chapter 4 (qualitative) and Chapter 5
(quantitative). Chapter 6 discusses and integrates study findings to extract seven
primary results, details the limitations and assumptions of the research, updates the
study’s conceptual framework, provides strategies for policy change, and concludes with
questions for future research.
1

Section 1.1. Contemporary Issues and Action
The undertreatment and subsequent preventable suffering and deaths of
persons with OUD are pressing public health issues. An estimated 33 million people
globally use opioids (United Nations [UN] Office on Drugs and Crime, 2016), 2.3 million
people in the United States (U.S.) live with an OUD (Center for Behavioral Health
Statistics and Quality, 2016), and in 2017, opioids were involved in nearly 48,000
overdose deaths (Centers for Disease Control and Prevention [CDC], 2018). In addition
to mortality, OUD incurs total annual costs of $78.5 billion related to loss of
productivity, crime, and health care (Florence, Zhou, Luo, & Xu, 2016). The largest
contributor to annual costs is health care service delivery (33%), which starkly contrasts
with the costs of providing OUD treatment (4%) (Florence et al., 2016).
OUD related hospitalizations likely drive health care costs for persons with OUD.
Between 2005 and 2014 the national rate of OUD-related hospitalizations increased
64% (Weiss et al., 2016). As compared with hospitalizations for other conditions,
persons with OUD were admitted for almost a day longer (4.5 days vs. 5.2 days) and had
nearly triple the costs ($10,400 vs. $28,543) (Ronan & Herzig, 2016; Weiss & Elixhauser,
2014). Moreover, for persons with OUD with a concurrent drug-use related infection
(e.g., endocarditis, osteomyelitis), the length of stay more than tripled (14.6 days) and
the costs rose to $107,217 (Ronan & Herzig, 2016). Hospitalization costs for persons
with OUD are estimated at $15 billion annually, the majority of which are associated
with publicly insured and uninsured individuals (Ronan & Herzig, 2016).
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The loss of life and the financial costs attributed to OUD may be mitigated with
treatment, specifically using OAT: methadone and buprenorphine. The Food & Drug
Administration (FDA) approved methadone for OUD treatment in 1972 (Institute of
Medicine Committee on Federal Regulation of Methadone, 1995) and buprenorphine in
2002 (FDA, 2002). Despite decades of FDA approval and years of robust research
(Mattick, Breen, Kimber, & Davoli, 2009, 2014; Nielsen et al., 2016), the number of
treatment facilities offering OAT is lower than the growing need. Only 34% of substance
use disorder (SUD) treatment facilities in the U.S. offer OAT or antagonist therapy (i.e.,
naltrexone) (Knudsen, Abraham, & Roman, 2011) and only 10% of patients in these
clinical settings received OUD pharmacotherapy (Knudsen & Roman, 2012).
Explanations for OAT underuse are well described in outpatient and addiction treatment
facility settings, and are attributed to financial, regulatory, geographic, and health care
professional attitudinal factors (Sharma, Lamba, Cauderella, Guimond, & Bayoumi,
2017). Systemic and institutionalized structural and sociologic elements (e.g., racism,
criminal justice status, insurance benefits) further exacerbate OAT underuse (Cummings,
Wen, & Ko, 2016; Grogan et al., 2016; Merrall et al., 2010; Saloner, Bandara, McGinty, &
Barry, 2016; Saloner & Cook, 2013).
The nationwide opioid overdose crisis has sparked the attention, action, and
collaboration of policymakers in federal and state government offices, legislative bodies,
and agencies. In the past decade, legislation has shaped OUD treatment practices, such
as the Comprehensive Addiction Recovery Act of 2016, the 21st Century Cures Act, and
3

the 2018 SUPPORT for Patients and Communities Act. During President Barak Obama’s
administration, the Office of the Surgeon General launched the Turn the Tide RX
Campaign (Surgeon General of the United States, n.d.) and published the first Surgeon
General’s Report on SUDs (U.S. Department of Health & Human Services, 2016).
President Donald Trump issued an executive order establishing the President’s
Commission on Combating Drug Addiction and the Opioid Crisis recommending actions
to address the opioid crisis (White House, 2017). The policy efforts and awareness
campaigns contributed to the Presidential declaration of the opioid crisis as a federal
public health emergency on October 26, 2017 (Substance Abuse and Mental Health
Services Administration [SAMHSA], 2017a).
Federal agencies (e.g., Centers for Medicare & Medicaid Services (CMS) and
SAMHSA) and state Governor’s offices have supported initiatives to address the opioid
overdose epidemic. In 2015 and 2016, CMS provided opportunities for state Medicaid
agencies to redesign their SUD delivery systems to expand access to treatment using
§1115 waivers, and updated the Medicaid managed care rules to allow for treatment in
Institutions for Mental Diseases (Priest, Leof, McCarty, & King, 2017). SAMHSA’s Center
for Substance Abuse Treatment and Center for Substance Abuse Prevention provided
additional treatment funding opportunities for single state agencies through the State
Targeted Response to the Opioid Crisis Grants program (SAMHSA, 2017b). An
assessment of program funding allocation observed that 71% of grantees used the
awards to expand OAT capacity (Beletsky, 2018). Other state-level interventions
4

included declarations of emergency by the Governor’s Offices of Alaska, Arizona,
Florida, Maryland, Massachusetts, and Virginia, which allowed for increased access to
state funds and resources to expand addiction services and to develop prescribing
guidelines (Baker-White, 2017).
Although policymakers are acting, many public health officials and clinical
leaders are calling urgently for a more robust national public health strategy to decrease
mortality and morbidity associated with the opioid overdose epidemic (Saloner et al.,
2018). In 2018, experts identified seven key priorities for U.S. policymakers: 1) improved
data collection; 2) safer opioid prescribing; 3) stigma reduction; 4) harm reduction; 5)
criminal justice reform; 6) regulatory changes; and 7) treatment expansion (Saloner et
al., 2018). Treatment expansion, in the hospital setting, is the focus of this dissertation.
Section 1.2. Background
The U.S. has a long and complex history with opioids, OUD, and OUD treatment.
Health professionals and society more broadly may simultaneously view opioids as legal
medicine for patients and as an illegal drug used by criminals. This dissertation considers
the existence of these different perspectives, the influence of these perspectives on
system design, and the institutionalization of these perspectives through policy.
1.2.1. Opioids. Throughout history, healers and medical professionals used
opioids to decrease pain (Benyamin et al., 2008). The term opioid is attributed to
Professor George Acheson, who was the first to use this nomenclature to categorize
compounds with morphine-like pharmacological and agonist effects (Martin, 1983).
5

Opioids are produced endogenously, within the body, and may be ingested exogenously
from sources external to the body (Feng et al., 2012). Exogenous opioids may be
environmentally derived (e.g., opium from the plant Papaver Somniferum) (Hurley et al.,
2007) or synthesized through pharmaceutical manufacturing (e.g., hydrocodone). Upon
ingestion of opioids—oral, intravenous, inhalation, nasal insufflation—the compound
binds to mu, kappa, and delta opioid receptors located predominantly in the limbic
areas of the brain (Hurley et al., 2007). Opioid receptors are involved in a variety of
physiologic processes such as, but not limited to: pain modulation; emotional response;
feeding; the regulation of membrane ionic homeostasis; cell proliferation; immune
function; respiratory and cardiovascular control; and pathophysiological processes (e.g.,
epileptic seizures, obesity, addiction) (Feng et al., 2012).
Individuals may obtain opioids through legal and illegal markets. The allowable
possession and manufacturing of opioids is statutorily defined by the Controlled
Substances Act of 1970 and monitored by the Drug Enforcement Administration (DEA).
In 1970, Congress established a scheduling system to categorize legal and illegal opioids.
Illegal opioids, Schedule I substances, such as diacetylmorphine (also known as heroin),
are deemed by the U.S. federal government to not have a currently accepted medical
use (DEA, n.d.). The government categorizes legal FDA-approved opioids (e.g.,
morphine) as Schedule II, III, IV, or V (DEA, n.d.). These opioids have medically accepted
uses and are manufactured through legal manufacturing processes, but their use is
illegal, in most circumstances, when used for non-FDA approved indications.
6

The U.S. is the world’s largest consumer of opioids (University of Wisconsin,
2017). Between 1999 and 2012 the number of U.S. opioid prescriptions tripled, and in
2012 opioid prescription expenditures across all payers, including self-insured, totaled
$7.4 billion dollars (Zhou, Florence, & Dowell, 2016). Opioid overconsumption is not
limited to the last 25 years. The current opioid overdose epidemic follows a succession
of past epidemics, such as the morphine crisis post-civil war in the 1870s (Courtwright,
2015), the youth heroin epidemic of the 1950s (Campbell, Olsen, & Walden, 2008), and
the Vietnam war veteran heroin emergency of the 1970s (Schmidt, 1971).
It is also important to recognize the changes in the contemporary opioid supply,
which has been coined the “triple epidemic” and features a “rising waves of deaths due
to separate types of opioids each building on top of the prior wave” (Ciccarone, 2017, p.
107). The first wave of overdose deaths in the 1990s was predominantly from
prescription opioids (Ciccarone, 2017). The second wave, starting in 2010, was due to
heroin (Warner, Trinidad, Bastian, Miniño, & Hedegaard, 2016), and the third and
current wave is attributed to the growing supply of synthetic opioids, including illicitly
manufactured fentanyl and fentanyl analogues (R. G. Frank & Pollack, 2017; Gladden,
Martinez, & Seth, 2016; Warner et al., 2016). The shift in the illegal drug supply from
heroin to fentanyl has already happened in parts of Canada. In Vancouver, British
Columbia, recent data reflects that 90% of presumed heroin tested positive for fentanyl
(Tupper, McCrae, Garber, Lysyshyn, & Wood, 2018). The shift in the Vancouver supply is
a harbinger of changes to the U.S. opioid drug supply.
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1.2.2. Opioid use disorder. Health experts are concerned with the excessive use
of opioids because of the association with increased morbidity and mortality, in
particular for men and early onset users (Cottler et al., 2016). When taken in excess,
opioids can cause central nervous system depression leading to respiratory failure and
death (Bollinger et al., 2012), shortened life expectancy (Hayes et al., 2011), and
increase the risk of addiction (Compton & Volkow, 2006). In 2016, the CDC published
recommendations on the safety of consuming opioids for the treatment of chronic noncancer pain (Dowell, Haegerich, & Chou, 2016). The CDC prescription opioid guidelines
specified that prescribers should avoid prescription opioids for chronic non-cancer pain
and stated that opioid consumption is not safe at any dose (Dowell et al., 2016). In 2017,
the National Academy of Sciences published Pain Management and the Opioid
Epidemic: Balancing Societal and Individual Benefits and Risks Of Prescription Opioid Use
and recommended that the FDA and other organizations take action to reduce OUDrelated harms (Committee on Pain Management and Regulatory Strategies to Address
Prescription Opioid Abuse, 2017).
For the purpose of this dissertation OUD is conceptualized as a brain disease that
is treated through the medical model. The diagnosis of opioid addiction follows the
criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(American Psychiatric Association [APA], 2013). The diagnosis criteria characterize OUD
as a problematic pattern of opioid use that leads to clinically significant impairment or
distress occurring within a 12-month period (APA, 2013). The diagnostic criteria for OUD
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states that a patient must have at least two of 11 symptoms, and that the severity of
illness is to be categorized as mild (2 to 3 symptoms), moderate (4 to 5 symptoms), or
severe (6 or more symptoms). The symptom criteria are listed in Appendix A (APA,
2013). The DSM also requires clinicians to distinguish among early remission, sustained
remission, the use of pharmacotherapy, or if the patient is receiving care in a controlled
environment (APA, 2013). Other definitions of addiction do exist. The American Society
of Addiction Medicine [ASAM] (2011) defines addiction as:
A primary, chronic disease of brain reward, motivation, memory and related
circuitry. Dysfunction in these circuits leads to characteristic biological,
psychological, social and spiritual manifestations. This is reflected in an individual
pathologically pursuing reward and/or relief by substance use and other
behaviors. Addiction is characterized by inability to consistently abstain,
impairment in behavioral control, craving, diminished recognition of significant
problems with one’s behaviors and interpersonal relationships, and a
dysfunctional emotional response. Like other chronic diseases, addiction often
involves cycles of relapse and remission. Without treatment or engagement in
recovery activities, addiction is progressive and can result in disability or
premature death.
1.2.3. Treatment. The gold standard treatment for OUD is OAT because it is well
studied, safe, and effective (Mattick, Breen, Kimber, & Davoli, 2003; Mattick et al.,
2014). There are three FDA-approved OATs, with multiple formulations: 1)
buprenorphine (sublingual tablet, implant, extended-release, injection, and implant); 2)
buprenorphine/naloxone (sublingual tablet and buccal film); and 3) methadone (liquid,
tablet). The World Health Organization (WHO) lists OAT on their essential medication
list (WHO, 2017) and recommends that all national health systems provide widespread
OAT access for persons with OUD (WHO, 2009). Unfortunately, OAT access in the U.S. is
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constrained because of special federal regulations that govern where, when, and who
may administer or prescribe OAT.
1.2.3a. Opioid treatment programs. Methadone administration for OUD, a
Schedule II controlled substance, is governed by the Certification of Opioid Treatment
Programs (OTPs), 42 Code of Federal Regulations (CFR) 8 (SAMHSA, 2015). Under these
rules, methadone must be administered daily under direct observation in a federallylicensed OTP with two exceptions: 1) during hospitalization; and 2) approved take
home-doses (Priest et al., 2019). OTPs may also administer buprenorphine, offer other
services such as recovery fellowship (e.g., 12-Step), and require patient participation in
non-pharmacotherapy services such as counseling (SAMHSA, 2015).
1.2.3b. Community treatment programs. Currently, the only FDA-approved OAT
that may be legally prescribed by federally-certified prescribers is buprenorphine (with
and without naloxone), a Schedule III controlled substance (SAMHSA, 2016). To become
a certified prescriber, a health professional must meet the requirements of the Drug
Addiction Treatment Act of 2000, including: licensed to practice under state law,
registered with the DEA, and completed prescriber training (SAMHSA, 2016). A variety
of primary care models for buprenorphine delivery have emerged (e.g., office-based
opioid treatment programs, the Buprenorphine HIV Evaluation and Support
Collaborative Model) (Korthuis et al., 2017).
1.2.3c. Integrated health systems. There is much to learn about the delivery of
OAT and OUD services from integrated health systems because of the disjointed nature
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of the U.S. addiction treatment system. The largest integrated health system in the U.S.
is the Veterans Health Administration (VHA), which has a long-standing history of
providing services for OUD. The VHA is facing a growing OUD patient population (Finlay
et al., 2016; Oliva, Trafton, Harris, & Gordon, 2013) that is twice as likely to die from
accidental overdose than non-veterans (Bohnert, Ilgen, Galea, McCarthy, & Blow, 2011).
The VHA OUD treatment services system began nearly 60 years ago, with the
creation of the Alcohol and Drug Dependence Service, to meet the needs of veterans
returning from the Vietnam War (Wyse et al., 2018). Since that time, the VHA has
implemented policy, educational, and quality improvement initiatives to increase OAT
capacity across the system (Wyse et al., 2018). The VHA added OAT, specifically
buprenorphine, to the VHA formulary in 2006, and in 2008, mandated the use of OAT as
a “minimum clinical requirement” for OUD treatment (Wyse et al., 2018). Further, in
2015, the VHA published system-wide clinical guidance documents on OAT delivery
(Wyse et al., 2018). Despite these system-wide initiatives, recent utilization data reports
that only 38% of OUD patients receive pharmacotherapy and that there is significant
variation in facility pharmacotherapy performance (3% to 74% delivery) (Finlay et al.,
2018).
Data from outside the VHA suggests similar or worse OAT delivery performance.
In 2016, a national survey of U.S. SUD facilities observed that only 36% of facilities
offered all three types of OUD pharmacotherapy (OAT or opioid antagonist).
Additionally, in a study of 154 non-VHA specialty addiction treatment programs, only
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10% of patients received some form of OUD pharmacotherapy (Knudsen & Roman,
2012). These studies suggest there is still a need to improve access to and the delivery
of OAT in the community, both inside and outside the VHA. Although warranted and
important, VHA research and system-wide initiatives to date have focused on outpatient
OAT delivery, and research on hospital OAT delivery has not yet occurred.
1.2.3d. Hospital OAT delivery. There is historic precedent for hospital-based
OUD treatment. Similar to contemporary outpatient OAT delivery systems informed by
public policy, hospital OAT delivery was born out of necessity. In the mid-1920s, the
Supreme Court ruled that it was illegal for physicians to provide opioids to patients with
OUD in the outpatient setting (Hohenstein, 2001) and care shifted to the hospital
(White, 2002). This care delivery trend lasted for about 10 years, falling out of favor
because of the ineffectiveness of the approach (White, 2002). In its place, the federal
government created two addiction hospitals called “narcotic farms” managed by the
U.S. Public Health Service and the U.S. Bureau of Prisons (White, 2002). The narcotic
hospitals, one in Lexington, Kentucky, and the other in Fort Worth, Texas, were the
primary source of addiction treatment until the advent of outpatient methadone
maintenance therapy in the late 1960s (White, 2002). The addiction hospitals closed in
the 1970s (White, 2002).
Nearly 40 years later, there is a renewed interest in hospital-based services for
OUD, likely inspired by the ongoing opioid overdose epidemic and the subsequent
increased utilization of acute care delivery resources. The following sub-sections provide
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evidence suggesting that hospital-based OUD treatment services are urgently needed,
care for this population is feasible and effective, and potential barriers to care in this
setting should be explored.
1.2.3d.1. The need. The national rate of OUD-related hospitalizations increased
64% between 2005 and 2014 (Weiss et al., 2016). Moreover, between 2013 and 2015,
opioid-related admissions (217 per 100,000 people) were the second most common
SUD admission behind alcohol (558 per 100,000) (Fingar et al., 2018). In 2015, the
cumulative costs for OUD-related hospitalizations were estimated at $15 billion annually
(Ronan & Herzig, 2016). Costs for OUD-related hospitalizations were higher ($28,543 vs.
$10,400 days), and stays were longer (5.2 days vs. 4.5 days), in contrast with non-OUD
related admissions (Ronan & Herzig, 2016; Weiss & Elixhauser, 2014). The distribution of
costs by payer for OUD-related hospitalizations disproportionately burdens public
payers—72% of admissions were paid for by Medicaid (40%) and Medicare (32%) (Weiss
& Heslin, 2018).
Persons with OUD-related hospital admissions have a relatively low rate of
hospital death, although the in-hospital mortality rates are increasing for patients who
receive higher levels of care during admission. In 2012, 1% of OUD-related hospital
admission patients and 3% of OUD-related co-infection admissions patients died (Ronan
& Herzig, 2016). There was a significant increase in hospital deaths in the ICU for opioid
overdose between 2009 (mean mortality rate 7%) and 2015 (mean mortality rate 10%)
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(Stevens et al., 2017). However, little is known about OUD-related health outcomes that
occur after discharge, a potentially vulnerable time for overdose.
A limited literature base characterizes the sub-optimal and potentially
inappropriate care received during and after hospital admission for patients with OUD.
Sub-optimal care for OUD may be reflected in three ways: 1) elevated rates of leaving
the hospital against medical advice (Ronan & Herzig, 2016; Stranges, Wier, Merrill, &
Steiner, 2009); 2) low OAT use during admission (Rosenthal, Karchmer, Theisen-Toupal,
Castillo, & Rowley, 2015); and 3) low OAT use in the 30 days after hospital discharge
(Frazier et al., 2017; Naeger, Ali, Mutter, Mark, & Hughey, 2016). Inappropriate care
may be further reflected in the increased use of short-acting opioids during (Herzig et
al., 2014) and after admission (Larochelle, Liebschutz, Zhang, Ross-Degnan, & Wharam,
2016; Naeger, Mutter, Ali, Mark, & Hughey, 2016).
1.2.3d.2. The solution. A growing evidence base supports the use of
interventions to enhance services for patients hospitalized with OUD, including: a
clinical trial on OAT delivery (Liebschutz et al., 2014); several hospital practice checklists
and recommendations based on narrative reviews (Noska, Mohan, Wakeman, Rich, &
Boutwell, 2015; Sharma et al., 2017; Thakarar, Weinstein, & Walley, 2016; TheisenToupal, Ronan, Moore, & Rosenthal, 2017; Weinstein, Wakeman, & Nolan, 2018);
federal guidance documents (SAMHSA, 2018; Institute of Medicine Committee on
Federal Regulation of Methadone, 1995); and the retrospective and prospective
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evaluations of addiction medicine consult (AMC) services (Nordeck et al., 2018; Suzuki,
2016; Trowbridge et al., 2017; Wakeman, Metlay, Chang, Herman, & Rigotti, 2017).
1.2.3d.3. The barriers. A limited literature base describes how supply-side
attributes, inside and outside the hospital, may contribute to hospital OAT underuse.
Potential barriers outside the hospital include treatment coverage policies imposed by
third-party payers (Hassamal et al., 2017) and broader federal treatment regulations
(Hassamal et al., 2017). Not explored explicitly in the literature is the potential
misinterpretation of specific federal regulations that dictate practice for opioid
withdrawal in the hospital setting (i.e., 21 CFR 1306.07, sections b and c) (Nagel, 2002).
Within the hospital, potential barriers to OAT delivery are likely connected to a
number of factors, including: 1) provider knowledge deficits related to OAT and OUD
treatment; 2) the perpetuation of stigmatizing behavior by providers towards patients
with OUD because of knowledge deficits; 3) concerns about external federal regulations
(e.g. DEA audits); 4) concerns about outside perceptions (e.g., worried about attracting
OUD patients); 5) a lack of support staff and institutional support; 6) frequent laboratory
testing; and 7) an inadequate referral network (Hassamal et al., 2017). Another
potential barrier is whether the hospital has the correct staff employed. Patients with
OUD and other SUDs, for example, have expressed interest in receiving services from
peer support providers (i.e., professional with lived experience) during hospitalization
(Velez, Nicolaidis, Korthuis, & Englander, 2017). Despite this, peer support providers are
a group of professionals not ususally employed by hospitals.
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Section 1.3. Problem Statement
Limited information exists describing hospital OAT care delivery patterns and
why hospital OAT is likely underused. This dissertation seeks to enhance the
understanding of supply-side attributes on hospital OAT delivery by considering the
broader contextual elements that shape practice through an interdisciplinary research
lens grounded in theories, models, and frameworks from policy theory (Ingram &
Schneider, 1990, 1991; MacCoun, Saiger, Kahan, & Reuter, 1993; Pierson, 1993; A. L.
Schneider & Ingram, 1988, 1993; Skocpol, 1992), organizational behavior (DiMaggio &
Powell, 1983, 1991; Katz & Kahn, 1978; Leavitt, 1962; Scott, 2003; Scott & Meyer, 1991;
Thompson, 1967), systems science (Basole & Rouse, 2008; Ferlie & Shortell, 2001;
Lipsitz, 2012; Perrow, 1986; Plsek & Greenhalgh, 2001; Sallis, Owen, & Fisher, 2015),
economic theory (Alchian & Demsetz, 1972; Allison & Zelikow, 1999; Eisenhardt, 1989;
Friedman, 2002; Jensen & Meckling, 1976; Simon, 1985; Williamson, 1979, 1985, 1994;
Williamson & Ouchi, 1981; Zeckhauser & Pratt, 1985), and health services delivery
(Levesque, Harris, & Russell, 2013).
Section 1.4. Research Purpose and Questions
An integrated mixed methods design (i.e., qualitative followed by quantitative),
comprised of three aims and 16 research sub-questions, explored this broad research
question: How do supply-side attributes influence hospital OAT delivery, health
outcomes, and health services utilization for persons hospitalized with OUD? The data
for Aim 1, the qualitative aim, were 17 key informant interviews from 16 non-VHA U.S.
hospitals, and 25 non-VHA hospital guidance documents. The data for Aims 2 and 3, the
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quantitative aims, were deidentified administrative data from a retrospective national
sample of patients with OUD from the VHA health system in the fiscal year of 2017. Aim
1 examined how addiction medicine experts and their hospitals delivered OAT for
patients with OUD and Aims 2 and 3 described current OAT delivery practices in VHA
hospitals:
•

Aim 1: Examine the influence of supply-side attributes inside and outside of nonVHA hospitals that shape hospital OAT delivery;

•

Aim 2: Describe and test variation in VHA hospital OAT delivery;

•

Aim 3: Test associations among patient and hospital characteristics on VHA
hospital OAT delivery.

Section 1.5. Study Purpose and Significance
This study sought to describe and understand the patterns and determinants of
evidence-based hospital OAT delivery, a first step towards ensuring that hospitalized
patients with OUD receive effective treatments, and that treatment policies are crafted
and systems are designed to support the delivery of these modalities. This study has the
potential to contribute to health services delivery improvement because it explores the
potential contributory contextual elements (e.g., policy, organization, system, and
economic factors) and analyzes administrative data from an integrated health system to
describe current practice. This study addresses public health, clinical practice, and
health system delivery knowledge gaps by connecting the research domains of public
health, health systems, health policy, and health services delivery.
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Section 1.6. Conclusion
Hospital OAT underuse engages issues of care quality, safety, and cost.
Understanding the barriers and facilitators to hospital OAT delivery is a first step
towards informing interventions inside and outside the hospital to ensure that OUD
hospitalized patients receive effective treatments. Obtaining a greater understanding of
where and how OAT delivery may be improved across the health services delivery
system is especially important due to the current opioid overdose epidemic.
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Chapter 2: Literature Review
The ongoing opioid overdose epidemic has increased the number of persons in
the United States (U.S.) with opioid use disorder (OUD) and OUD-related
hospitalizations. A limited literature base describes hospital OAT underuse and nearly no
literature exists exploring why OAT is underused in the inpatient setting. OAT is a wellstudied life-saving treatment for persons with OUD. Hospitals may play an important
role in the contemporary OUD treatment pathway. Policy, regulatory, and system-level
factors likely complicate hospital-based OAT delivery, therefore this dissertation seeks
to understand the influence of these attributes on the underuse and variation of
hospital OAT delivery. Chapter 2 includes a comprehensive literature review organized
into 15 sections:
1. Section 2.1 provides study definitions for drugs, drug use disorders, and OAT.
2. Section 2.2 explains how drug use disorders and drugs are socially
constructed and the two frames dominating the narrative in health policy
and practice.
3. Section 2.3 outlines policy frameworks (the Social Construction Framework;
the Comparative Drug Policy Analytic Framework; and the Policy Feedback
Theory) to support the rationale that national, state, and local health care
policies influence hospital OAT delivery.
4. Section 2.4 provides a 150-year historical overview of OUD treatment
practice and policy.
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5. Section 2.5 describes the contemporary drug policy environment, including
the policy regimes, laws, and regulations informing OAT delivery.
6. Section 2.6 reviews organizational behavior scholarship relevant to
understanding hospital OAT delivery.
7. Section 2.7 examines systems science models and theory that may affect
hospital OAT delivery.
8. Section 2.8 discusses economic theory relevant to understanding and
exploring deficits in hospital OAT delivery.
9. Section 2.9 contextualizes hospitals in the broader health services delivery
market.
10. Section 2.10 summarizes a health services delivery research framework that
contributes to the study’s conceptual framework (the Health Care Access
Framework).
11. Section 2.11 outlines how OAT is delivered outside the hospital.
12. Section 2.12 describes how OAT is delivered within an integrated health
services delivery system, the Veterans Health Administration (VHA).
13. Section 2.13 provides an overview of hospital OAT delivery.
14. Section 2.14 synthesizes and integrates the literature reviewed in this
chapter to construct the study’s conceptual framework.
15. Section 2.15 reiterates chapter conclusions.
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Section 2.1. Defining Drugs, Drug Use Disorders, and Treatment
For the purpose of this dissertation, drugs are defined as legal or illegal
psychoactive substances (e.g., opioids, cocaine) that are “capable of influencing brain
systems linked to reward and pleasure” (Babor et al., 2010, p. 9). This dissertation is
focused on a psychoactive class of substances called opioids. Opioids are endogenous
and exogenous pain-relieving substances that humans have used for thousands of years
(Trescot, Datta, Lee, & Hansen, 2008). Opioid is a broad contemporary term describing
compounds with pharmacological effects at opioid receptors primarily in the central
nervous system (mu, delta, kappa) (Trescot et al., 2008). An outdated term, frequently
used in policy, is the word “narcotic”, originating from the Greek word for stupor
(Trescot et al., 2008). The term initially described any medication that promoted sleep,
then referred more specifically to opioid products, and finally became used in laws and
regulations the describe drugs of abuse (Trescot et al., 2008).
All opioids have similar pharmacological effects, such as the capacity to relieve
pain, produce euphoria, induce respiratory depression, drowsiness, and impair
judgment (Babor et al., 2010). Continued use of opioids leads to tolerance and may
result in an OUD. According to the American Psychiatric Association (APA) (APA, 2013),
OUD occurs when a person has: “A problematic pattern of opioid use leading to clinically
significant impairment or distress,” and the person meets at least two of the 11 listed
criteria (e.g., craving, unsuccessful efforts to cut down) within a 12-month period. A fulldefinition is in Appendix A.
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The recommended first-line treatment for OUD is OAT (World Health
Organization, 2009, 2017). OATs are long-acting opioids that occupy the mu-opioid
receptors in the central nervous system to prevent withdrawal and reduce cravings
associated with OUD (Schuckit, 2016). OAT decreases mortality risk and improves
treatment outcomes (Sordo et al., 2017). The two FDA approved OATs, available in a
variety of formulations, are buprenorphine (with and without naloxone; sublingual
tablet, sublingual film, long-acting injectable, and implant) and methadone (oral
solution).
Section 2.2. Social Construction of Drugs
This section introduces and applies social constructionism as it relates to the
historical and contemporary discourse of drug use disorders. Social constructionism
draws upon the foundational scholarship of Spector and Kitsuse (1977), Foucault (1966),
and Turner (1992). Social construction is broadly understood as the “multiplicity of
social forces that combine to create and modify [a] phenomenon” (Brown, 1995, p. 37).
In the context of health services delivery, medical historian Charles Rosenberg states
“[a] disease does not exist until we have agreed that it does” (Rosenberg, 1989, p. 1).
Disease creation, moreover, occurs through the generation of specific verbal constructs
reflecting the intellectual and institutional history of medicine within the era’s social and
political context (Rosenberg, 1989). From this approach, the disease is a “social actor”
(Rosenberg, 1989) and its application to an individual or group of people can “change
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the narrative and thereby rearrange how we understand the person or behavior”
(Reinarman & Granfield, 2014, p. 2).
In medical sociology, a social construction lens critically evaluates the illness
identification process through the influence of social stratification and an assessment of
the contributions of health professionals, health service delivery facilities, the
government, the media, pharmaceutical companies, other industry profit makers,
people with the illness, and their families (Brown, 1995). This approach is useful for
studying interactions among the micro (i.e., individual), the meso (i.e., the institutional),
and the macro (i.e., the governmental) levels (Brown, 1995). A social construction
analysis begins with an exploration of five underlying assumptions about the problem:
1) What are the origins of problem representation?; 2) What elements are missing from
the problem?; 3) Are there other ways of thinking about the problem?; 4) In what
context does the production, dissemination, and defense of the problem occur?; and 5)
What are alternatives to thinking about the problem? (Bacchi, 2012).
For drug use disorders, two common social constructions reflected in historical
and contemporary discourse, institutionalized through research, policy, and practice are
the moral and the addiction as disease models. The foundational premise of each
model, respectively, is that addiction is a deviant behavior or an illness. From a social
construction frame, deviant behavior includes the acts, beliefs, and characteristics that
violate predominant social norms and attract condemnation, stigma, social isolation,
censure, and punishment (Clinard, 1957; Clinard & Meier, 2011; Goode, 2015a, 2015b).
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Sociologists argue that it is “not a quality of the acts the person commits, but rather a
consequence of the application or rules and sanction to an ‘offender’” (Pfohl, 1994, p.
345) and that certain behaviors are categorized as deviant because of the “political and
social artifacts of human activity” (Boyd, Carter, & Macpherson, 2016, p. 8). These
scholars reject the premise that punishment deters crime and question how the
inequitable exercise of power in society produces crime and deviance (Boyd et al.,
2016). A summary of the two socially constructed drug use disorder models, and a third,
less common and emergent model, a multi-sourced model of addiction, is presented in
the following sub-sections.
2.2.1. The moral model. The central thesis of the moral model is that addiction is
a disease of will (Valverde, 1998). Moralists assert that the use of illegal drugs is
inherently bad, that drug use and dependency is a consequence of poor decision-making
and a lack of personal discipline (Boyd et al., 2016). The moral model is intertwined with
the criminal model, which associates substance use disorders (SUDs) with deviance and
criminality (Boyd et al., 2016). The moral model came into popular thinking in the 19th
century bolstered by the proponents of alcohol prohibition (Reinarman & Granfield,
2014). Temperance advocates popularized the idea that the deviant behavior behind
every excessive drinker was a corrupt moral character and that anyone who drank
alcohol was at risk of succumbing to this evilness (Reinarman & Granfield, 2014). This
discourse, in part, led to alcohol prohibition in 1919, and dominated the substance use
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discourse until the early to mid-20th century (Reinarman & Granfield, 2014), informing
and shaping contemporary policies and practices related to drug use.
2.2.2. Addiction as disease model. Scholars assert that the development of the
addiction as disease model represents a historical shift from one system of social control
to another (i.e., church and state to science and medicine) (J. Schneider, 2014). This shift
occurred in parallel with the consolidation and accumulation of power by physicians and
the growing dominance of the health care industry (Boyd et al., 2016). In contrast with
the moral model, the addiction as disease model explains the loss of self-control that
occurs with addiction as a pathophysiological process versus a byproduct of the moral
failing of the spirit (Reinarman & Granfield, 2014). The addiction as disease model
emerged during the mid-20th century, a time in which the medicalization of deviant
behavior was common (e.g., mental illness) (Reinarman & Granfield, 2014). The
invention of brain imaging technology in the 1990s led to the latest iteration of the
addiction as disease model: the brain disease model (Reinarman & Granfield, 2014).
Founders of the brain disease model assert that SUDs are explained by the changes in
brain structure and function; addiction is, therefore a chronic progressive, permanent,
relapsing brain disorder (Leshner, 1997; Volkow & Collins, 2017; Volkow, Koob, &
McLellan, 2016).
2.2.3. Multi-sourced model of addiction. An emergent field of scholarship,
critical addiction studies, posits that the historical, cultural, and contextual specificity of
drug use contribute to the development and visibility of SUDs (Reinarman & Granfield,
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2014). This scholarship emerged in the latter half of the 20th century to challenge the
dominant brain disease model discourse (Reinarman & Granfield, 2014). Emerging from
the critical addiction studies approach was the multi-source model of addiction (Kovac,
2014). This model is grounded in theory across disciplines (i.e., philosophy, sociology,
biochemistry, neurobiology, physiology, genetics, political science, economics, and
psychology) and asserts that there are five interacting contributory processes at the
macro and micro-level leading to addictive behaviors: 1) past actions and current
choices; 2) pre-dispositions; 3) social, historical, and cultural environment; 4)
neurobiology; and 5) underlying processes (Kovac, 2014). This model does not favor one
mechanism as the primary cause of addiction and emphasizes that every case is a
unique combination of circumstances (Kovac, 2014). This broader lens of addiction
etiology is further supported in forthcoming sections in this chapter that include the
macro-level historical, cultural, and contextual perspectives.
Recognizing that different socially constructed models of addiction exist
facilitates a nuanced interpretation of contemporary opioid control policies and
regulations, and explains, in part, contemporary OUD care. As aptly stated by Dr. Walter
Ling: “From the very beginning our policy has been: Addicts are sick, they need help; but
they also sin and must suffer a little. So, we built treatment programs and put up
barriers making it difficult for patients to get into treatment” (Ling, 2016). Relevant to
this dissertation is the influence of the social construction of opioids (e.g., illicit drug or
medicine) and opioid users (e.g., morally deficient or patients). The social construction
26

of drug use disorders is the meta-influencer of the dissertation’s rationale and research
design. The next section explores the theoretical connection between social
construction and policy design.
Section 2.3. Policy Frameworks
This section provides complementary and additive theoretical support that social
construction and contextual phenomena influence contemporary policy and practice
related to hospital OAT delivery. Three policy frameworks are reviewed: The Social
Construction Framework, the Policy Feedback Theory, and the Comparative Drug Policy
Analytic Theory.
2.3.1. The Social Construction Framework. The underlying assumption of the
Social Construction Framework (Ingram & Schneider, 1990, 1991; A. L. Schneider &
Ingram, 1988, 1993) is that policies define and determine who receives societal benefits
or burdens (A. L. Schneider, Ingram, & deLeon, 2014). Policymakers use socially
constructed target populations as justification for policy design and do this through the
presentation of powerful images or stereotypes that become embedded within the
policy (A. L. Schneider et al., 2014).
This framework has five propositions. First, benefit or burden allocation depends
on the target population’s political power, which may be positive or negative and highpower or low-power (A. L. Schneider et al., 2014). The power typology for substance
users is low-power and negative; thus, under this framework people who use drugs are
undeserving of benefits. Second, the framework asserts that policy design has material
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and symbolic effects on the target population (A. L. Schneider et al., 2014). Policy design
may impact a group’s attitude and political participation through the creation of
structures that influence life opportunities (A. L. Schneider et al., 2014). Third,
emotional and intuitive reactions (i.e., biases) are at the origins of social construction,
and these biases justify the selection of evidence to support policy design (A. L.
Schneider et al., 2014). The fourth proposition is that social construction may change
frequently through “unanticipated or unintended consequences of previous policy
designs” (A. L. Schneider et al., 2014, p. 124). Note, that changing the narrative for a
negatively constructed group of people is challenging, and frequently the target
population continues to exist as “a negative degenerative social memory” (A. L.
Schneider et al., 2014, p. 125). The fifth proposition is that future policy change is
dependent on the social construction of the target population (A. L. Schneider et al.,
2014).
2.3.2. Policy Feedback Theory. The grounding premise of the Policy Feedback
Theory (Pierson, 1993; Skocpol, 1992) is that other policies influence policy design. This
theory asserts that policy creation is “deeply influenced” by the existence of other
policies that shape political landscapes, foster partisan identities, provide precedent,
build governmental capacities affecting policymaker choice, and the dictation of
administrative arrangements (Mettler & SoRelle, 2014). This theory is grounded in
historical institutionalism, an approach that views policies as possessing the attributes
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of formal institutions; thus, policies may bestow resources, impose coercive rules, and
convey messages and norms (Mettler & SoRelle, 2014).
The Policy Feedback Theory’s four proposed mechanisms that lead to policy
adaptation over time include that policies: 1) can shape the meaning of citizenship; 2)
can affect the form of governance; 3) can influence the power of groups; and 4) can
affect political agendas and policy problem definition (Mettler & SoRelle, 2014).
Moreover, policies can have resource effects (e.g., increased education increases civic
engagement) and interpretative effects (e.g., constructed identities may be normative
and evaluative or positive or negative) (Mettler & SoRelle, 2014).
2.3.3. Comparative Drug Policy Analytic Framework. The Comparative Drug
Policy Analytic Framework, like the Policy Feedback Theory, proposes that drug policy is
influenced through dynamic and interactive relationships with other social phenomena
(MacCoun et al., 1993). Scholars of this framework identified three influencers: 1) the
social context (i.e., the attitudes, norms, economics, demographics of a community); 2)
the ongoing drug problem (i.e., community rates of addiction, overdose, criminality, and
drug-related accidents); and 3) the existence of other social policies (i.e., health policy,
welfare policy, and citizenship rights) (MacCoun et al., 1993).
2.3.4. Summary. These frameworks, as a collective, support the assertion that
the social construction of drug users and other contextual phenomena influence the
design, implementation, and enforcement of contemporary opioid and OUD-related
policies. Moreover, the frameworks provide the rationale that policies confer either
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benefit or burden to persons with OUDs through delivery system design (e.g.,
methadone clinics), the distinction of criminal versus patient (e.g., federal drug
scheduling laws), and access to treatment (e.g., insurance coverage).
Section 2.4. History of OUD Treatment: Policy and Practice
This section highlights the influence of historical policies and practice on
contemporary opioid-related policies and treatment systems. The review begins in the
19th century because prior to this time opioid importation and consumption occurred
with public indifference and little government involvement. Over the course of the 19th
and 20th centuries, specific opioid products were designated as legitimate or illegitimate
through policies attributed to different groups of people. These shifting regulatory
designations determined that some opioids were taxable and tradeable (e.g., raw
opium), that some opioids were medicine (e.g., morphine), and that some opioids were
illegal (e.g., smoking opium, diacetylmorphine).
2.4.1. Opium, morphine, and diacetylmorphine. Prior to the advent of modern
chemistry and the pharmacy distribution system, there was opium. Opium was sold in
general stores and groceries as a medicinal product (Aurin, 2000). Opium was the first
federally regulated opioid. Beginning in the late 19th century, smoking opium was
banned from importation from China (1880), was taxed domestically (1890), and
eventually designated an illegal substance (1909) with criminal sanctions for possession
except for medical purposes (Martin, 1977). Historians attributed the shift of this opioid
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product from taxable good to a socially menacing illicit substance as primarily due to
racist anti-Chinese sentiment (J. P. Hoffmann, 1990).
As smoking opium became illegal, the legitimation of opioids through medical
practice was flourishing, specifically the use of morphine. In the 19th century opioid
medicalization was possible because of the advent of modern chemistry, which allowed
for the compounding, production, and marketing of opioid products to druggists and
physicians. In 1803, a German pharmacist isolated morphine from the juice of the opium
poppy (Musto, 2002), and 30 years later, in 1832, morphine manufacturing and
distribution began (Musto, 1973). By mid-century, morphine was a common medical
treatment (Musto, 2002) ingested either orally or intravenously (Musto, 1999).
From 1870 to 1880, the U.S. per capita opioid consumption nearly tripled
(Courtwright, 2015). Increased use was attributed to self-medication, the advent of
opioid-laced patent medications, disease and trauma from the Civil War, the spread of
opium smoking, the promotion of new drugs, and physicians providing and
compounding opioids (Courtwright, 2015). The result of increased opioid access and use
culminated in the 1870s morphine crisis primarily afflicting affluent white women
(Courtwright, 2015).
Although this opioid crisis was discussed in the public discourse, federal policies
were not implemented to delegitimize morphine or to support the treatment of persons
with morphine addiction. During this era, the late 19th century and early 20th century,
persons with OUD could receive treatment from a scattered collection of private
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physicians, rest homes, private hospitals, or state asylums (White, 2002). The primary
treatment provided in those facilities were withdrawal protocols using other
psychoactive substances, such as cannabis, cocaine, alcohol, other opioids, and
sedatives (White, 2002). The most common approaches were: 1) abrupt opioid
withdrawal over 24 to 36 hours; 2) rapid opioid withdrawal over four to 10 days; or 3)
gradual withdrawal over a period of weeks or months (White, 2002). Generally, these
modalities were ineffective and return to use was common (White, 2002).
Ironically, the morphine crisis may have contributed, in part, to diacetylmorphine
development at the end of the 19th century. Chemists sought to reduce the negative
side effects of morphine (e.g., dependency, constipation) and expand the positive
effects (e.g., cough suppression) (Musto, 2002). Scientists at Bayer Pharmaceuticals
extracted and manufactured diacetylmorphine as a morphine derivative in 1898
(Moynihan, 2002). It was imported to the U.S. as a cough suppressant for pneumonia
and tuberculosis (Musto, 2002), and also as a treatment for morphine dependence
(White, 2002).
2.4.2. The 1906 Pure Food and Drugs Act. At the turn of the 19th century
medicalized opioids were largely unregulated and widely available, and druggists and
physicians became concerned (Spillane & McAllister, 2003). Health professionals feared
“becoming slaves to an industry whose desire for profit would overwhelm care for
public health and safety” and sought to protect the drug supply by proposing the
creation of a regulatory system requiring the recommendation or prescription by a
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physician for the use of opioids and other substances (Spillane & McAllister, 2003, p. 6).
The powerful coalition of physicians and druggists contributed to the political support
necessary to pass the 1906 Pure Food and Drug Act (Spillane & McAllister, 2003).
The 1906 Pure Food and Drug Act established the U.S. domestic prescription
drug policy regime. The Act regulated drug promotion, packaging, distribution of specific
compounds, and created the first list of restricted “dangerous drugs” including
morphine, opium, and diacetylmorphine (Spillane & McAllister, 2003). In addition,
enforcement of the Act occurred under the authority of the Federal Bureau of
Chemistry, an organization that would later become an important opioid treatment
regulator: the U.S. Food & Drug Administration (FDA) (Swann, 1998). The authority of
the FDA grew with the 1938 Food, Drug, and Cosmetic Act, expanding the agency’s
authority to oversee cosmetics and medical devices, and mandated labeling for drugs
with directions for safe use, and the pre-market approval of all new drugs (Swann,
1998). Under this new regulatory system manufacturers had to prove to the FDA that a
drug was safe before it could enter the market (Swann, 1998).
2.4.3. The narcotic clinics. At the same time as the development of the
pharmaceutical regulatory system a more robust addiction treatment system began to
form without the support of the federal government, the narcotic clinics (White, 2002).
The narcotic clinics, created by physicians, were the first community-based facilities
dedicated to providing OAT for patients with OUD (White, 2002). Patients with severe
OUD would receive OAT to “stabilize” their condition and patients who were more
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“able-bodied” would undergo gradual outpatient withdrawal (White, 2002). The
purpose of the clinics was to provide consistent medical management of OUD, to
suppress the illegal drug market, and to prevent “drug peddlers” from selling opioids to
people with addiction (White, 2002). The clinics ranged from effective and reputable to
ineffective and disorganized (White, 2002).
2.4.4. The 1914 Harrison Narcotic Act. In 1912, international delegates
convened at the Hague Convention to establish a worldwide supply control standard for
the manufacturing and trade of raw opium, morphine, diacetylmorphine, and cocaine
(Martin, 1977). U.S. policymakers used the momentum and policy design from the 1912
Hague Convention to enact the 1914 Harrison Narcotic Act. The 1914 Harrison Narcotic
Act regulated the importation, manufacturing, and distribution of psychoactive
substances as determined by the 1912 Hague Convention (Sacco, 2014). The Act
required persons involved in any part of the drug distribution processes to register with
the U.S. Department of the Treasury, pay special taxes, and to track all transactions
(Sacco, 2014). The Act technically allowed physicians to prescribe opioids and cocaine
for treating persons with OUD; however, in contravention of the text, many physicians
were arrested, prosecuted, and incarcerated for providing diacetylmorphine or
morphine as a treatment for OUD (Sacco, 2014).
A series of three U.S. Supreme Court cases reviewed in 1916 and 1919
challenged the Act’s legality: Jin Fuey Moy v. United States (1916); Webb et al. v. United
States (1919); and United States v. Doremus (1919) (Hohenstein, 2001). In Jin Fuey Moy
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v. United States, the Supreme Court overruled a lower court ruling that Dr. Moy, a
physician who provided opium for a non-registered patient did not violate the
provisions of the Act (Hohenstein, 2001). Three years later in Webb et al., v. United
States and United States v. Doremus the U.S. Supreme Court affirmed the rulings of the
lower courts finding the physicians in violation of the Act because the doctors had
provided opioids to “dope fiends” (Hohenstein, 2001). Hereinafter, according to the
Supreme Court, only physicians who prescribed opioids to their patients as medical
treatment, versus for their addiction, could avoid the provisions of the Act (Hohenstein,
2001). Contemporary OAT policies reflect this foundational ruling—it is illegal, in most
clinical scenarios, for health care professionals to prescribe opioids for OUD treatment,
unless a specific product has received FDA approval for that indication. In addition to
federal action to delegitimize the use of specific opioids, in 1920 the American Medical
Association’s (AMA) House of Delegates passed a resolution banning the use and
importation of diacetylmorphine for medical purposes (Courtwright, 2002).
The culmination of these policies and resolutions resulted in the destruction of
the narcotic clinics (AMA: Council on Mental Health, 1966). By the end of 1920, all
narcotic clinics were closed because of prosecutorial threat; as a result, in less than a
decade the “fledging specialty of addiction medicine was all but obliterated” (White,
2002, p. 136). It is at this point in history that many subsequent opioid-related federal
policies shifted from taxable product to the criminal sanctions policy regime (White,
2002). In 1924, Congress enacted the Heroin Act, which created a federal prohibition for
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importing, manufacturing, and possessing diacetylmorphine, including for medical use,
and criminalized all persons who used, sold, or administered diacetylmorphine (Musto,
1973).
2.4.5. Early treatment in hospitals. From 1924 to 1935, after diacetylmorphine
distribution and use became illegal, and the community-based narcotic clinic system
collapsed, OUD treatment resources were limited (White, 2002). Treatment access was
dependent on the race and social class of the patient. Affluent middle-aged patients
sought discreet withdrawal management in private hospitals. Young people with heroin
addiction, in contrast, were more likely to undergo opioid withdrawal in a correctional
facility (White, 2002). Physicians practicing in private and community-based hospitals
continued to focus on opioid withdrawal management resulting in the development of
several withdrawal regimens, such as the “Towns-Lambert Treatment,” the “Pettey
Method,” and the “Nellens and Masse Method” (White, 2002). Eventually, the health
care professional community recognized that these protocols were ineffective for curing
addiction (White, 2002), and hospitals began denying OUD patients access, resulting in a
substantial increase in people with OUD entering the criminal justice system (White,
2002).
Moreover, a eugenics movement successfully lobbied for the inclusion of
“addicts” in state mandatory sterilization laws, and inebriate commitment laws were
expanded to provide for the involuntary commitment of persons addicted to opioids to
state asylums (White, 2002). These practices reflected the socially constructed policy
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targets of the 1924 Heroin Act, which dictated that persons who used specific opioids
(i.e., diacetylmorphine) were criminals and immoral. One of the consequences of this
shifting discourse was the invention of cruel and invasive interventions for OUD such as
“serum therapies,” which created blisters on a person’s body and withdrew fluid and
reinjected it into the blisters (Reddish, 1931) or “bromide sleep treatments” that had a
20% death rate (Church, 1900).
2.4.6. The 1929 Porter Act and the narcotic farms. By 1928, persons with
addiction comprised nearly two-thirds of federally incarcerated persons, because of
facility crowding Congress legislated the creation of specialized addiction treatment
hospitals (White, 2002). The Porter Act, with support from Dr. Lawrence Kolb of the U.S.
Public Health Service, approved the construction of two “narcotic farms” one in
Lexington, Kentucky, and the other in Fort Worth, Texas (White, 2002). Together, these
facilities had the capacity to treat 2,400 criminally-justice involved persons and
voluntary patients (White, 2002). The hospitals divided treatment into three phases:
withdrawal, convalescence, and rehabilitation (White, 2002). Interprofessional teams of
physicians, nurses, social workers, chaplains, and recreational therapists administered
treatment modalities within the hospitals (White, 2002). Once patients completed their
opioid withdrawal protocol they spent their time working on the farm (White, 2002).
There was limited programmatic success as 90 to 95% of patients returned to drug use
upon leaving the farms (Maddux, 1978).
The testing of many contemporary OUD treatment modalities, such as
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methadone, occurred at the farms as part of the Addiction Research Center (ARC)
(Campbell et al., 2008). However, most of the research practices would be considered
unethical by 21st century human subjects research protection standards. Until 1955, for
example, patients would receive drugs in return for their participation in experimental
studies (Campbell et al., 2008) and these studies were conducted primarily on
incarcerated individuals. The narcotic farms, up until the 1960s, were the primary
addiction treatment facilities in the U.S. (White, 2002). Operations changed significantly
with the passage of the 1966 Narcotic Addict Rehabilitation Act (Campbell, 2010), and in
1974, the hospitals were closed and converted into minimum security prisons (White,
2002). The history of the ARC post-narcotic farm is convoluted but the research program
was eventually absorbed as part of the broader intramural research program at the
National Institute on Drug Abuse (Campbell et al., 2008).
During the narcotic farm era, some states experimented with state-operated
addiction treatment hospitals or created “addict wards” in community hospitals (White,
2002). These experimental delivery systems, however, failed to spread across the U.S.
Subsequently, two other outpatient treatment delivery approaches emerged: the
therapeutic community and methadone maintenance therapy (White, 2002). The
therapeutic community model started in 1958 with the creation of a mutual aid group
called Synanon (White, 2002). This model required participants to commit to one to two
years of “re-socialization” through authoritarian surrogate families (White, 2002). By
1975, there were more than 500 therapeutic communities in the U.S. (Mitchell, Mitchell,
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& Ofshe, 1980; Yablonsky, 1967).
German scientists synthesized methadone during World War II (Kleber, 2002)
and it was FDA approved for the treatment of pain 1947 (Institute of Medicine
Committee on Federal Regulation of Methadone, 1995). Methadone has a longer
duration of action than other opioids and a single dose is sufficient to prevent opioid
withdrawal for up to 24 hours. Methadone maintenance in community-based treatment
centers emerged in the 1960s (Kleber, 2002). Drs. Marie Nyswander and Vincent Dole
pioneered this treatment delivery mechanism and conceptualized OUD as a metabolic
disease that necessitated the daily oral administration of methadone to stabilize the
metabolism (Kleber, 2002).
During the 1960s, the social construction of drug use disorders shifted towards
the addiction as disease model. In 1961, a joint committee of the American Bar
Association and the AMA questioned the long-standing repressive drug policies of the
prior forty-years and encouraged OAT research (Musto, 1987). In 1962, the U.S.
Supreme Court in Robinson v. California declared that narcotic addiction was a disease
and that persons with addiction should be “proper subjects for medical treatment”
(White, 2002). The 1966 Narcotic Addict Rehabilitation Act reflected this change in the
social construction of drug users. The Act authorized, treatment of “narcotics addicts” in
lieu of incarceration for federal drug offenses and promoted the development of
community-based outpatient services (Besteman, 1992).
2.4.7. International drug conventions. International treaties are the foundation
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of contemporary U.S. opioid regulations. In 1925, at the International Opium
Convention delegates created the first psychoactive regulatory mechanism for opioids
and other drugs (League of Nations, 1925). These efforts were expanded upon with the
1931 Manufacturing Convention (League of Nations, 1931), which was strongly
influenced by a turbulent social environment. First, the convention occurred during a
worldwide economic recession, the European banks were failing, countries were
experiencing currency destabilization, and foreign trade had “imploded” (McAllister,
2004). Thus, delegates did not want to impose limits on the export of profitable
medicalized opioids (e.g., codeine in Germany) because countries needed the revenue
(McAllister, 2004). Second, international delegates received conflicting pressure from
scientists, who were concerned about policies limiting research capabilities; and
temperance advocates, who wanted the strictest limits on drugs (McAllister, 2004).
Third, the moral model dominated the social construction of drug users at this time;
thus, delegates believed if the illicit drug supply was eliminated drug misuse would end
(McAllister, 2004). The delegates created a two-tiered regulatory structure for
psychoactive substances to meet the needs of all of their stakeholders and to adhere to
the socially constructed narrative of drug users at the time: Group I (e.g., morphine,
heroin, cocaine) and Group II (e.g., codeine) (League of Nations, 1931). The policy
required that countries track Group I drugs during retail transaction and distribution
(McAllister, 2004).
Thirty years later, at the 1961 United Nations (UN) Single Convention on Narcotic
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Drugs, delegates from 97 nations extended prior regulatory efforts from the
Manufacturing Convention and designed and ratified the contemporary prescription
policy regime (UN, 2013). The treaty’s primary intention was to create worldwide opioid
prohibition, except for medical and research purposes (UN, 2013). Convention
representatives crafted the regulations with two assumptions: 1) limiting the worldwide
opioid supply would eradicate illicit use; and 2) opioid control and prohibition would be
imposed until evidence demonstrated that a drug did not have addictive potential
(Spillane & McAllister, 2003). The treaty created four drug schedules with different
levels of regulation; provided definitions for legal and illegal trade; provided definitions
for medical and research purposes; and created penalties for recreational consumption
(Spillane & McAllister, 2003).
2.4.8. Summary. Over the course of the 19th and 20th centuries drug policies
institutionalized opioids as a taxable product (e.g., the 1914 Harrison Narcotic Act),
illegal substance (e.g., the 1924 Heroin Act), or pharmaceutical treatment (e.g., the UN
Conventions) and subsequently categorized specific opioid users as patients or
criminals. These policies shape the contemporary treatment policy regimes, dictating
how, when, and where persons with OUD can access treatment.
Section 2.5. Contemporary Drug Policy: Regimes, Law, and Regulations
This section provides an overview of the contemporary drug policy regimes, and
U.S. law and regulations informing access and delivery of OAT.
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2.5.1. Drug policy regimes. Policy regimes are collections of policies intended to
achieve a broad goal (Birkland, 2015). Drug policies are trans-disciplinary (Babor et al.,
2010; Boyd et al., 2016; MacCoun et al., 1993) and enact a broad range of administrative
actions related to substance use. Babor et al. (2010) identified five drug policy regimes:
1) criminal sanctions; 2) health and social services; 3) prescription; 4) prevention; and 5)
supply control. Policies may exist in multiple regimes or sub-regimes. The purpose of
drug policies is to achieve three goals: 1) prevalence reduction (i.e., decreasing the
number of users); 2) quantity reduction (i.e., reducing the amount consumed); and 3)
micro-harm reduction (i.e., reducing the average harm per dose to users and non-users)
(MacCoun & Martin, 2008). Each micro-goal contributes to the broader overarching goal
of macro-harm reduction, which is to decrease the total harm of drug use to society
(MacCoun & Martin, 2008).
2.5.1a. Criminal and punitive sanctions regime. The criminal and punitive
sanctions policy regime includes policies intended to deter drug use, to prevent the
normalization and spread of drug use, and to prevent the negative effects of
criminalizing less harmful forms of drug use (Babor et al., 2010). This regime includes
policy strategies such as deterrence (e.g., threatening to arrest), incapacitation (e.g.,
incarceration), rehabilitation (e.g., coercive treatment), and penalty modification (e.g.
decriminalization, depenalization) (Babor et al., 2010).
2.5.1b. Health and social services regime. The health and social services policy
regime includes policies that promote treatment and recovery modalities for persons
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with SUDs from a non-punitive approach (Babor et al., 2010). Treatment policies, a
policy sub-regime, affect treatment access through planning, financing, and monitoring
of addiction services, as well as the development of the professional workforce
(Klingemann, Holder, & Gutzwiller, 1993; Klingemann & Klingemann, 1999). Regulatory
and allocative treatment policies; moreover, may determine the structural resources
available to treat SUDs, such as the number of facilities, the types of programs (e.g.,
opioid treatment programs [OTP]), the delivery setting (e.g., hospitals), and the health
care professionals who can deliver services (e.g., prescribers). Additionally, treatment
policies may affect where services are located, and the organization and integration of
services (Klingemann et al., 1993; Klingemann & Klingemann, 1999).
2.5.1c. The prescription regime. For opioids, the prescription policy regime is
“the major control structure through which these substances are made legally available
for consumption in the modern world” (Babor et al., 2010, p. 179). The two goals of this
regulatory system are to permit opioid use for approved medical purposes and to
prevent non-approved use (Babor et al., 2010). The prescription regime, although less
than a century old, is the normative approach for pharmaceutical regulation globally
(Babor et al., 2010). The prescription regime is influenced by consumer groups,
international conventions, government regulations, and professional associations
(Babor et al., 2010).
2.5.1d. The prevention regime. The prevention policy regime includes policies
intended to reduce SUD incidence (Kolodny et al., 2015) by preventing drug use by
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changing attitudes and improving health literacy (Babor et al., 2010). Prevention efforts
to decrease OUD and opioid exposure may include policies to support educational
programming for prescribers, patients, families, and the public. For example, some
states (e.g., Iowa, Kentucky, Massachusetts, Ohio, Tennessee, and Utah) mandate
provider opioid education (Executive Office of the President of the United States, 2014).
Another prevention policy approach is to decrease the number of opioids in circulation
with the purpose to reduce long-term exposure and new exposure to opioids (Kolodny
et al., 2015).
2.5.1e. The supply-control regime. The primary goal of the supply-control policy
regime is to keep illegal drug prices high and to reduce illegal drug availability (Babor et
al., 2010). Commonly used supply control approaches include polices for alternative
crop development, crop eradication, precursor chemical control, interdiction, high-level
enforcement through criminal investigations, street-level enforcement, and
imprisonment (Babor et al., 2010).
2.5.2. Contemporary laws and regulations. The 20th and 21st century opioidrelated policies germane to this dissertation cross all drug policy regimes and build upon
the foundations of previously reviewed historic policies. The result is a complex
contemporary regulatory environment comprised of discordant rules for specific opioids
that is shaped by social construction. This section includes a summary of contemporary
OAT-related policies and regulations.
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2.5.2a. The 1970 Comprehensive Drug Abuse Prevention and Control Act. This
Act is the cornerstone of contemporary opioid regulations with elements from all five
policy regimes (Babor et al., 2010). The enactment of this legislation reflected assorted
interrelated social phenomena including the actions taken by President Richard Nixon.
As a candidate, Nixon ran on a platform of domestic crime control and, in his view, the
primary cause of increased crime was SUDs (Courtwright, 2004). Within the first six
months of his presidency, in July 1969, President Nixon submitted to Congress the
legislative architecture of what would eventually become the 1970s Comprehensive
Drug Abuse Prevention and Control Act (Courtwright, 2004). The proposed legislation,
addressed multiple aspects of SUDs through supply control, education, research,
treatment, and training (Courtwright, 2004).
At the time, methadone was the only medication available for persons with
OUD. Patients received methadone at experimental treatment centers. To circumvent
the federal prohibition of treating persons with OUD with opioids, methadone
maintenance treatment centers operated as research facilities using Investigational New
Drug (INDs) waivers from the FDA (Jaffe & O'Keeffe, 2003). Between 1967 and 1970
several thousand patients received methadone in these research programs (Institute of
Medicine Committee for the Substance Abuse Coverage Study, 1990; Jaffe, 1975;
Jonnes, 1996; Kreek & Vocci, 2002). In June of 1970, the FDA proposed a new rule for
methadone IND applications with strict requirements on entry into treatment, dosage,
and duration of treatment (Jaffe & O'Keeffe, 2003). With this rule in place the FDA
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allowed methadone to be more restrictively used but still “thinly disguised as research”
(Jaffe & O'Keeffe, 2003). Other interventions for OUD in the 1960s and 1970s included
civil commitment, narcotic antagonists, non-opiate withdrawal medications (e.g.,
clonidine), and drug testing as a form of treatment monitoring (White, 2002).
On October 27, 1970, President Nixon signed the Comprehensive Drug Abuse
Prevention and Control Act of 1970 into law repealing and replacing the long-standing
1914 Harrison Narcotic Act. This omnibus bill included three titles. Title I authorized the
Department of Health, Education, and Welfare to engage in drug use prevention and
treatment through community mental health centers and public service hospitals, and
authorized increased research funding through the National Institute of Mental Health.
Title II, named the 1970 Controlled Substance Act, provided the regulatory framework
for opioids and other psychoactive drugs. Title III addressed importation and
exportation of controlled substances.
The 1970 Controlled Substances Act, informed by the scheduling structure
created in the earlier international conventions, provided a regulatory mechanism for
categorizing “controlled substances” into five schedules based on acceptable medical
use and the potential for abuse, which is in place today:
•

Schedule I substances have no currently accepted medical use in the U.S. and
have a high potential for abuse (e.g., diacetylmorphine);

•

Schedule II substances are considered dangerous, have a high potential for abuse
which may lead to severe psychological or physical dependence (e.g.,
methadone);
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•

Schedule III substances have less potential for abuse than Schedule I or II, but
more than Schedule IV, with a moderate to low potential for physical and
psychological dependence (e.g., buprenorphine);

•

Schedule IV substances have a low potential for abuse and risk of dependence
(e.g., lorazepam); and

•

Schedule V substances have a lower abuse potential as compared to Schedule IV
and consist of preparations containing limited quantities of certain opioids (e.g.,
Phenergan® with codeine) (DEA, n.d.).
The Act does not describe how drug abuse potential is determined, but does

provide a legislated review mechanism for scheduling additional drugs and rescheduling
or decontrolling already regulated substances (Courtwright, 2004). At the time, the 1970
Controlled Substances Act was seen as “an overdue and noncontroversial piece of
legislation” designed to tighten and clarify a statutory and administrative “mess”
because the regulatory system prior to that time was unstable and rapidly changing
(Courtwright, 2004, p. 10). The major contribution of the Act was the creation of a
common regulatory process that shifted drug control from Congressional action to
administrative control (Spillane, 2004).
2.5.2b. The 1972 Drug Abuse Office and Treatment Act. After the enactment of
the 1970 Controlled Substances Act, the treatment and prescription policy regime
expanded rapidly along with access to OUD treatment. In June of 1971, the Nixon
administration decided to mainstream methadone, which led to a 1972 revision of the
1970 FDA regulations (Jaffe & O'Keeffe, 2003). These regulations created a closed
treatment system restricting methadone administration to federally approved facilities
and hospital pharmacies (Institute of Medicine Committee on Federal Regulation of
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Methadone, 1995; Jaffe, 1975, 1997; Kreek & Vocci, 2002). The policy was supposed to
tightly control methadone distribution until the treatment became less controversial
and more well-studied (Jaffe, 1975, 1997). The regulations were in full effect by 1973,
and today, are largely in the same form. Methadone is considered to be “the most
highly regulated of all medical treatments” (Strain & Stoller, 1999).
The 1972 Drug Abuse Office and Treatment Act legislatively empowered the
Special Action Office for Drug Abuse Prevention and required this new federal office to
support the development of opioid antagonist therapy for OUD treatment (Julius, 1976).
Moreover, this Act enacted a federal-state-local partnership requiring shared
responsibility in the design, implementation, operation, and evaluation of communitybased opioid addiction treatment programs (White, 2002). In the same year, the Social
Security Act Amendment addressed addiction-related conditions and stated that both
alcoholism and drug addiction would not qualify as a disability unless the person was
receiving “appropriate available treatment in an approved facility” (Ball, 1973). Shortly
following that amendment, in July 1973, President Nixon established the Drug
Enforcement Administration (DEA) through Executive Order 11727, merging together
the Office for Drug Abuse Law Enforcement and the Office of National Narcotics
Intelligence in the Department of Justice (Nixon, 1973).
2.5.2c. The 1974 Narcotic Addict Treatment Act. This Act amended the 1970
Controlled Substances Act to legislate DEA authority over the storage and security of
addiction treatment drugs (Jaffe & O'Keeffe, 2003). It also required practitioners and
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treatment sites to annually register with the DEA (Jaffe & O'Keeffe, 2003) .The Secretary
of Health, Education, and Welfare (now the Department of Health and Human Services)
retained the responsibility for setting standards for proper professional practice in the
medical treatment of addiction (Jaffe & O'Keeffe, 2003), and today, that responsibility is
with SAMHSA.
2.5.2d. The 2000 Drug Addiction Treatment Act. This law is the most important
OUD treatment policy of the 21st century because it expanded OAT access. Prior to
enactment, federal legislation prohibited the prescribing of opioids for OUD treatment,
a holdover from the Supreme Court rulings related to the 1914 Harrison Narcotic Act
(McCarty, Priest, & Korthuis, 2018). The 2000 Drug Addiction Treatment Act permits
physicians, after registering with the DEA and completing eight of hours of SAMHSAverified training, to prescribe Schedule III, IV, or V controlled substances that are FDA
approved for OUD treatment. Currently, buprenorphine (Schedule III) is the only opioid
that meets these requirements. Although buprenorphine was approved by the FDA in
2002, it was discovered more than 40 years ago in the United Kingdom (Courtwright,
2004) and its treatment efficacy was hypothesized in the late 1970s (Jasinski, Pevnick, &
Griffith, 1978). The delay in the use of buprenorphine to treat OUD was due primarily to
policymakers obtaining the necessary amendments to the 1970 Controlled Substances
Act and the 1974 Narcotic Addict Treatment Act (Jaffe & O'Keeffe, 2003).
2.5.2e. The 2016 Comprehensive Addiction and Recovery Act and the 21st
Century Cures Act. The 2016 Comprehensive Addiction and Recovery Act authorized the
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expansion of SUD treatment services and overdose reversal medications, including
prevention, OAT, and other non-pharmacological recovery supports. This Act also
authorized nurse practitioners and physician assistants to become buprenorphine
prescribers through the federal waiver program. Importantly, the 21st Century Cures Act,
which was passed a few months later, provided $1 billion in funding for the treatment
expansion efforts outlined in the 2016 Comprehensive Addiction and Recovery Act
(ASAM, 2016), including the State Targeted Response to the Opioid Crisis Grants
program (SAMHSA, 2017b).
2.5.2f. The 2018 SUPPORT for Patients and Communities Act. This law
authorized a variety of interventions (e.g., programs and demonstration projects) to
address the opioid overdose epidemic through treatment, prevention, recovery, and
enforcement (Musumeci & Tolbert, 2018). Treatment and recovery highlights germane
to this dissertation include (Musumeci & Tolbert, 2018): A limited repeal of the
Institutions for Mental Diseases exclusion; the authorization of grants to academic
health centers to develop curricula to support provider buprenorphine waiver
attainment; and codifying the ability of qualified physicians to prescribe OAT for up to
275 patients.
2.5.6. Summary. The contemporary federal OAT policy regime, created over the
last 45 years, dictates where and when persons with OUD can access OAT, and further,
how health professionals and health facilities may prescribe or administer OAT. The OAT
policy landscape is likely one of many contributory elements informing how patients
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with OUD are treated during hospitalization. How health services delivery organizations
are shaped by internal and external elements (e.g., policies) are explored in the next
section.
Section 2.6. Organizational Behavior Scholarship
Organizations are “social structures created by individuals to support the
collaborative pursuit of specified goals” (Scott, 2003, p. 11). The core operational
requirements of an organization, include: 1) defining their objectives; 2) inducing
participants to contribute; 3) controlling and coordinating participant contributions; 4)
participant selection, training, and replacing; and 5) working with neighbors (Scott,
2003). Organizations must also devote resources to maintain the organization (Scott,
2003).
2.6.1. Leavitt’s Diamond. Four central, inter-related organizational elements are
included in Leavitt’s Diamond (Leavitt, 1962). This model, recently modified by Scott
(2003), asserts that organizations are influenced by the environment and comprised of
social structures, goals, technology, and participants (Leavitt, 1962; Scott, 2003).
2.6.1a. Social structures. Social structures are the patterned, regularized
interactions or relationships among participants in an organization (Scott, 2003). Social
structures may be formal (e.g., specified roles) or informal (e.g., indistinguishable roles)
(Scott, 2003) and embody a “duality” (Giddens, 1979), meaning they exist as a medium
and an outcome. There are three categories of social structures: normative (Davis, 1949;
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Scott, 2003); cultural-cognitive (Berger & Luckmann, 1966; Scott, 2003; Weick, 1995);
and behavioral (Davis, 1949; Homans, 1950; Scott, 2003).
Normative social structures include organizational values, norms, and role
expectations (Davis, 1949; Scott, 2003). Normative structures impose constraints on
behavioral structures, shaping, and channeling behavior through mutually held
expectations and obligations (Davis, 1949; Scott, 2003). Organizational values are the
criteria that inform the selection of goals and behavior; norms are the generalized rules
governing behaviors; and roles are the behavior expectations for occupants of specific
social positions (Davis, 1949; Scott, 2003).
Cultural-cognitive structures are the beliefs and understandings that participants
in an organization share about the nature of their situation, providing a common
interpretative framework (Scott, 2003)—an organizational culture. Organizational
culture formation occurs through the interaction of observable artifacts, espoused
values, and basic assumptions (Kinicki & Kreitner, 2009; Ostroff, Kinicki, & Tamkins,
2003) and is passed on to new employees through socialization (Kinicki & Kreitner,
2009). Organizational culture is structuralized through the creation of reward systems,
and enacted through socialization, mentoring, group dynamics, decision-making,
communication, influence and empowerment, and leadership (Kinicki & Kreitner, 2009;
Ostroff et al., 2003).
Behavioral social structures are the actual behaviors that occur within an
organization (Scott, 2003), comprised of individual or group activities, interactions, and
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sentiments (Homans, 1950). The repetition of actual behaviors into patterns or
networks, within an organization, provides rich insight into the understanding of the
organizational power structures and the sociometric structure (i.e., who is attracted to
whom, and who is rejected by whom) of the group (Scott, 2003).
2.6.1b. Participants. Participants are individuals who, in exchange for
inducements, make contributions to an organization (Scott, 2003). Participants are
usually involved in multiple organizations, and these outside involvements may
constrain or influence the behavior of participants (Scott, 2003). Participants are social
actors; thus, it is their energy, ideas, conformity or non-conformity that constitute the
shape and structure of organizations and resulting functions (Scott, 2003). The
demographic characteristics of participants (e.g., age, gender, ethnicity) may have
important consequences for organizational structure and function (Scott, 2003). From
an organizational perspective, organizations must be able to relate to a range of
participant interests and demands. This broader collection of individuals is often called
stakeholders. Stakeholders are affected by the organization and have “legitimate claims
on an organization” (Scott, 2003, p. 21).
2.6.1c. Goals. Organizational goals are defined as the desired ends that
participants attempt to achieve through task performance that involve culturalcognitive and normative elements (Scott, 2003). From a resource dependency
perspective, goals and actions are intended to minimize environmental uncertainties
(Hillman, Withers, & Collins, 2009) and dependencies (Pfeffer & Salancik, 1978) through
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mergers, vertical integration, creation of joint ventures and other interorganizational
relationships, board of director actions, political action, and executive succession
(Pfeffer & Salancik, 1978). Another approach to understanding organizational goals is
through the use of Chandler’s (1962) definition of strategy: “Strategy is the
determination of the basic long-term goals and objectives of an enterprise, and the
adoption of courses of action and the allocation of resources necessary for carrying out
these goals” (p. 13). This approach includes integrated decisions, actions, or plans that
will set and achieve organizational goals; the setting of goals and the achievement of
goals are the results of strategic decisions (Chaffee, 1985).
2.6.1c. Technology. Technology may be a place where a specific type of work is
conducted, a location in which energy transforms materials (Scott, 2003). Every
organization does “work” and has a technology for completing the work (Scott, 2003). In
the context of health care delivery, health systems “process people” and the product is
healthier or healed individuals (Scott, 2003). Technology may be embedded in physical
machines, but importantly, it is also the technical knowledge and skills of participants
(Scott & Davis, 2015). Finally, similar to the “duality” of social structures (Giddens,
1979), technology influences and shapes organizational design, by attempting to match
the complexity of an organization’s structure with the complexity of its environment and
technology (Galbraith, 1982).
2.6.1d. The environment. The physical, technological, cultural, and social milieu
are the environment in which organizations exist and adapt (Scott, 2003). No
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organization is completely self-sufficient; thus, it depends on relationships established
with the larger external system (Scott, 2003). The environment influences the
comprising elements of an organization, the social structures, the participants, the
goals, and the technology (Scott, 2003).
Few organizations assume responsibility for training and socialization of their
participants; thus, employees join organizations with “heavy cultural and social baggage
obtained from interactions in other social contexts” (Scott, 2003, p. 23). Further, few
organizations create their own technologies; most are imported from other
organizations, including employee rules and professional norms (Scott, 2003). Goals may
be influenced by the external environment through societal support and informed by
societal values (Scott, 2003). Social structures are also borrowed from the environment,
as organizations frequently follow models that already exist (Scott, 2003). It is,
therefore, an imperative that studies of organizational behavior include considerations
of the larger environment.
Another approach to understanding the influence of the external environment
on organizational behavior is institutional theory. This theory asserts that there are
three mechanisms in the environment that shape organizations towards homogeneity
through a process called isomorphism (DiMaggio & Powell, 1983). There are three
isomorphic mechanisms: coercive, mimetic, and normative (DiMaggio & Powell, 1983).
Coercive isomorphism is caused by external political influence, legitimacy, formal and
informal cultural pressures, or governmental mandate (DiMaggio & Powell, 1983).
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Mimetic isomorphism occurs when an organization mimics another in the environment
due to environmental uncertainty (DiMaggio & Powell, 1983). Normative isomorphism is
associated with professionalization, which is the collective struggle by occupational
members to define the conditions and methods of their work, control the number of
persons entering the profession, and establish a cognitive base and legitimate
occupational autonomy (DiMaggio & Powell, 1983).
Section 2.7. Systems Science Scholarship
Organizations are coordinated systems producing controlled activities embedded
within complex networks participating in technical and boundary-spanning exchanges
(Meyer & Rowan, 1977). There are a variety of system typologies and sub-typologies:
rational; natural; open; closed; or a combination (Scott, 2003). For this dissertation,
health service delivery organizations are conceptualized as sociotechnical and complex
adaptive systems. Sociotechnical systems function as closed (i.e., technical) and open
systems (i.e., institutional) (DiMaggio & Powell, 1991; Scott & Meyer, 1991; Thompson,
1967). A closed, technical system produces a product or service within a contained
environment that is exchanged in a market that rewards the organization for effective
and efficient control of the production systems (Scott & Meyer, 1991). An open system
is comprised of inputs, the inflow of external energy and information, throughputs, the
energies inside the system, outputs, the exported product, cycles of events, the
repeated activities to exchange and transform energy, and negative feedback, the
internal information used to correct and adjust activities (Katz & Kahn, 1978). The
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definition of an open system is “Congeries of interdependent flows and activities linking
shifting coalitions of participants embedded in a wider material-resource and
institutional environments” (Scott, 2003, p. 29). Complex adaptive systems are “A
collection of individual agents with freedom to act in ways that are not always totally
predictable, and whose actions are interconnected so that one agent’s actions changes
the context for other agents” (Plsek & Greenhalgh, 2001, p. 625).
There is unresolvable tension and paradox within a complex adaptive system
reflected in the amalgamation of contradictory properties, which are found in health
service delivery settings, including:
•

The system has unclear and fuzzy boundaries;

•

The system has non-linear behaviors;

•

The system has unpredictable outcomes;

•

The system has inherent patterning;

•

The system has embedded co-evolving systems;

•

The agents within the system are adaptive; or

•

The agents within the system act based on internalized rules (Plsek &
Greenhalgh, 2001).
Complex systems are comprised of functional units that interact non-linearly

with other units within a system (Lipsitz, 2012). Hospitals exist as functional units within
the nested context of a larger complex health services delivery systems, including: the
patient, the care team, the department, the division, the hospital, the health system,
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the relationships among multiple hospitals and health systems, a system of hospitals,
hospital networks, all hospitals, the industry, the region, the nation, and the global
community (Ferlie & Shortell, 2001; Perrow, 1986). The nesting phenomena causes
continuous evolution and interaction within each level; thus, theoretical multilevel
frameworks examine health behavior interventions (Sallis et al., 2015), health care
improvement leverage points (Ferlie & Shortell, 2001), the health care delivery
enterprise, health service utilization (Andersen, Davidson, & Baumeister, 2013;
Levesque et al., 2013) and health care value-networks (Basole & Rouse, 2008).
Scholars describe the production of health services as existing within a nested
context—patient, care team (e.g., frontline health professionals), organization (e.g.,
facility infrastructure and resources), and the environment (e.g., regulatory, market, and
policy frameworks (Fanjiang, Grossman, Compton, & Reid, 2005; Ferlie & Shortell,
2001); thus environmental attributes (e.g., regulatory pressures and statutory
requirements) may influence hospital structures and hospital attributes (Covaleski,
Dirsmith, & Michelman, 1993; Goodrick & Salancik, 1996; Ruef & Scott, 1998).
Section 2.8. Economics Scholarship
Economic theories and analyses attempt to predict and explain human behavior
through the modeling of agents (e.g., individuals, organization) and resources (e.g.,
labor, monetary) (Feldstein, 2005; Friedman, 2002). A neoclassical economics approach
assumes that individual agents are rational, that transactions are governed by market
equilibria, that organizations are committed to efficiency, that high profits are evidence
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of efficiency, and that efficiency benefits society (Perrow, 1986). Rationality is
articulated as either procedural (i.e., bounded) or substantive (i.e., objective) (Simon,
1985). In bounded rationality, three elements are necessary to understand decisionmaking: 1) the individual’s goal; 2) the information and conceptualization of the
situation; and 3) the individual’s ability to draw inferences from information in
possession (Simon, 1985). In objective rationality, only two elements are necessary for
understanding choice: the individual’s goals and the objective situational characteristics
(Simon, 1985). Thus, bounded rationality accounts for the limits of human cognition and
recognizes the resources necessary for processing information and making a decision
(Simon, 1985).
A transaction, from an economics perspective, is an exchange that occurs
between two parties in the market that may incur costs (Friedman, 2002). A market is
an allocative mechanism and an institutionally specific cultural system that generates
and measures value (Friedland & Alford, 1991). New market equilibrium situations are
predicted and explained using supply and demand principles (Feldstein, 2005). Supply is
the quantity of a good sold at a given price and demand is the quantity of a good
purchased at a given price (Friedman, 2002). Budget constraints and income level also
impact the supply and demand curve (Friedman, 2002). When a price changes along the
supply and demand curves, the quantitative impact is called elasticity (Feldstein, 2005).
Market equilibrium occurs when consumer quantity demand is equal to supplier
quantity, which is a state of economic efficient allocation, meaning organizational
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resources are being used to maximize value to its members (Friedman, 2002). Efficiency
is the use of a firm’s resources to maximize value to its members through the goods and
services produced (Friedman, 2002). In the market, resources are scarce; thus, specific
resource allocation involves an opportunity cost, meaning that resources spent on one
item are not spent on another (Friedman, 2002).
Resource allocation is either efficient or inefficient (Friedman, 2002). An efficient
allocation of resources is one where there is no waste and everyone gains. In reality,
there is no perfectly efficient allocation; therefore, the concept of relative efficiency
exists. Relative efficiency compares the efficiency of one allocation to another
(Friedman, 2002). There is always room to improve efficiency, and efficient allocation
does not always mean an optimal or equitable allocation of resources (Friedman, 2002).
Efficiency and allocation are the cornerstones of government economic objectives,
which are to improve market efficiency and achieve appropriate allocation of resources
(Feldstein, 2005).
2.8.1. Agency theory. Agency theory is based on the premise that relationships
are represented by contracts between principals and agents (Perrow, 1986). The
principal (e.g., the hospital) delegates work to the agent (e.g., the physician) who
performs the work (Eisenhardt, 1989). Agency theory has several assumptions. First,
people are self-interested, bounded rationally, and risk averse (Eisenhardt, 1989).
Second, the principal-agent relationship is fraught with goal conflict and information
asymmetry (Eisenhardt, 1989). Third, efficiency is the criterion for effectiveness
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(Eisenhardt, 1989). Agency theory explores conflicts in contract design (Alchian &
Demsetz, 1972; Jensen & Meckling, 1976; Zeckhauser & Pratt, 1985), particularly the
influence of third-party enforcers (Scott, 1995). Third-party contract enforcers have
their own utility functions (North, 1990) and monitoring costs (Zeckhauser & Pratt,
1985).
2.8.2. The rational actor model. The rational actor model uses the utility
maximizing model as a theoretical base, is frequently applied in political analysis, and
describes unitary decision-makers (Allison & Zelikow, 1999). The utility maximizing
model is a common framework for understanding resource allocation choices. The utility
maximizing model makes four assumptions about the consumer: 1) she has consistent
preferences and preference-ordering; 2) she is non-satiable; 3) she prefers a specific
proportion of goods; and 4) she makes choices based on information and her selfinterest (Friedman, 2002).
2.8.3. Transaction cost theory. Transaction cost theory explains and explores
economic transaction design associated with organizations (Williamson, 1994). The
transaction cost theory assumptions include two elements: 1) humans will behave
opportunistically with guile under a frame of bounded rationality; and 2) there are
exchange characteristics that may determine design, such as asset specificity,
uncertainty, and frequency of transactions (Williamson, 1979, 1985; Williamson &
Ouchi, 1981).
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Section 2.9. The U.S. Health Services Delivery Market
This section provides an overview of the U.S. health services production market
and explores why care delivery variation persists despite advancements in health care
technology.
2.9.1. Health services commodification. The construction of the U.S. health
services delivery system reflects the needs of a political and an economic environment
that has institutionalized a system of “capitalist relations of production” (Christiansen,
2017, p. 83). From this lens, capitalists seek to “Augment (and realize) surplus value, as
well as to increase that portion of surplus value that becomes their profit…while
simultaneously offering only those ‘benefits’ necessary for retaining their workforce”
(Christiansen, 2017, p. 83). Under this approach, health service delivery is commodified
and private enterprise manages a large portion of health care expenditures and profits
(Christiansen, 2017). The primary goals of the health service delivery system are the
provision of services and the maximization of profit for shareholders (Christiansen,
2017). The U.S. health care delivery system is “a loose federation of independent
enterprises, all trying to optimize the market from their perspective and for their
benefit” (Basole & Rouse, 2008). In 2015, the delivery of health care services accounted
for 17.5% of the U.S. Gross Domestic Product (National Center for Health Statistics,
2017). Out of the total national health expenditure of $3.0 trillion, hospital services
accounted for 32% of expenditures (National Center for Health Statistics, 2017).
Therefore, in addition to the contributions of organizational and system-level attributes
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as previously described, the U.S. economic production system of health services delivery
influences hospital OAT delivery.
The quantification of the economic value of the health services produced in the
hospital setting is based on the hospital’s self-designated procedure and supply list—the
“chargemaster” (Reinhardt, 2006). There are two steps in hospital billing and
reimbursement. First, the hospital bills third-party payers or patients directly using the
defined prices on the chargemaster; and second, the hospital is reimbursed through a
unique negotiated payment contract with a third-party payer or the uninsured patient
(Reinhardt, 2006). Third-party payer contracts with hospitals may be based on steeply
discounted charges, negotiated per diems, or flat charges per episode dependent on
negotiations (Reinhardt, 2006). Medicare reimburses hospital-based services using a flat
fee per case payment structure (Reinhardt, 2006) and Medicaid reimburses hospitals
using a legislated formula that includes a base payment and a variety of statedetermined supplemental payments (Cunningham, Rudowitz, Young, Garfield, & Foutz,
2016). One of the most common contractual arrangements in U.S. hospitals, based on
the Medicare payment model is diagnostic related grouping (DRG). DRG billing is a
contractually agreed upon amount, set between the hospital and the third-party payer,
for a specific condition or treatment bundle (Quinn, 2008).
2.9.2. Variation in service delivery. Health services delivery variation, herein
referred to as care variation, has been a topic of interest since the first scientific study
on tonsillectomy variation in United Kingdom school children (Glover, 1938). From a
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variation perspective, health care services are categorized as: effective (Category I),
preference-sensitive (Category II), and supply-sensitive care (Category III) (Chandra &
Skinner, 2012; Skinner, 2011; Wennberg, Fisher, & Skinner, 2002). Category I care
includes highly effective treatments that are inexpensive and productive across the
population (e.g., antibiotics for bacterial infections) or are highly productive and
expensive for a well-defined group of patients (Chandra & Skinner, 2012; Skinner, 2011;
Wennberg et al., 2002). In general, Category I treatments will eventually diffuse across
the system to near-universal use, although this process can be slow (Berwick, 2003).
Category I treatments may have substantial impact on health outcomes, but are not
likely to play a large role in explaining variation in expenditures (Skinner, 2011)
Category II care includes preference-sensitive care—treatments that exhibit
considerable benefit heterogeneity across different populations (Chandra & Skinner,
2012; Skinner, 2011; Wennberg et al., 2002). An example of this type of care is the use
of stents, which only benefits a very specific group of people (Hartwell et al., 2005).
Category II treatment variation is observed in national health systems with salaried
physicians, which suggests that variation is not solely due to the presence of fee-forservice or income-maximization by physicians (Skinner, 2011).
Category III care is supply-sensitive treatments, where there is limited evidence
of benefit (e.g., knee arthroscopy) or the benefit is unknown (Chandra & Skinner, 2012;
Skinner, 2011; Wennberg et al., 2002). Skinner (2011) proposes that Category III
treatment utilization plays a significant role in explaining expenditure differences across
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regions. Hospital utilization is considered a Category III treatment because the
incremental health value of greater hospital capacity is either small, zero or unknown
(Fisher, Wennberg, Stukel, & Sharp, 1994). Skinner (2011) proposes that patterns of
geographic variation can be explained in part by the theory of reasoned action (Ajzen &
Fishbein, 1980). In this model, individual behavior is disaggregated into goals and beliefs
about how to attain goals (Skinner, 2011). Patients and physicians are assumed to share
the same goals: better functioning and longer lifespan for the patient. However, local
health care systems may perceive different approaches for attaining those goals
(Skinner, 2011). One of the proposed solutions for care variation is to standardize care
in clinical scenarios with high levels of certainty, clinical agreement, and definitive
science (Institute of Medicine Committee on Quality of Health Care in America, 2001).
For the purposes of this dissertation, OAT is a category I treatment.
Section 2.10. The Health Care Access Framework
The integration and synthesis of scholarship from sociology, policy,
organizational behavior, systems science, and economics, supports the proposition that
supply-side attributes, inside and outside the hospital, influence hospital OAT delivery.
Levesque et al. (2013) proposed an updated conceptual framework on health services
access through a synthesis of work from Bashshur, Shannon, and Metzner (1971),
Donabedian (1974), Salkever (1976), Aday and Andersen (1974), Penchansky and
Thomas (1981), Dutton (1986), Frenk and White (1992), Haddad and Mohindra (2002),
Shengelia, Murray, and Adams (2003), and Peters et al. (2008).
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Levesque et al. (2013) defined health care access as “the possibility to identify
healthcare needs, to seek healthcare services, to reach the healthcare resources, to
obtain or use health care services, and to actually be offered services appropriate to the
needs for care” (p. 4). The outcomes of achieving access are the utilization of services
and health care consequences (i.e., economic, satisfaction, and health). From this
perspective, access enables people to take steps to enter into contracts with health
professionals and health care facilities to obtain health care services (Levesque et al.,
2013). Levesque et al. (2013) explains that the differences in access (e.g., variation,
underuse) may be due to either supply-side or demand-side attributes. The supply-side
attributes include five categories applied to health professionals, facilities, health
delivery systems, and broader influencing social factors (e.g., health insurance policy)
(Levesque et al., 2013):
•

Approachability—the articulation that a service exists for treatment;

•

Acceptability—the cultural and social factors for the treatment;

•

Availability and accommodation—the physical and timely manner of treatment;

•

Affordability—the economic capacity to spend resources for treatment; and

•

Appropriateness—the fit of the needs of the patient and service.

The demand-side determinants, focused largely on the capabilities of individuals,
families, and communities to access care (Levesque et al., 2013):
•

Perceive—the ability for the patient to perceive the need for treatment;
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•

Seek—the ability for the patient to have the capacity to choose to pursue
treatment;

•

Reach—the ability for the patient to physically access treatment;

•

Pay—the ability for the patient to generate economic resources to pay for
treatment; and

•

Engage—the ability for the patient to participate in treatment decision-making.

The dissertation’s focus is primarily on the supply-side determinants, and uses the
Levesque et al. (2013) conceptual framework as a scaffold from which to apply the other
previously described, potential contributors to hospital OAT delivery.
Section 2.11. OAT Delivery Outside the Hospital
This section describes the contemporary U.S. OAT delivery system, specifically,
the OTP and non-OTP delivery settings informed by the special regulatory frameworks
overseen by the DEA and SAMHSA described previously. The regulatory frameworks are
“special” because they are exceptional. No other FDA-approved pharmaceutical
products require separate federally mandated prescriber registration programs and
separate systems of delivery (i.e., non-pharmacy based) (Priest et al., 2019).
2.11.1. Opioid treatment programs (OTP). The administration of methadone for
OUD treatment is governed by the Certification of Opioid Treatment Programs, 42 Code
of Federal Regulations (CFR) 8 (SAMHSA, 2015). Methadone must be administered daily
under direct observation in a federally licensed OTP. There are only two delivery
exceptions: 1) during hospitalization; and 2) approved take home-doses (Priest et al.,
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2019). The SAMHSA regulations require OTPs to be certified, accredited, and registered
with the DEA (SAMHSA, 2015). OTPs are not permitted to prescribe methadone, they
are only permitted to dispense methadone; thus, most patients are required to
physically attend the OTP for daily observed dosing (McCarty et al., 2018). OTPs may
also administer buprenorphine, and they may offer other services, such as recovery
fellowship (e.g., 12-Step), and they require patient participation in nonpharmacotherapy services such as counseling (SAMHSA, 2015). In 2016, approximately
1,500 OTPs operated in the U.S. serving 350,000 people (Alderks, 2017). Patient
challenges to accessing OTPs are documented and include system-level (e.g., insurance
policies, program characteristics) and patient-level barriers (e.g., information barriers)
(Oliva, Maisel, Gordon, & Harris, 2011).
2.11.2. Non-OTP delivery. At present, buprenorphine, with and without
naloxone, is the only FDA approved OAT that may be prescribed for OUD treatment.
Buprenorphine prescribing is only allowed by federally certified prescribers (SAMHSA,
2016). To become a certified prescriber a health professional must meet the
requirements of the Drug Addiction Treatment Act of 2000, including: licensed to
practice under state law; registration with the DEA; and training or certification
(SAMHSA, 2016). Until recently, certified prescribers only included physicians, nurse
practitioners, and physician assistants; however, with the passage of the 2018 SUPPORT
for Patients and Communities Act for Patients Act, clinical nurse specialists, certified
registered nurse anesthetists, and certified nurse midwifes are now eligible to prescribe
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(American Nurses Association, 2018).
After the completion of the waiver requirements, and DEA approval, a certified
provider may prescribe buprenorphine for a certain number of patients depending on
their clinical licensure. For physicians in the first year they may prescribe to no more
than 30 patients at a time; in the second year, they may request to prescribe for up to
100 patients; and in the third year they may request to prescribe for up to 275 patients
(SAMHSA, 2016). Nurse practitioners and physician assistants are limited to prescribing
for 30 patients (ASAM, 2018a). Finally, in addition to having the waiver, providers who
wish to administer non-oral forms of buprenorphine (e.g., implant and long-acting
injectable) must also become certified by the patent-holding pharmaceutical company
(SAMHSA, 2018).
In contrast with the methadone system, a variety of innovative primary care
models for OAT delivery have emerged (Korthuis et al., 2017). These practice-based
models include office-based opioid treatment programs, the Buprenorphine HIV
Evaluation and Support Collaborative Model, the One-stop Shop Model, and the
Integrated Prenatal Care and Medication Assisted Treatment Model (Korthuis et al.,
2017).
Section 2.12. OAT Delivery within an Integrated Health System
In the U.S. there is a dearth of integrated health systems; thus, there is much to
be learned from the VHA, which has a longstanding history of providing services for
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patients with OUD. The VHA’s journey with OAT delivery is described below, including
system design, formulary decisions, and building system-wide treatment capacity.
2.12.1. VHA system design. The VHA provides insurance coverage and the
delivery of health services to over 9 million U.S. veterans in 170 VHA-owned and
operated medical centers and 1,063 outpatient sites (U.S. Department of Veterans
Affairs, 2016a). The development of the VHA SUD treatment and service delivery system
began in the late in response to increased OUD prevalence in veterans returning from
the Vietnam War (Wyse et al., 2018). To meet the needs of these service members, the
VHA created the Alcohol and Drug Dependence Service and developed specialized OUD
treatment facilities (Wyse et al., 2018). The program grew rapidly and, by the end of
1972, 44 VHA Drug Dependency Treatment Centers were operational; by 1973, more
than half of VHA patients (58%) receiving outpatient OUD services were receiving
methadone (Cantor, 1974). The original VHA Drug Dependency Treatment Centers
operated similarly to OTPs (Wyse et al., 2018). In the decades that followed, the number
of VHA facilities offering methadone declined. By 2008, only 28 VHA medical centers
had onsite OTPs, and only six of 128 centers offered offsite OTP access through
community-based programs (Oliva, Harris, Trafton, & Gordon, 2012). As of 2018, the
VHA operates 32 OTPS and the number of offsite OTPS at present is unknown (Wyse et
al., 2018).
2.12.2. VHA formulary. The VHA’s Pharmacy Benefits Management Service
approved sublingual buprenorphine as non-formulary medication in 2003, meaning that
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additional administrative approvals were necessary prior to prescribing (U.S.
Department of Veterans Affairs, 2017a). Buprenorphine use during that time was
limited, and after three years of non-formulary status, in 2006, only 3% of patients with
OUD received buprenorphine (Gordon et al., 2007). In 2006, the VHA had an internal
policy change and sublingual buprenorphine was added to the formulary, removing
administrative prescribing barriers (Wyse et al., 2018). Since that time, buprenorphine
accessibility has increased in the VHA system; by fiscal year 2011, 88% of VHA facilities
offered buprenorphine (n = 123 out of 140 eligible facilities) (VA Office of Inspector
General, 2012).
2.12.3. VHA OAT capacity. The VHA used a variety of initiatives to build OAT
capacity and increase access across the system, including: educational and quality
improvement initiatives; targeted funding; and national policy and clinical guidelines
(Wyse et al., 2018). In 2007, the VHA provided $300,000 to institutions without OTPs
but a high need for care (Gordon et al., 2011) and instituted a national buprenorphine
consult service, the Buprenorphine in the VA Initiative (Gellad, Good, & Shulkin, 2017).
In 2008, VHA national clinical guidelines outlined the “minimum clinical requirements”
to be provided in VHA facilities, which included OAT provision (Wyse et al., 2018). This
was the first time in VHA history that OAT was mentioned as an OUD clinical
requirement (Wyse et al., 2018). One year later, in 2009 (updated in 2015), the VHA
published the Clinical Practice Guidelines for the Treatment of Substance Use Disorders,
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which recommended OAT for OUD treatment (U.S. Department of Veterans Affairs,
2017b).
In spite of all these efforts, OAT is still underused in the VHA system even in the
midst of increasing need. The number of veterans with OUD increased between 2004 (n
= 30,093) (Oliva et al., 2013) and 2012 (n = 48,689) (Finlay et al., 2016). Recent data
from fiscal year 2017 reported that 54,000 VHA patients had an OUD diagnosis, 38% of
them received some pharmacotherapy (OAT or opioid antagonist), and the OAT facility
delivery performance ranged from 3% to 74% (Finlay et al., 2018). To date, however,
little is known specifically about hospital OAT care delivery processes in the VHA.
Research has focused on the receipt of OAT generally, and discussions of access to OAT
across the OUD care continuum have not occurred.
Section 2.13. OAT Delivery within the Hospital
This section highlights the need for hospital-based OAT delivery, how it can be
feasibly and effectively delivered, and the potential delivery constraints. To make this
argument, the presentation of evidence includes an overview of OUD-related
hospitalization trends, a review of hospital-based OUD treatment interventions, and a
synopsis of the potential external and internal supply-side attributes informing hospital
OAT delivery.
2.13.1. Utilization, costs, and outcomes. This sub-section describes the OUDrelated hospitalization utilization trends (e.g., national rates), health outcomes (e.g., inhospital mortality), hospital outcomes (e.g., leaving against medical advice), and
72

financial implications (e.g., elevated costs of OUD-related admissions). These analyses
depict the growth of OUD related admissions to support the assertion that hospitals are
an important part of the OAT delivery system.
2.13.1a. Utilization trends. Three descriptive analyses (Fingar et al., 2018; Weiss
et al., 2017a; Weiss et al., 2016) examined nationwide OUD-related hospitalization
trends using data from the Healthcare Cost and Utilization Project (HCUP) National
Inpatient Sample (NIS).1 Between 2005 and 2014 the national rate of OUD-related
hospitalizations increased 64% (Weiss et al., 2016). The national rate of inpatient stays
across U.S. states, for OUD-related admissions, averaged across 2013, 2014, and 2015,
was 217 per 100,000 people, a rate second to alcohol (558 per 100,000 people), and
ahead of cannabis (193 per 100,000 people) (Fingar et al., 2018). During this time
period, state-level rates for opioid-related admissions were highest for Maryland (411
per 100,000 people), West Virginia (201 per 100,00 people), and Massachusetts (373
per 100,000 people) (Fingar et al., 2018).
Specific trends across the population were observed for patient gender and
patient income quartile. In 2014, women had a higher rate of OUD-related inpatient
stays than men in nearly 75% of jurisdictions (i.e., states and the District of Columbia)
(Weiss et al., 2017a). In the same year, the OUD-related admission rates were highest
for patients with the lowest income (297 per 100,000) and were lowest for patients with

1

HCUP NIS is a database of hospital inpatient admissions from a nationally representative of
community hospitals, from all payers, and uses a hospital sampling frame comprising more than
95% of all U.S. discharges (Fingar et al., 2018; Weiss et al., 2017a; Weiss et al., 2016).
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the highest income (158 per 100,000) (Weiss et al., 2017b). In contrast, there was
variation in the highest rates of admission based on patient age and area of residence
(urban vs. rural) (Weiss et al., 2017a, 2017b).
2.13.1b. Costs. Using HCUP data, researchers estimated that OUD-related
hospitalizations in the U.S. cost $15 billion annually and that these costs increased over
time (Ronan & Herzig, 2016). Costs for OUD-related admissions and OUD-related
admissions with co-infection increased between 2002 and 2012 (Ronan & Herzig, 2016).
For OUD-related admissions without an infection, charges more than tripled from $4.6
billion in 2002 to $14.9 billion in 2012 (p < 0.001) and for patients with a co-occurring
infection the costs increased from $190.7 million in 2002 to $700.7 million in 2012 (p <
0.001) (Ronan & Herzig, 2016). In 2012, the estimated total charge per OUD-related
hospitalization was $28,543 and for OUD-related hospitalization with associated
infection, the cost was $107,217 (Ronan & Herzig, 2016). Similarly, an analysis of opioidassociated overdose admissions to the intensive care unit (ICU) between 2009 and 2015
using data from 162 hospitals in 44 states found the mean cost per ICU overdose
admission increased from $58,517 (2009) to $92,408 (2015), a 58% increase (p < 0.0001)
(Stevens et al., 2017).
Costs for OUD-related hospitalizations were higher and longer than non-OUD
related admissions. General hospital admissions had a mean length of stay of 4.5 days,
costing $10,400 per stay (Weiss & Elixhauser, 2014). OUD-related hospital admissions, in
comparison, were 15% longer (5.2 days) and nearly three times more expensive at
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$28,543 per stay (Ronan & Herzig, 2016). When patients with an OUD-related
concurrent infection (e.g., endocarditis) were hospitalized, the length of stay more than
tripled to 14.6 days with costs escalating more than ten times ($107,217 per stay)
(Ronan & Herzig, 2016).
Some of these costs may be due to the acuity of services received. The use of ICU
services for patients with opioid overdose increased between 2009 and 2015. Adjusting
for covariates, there was a 0.5% per month increase over the study period (RR, 1.005;
95% CI, 1.003 to 1.006; p < 0.0001) (Stevens et al., 2017). On average, approximately
10% of ICU overdose patients required mechanical ventilation, 7% required noninvasive
ventilation, 4% required vasopressors, and 6% required renal replacement (Stevens et
al., 2017).
The distribution of costs by payer for OUD-related hospitalizations
disproportionately burden public payers. An analysis of 2015 HCUP data found that 72%
of OUD admissions were paid for with public funds (Medicaid 40%; Medicare 32%)
(Weiss & Heslin, 2018). Between 2010 and 2015, the share of opioid-related inpatient
stays increased for public payers and decreased for private payers and the uninsured
(Weiss & Heslin, 2018). Ronan and Herzig (2016) also found that Medicaid was the most
common payer for patients with an OUD-related diagnosis code or any OUD-related
infection diagnosis code (i.e., endocarditis, osteomyelitis, septic arthritis, or epidural
abscess). In 2012, Medicaid covered 37% of all OUD-related admissions without
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infection and 43% of all admissions with OUD-related co-infections (Ronan & Herzig,
2016).
2.13.1c. Health outcomes. Persons with OUD-related hospital admissions have a
relatively low rate of in-hospital death, although the rates are increasing for persons
receiving higher levels of care. In 2012, 1% of OUD-related hospital admission patients
died and 3% of OUD-related co-infection admissions patients died (Ronan & Herzig,
2016). In the ICU, there was a significant increase in hospital deaths for opioid overdose
over time: in 2009 the average mortality was 7%; and increased to 10% by 2015
(Stevens et al., 2017).
The rates of in-hospital mortality for persons with OUD may depend on the type
of opioid used and the presence of a co-infection. An analysis of the HCUP data between
2001 and 2012 found that heroin overdose admissions were twice as likely to lead to inhospital death as compared to prescription opioid overdose admissions (Hsu, McCarthy,
Stevens, & Mukamal, 2017). In multivariate models studying OUD-related ICU
admissions, the number of hospitalizations with heroin overdose each month was
associated with an increase in the monthly mortality rate among ICU patients with OUDrelated overdoses (relative rate [RR] 1.25; 95% confidence interval [CI] [1.14, 1.37]; p <
0.001) and ICU admissions with an overdose during the summer were associated with
lower mortality (RR, 0.87; 95% CI [0.78, 0.97]; p = 0.012) (Stevens et al., 2017). Finally,
patients with an OUD-related hospitalization and an associated co-infection were more
likely to die than those without infection (Ronan & Herzig, 2016). These findings were
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observed at two time points: 2002 and 2012 (p < 0.001 for each comparison) (Ronan &
Herzig, 2016).
These analyses suggest that in-hospital mortality is a relatively rare event and
occurs at a stable rate for aggregated OUD-related admissions. The data also illustrates
that the use of heroin and the presence of a co-infection were associated with increased
risk of death. What is not captured is the mortality risk to patients withdrawn from
opioids or OAT upon discharge. Research in other settings found elevated mortality
during the first two-weeks following release from U.S. correctional facilities. In one
study, persons with drug use disorders had a three to eight times increased risk of drugrelated death (Merrall et al., 2010). No research to date has completed an assessment
of overdose risk upon discharge from the hospital setting. Thus, it is possible that inhospital mortality does not fully capture death risk related to OUD-related
hospitalizations.
2.13.1d. Sub-optimal and inappropriate care. For hospitalized patients suboptimal OUD care may be reflected by three indicators: 1) elevated rates of leaving
against medical advice; 2) low use of OAT during admission; and 3) low OAT use in the
30 days after hospital discharge. Inappropriate care may be reflected in the increased
use of short-acting opioids during and after admission.
In the 2012 HCUP data, 12% of patients admitted with an OUD-related condition
left against medical advice (AMA) (Ronan & Herzig, 2016). This rate is elevated when
compared to the 1% AMA rate for all cause admissions (Stranges et al., 2009). The top
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five diagnoses with the highest relative rate of leaving AMA included patients with a
primary diagnosis of: alcohol-related disorders (RR, 11.6), substance-related disorders
(RR, 10.8), nonspecific chest pain (RR, 3.6), diabetes with complications (RR, 2.7), and
mood disorders (RR, 1.9) (Stranges et al., 2009). High rates of leaving AMA may be a
proxy measure for hospital care quality, reflecting that patient’s physical and emotional
needs are not being met during hospitalization.
Limited research supports the assertion that OAT initiation and continuation is a
relatively rare event during OUD-related hospitalizations. In a ten-year (2004 to 2014)
retrospective chart review of hospitalized patients with injection drug use-associated
infective endocarditis in Boston, Massachusetts, OAT was documented in 11% of
admissions (n = 26) (Rosenthal et al., 2015). Upon closer review of the 26 admissions,
one patient was started on methadone, one was provided a phone number for an
outpatient buprenorphine clinic, and the other 24 patients were continued on their
previously initiated OAT-related treatments, none of which were arranged during their
hospitalization (Rosenthal et al., 2015).
Even the occurrence of serious OUD-related sentinel events—outpatient and
inpatient medical attention because of an overdose—does not dramatically increase
OAT provision upon hospital discharge. A retrospective analysis assessed the association
between prescription opioid overdose and post-overdose OAT provision using Medicaid
claims data from 2008 to 2013 in Pennsylvania (Frazier et al., 2017). Among patients
who survived a heroin overdose, there was a 1% increase in buprenorphine prescribing
78

(95% CI [-0.8, 2.9]; p = 0.27) and a 2% increase in admissions to methadone treatment
(95% CI [0.7, 3.8]; p = 0.005) (Frazier et al., 2017). For persons with a prescription opioid
overdose, the use of buprenorphine increased 1% (95% CI [0.5, 2.0]; p = 0.001) and
methadone use increased 0.1% (95% CI [-0.5, 0.7]; p = 0.75) (Frazier et al., 2017).
Similarly, the provision of OAT post-OUD related admission discharge for privately
insured persons was also low. An analysis of claims for privately insured adults with an
OUD-related diagnosis who were admitted to an acute care hospital or psychiatric
hospital found low rates of OAT within the first 30 days post-discharge: just one in six
patients (17%; n = 6,132) received an FDA-approved OUD treatment medication
(buprenorphine, methadone, naltrexone) and 35% (n = 12,852) did not have any
prescriptions filled upon discharge (Naeger, Ali, et al., 2016).
The use of short-acting opioids, instead of OAT, to manage OUD during
hospitalization is not explicitly described in the literature. A retrospective cohort study
of adult non-surgical hospital admissions from 286 U.S. non-federal acute care facilities
found that opioid exposure in the hospital was very common (51% of 1.1 million patient
admissions). The average opioid exposure in this sample was a mean daily morphine
milligram equivalent (MME) of 68 ± 185, and 23% of opioid exposed admissions had an
MME dosage greater than or equal to 100 (Herzig, Rothberg, Cheung, Ngo, &
Marcantonio, 2014). Moreover, there was substantial variation in opioid exposure
across hospitals, ranging from 5% of all admissions in a hospital to 72% of admissions
(Herzig et al., 2014).
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There is research, however, describing the inappropriate use of opioids in the
time period post-admission for patients with OUD (Larochelle et al., 2016; Naeger,
Mutter, et al., 2016). Naeger, Mutter, et al. (2016) observed that in the first 30 days
after discharge from an OUD-related hospital admission 22% (n = 8,225) of patients
filled a prescription for a non-OAT opioid pain medication, 14% of patients filled a
prescription for a benzodiazepine (n = 5,104), and 7% of patients (n = 2,717) filled a
prescription for a benzodiazepine and a non-OAT opioid. A retrospective cohort study
from May 2000 to December 2012, using the Optum claims database (a large private
U.S. health insurer with members in all 50 state), observed that 91% of patients with a
nonfatal opioid overdose who were receiving long-term opioid therapy prior to their
opioid overdose continued to receive non-OAT opioids after hospital discharge
(Larochelle et al., 2016).
2.13.2. Evidence for OUD treatment. This section summarizes a limited, but
growing evidence base of interventions to enhance services for patients hospitalized
with OUD. This narrative review includes a summary of the single clinical trial that exists
on hospital OAT delivery, a summary of published hospital practice checklists and
recommendations, and the retrospective and prospective evaluations of addiction
medicine consult (AMC) services.
2.13.2a. OAT initiation. A robust literature exists supporting OAT initiation and
long-term use in community-based settings, including specialty addiction facilities, OTPs,
and primary care clinics, but only one randomized control trial has been published
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assessing hospital-based OAT initiation (Liebschutz et al., 2014). The primary finding
from this study was that participants who initiated OAT (i.e., buprenorphine) while
hospitalized were more likely to engage in treatment post-discharge (Liebschutz et al.,
2014). Participants (n = 145) were randomized into either a detoxification protocol (i.e.,
a five-day buprenorphine taper) or a linkage protocol (i.e., buprenorphine induction,
stabilization and transition to a primary care clinic for continued) (Liebschutz et al.,
2014). Buprenorphine engagement, verified by medical record, and self-reported prior
30-day use of illicit opioids, was assessed at one, three, and six months (Liebschutz et
al., 2014). The linkage group was more likely to start buprenorphine (n = 52; 72%) than
those in the detoxification group (n = 8; 12%; p < 0.001). At six months, 12 linkage
participants (17%) and two detoxification participants (3%) were still receiving
buprenorphine (p = 0.007) (Liebschutz et al., 2014). Linkage participants reported less
illicit opioid use in the 30 days prior to the six-month follow-up interview (incidence rate
ratio [IRR] 0.60; 95% CI [0.46, 0.73]; p < 0.01) and linkage participants were more likely
to report no illicit opioid use (n = 24; 38% vs. n = 5; 9%) (Liebschutz et al., 2014). The
estimated OAT rate among linkage participants was almost 2.4 times higher throughout
the six-month study period (IRR, 2.44; 95% CI [1.99, 3.36]; p < 0.01) (Liebschutz et al.,
2014). Six participants died over the course of the study, and only one death was related
to drug overdose (Liebschutz et al., 2014).
2.13.2b. OUD treatment practice and delivery recommendations. There is a
growing collection of published narrative reviews and clinical checklists on service
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delivery for hospitalized patients with OUD and other SUDs (Noska et al., 2015; Sharma
et al., 2017; Thakarar et al., 2016; Theisen-Toupal et al., 2017; Weinstein et al., 2018)
and federal guidance documents (SAMHSA, Institute of Medicine Committee on Federal
Regulation of Methadone, 1995; 2018). The reviews and checklists suggest the
implementation of a variety of interventions for patients (i.e., psychosocial, medical, and
harm reduction) and for systems (e.g., AMC services and education on addiction and
stigma for health professionals), summarized in Table 2.1. The federal guidance
documents recommend hospital OAT delivery.

82

Table 2.1. Summary of Narrative Review Recommendations for Hospital-Based Treatment of OUD
Authors
TheisenToupal et
al. (2017)

Thakarar
et al.
(2016)

Psychosocial
• Involve social work
• Involve case
management

• Collaborate with
mental health
service providers
• Provide case
management for
supportive services

Patient-Level Interventions
Medical
• Manage opioid withdrawal
• Initiate OAT or antagonist therapy
• Treatment of special populations
(e.g., acute pain/breastfeeding)
• Discharge checklist
• Conduct addiction history
• Assess treatment readiness
• Provide treatment options (OAT or
antagonist therapy)

Sharma et
al. (2017)

Future Research Directions
• Optimal use of peripherally
inserted central venous catheters
• Treatment contracts
• Inpatient supervised injection
services

Noska et
al. (2015)

• Establish OUD diagnosis
• Manage opioid withdrawal
• Initiate OAT and linkage to care

Weinstein
et al.
(2018)

• Referral and linkage

• Addiction history
• Physical examination/laboratory
tests
• Withdrawal management
• Long-term medication titration

System-Level Interventions
Harm Reduction
• Provide opioid overdose
education
• Provide safer injection
education

• Partnerships between hospitals and
outpatient addiction treatment
facilities

• Provide opioid overdose
prevention
• Provide infection prevention

• Implement the checklist

Implementation Research
• Provide injectable
diacetylmorphine
• Provide sterile drug use
equipment.
• Future harm reduction

For Immediate Implementation
• Establishment of AMC service
• Education for health professionals on
stigma and addiction
Implementation Research
• Care retention and continuity at
discharge
• Educate providers on federal, state,
and hospital policies
• Educate providers on medications
available to treat opioid withdrawal
• Establishment of AMC service

• Provide opioid overdose
education
• Provide safer injection
education
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Federal guidance documents from SAMHSA (SAMHSA, 2018) and the Institute of
Medicine (Institute of Medicine Committee on Federal Regulation of Methadone, 1995)
describe the most effective approaches to hospital OAT delivery. The SAMHSA
document dedicated an entire chapter to the “Medical Management of Patients Taking
OUD Medications in Hospital Settings” (SAMHSA, 2018, pp. 3-99). The recommendations
for effective care for patients with OUD who are hospitalized include balancing OUD
pharmacotherapy with other medical concerns, careful management after discharge,
and seamless transfer to OAT upon discharge (e.g., either OTP or non-OTP) (SAMHSA,
2018). The document included clinical management guidance for initiating and
continuing OAT during admission (SAMHSA, 2018).
The 1995 Institute of Medicine provided six recommendations on how to care
for patients already on methadone during an inpatient admission (Institute of Medicine
Committee on Federal Regulation of Methadone, 1995):
•

Hospital staff should notify the OTP, confirm enrollment, and verify methadone
dose, and time and date of last dose;

•

Hospital staff should ensure the continuity of methadone pharmacotherapy
through the hospital's pharmacy or make arrangement for its supply through the
OTP in the event that the hospital does not stock methadone;

•

Hospital staff should be prohibited from reducing or denying the methadone
dose;
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•

Any changes in methadone dose should be made only after consultation with the
OTP physician and with the informed consent of the patient;

•

Before discharge, the hospital staff should notify the OTP of the time and
amount of last dose of methadone to ensure that outpatient treatment resumes
without interruption; and

•

If patients are discharged from acute care to continuing care facilities,
arrangements for continued provision of methadone should be part of the
discharge plan.

The committee also recommended that rule-making agencies modify the federal
regulations to allow hospitals to continue to provide methadone if the patient is unable
to get into an OTP or if they need to complete a methadone taper (Institute of Medicine
Committee on Federal Regulation of Methadone, 1995).
2.13.2c. The AMC services. A growing literature base suggests that the AMC
service is an effective health services delivery intervention. The literature on AMCs,
however, should be interpreted conservatively because it is comprised of non-blinded
and non-randomized prospective (Trowbridge et al., 2017; Wakeman et al., 2017) and
retrospective studies (Nordeck et al., 2018; Suzuki, 2016).
Two prospective AMC service evaluation studies found that patients who
received AMC services had an increased number of drug free days post-discharge,
compared with those who did not (Wakeman et al., 2017), and that hospital OAT
initiation was possible (Trowbridge et al., 2017).
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A prospective quasi-experimental evaluation at an urban academic hospital in
the northeast compared 30-day post-discharge outcomes between hospitalized
participants who received or did not receive an AMC service (Wakeman et al., 2017).
The AMC service intervention included a multidisciplinary team offering
pharmacotherapy initiation, motivational counseling, treatment planning, and direct
linkage to external addiction treatment resources (Wakeman et al., 2017). The majority
of patients (61%) had an OUD-related diagnosis (Wakeman et al., 2017). In this nonrandomized intervention, patients who received an addiction consult, compared to
those who did not, had a mean drug Addiction Severity Index decrease pre-and post (p =
0.003) and increased days of abstinence at 30-day follow-up (+12.7 days vs. +5.6; p <
0.001) (Wakeman et al., 2017).
A prospective evaluation at Boston Medical Center assessed the process and
care delivery measures of an AMC service (Trowbridge et al., 2017). Over a 26-week
period the AMC service completed 337 of 367 requested consults for 319 unique
patients; of those 78% were for persons with an OUD (n = 264) (Trowbridge et al., 2017).
For those with OUD, methadone was initiated in 27% of patients (n = 70) and
buprenorphine was initiated in 15% of patients (n = 40), with 42% of patients with OUD
initiated on OAT (Trowbridge et al., 2017). Of those initiated on methadone, 76% were
linked to methadone clinics and for buprenorphine, 49% were linked to a clinic
(Trowbridge et al., 2017). Researchers observed that OAT initiation was feasible in the
hospital setting; however, effectively linking and retaining patients in post-discharge
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addiction care was challenging, warranting future program development (Trowbridge et
al., 2017).
The two retrospective AMC service studies found that most patients were
interested in receiving AMC services (Nordeck et al., 2018; Suzuki, 2016). The University
of Maryland Medical Center SUD consultation liaison service—operational for over
three decades with an interprofessional team of a psychiatrist director, two part-time
addiction-boarded psychiatrists, a licensed addiction counselor, a licensed social worker,
nurses, and medical trainees—reported service delivery for 267 patients (Nordeck et al.,
2018). A majority (57%) had a current OUD diagnosis (n = 152) and OAT with
buprenorphine or methadone was initiated for 14%. Within patients with OUD who
were referred to an affiliated program during hospitalization (n = 45), 42% of patients
who initiated hospital OAT kept their intake appointment (Nordeck et al., 2018). A final
observation was that only 10% of patients expressed no interest in treatment or refused
a formal consultation (Nordeck et al., 2018); indicating, that hospitalization was a
reachable moment.
A retrospective chart review examined the health records for patients with OUDrelated admissions and infective endocarditis who received AMC services between May
2013 and July 2015 (Suzuki, 2016). Twenty-nine patients were admitted for the
treatment of infective endocarditis secondary to associated intravenous drug and had a
request for an addiction psychiatry consultation (Suzuki, 2016). All patients were
evaluated to initiate OAT, efforts were made to find community-based prescribers to
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continue treatment, and patients were encouraged to have an initial appointment
established prior to discharge (Suzuki, 2016). The majority (72%) of hospitalized patients
in this cohort had previous experience with OAT. Almost two-thirds (62%) of patients
accepted and received OAT (n = 18), of those, half initiated buprenorphine and half
initiated methadone maintenance (Suzuki, 2016).
2.12.3. External supply-side attributes. External influencers on hospital OAT
delivery are essentially unstudied. This section is a summary of potential external
attributes that may facilitate or impede hospital OAT delivery, such as third-party payer
policies (e.g., pharmacy benefit management strategies) and federal regulations.
2.12.3a. Payer policies. Payer policies may contribute to limited hospital OAT
access, although most of hospital billing occurs through bundled payments. Limitations
imposed by third-party payers on OAT in the outpatient setting may constrain services
delivered in the hospital setting, particularly when starting people on OAT during
hospitalization (Hassamal et al., 2017).
OAT insurance barriers are well-described for public and private third-party
payers. Medicaid, the most common payer for OUD-related hospitalizations (Weiss &
Heslin, 2018) imposes a variety of pharmacy benefit management strategies for OAT
(i.e., prior authorization, quantity limits, and lifetime limits). In an analysis of Medicaid
Preferred Drug Lists (2011 to 2013), 31 State Medicaid agencies covered methadone
and all 50 Medicaid agencies covered buprenorphine (SAMHSA, 2014). However, 48
Medicaid programs required prior authorization for buprenorphine and 21 programs
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required evidence that the patient was receiving psychosocial addiction services
(SAMHSA, 2014). Further, 34 Medicaid programs had buprenorphine quantity limits and
some states had lifetime treatment limits. Four jurisdictions (District of Columbia,
Illinois, Michigan, and Washington) established a one-year limit, six states (Arkansas,
Maine, Mississippi, Montana, Virginia, and Wyoming) established a two-year treatment
limit, and one state (Utah) established a three-year treatment limit (SAMHSA, 2014).
Like Medicaid, Medicare coverage of OAT is restrictive. Methadone was not an
allowable service until the recent passage of the 2018 SUPPORT for Patients and
Communities Act, and coverage restrictions for buprenorphine are common (Hartung et
al., 2019). From 2007 to 2018, Medicare coverage for Suboxone® and Subutex® branded
buprenorphine/naloxone tablets and films declined by 25%, going from 100% plan
coverage (n = 3,281) to 74% (n = 2,873) (Hartung et al., 2019). Moreover, among plans
offering coverage, prior authorization requirements for branded buprenorphine/
naloxone increased from 16% in 2007 to 58% in 2018. In 2018, moreover, 57% of plans
required prior authorization for generic buprenorphine/naloxone sublingual tablets
(Hartung et al., 2019). The proportion of plans covering any buprenorphine product
without any restriction declined from 89% to 35% in this same time period (Hartung et
al., 2019).
Private payers, follow public payer practice, limiting OAT access through
pharmacy benefit management strategies (Reif et al., 2016). In an analysis of 8,427 plans
in the 2010 benefit year, 100% of the plans had buprenorphine coverage but 40% had
89

prior authorization requirements, and only 41% of plans covered methadone for OUD
(Reif et al., 2016).
2.12.3b. Federal regulations. It is possible that confusion about federal
regulations may contribute to limited hospital OAT access. In 2002, the DEA director
addressed provider uncertainty in a letter reminding hospital providers that it is legal to
administer OAT during hospitalization (Nagel, 2002). The regulations in 21 CFR 1306.07
sub-section (b) state:
(b): Nothing in this section shall prohibit a physician who is not specifically
registered to conduct a narcotic treatment program from administering (but not
prescribing) narcotic drugs to a person for the purpose of relieving acute
withdrawal symptoms when necessary while arrangements are being made for
referral for treatment. Not more than one day's medication may be administered
to the person or for the person's use at one time. Such emergency treatment may
be carried out for not more than three days and may not be renewed or
extended. (DEA, 2005)
These regulations, known as the three-day rule or 72-hour rule, allow hospital providers
without a buprenorphine waiver or OTP facility designation, to administer OAT for 72
hours for patients who have a primary diagnosis of opioid withdrawal. If a patient is
discharged with a buprenorphine bridge script, a provider with a buprenorphine waiver
must issue that prescription. Further, if the provider has a buprenorphine waiver, they
could continue to administer buprenorphine for more than 72 hours as needed.
The second part of the rule allows for unconstrained OAT or other non-FDA
opioid administration for hospital providers without a buprenorphine waiver or OTP
facility designation for patients who are hospitalized with a non-withdrawal primary
diagnosis (e.g., opioid withdrawal in the setting of a hospital admission for pneumonia):
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(c): This section is not intended to impose any limitations on a physician or
authorized hospital staff to administer or dispense narcotic drugs in a hospital to
maintain or detoxify a person as an incidental adjunct to medical or surgical
treatment of conditions other than addiction, or to administer or dispense
narcotic drugs to persons with intractable pain in which no relief or cure is
possible or none has been found after reasonable efforts. (DEA, 2005)
This policy is nuanced, but sub-sections b and c in 21 CFR 1306.07 explicitly state
that federal law allows for the continuation and initiation of OAT in the hospital setting
within certain parameters. It is possible that this policy constrains hospital OAT delivery,
Hassamal et al. (2017) described provider concerns about DEA audits. Other federal
policies that may constrain hospital OAT delivery include the buprenorphine patient
panel limits and the administrative requirements of the special regulatory system, which
has been described elsewhere in this dissertation (Sections 2.5 and 2.11).
2.13.4. Internal supply-side attributes. A limited literature (Hassamal et al.,
2017; Velez et al., 2017) characterizes the constraints within the hospital environment
on OAT delivery. This section is a summary of this literature and includes proposed
internal attributes that may facilitate or impede hospital OAT delivery including hospital
providers and hospital structures.
2.13.4a. Hospital providers. Hassamal et al. (2017), through a clinical case study
and narrative literature review, describe potential OAT delivery barriers imposed by
hospital providers, specifically, provider knowledge deficits (e.g., concerns about OAT
misuse, lack or training), and stigmatizing behavior by providers towards patients with
OUD. Further, from the patient perspective, qualitative research suggests that patients
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would benefit from the inclusion of other non-traditional types of providers in the
hospital setting, such as peer support providers (Velez et al., 2017).
2.13.4b. Hospital attributes. Hassamal et al. (2017) also discussed how hospital
organizational attributes likely inhibit hospital OAT delivery including concerns about
outside perceptions (e.g., worried about attracting too many OUD patients), a lack of
support staff and institutional support, frequent laboratory testing, and inadequate
referral networks. Patients described hospitalizations as a limited context for treating
addiction-related issues because hospitalizations generally do not address life stressors,
trauma, or basic needs (Velez et al., 2017).
Other internal hospital delivery structures that may influence hospital OAT
delivery are the hospital formulary governance body (the Pharmacy & Therapeutics
Committee [P&T]) and other OAT-related hospital policies, procedures, and guidelines.
The P&T committee manages the hospital formulary system (American Society of
Health-System Pharmacists [ASHSP], 2008). Formulary system management is a process
for making hospital-wide pharmaceutical and therapeutic policies (ASHP, 2000). A
formulary—a document created and maintained by the P&T committee—includes
medications, devices, medication-use policies, decision support tools, ancillary drug
information, and organizational guidelines (ASHP, 2008). P&T committees include
clinicians (e.g., physicians, pharmacists, nurses) and hospital administrators. The
committee’s decision-making authority is generally outlined in organizational bylaws,
medical staff rules, and regulations specific to each hospital or health system (ASHP,
92

2008). Formulary decisions should include the consideration of patient care and an
unbiased literature review (ASHP, 2008), including the assessments of the
pharmaceutical evidence-base and pharmaco-economic literature (M. Hoffmann, 2013).
The existence of P&T committees is nearly universal in hospitals around the
world (Durán-García, Santos-Ramos, Puigventos-Latorre, & Ortega, 2011). In the U.S.,
the Joint Commission, the primary hospital accrediting body, requires a hospital P&T
committee (Balu, Connor, & Vogenberg, 2004). P&T committee outputs may include
policy statements, procedures, and guidelines that provide guidance on service delivery
within the hospital (O’Donnell & Vogenberg, 2012). These documents are commonly
created because of accreditation requirements and, to avoid litigation, align hospital
services with the standard of practice for reasonable and prudent hospital pharmacists
(O’Donnell & Vogenberg, 2012).
2.13.5. Summary. Interest is growing, and the literature base is expanding, to
support the assertion that hospital OAT delivery is needed, feasible, and effective. OUDrelated hospital admissions and costs are increasing. Communicating and framing
hospital OAT delivery as a supply-side issue may help motivate hospitals and health
services administrators to support hospital OAT delivery because people with OUD are
publicly insured or uninsured. Keeping patients with OUD from readmission by providing
evidence-based OAT during and after hospitalization could benefit the hospital
financially in the long-term.
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Although, comparative-effectiveness research examining the best way to design
AMC services has not yet occurred, it seems likely that AMC services are feasible to
implement and effective in providing evidence-based services. Further, it is possible that
unexplored internal hospital attributes may influence hospital OAT delivery such as the
OAT-related decisions made by members of the P&T committee or the adoption of
hospital guidelines.
There is limited evidence to suggest that elements within the hospital and
outside the hospital contribute to hospital OAT delivery. Outside the hospital potential
external attributes that may impede hospital OAT delivery are third-party payer policies
(e.g., pharmacy benefit management strategies) and federal regulations, specific to
hospital delivery, and more broadly, the special OAT regulatory system. Within the
hospital potential internal attributes informing hospital OAT delivery include the
behavior and training of hospital providers and hospital structures. This dissertation
aims to explore these issues and other unidentified facilitating and constraining
elements.
Section 2.14. Development of the Conceptual Framework: Synthesis of the Literature
This section synthesizes the reviewed literature to support the underlying
premise of this dissertation that OAT provision is influenced by a complex array of
dynamically related supply-side factors, external and internal to the hospital (see Table
2.2).
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Table 2.2. Literature Reviewed
Scholarship
Domain
Medical
Sociology

Policy Process

Organization
Behavior

System Science

Economics

Health Services
Delivery

Theory, Model, Framework
• Social Construction Theory (Bacchi, 2012; Brown, 1995; Reinarman & Granfield,
2014; Rosenberg, 1989)
• Moral Model (Boyd et al., 2016; Reinarman & Granfield, 2014; Valverde, 1998)
• Disease Model (Boyd et al., 2016; Reinarman & Granfield, 2014; J. Schneider,
2014)
• Multi Model (Kovac, 2014; Reinarman & Granfield, 2014)
• The Social Construction Framework (Ingram & Schneider, 1990, 1991; A. L.
Schneider & Ingram, 1988, 1993)
• Policy Feedback Theory (Pierson, 1993; Skocpol, 1992)
• Comparative Drug Policy Analytic Framework (MacCoun et al., 1993)
• Drug Policy Regimes (Babor et al., 2010)
• Elements of Leavitt’s Diamond (Berger & Luckmann, 1966; Chaffee, 1985;
Chandler, 1962; Davis, 1949; Galbraith, 1982; Giddens, 1979; Hillman et al., 2009;
Homans, 1950; Kinicki & Kreitner, 2009; Leavitt, 1962; Ostroff et al., 2003; Pfeffer
& Salancik, 1978; Scott, 2003; Weick, 1995)
• Institutional Theory (DiMaggio & Powell, 1983)
• Sociotechnical Organizations (DiMaggio & Powell, 1991; Katz & Kahn, 1978; Scott,
2003; Scott & Meyer, 1991; Thompson, 1967)
• Multilevel Attributes (Andersen et al., 2013; Basole & Rouse, 2008; Covaleski et
al., 1993; Fanjiang et al., 2005; Ferlie & Shortell, 2001; Goodrick & Salancik, 1996;
Levesque et al., 2013; Lipsitz, 2012; Perrow, 1986; Ruef & Scott, 1998; Sallis et al.,
2015)
• Complex Adaptive System Theory (Lipsitz, 2012; Plsek & Greenhalgh, 2001)
• Agency Theory (Alchian & Demsetz, 1972; Eisenhardt, 1989; Jensen & Meckling,
1976; Perrow, 1986; Zeckhauser & Pratt, 1985)
• Neo-Classical Economic Principles (Feldstein, 2005; Friedman, 2002; Perrow, 1986)
• Transaction Cost Theory (Williamson, 1979, 1985, 1994; Williamson & Ouchi,
1981)
• Rational Actor Model (Allison & Zelikow, 1999; Simon, 1985)
• Health Care Access Framework (Levesque et al., 2013)

2.14.1. Study principles. There are four foundational principles that support the
study rationale and the development of the conceptual framework. First, the social
construction (Brown, 1995; Rosenberg, 1989) of opioids and OUD is a meta-influencer of
external and internal environmental attributes. Second, a hospital is a sociotechnical
(DiMaggio & Powell, 1991; Katz & Kahn, 1978; Scott & Meyer, 1991; Thompson, 1967),
complex adaptive (Plsek & Greenhalgh, 2001), economic production system that exists
as a functional unit (Lipsitz, 2012) within the nested context of a broader environment
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(Basole & Rouse, 2008; Ferlie & Shortell, 2001; Perrow, 1986; Sallis et al., 2015). Third,
an inherent property of this type of system is the influence of external and internal
environmental factors (Katz & Kahn, 1978; Plsek & Greenhalgh, 2001; Scott, 2003). The
environment, inside and outside the hospital, includes the physical, technological,
cultural, and social milieu (Scott & Davis, 2015), and policy, which is frequently both a
product and an influencer of social phenomena (Ingram & Schneider, 1990, 1991;
MacCoun et al., 1993; Pierson, 1993; A. L. Schneider & Ingram, 1988, 1993; Skocpol,
1992). Fourth, hospitals are considered to be rational unitary decision-making bodies
that select actions with the highest payoff after ranking and understanding the
consequences (Allison & Zelikow, 1999; Simon, 1985). This perspective suggests a
hospital’s decision to provide OAT reflects strategic goals, organizational objectives, and
a value-maximizing activity (Allison & Zelikow, 1999; Simon, 1985). The rational actor
model application is limited in this context because within the hospital environment
there are sub-systems of internal stakeholders (e.g., providers, staff, patients) and
external stakeholders (e.g., payers, regulatory bodies, community, government,
industry); thus, the ability of a hospital to behave strategically to produce valuemaximizing decisions is in constant tension with the values and needs of stakeholders.
2.14.2. Supply-side focus. The study’s focus on the supply-side versus demandside is because demand-side factors may have a smaller contribution for this specific
care delivery setting: a) hospitalized persons with OUD will physiologically experience
the need for opioids and seek opioids to prevent withdrawal symptoms; b) the patient
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can receive OAT in the hospital only if the hospital provides it; and c) OUD patients
generally do not choose which hospital they are admitted to.
2.14.3. Conceptual framework. The four foundational study principles and the
literature review provide the scaffolding of the study’s conceptual framework and how
the study is operationalized. The conceptual framework (see Figure 2.1) depicts the
interactions, contributions, and feedback among the nested layers of supply-side
attributes, inside and outside the hospital, on hospital service delivery, outcomes, and
demand-side attributes. The elements existing within each nested layer dynamically
interact across levels shaping and modifying OAT service delivery over time. The
culmination of these complex interactions results in hospital OAT service delivery, and
the subsequent clinical and utilization outcomes. The clinical and utilization outcomes,
in turn, influence the nested supply-side attributes through feedback. The categories are
interdependent and overlapping in nature.
2.14.3a. Defining hospital OAT delivery. There are few clinical scenarios that
would prohibit OAT initiation or continuation for the treatment of OUD in the hospital.
Clinical experts and the peer-reviewed literature described potential OAT care delivery
scenarios as: 1) starting OAT in the hospital; 2) continuing OAT in the hospital; and 3)
linking patients to OAT upon discharge. Part of the exploratory component of this study
required further defining these care delivery scenarios, and the discovery of others.
2.14.3b. Internal hospital elements. Categories of potential hospital supply-side
attributes include: 1) physical structure (e.g., urban vs. rural); 2) social structures (e.g.
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organizational culture); and 3) technology and resources (e.g., polices, regulations, and
procedure; and resources and staffing).
A hospital’s physical location may affect OAT delivery. Physical location may
mediate hospital characteristics and processes such as hours of operation, the ability of
the hospital to match the needs of the patient, and the availability of treatment
(Levesque et al., 2013). Elements within the proximal physical environment, such as the
urbanicity or rurality, or being located in an area with elevated or lower opioid
overdose, or the proximity to other hospitals providing addiction related services, could
also influence hospital OAT delivery (DiMaggio & Powell, 1983). Other hospital
attributes such as size and status as a teaching hospital affect quality of care (Keeler et
al., 1992).
Hospital social structures could influence OAT delivery (e.g., the organizational
values, norms, and role expectations) (Davis, 1949; Scott, 2003). Social structures may
also inform hospital resource allocation. Deciding to invest, or not invest, in addictionrelated treatment technologies within the hospital is based, in part, by the alignment of
this investment with current organizational strategic goals, objectives, and the
determination that this is a value-maximizing activity for the hospital (Allison & Zelikow,
1999; Simon, 1985). Another component of social structures, influencing care delivery, is
the shared cultural-cognitive elements among hospital staff (Berger & Luckmann, 1966;
Scott, 2003; Weick, 1995). For example, a hospital that collectively believes in the social
construction of addiction as a moral or criminal issue may be more likely to hire health
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professionals with similar beliefs, and could be less likely to provide evidence-based
OAT. In contrast, a hospital with a shared philosophy across staff that addiction is a
brain disease may be more likely to hire professionals with shared beliefs, and increase
the likelihood of providing evidence-based OAT.
Differences in organizational structures of practice may also change delivery (De
Jong, 2008). Hospital technologies, in this context, include dedicated resources, staffing,
and internal policies and regulations. The existence, or lack thereof, of these attributes
could influence hospital OAT delivery. Staffing technologies of interest include the
existence of specific staffing structures and models of care for patients with OUD (e.g.,
AMC services to deliver care for patients with OUD), the availability of addiction trained
specialists (e.g., board-certified addiction medicine physicians), and graduate medical
education training programs (e.g., addiction medicine fellowships). Other internal
resources that may influence care include access to OAT on the hospital formulary and
the existence of hospital policies that either enhance or constrain this practice.
2.14.3c. Elements outside the hospital. Domains of potential hospital supplyside attributes external to the hospital include: 1) social structures; 2) the influence of
other hospitals; 3) polices and regulations; and 4) economic factors.
The cultural and social contexts outside the hospital environment are also likely
to influence hospital OAT delivery through communities’ professional values, norms,
culture, and gender of the health professionals (Levesque et al., 2013; Scott, 2003). The
training and socialization of health professionals largely occurs, at least at the start of
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employment, from outside the employing hospital (Scott & Davis, 2015). Health care
professionals who trained during in a different era may not know that hospital OAT
delivery is evidence-based practice or that only treating withdrawal symptoms is not
sufficient care. In contrast, a hospital staffed with health care professionals who are
knowledgeable about OUD treatment may be more likely to provide hospital OAT. It is
also likely that internal hospital cultural-cognitive elements (Berger & Luckmann, 1966;
Scott, 2003; Weick, 1995), such as how OUD is conceptualized (moral model vs. brain
disease model), are informed by the external environment either through public
discourse (e.g., the media) and values, or the narratives espoused by external health
professional training programs or organizations (e.g., the Joint Commission).
Informal and formal coercive isomorphic pressures from other organizations may
influence hospital OAT delivery (e.g., the government, influential organizations)
(DiMaggio & Powell, 1983). Other potentially influential elements in the external
environment (e.g., coercive policies) drive isomorphic hospital behavior (DiMaggio &
Powell, 1983). Moreover, institutional theory (DiMaggio & Powell, 1983) posits that
hospitals attempt to mimic each other; thus, hospital OAT delivery could become
acceptable practice through this process. The proximity to other hospitals is also
relevant because few organizations create their own technologies (Scott & Davis, 2015).
Further, other organizations such as third-party contract enforcers (North, 1990;
Zeckhauser & Pratt, 1985) could influence hospital OAT delivery. Third-party contract
enforcers could be patient-derived (e.g., addiction advocacy groups), non-governmental
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regulatory bodies (e.g., the Joint Commission), governmental regulatory bodies (e.g.,
CMS), local and state regulatory bodies (e.g., licensing boards), and professional
associations (e.g., ASAM). These groups could influence hospital behavior because they
bring their own values and preferences to the contractual relationship (North, 1990;
Zeckhauser & Pratt, 1985).
External polices and regulations that affect treatment access through planning,
financing, and monitoring of addiction services, as well as the development of the
professional workforce, are likely to influence hospital OAT delivery (Klingemann et al.,
1993; Klingemann & Klingemann, 1999). Influential policies include federal treatment
regulations that govern allowable treatment in the hospital setting (e.g., the 72-hour
rule), or more broadly the special regulatory framework dictating OAT delivery (e.g.,
OTPs).
Beyond federal regulations, policies created by non-governmental organizations
could influence care. Organizations such as the Joint Commission may enhance or deter
hospital OAT delivery through the creation of policies. In 2008, the Joint Commission
received funding to develop, specify, and test performance measures addressing alcohol
screening and pharmacotherapy for persons with SUDs, including OUD (Joint
Commission, 2015). The Joint Commission has the authority to mandate the inclusion of
these measures or the requirement of addiction trained staff as part of hospital
accreditation. At present, there is a lack of external coercive policies and pressures from
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external organizations to mandate hospitals to deliver OAT (e.g., the Joint Commission
mandating delivery of OAT in the hospital setting).
Another important policy domain is the third-party payer coverage policies that
increase barriers to OAT access in the community setting and that potentially constrain
hospital care. Public and private payers commonly impose pharmacy benefit
management strategies on OAT and, as is the case for methadone, more commonly do
not provide reimbursement (Hartung et al., 2019; Reif et al., 2016; SAMHSA, 2014).
External market forces may also influence hospital OAT delivery. Interestingly,
from a supply-demand perspective, OAT is a service that promotes the best value for
the patient (i.e., the demand) but it is still largely unavailable in the hospital setting (i.e.
the supply). A mismatch between supply and demand means that OAT is an
economically inefficient good because neither the supplier (e.g., the hospital) nor the
demander (e.g., the patient) fully benefits. This discrepancy may be due to hospital
reliance on contracts with external third-party payers that do not financially reward
hospitals for OAT delivery.
2.14.4. Summary. The final product of this chapter is the conceptual framework
(see Figure 2.1), which depicts the complex nature of hospital OAT delivery between the
supply-side (i.e., the hospital, the broader environment) and the demand-side (i.e.,
patient demographics). The conceptual framework supported the study’s rationale,
design, analyses, and conclusions.
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Figure 2.1. Original Conceptual Framework

103

Section 2.15. Conclusion
In an era of increased OUD prevalence and care delivery in the hospital, there is
an urgency to study and improve care delivery in this setting as part of the broader
pathway for persons with OUD. The literature review described, summarized, and
synthesized an interdisciplinary body of literature to support the research on hospital
OAT delivery, and how this phenomenon is likely influenced by complex interrelated
internal and external attributes. In the next chapter, Chapter 3, the study methodology
is described.
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Chapter 3: Methods
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., &
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose
epidemic: The addiction medicine consult service. Journal of Addiction Medicine,
Advance online publication. doi: 10.1097/ADM.0000000000000496.
Chapter 3 describes the research approach used for exploring how supply-side
attributes are associated with hospital opioid agonist therapy (OAT) delivery for patients
with opioid use disorder (OUD). Complex social phenomena, such as health services
delivery, required a mixed methods approach, using both qualitative and quantitative
data and analyses to illuminate relationships and balance methodologic limitations. The
chapter is organized in six sections:
1. Section 3.1 restates and operationalizes the elements within the core
research question.
2. Section 3.2 outlines the three specific aims, the 16 research sub-questions,
and study design.
3. Section 3.3 justifies the research approach and outlines the study
assumptions.
4. Section 3.4 provides an overview of the human subjects protections.
5. Section 3.5 describes the qualitative analytic approach for Aim 1.
6. Section 3.6 describes the quantitative analytic approach for Aims 2 and 3.
7. Section 3.7 presents the chapter’s conclusions.
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Section 3.1. Research Question
The interdisciplinary theoretical literature review and the Levesque Health Care
Access Framework (Levesque et al., 2013) guided the creation of the study’s core
research question: How do supply-side attributes influence hospital OAT delivery, health
outcomes, and health services utilization for persons hospitalized with OUD?
Supply-side attributes refer to the contextual elements inside and outside a
hospital that may be associated with hospital OAT delivery performance. Attributes of
interest include hospital structural characteristics (e.g., size), social structures (e.g.,
organizational culture and values), and external attributes (e.g., local and federal
policies, and the behavior of other hospitals). Service delivery in the hospital is
predominantly dictated by the availability of hospital resources. For example, if a
hospital does not have OAT on the formulary, or stocked in the inpatient pharmacy, a
hospitalized patient cannot access OAT. The patient’s perspective on hospital OAT
delivery was not directly addressed and is a study limitation. As proxies for patientinformed data, the study assessed the influence of demand-side attributes using the
qualitative and quantitative data. Key informants discussed their perceived barriers for
patients (i.e., the demand-side), and the Veterans Health Administration (VHA) data
included demographic information (e.g., patient age) and characteristics about the
admission (e.g., length of stay).
The three categories of outcomes for this study were hospital OAT delivery (e.g.,
OAT receipt during hospitalization), clinical outcomes (e.g., in-hospital mortality), and
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post-admission health services utilization (e.g., hospital readmission, emergency
department visits, and OAT receipt). Table 3.1 defines and operationalizes the
overarching research question and the method and data source for each element.
Table 3.1. Primary Research Question Operationalized
Concept
Supply-Side Attributes
Inside the Hospital

Outside the Hospital
Outcomes
Hospital OAT Delivery

Admission
Post-Admission

Definition

Method &
Data Source

Social structures (e.g., hospital standards of
care), technology and resources (e.g., hospital
policies), patient population (e.g., OUD patient
volume), and physical structure (e.g.,
geographic location)
Social structures (e.g., behavior of other
organizations) and technology and resources
(e.g., treatment policies)

Quantitative
Qualitative

Hospital OAT delivery during an OUD-related
admission, further specified by care delivery
mechanism: OAT continued, OAT
initiation/linkage; OAT sustained; OAT
withdrawal
In-hospital mortality; leaving against medical
advice
Events in the 30 days after discharge: Death;
readmission; emergency department visit; and
OAT receipt

Quantitative

Qualitative

Quantitative
Quantitative

Section 3.2. Study Design, Specific Aims, and Research Sub-Questions
An integrated mixed method sequential explanatory research design with three
aims investigated the contributions of multilevel supply-side attributes on hospital OAT
delivery. Aim 1 is the qualitative portion of the study and Aims 2 and 3 rely upon the
quantitative data (see Figure 3.1).
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Figure 3.1. Study Design Diagram
A directed content analysis (Aim 1) of 17 key informant interview transcripts
from 16 non-VHA hospitals and a framework analysis of 25 hospital guidance documents
from 10 non-VHA hospitals examined how addiction medicine experts and their
hospitals delivered OAT for patients with OUD. The study concluded with analyses of
two quantitative aims (Aims 2 and 3) using administrative data from a retrospective
national sample of patients hospitalized with OUD within the VHA system, fiscal year
2017. The study’s three aims and 16 research sub-questions are presented below:
Aim 1: Examine the influence of supply-side attributes inside and outside of non-VHA
hospitals that shape hospital OAT delivery.
•

Q1a: How is OAT delivered for patients with OUD in the hospital setting?

•

Q1b: Which internal and external environmental supply-side elements
facilitate hospital OAT delivery?

•

Q1c: Which internal and external environmental supply-side elements
impede hospital OAT delivery?

•

Q1d: How do hospital policies and guidance documents inform hospital OAT
delivery?
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Aim 2: Describe and test variation in VHA hospital OAT delivery.
•

Q2a: Do the characteristics of the patients who received OAT differ from
those who did not receive OAT while hospitalized?

•

Q2b: Does non-OAT pharmacotherapy delivery differ for patients who
received OAT and for those who did not receive OAT while hospitalized?

•

Q2c: Do outcomes differ for patients who received OAT and for those who did
not receive OAT while hospitalized?

•

Q2d: Do the characteristics of the patients who were discontinued from OAT
differ from those who were continued on OAT at admission?

•

Q2e: Does non-OAT pharmacotherapy delivery differ for patients who
received OAT and for those who did not receive OAT while hospitalized?

•

Q2f: Do outcomes differ for patients who received OAT and for those who did
not receive OAT while hospitalized?

•

Q2g: Are specific OAT care scenarios associated with hospital OAT delivery
quartile?

•

Q2h: Which hospital attributes are associated with hospital OAT delivery?

•

Q2i: Are non-OAT pharmacotherapy services associated with hospital OAT
delivery quartile?

•

Q2j: Were outcomes associated with hospital OAT delivery performance?
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Aim 3: Test associations among patient and hospital characteristics on VHA hospital OAT
delivery.
•

Q3a: How much of the variation in OAT delivery is attributable to the
hospitals?

•

Q3b: How do patient and hospital attributes affect hospital OAT delivery?

The Aim 1 research questions identified supply-side attributes inside and outside
the hospital that explain, in part, variability in hospital OAT care and the common
practices used to enhance hospital treatment of persons with OUD. The Aim 2 research
questions described and explored care practices and variables associated with VHA
hospital OAT delivery variation. The Aim 3 research questions tested for the
contributions of the multilevel attributes on OAT care variation.
Section 3.3. Research Approach Justification and Study Assumptions
This section discusses the use of an integrated quantitative and qualitative mixed
methods study from paradigmatic and methodologic perspectives (Creswell & Clark,
2011), and concludes with study assumptions. Over many years the definition of “mixed
methods” has varied (Creswell & Clark, 2011). Mixed methods may refer to a research
philosophy, design, or methodologic approach (Creswell & Clark, 2011). Creswell and
Clark (2011) summarized the six core characteristics inclusive of these different
viewpoints. In mixed methods, the researcher:
•

Mixes, integrates or links the two forms of data either concurrently,
sequentially, or through embedding one within the other;

•

Prioritizes one or both forms of data;
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•

Uses both techniques in a single study;

•

Frames research techniques in a paradigm and a theoretical lens; and

•

Combines the methods into a specific research design guiding the study
(Creswell & Clark, 2011).

In the 1970s and 1980s, the mixed methods approach was subject to a
philosophical debate centered on whether combining quantitative and qualitative
approaches was possible because of their different and seemingly conflicting research
paradigms. A research paradigm is a shared belief system among a research community
that dictates a field’s salient questions and dominant use of research techniques (Kuhn,
1970). During this debate, the purists held that mixing quantitative and qualitative
paradigms was philosophically and theoretically impossible (Rossman & Wilson, 1985),
the situationalists asserted that adaptation of research paradigms and methods for
specific situations was possible (Creswell & Clark, 2011), and the pragmatists promoted
the use of multiple paradigms to address a singular research problem (Rossman &
Wilson, 1985). Thus, a pragmatic research paradigm is inclusive of other research
worldviews such as post-positivism or constructivism to meet the needs of the research
question (Creswell & Clark, 2011).
3.3.1. Pragmatic research paradigm. The ontology, epistemology, axiology, and
methodology (Creswell & Clark, 2011; Crotty, 1998) of the pragmatic research paradigm
support the mixed methods approach used for this dissertation. A pragmatic research
philosophy asserts that the observation of a consequence or outcome furthers the
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understanding of both the behavior and the beliefs that led to that outcome; thus,
actions cannot be separated from context, actions are linked to mutable consequences,
and actions depend on a socially shared set of beliefs (Morgan, 2014). Ontology is the
orientation of reality, and in pragmatism, ontology holds that singular and multiple
perspectives exist, so researchers test hypotheses and provide multiple perspectives
(Creswell & Clark, 2011). Epistemology is the relationship between the researcher and
the research, and in pragmatism this relationship is one of practicality, meaning that the
researcher collects data from a “what works” approach to address the research
question (Creswell & Clark, 2011). Axiology is the role of values in research and in
pragmatism this includes biased and unbiased perspectives (Creswell & Clark, 2011).
Finally, the primary methodology of a pragmatic paradigm uses a mix of quantitative
and qualitative data collection and analyses (Creswell & Clark, 2011).
3.3.2. Study assumptions. There were several assumptions reflected in the
rationale, the research questions, the design, and analysis of this dissertation. The first
assumption was that OUD is a “medical condition” even though it may be better
understood as a complex manifestation of interacting contributory processes that exist
at the macro and micro-levels (e.g., individual pre-disposition; social, historical, and
cultural environment; neurobiology). A second assumption was that hospital-based OAT
delivery is a solution to caring for persons with OUD. The third assumption was that
demand-side attributes have a minimal contribution to hospital OAT delivery; for
example, some patients may refuse hospital OAT for unknown reasons. Fourth, the
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study assumed that OAT is a better treatment approach in the hospital than non-OAT
opioids, although a direct comparison has never been studied. A fifth assumption
posited that hospital finances, rather than patient and provider needs, drive many
hospital decisions.
Section 3.4. Human Subjects Protections
On January 8, 2018, the OHSU Institutional Review Board (IRB) [IRB #18092]
approved Aim 1 (the qualitative study), and on May 14, 2018, the Veterans Affairs (VA)
IRB [IRB #4045] approved Aims 2 and 3 (the quantitative study). Both IRBs determined
each of the study components to be minimal risk human subjects research. The primary
risks for Aim 1 were minimized by using an OHSU IRB approved information sheet prior
to interview initiation (see Appendix B), by requesting consent to participate and oral
consent for recording the interviews, and by labeling the qualitative data with unique
identifying codes instead of names. The primary risks for Aim 2 and 3 were minimized by
receiving a deidentified dataset (e.g., no dates of service, birthdate, medical record
number, social security number, or personal address) and by excluding hospitals with
less than 25 admissions from analyses.
Section 3.5. Aim 1: Qualitative Analyses
The qualitative analyses used two different, albeit similar, analytic approaches:
directed content analysis (Hsieh & Shannon, 2005) for the key informant interview
transcripts and a framework analysis (Ritchie & Spencer, 1994) for the hospital guidance
documents. A directed content analysis is a primarily deductive approach effective for
validating or extending prior theoretical frameworks (Hsieh & Shannon, 2005). A
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framework analysis, an approach developed for applied social policy research, has seven
fundamental principles: 1) it is grounded or generative; 2) it is dynamic; 3) it is
systematic; 4) it is comprehensive; 5) it is easily retrieved; 6) it allows between- and
within-case analysis; and 7) it is accessible to others outside the study team (Ritchie &
Spencer, 2002).
3.5.1. Data sources and study cohort. The Aim 1 study cohort included 17 key
informants from 16 U.S. non-VHA hospitals. The cohort members were national hospital
OUD experts who were professionally involved in direct care, research, or the
development of addiction-related hospital policies, procedures, and practices for
patients with SUD. They were addiction medicine physicians who were identified
directly or indirectly through the publicly available 2018-2019 fellowship list from the
Addiction Medicine Foundation (Addiction Medicine Foundation, 2018). The qualitative
data included 17 transcribed 45-to 60-minute key informant interviews, informant
demographic information, interview notes, and 25 hospital guidance documents from
10 of the 16 non-VHA hospitals.
3.5.2. Study sample selection and recruitment. Informants were recruited in
two waves of email sampling. The IRB approved email recruitment script is in Appendix
C. Potential key informants received email invitations to participate a minimum of once
and a maximum of three times. The email requested contact information for the most
appropriate person to speak with at their institution, which included themselves.
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Recommendations from dissertation mentors and respondent-driven recommendations
supplemented recruitment.
A word search of the publicly available Addiction Medicine Foundation’s 2018 to
2019 fellowship list (Addiction Medicine Foundation, 2018) for the word “consult”
identified 26 fellowships that appeared to include addiction medicine consult services.
Twenty-five of the 26 programs were contacted with an invitation to participate in the
study; one program was excluded because the program director’s email address was not
provided. Of the 25 programs contacted 13 individuals from 12 fellowship programs
completed interviews.
After exhausting the first recruitment sample, a second wave of sampling
proceeded with the remaining 20 programs that did not have the word “consult” in the
program description, excluding the two Canadian programs and three primarily based in
the VHA. The Canadian and VHA programs were excluded to focus the sampling frame
and increase the homogeneity of the types of hospitals and surrounding environments
within the study sample. From the remaining 20 programs, 11 program directors were
contacted based on geographic location, expert recommendation, respondent
recommendation, and publicly available programmatic information. Of the 11 additional
programs contacted, four additional individuals from four different institutions
participated in the study.
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3.5.4. Data collection and study tools. The OHSU IRB approved study tools
included: 1) the key informant demographic survey (Appendix D); and 2) the semistructured interview guide (Appendix E).
3.5.4a. Key informant demographic survey. Key informants completed a
demographic survey at the start of the interview providing basic personal and
professional demographic information and OAT-related characteristics at the hospital of
employment. Question examples included: “What health professional degree(s) do you
have?” and “For how many years have you worked at your respective hospital?”
3.5.4b. Semi-structured interview guide. The conceptual framework and the
guidance of addiction medicine experts shaped the development of the semi-structured
interview guide. The final interview guide probed four topics to identify external and
hospital supply-side attributes related to hospital OAT service delivery: 1) development
and implementation of known effective care delivery mechanisms for OUD treatment in
the hospital setting, focused on addiction medicine consult (AMC) services; 2) OUD care
delivery policies, procedures, and practices; 3) hospital barriers and facilitators to
hospital OUD treatment and OAT delivery; and 4) environmental barriers and facilitators
to hospital OUD treatment and OAT delivery.
Informants completed 45- to 60-minute telephone interviews with the primary
researcher. Participants did not receive a copy of the interview guide. Interviews were
electronically recorded. When a specific hospital policy was mentioned during the
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interview, a copy was requested via email after the interview to obtain electronic copies
of the documents. Interviews were transcribed by the primary researcher.
3.5.5. Data analysis. The data sources analyzed included: informant
demographic survey data; key informant interview transcripts; and hospital policies.
3.5.5a. Key informant demographic surveys. Key informant demographic
surveys provided a professional and educational context for the perspectives of the
informants and their current care delivery environment. Descriptive summaries, such as
mean age of the key informants, were generated using Microsoft Excel (Microsoft, 2018)
to contextualize the study findings.
3.5.5b. Key informant interview transcripts. Informant interviews were coded
using a directed content analysis approach (Hsieh & Shannon, 2005). Dedoose
(SocioCultural Research Consultants LLC, 2016), a qualitative analysis software, was used
to organize and manage the qualitative data and analytic process. The conceptual
framework served informed the creation of the preliminary codebook prior to data
collection.
Analysis of the interviews began prior to the completion of all interviews. Each
interview was coded and re-coded in iterative cycles. Initially the interviews were coded
with the draft codebook (Hsieh & Shannon, 2005). Throughout the course of data
collection and analysis, the codebook was modified to reflect emergent findings (Hsieh
& Shannon, 2005). Important and relevant data that did not fit clearly into the original
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coding scheme inspired the creation of new categories and codes (Hsieh & Shannon,
2005).
The original codebook had five categories, with 23 codes: 1) environmental
attributes; 2) hospital supply-side attributes; 3) demand-side attributes; 4) AMC service
attributes; and 5) current hospital policies. The final codebook was expanded to eight
categories, with 59 codes: 1) environmental attributes; 2) hospital supply-side
attributes; 3) demand-side attributes; 4) AMC service attributes; 5) hospital policy and
practice; 6) financing; 7) other models of care; and 8) care delivery topics. Changes to
the codebook reflected the focus and the granularity of information provided during the
interviews. Financing was added, as a single higher-level category, because it was a
frequently described and observed to be intrinsically connected to the other categories.
The category “hospital policies and practice” was expanded to include not only the
discussion of documented hospital policies but also typical practices because several
informants disclosed that their standard of care or common practices were not formally
documented. See Appendix F for a copy of the final codebook and frequency counts of
categories and codes.
Upon the completion of primary coding, a second coder (the dissertation
committee chair) reviewed the categories and codebook for all 17 coded interviews and
provided additional coding suggestions. The primary researcher reconciled the coding
changes and any discrepancies in codes were discussed as a research team until
consensus was reached. All documents received a second coding review by the primary
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coder to identify any text that was missing a relevant code or when redundant coding
occurred. The final themes presented in Chapter 4 were created through the
consolidation of the eight categories from the codebook, organized around the study’s
conceptual framework.
3.5.5c. Hospital guidance documents. A framework analysis approach guided
the analyses of the hospital guidance documents (Ritchie & Spencer, 2002). This
approach begins with becoming familiar with the documents for analysis, identifying a
thematic framework, indexing the policies, charting the policies, and completing the
analysis and policy interpretation (Ritchie & Spencer, 2002). The preliminary thematic
framework for this study was informed by expert opinion and a priori policy categories:
1) OAT continuation; 2) withdrawal management; 3) OAT induction; and 4) pain
management. The framework was modified throughout the course of data collection
and data familiarization with the 25 policies. The thematic framework expanded to
include five policy categories: 1) OAT continuation; 2) opioid withdrawal management;
3) OAT induction; 4) pain management; and 5) security and behavioral management
policy.
During the indexing and charting processes, policies were collapsed into two
broad policy themes comprised of eight policy sub-categories: 1) OAT management and
2) security and behavioral management. Qualitative tables were created to summarize
and organize findings by the broader themes and sub-categories. Thirty-three pages of
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text summarized the policies and supported the policy indexing and charting processes.
This documentation may be requested from the primary researcher.
3.5.6. Linking Aim 1 to Aims 2 and 3. The qualitative findings presented in
Chapter 4 provided the rationale for continuing to explore care delivery practice,
patterns, and organizational processes for hospitalized patients with OUD. The
qualitative findings also informed the subsequent coding of hospital OAT in the VHA
quantitative dataset, and the analyses of Aims 2 and 3 (reported in Chapter 5).
Section 3.6. Aims 2 and 3: Quantitative Analyses
The exploration of the Aims 2 and 3 research questions occurred through the use
of pre-specified statistical analytic techniques. The rationale for the use of these
techniques was based on the evidence presented in the Chapter 2 literature review
including previously conducted research on hospital care variation (Safavi et al., 2014).
The Aim 2 analytic techniques included descriptive statistics (e.g., frequency, range,
median, interquartile range [IQR]) and bivariate statistical tests to assess for differences
among groups of patients and hospital OAT delivery quartiles (e.g., Pearson chi-square
and Mann-Whitney U tests). The Aim 3 analytic technique used multilevel and
multivariable logistic regression models, justified both theoretically and statistically
(Luke, 2004). Two data analysis programs were used: 1) RStudio (RStudio Team, 2015)
for data management, coding, and for bivariate statistical tests; and 2) Stata (StataCorp,
2017) for the multilevel logistic regression models. The RStudio packages are provided in
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Appendix G (Dinno, 2017; Fox & Weisberg, 2011; Revelle, 2018; Wasey, 2018; Wickham,
2011, 2017).
3.6.1. Data sources and study cohort. A retrospective sample of VHA patients
was obtained from the VHA Corporate Data Warehouse. The VHA Corporate Data
Warehouse is a collection of databases accessed securely through the VHA Informatics
and Computing Infrastructure Workspace. This data source provides real-time
demographic, medical, and pharmacy health services utilization data for veterans who
receive care in the VHA system. In these databases patient data are linked across
multiple tables (e.g., diagnoses, outpatient visits, inpatient admissions, outpatient
prescription, methadone clinics) through a unique numeric identifier.
Each case was a unique patient admission in the VHA system. Patients were
included in this study if they had an OUD diagnosis (see Appendix H) from any source,
inpatient or outpatient, between October 1, 2015 and October 1, 2017, in the year
preceding the admission date of the index hospitalization as defined below. This
included clinical scenarios in which an OUD diagnosis occurred during the index
hospitalization. Eligible OUD diagnoses could be primary diagnoses coded when OUD
was the main reason for the clinical encounter, or as a secondary diagnosis. The
admitting facilities were restricted to “acute care hospitals” which was defined as
facilities that had at least 500 acute bed days of care during the study year.
Study validity was enhanced through the refinement of the study cohort. Each
step to generate the final study cohort was documented in the study consort diagram in
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Appendix I which included the removal of: 1) hospitals and admissions outside the
continental U.S. (hospitals = 1; cases = 134); 2) facilities with bed category discrepancies
(hospitals = 6; cases = 141); 3) admissions with non-hospital places of admission (cases =
7) or missing the place of admission (cases = 2); 4) admissions missing a primary or
secondary admission code (cases = 271); 5) admissions with an inconsistent death code
(hospitals = 1, cases = 4); 6) admissions with a cancer flag (cases = 2,062), as defined by
the Elixhauser flags (AHRQ, 2018), including cases with a solid tumor without metastasis,
metastatic cancer, or lymphoma present on admission; 7) admissions with a length of
stay in the 99th percentile (hospitals = 1; cases = 130); and 8) hospitals with less than 25
admissions (hospitals =21; cases = 262). The final dataset included 12,407 admissions
from 109 unique VHA hospitals within the continental U.S. There were no facilities
located in New Hampshire or Nebraska. Appendix J has additional details on the study
cohort definitions.
3.6.2. Quantitative variables. Variable selection was informed by the existing
literature, the data available from the VHA data source, and results of the qualitative
portion of the study. There were three time points of interest in this study: 1) 30 days
prior to index hospitalization (“pre-admission”); 2) index hospitalization (“admission”);
and 3) 30 days post index hospitalization (“post-admission”).
3.6.2a. Index hospitalization definition. The definition of an index hospital
admission was the first hospital admission during the 2017 VHA fiscal year (October 1
2016 to October 1, 2017) for veterans (aged 18 and older) with an OUD-related ICD-10
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diagnosis code (Appendix H) as an inpatient or outpatient, or within the FEE BASIS care
setting within the previous 12 months from the index hospital admission date, which
could include a diagnosis during index admission. FEE BASIS care refers to non-VHA
clinical care paid for by VHA on a veteran’s behalf, typically due to the service not being
offered by VHA or because the geographic distance from the patient to the VHA service
presents a barrier to access services.
3.6.2b. Patient and admission variables. The patient and admission variables were
either present upon data receipt or constructed and coded from the data; see Table 3.2
for summarized definitions. Appendix K includes additional details on variable
construction and Appendix L is the list of ICD-10 codes queried for co-occurring mental
health conditions and co-occurring SUDs.
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Table 3.2. Patient and Admission Variables
Variable
Type
Patient Characteristics
Age
Continuous
Co-Occurring
Binary/
Mental Health1
Categorical
Co-Occurring
SUD1

Binary/
Categorical

Gender
Ethnicity
OUD-Related
Diagnosis2
OUD-Related
Infections2

Binary
Categorical
Binary/
Categorical
Binary/
Categorical

OUD-Related
Diagnosis or
Infection
Primary
Diagnosis2
Race

Binary

Definition
Age in years present on admission
1) Adjustment Disorder Other; 2) Anxiety Disorder; 3) Mood Disorder;
4) Non-Mood Psychotic disorder; 5) PTSD; 6) Self-Harm; codes in
Appendix L
1) Alcohol Use Disorder; 2) Cannabis Use Disorder; 3) Cocaine Use
Disorder; 4) Hallucinogen Use Disorder; 5) Nicotine Dependence; 6)
Other Psychoactive Use Disorders; 7) Other Stimulant Related
Disorders; 8) Other Substance Use Disorder; 9) Sedative Hypnotic
Disorders; codes in Appendix L
Male or Female
1) Not Hispanic or Latino; 2) Hispanic or Latino; 3) Unknown
Primary or secondary ICD-10 OUD admission diagnosis codes; codes in
Appendix H
1) Endocarditis; 2) Candida Endocarditis; 3) Osteomyelitis; 4)
Bacteremia; 5) Discitis; 6) Septic Arthritis; 7) Brain Abscess; 8) Joint
Infection; 9) Necrotizing Fasciitis; 10) Empyema; and 11) Lung Abscess;
codes in Appendix H
Combined variable: OUD-Related Diagnosis or OUD-Related Infection
Diagnosis

Categorical

The primary ICD-10 admission diagnosis code for index hospitalization

Categorical

1) American Indian or Alaska Native; 2) Asian; 3) Black or African
American; 4) White; 5) Native Hawaiian or Other Pacific Islander; 6)
Unknown/Decline to Answer
The secondary ICD-10 admission diagnosis code for index
hospitalization

Secondary
Categorical
Diagnosis2
Admission Characteristics
Admission
Categorical
Point of admission for the index hospitalization: 1) Outpatient
Source
Treatment; 2) Other Direct admission; 3) Other
ICU Service
Binary
Use of ICU services during index hospitalization
Length of Stay
Continuous Length of time (days) of the index hospitalization
Surgical Service
Binary
Use of surgical services during index hospitalization
Table Notes. 1Present on admission = identified within prior 365 days; 2Occurred during admission;
PTSD = Post Traumatic Stress Disorder.

3.6.2c. Non-OAT pharmacotherapy variables. Pharmacotherapy variables were
coded for the three study time periods: 1) pre-admission, which included filled
prescriptions or medication procedure codes; 2) admission, which included
administered medication, filled prescriptions (<1 % of data points), or medication
procedure codes; and 3) post-admission, which included filled prescriptions or
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medication procedure codes. If a medication was used more than once in a study time
period, it was only counted once. See Table 3.3 for definitions and Appendix N for
additional details.
Table 3.3. Non-OAT Pharmacotherapy Variables1
Variable
Pre-Admission
Benzodiazepine
Concurrent Opioid/Benzodiazepine
Gabapentin/Pregabalin
Naloxone
Naltrexone
Opioid
Admission2
Benzodiazepine
Gabapentin/Pregabalin
Naltrexone
No Opioid and No OAT
Opioid
First-Line Withdrawal Adjuvant
Second-Line Withdrawal Adjuvant3
Any Withdrawal Adjuvants

Definition
Prescription filled for any Benzodiazepine
Prescription filled for any Opioid and any Benzodiazepine
Prescription filled for Gabapentin or Pregabalin
Prescription filled for Naloxone
Prescription filled or HCPCS code for Naltrexone
Prescription filled for any Non-OAT Opioids, not including
Methadone or Buprenorphine
Administration of Benzodiazepine
Administration of Gabapentin or Pregabalin
Administration of Naltrexone
No administration of an Opioid and OAT
Administration of any Non-OAT Opioid, did not include
Methadone or Buprenorphine formulations for pain
Administration of Clonidine
Administration of any second-line adjuvant: Baclofen or
Gabapentin or Pregabalin or Tizanidine
Administration of any of the adjuvants: Baclofen or
Clonidine or Gabapentin or Pregabalin or Tizanidine

Post-Admission
Benzodiazepine
Prescription filled for any Benzodiazepine
Concurrent Opioid/Benzodiazepine
Prescription filled for any Opioid and any Benzodiazepine
Gabapentin/Pregabalin
Prescription filled for Gabapentin or Pregabalin
Naloxone
Prescription filled for Naloxone
Naltrexone
Prescription filled or HCPCS code for Naltrexone
1
Table Notes. Appendix N describes variable construction; 2during admission <1% of pharmaceutical
data points were prescribed; 3Second line adjuvants are medications recommended for use by VHA
Opioid Taper Tool (U.S. Department of Veterans Affairs, 2016b); HCPCS = Healthcare Common
Procedure Coding System is a specific procedure billing code for medication administration.

3.6.2d. OAT pharmacotherapy variables. OAT pharmacotherapy variables were
created for the three study time periods. The pre-and post-admission OAT variables
included filled buprenorphine prescriptions, procedure codes for methadone
administration and non-specific OAT administration, or OTP visit documentation. The
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any OAT admission variable included all formulations of buprenorphine and methadone
and any OAT-related procedure codes. The decision to include non-FDA approved OAT
formulations (e.g., injectable methadone) was based on the findings from Aim 1 and the
federal rules that allow this practice. Table 3.4 provides a summary of the OAT variable
definitions and Appendix O provides additional details.
Table 3.4. OAT Variables1
Variable
Pre-Admission
Any OAT

Definition

Pharmacotherapy

Binary/
Categorical

Prescription filled for FDA-approved OAT or OAT
Procedure Code or OTP Visit
Administration of Any OAT

OAT Continuation

Binary/
Categorical
Binary

OAT Initiation & Linkage to Care

Binary

OAT Sustained

Binary

OAT Withdrawal

Binary

OAT with Adjuvant

Binary

OAT with First-line Adjuvant

Binary

OAT with Second-line Adjuvant

Binary

OAT with Opioid

Binary

OAT with Naltrexone

Binary

Post-Admission
Any OAT

Binary

Admission
Any OAT

OAT delivered during pre-admission and
admission, but not post-admission
OAT delivered during admission and postadmission, but not pre-admission
OAT delivered pre-admission, during admission
and post-admission
OAT delivered during admission, but not pre or
post-admission
Administration of OAT and
an any adjuvant during admission
Administration of OAT and
a first-line adjuvant during admission
Administration of OAT and
a second-line adjuvant during admission
Administration of OAT and
an any Non-OAT Opioid during admission
Administration of OAT and
naltrexone during admission

Prescription filled for FDA-approved OAT
or OAT Procedure Code or OTP Visit
1
Table Notes. Appendix O describes variable construction.
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3.6.2e. Patient health and utilization variables. Patient health and services
utilization variables were queried either directly from the VHA data or constructed from
the data through coding. Definitions are provided in Table 3.5 and additional details are
in Appendix P.
Table 3.5. VHA Patient Health and Utilization Variables1
Variable
In-Hospital Mortality
Left Against Medical Advice

Type
Binary/Categorical
Binary/Categorical

Death

Binary

Emergency Department Visit

Binary

Hospital Readmission

Binary

Definition
Death during admission
Leaving against medical advice during
admission
Death within the post-admission time
period
VHA emergency department visit within
the post-admission time period
VHA acute care visit within the postadmission time period

Table Notes. 1Appendix P describes variable construction.

3.6.2f. Hospital characteristic variables. Hospital characteristic variables were
queried either directly from the VHA data or constructed through coding. Definitions are
provided in Table 3.6 and additional details are in Appendix Q.
Table 3.6. VHA Hospital Characteristic Variables1
Variable
Acute OUD Diagnosis Volume

Binary

Type

Admission Volume
Hospital Region

Continuous
Categorical

Hospital Size

Categorical

Definition
The proportion of index admissions in a
facility with an acute OUD diagnosis (OUDinfection or OUD diagnosis)
The number of admissions in a facility
U.S. Census categories: 1) Northeast; 2)
Midwest; 3) South; 4) West
1) Small: 1 to 49 beds; 2) Medium: 50 to 99
beds; 3) Large: 100+

Table Notes. 1Appendix Q describes variable construction.

3.6.3. Descriptive and bivariate analyses. Frequencies and percentages were
calculated for hospital (admission volume, size, and location), patient (age, gender, race,
and ethnicity), and admission (length of stay, admission source, and service acuity)
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characteristics across the study cohort population (n = 12,407). The frequency of patient
health-related characteristics was also calculated for OUD-related infection diagnosis,
acute OUD-related diagnosis, the top 10 most common primary ICD-10 diagnosis codes,
top 10 most common secondary ICD-10 diagnosis codes, co-occurring mental health
conditions, and co-occurring SUDs. Pharmacotherapy frequency for the entire study
cohort was described for non-OAT and OAT in all three study time periods. Additional
system-wide descriptions of hospital OAT delivery across the study cohort and all
facilities were conducted for any OAT delivery (frequency, median, range, IQR, skew,
and kurtosis) and the four OAT scenarios: 1) OAT continued; 2) OAT initiation and
linkage to care; 3) OAT sustained; and 4) OAT withdrawal management.
Bivariate analyses compared sub-groups within the study cohort using Pearson
chi-square, Pearson chi-square with Yates’ continuity correction, and Mann-Whitney U
tests. Sub-group comparisons were made between patients who received OAT and
those who did not receive OAT during admission, and patients who were on OAT prior
to admission and discontinued with those who were continued on OAT during
admission. Differences were assessed for characteristics present on admission,
admission characteristics, non-OAT pharmacotherapy delivery during admission, and
health and utilization outcomes.
3.6.4. Hospital performance analyses. Hospitals were assigned to one of four
hospital OAT delivery performance categories dependent on the proportion of admitted
patients with OUD in each hospital who received OAT during their admission. Quartile 1
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hospitals had the lowest relative proportion of OAT delivered and Quartile 4 had the
highest. Quartiles were described using measures for any OAT delivered including
frequency, median, range, IQR, skew, and kurtosis. Differences across and between
quartiles were assessed for OAT and non-OAT pharmacotherapy delivery using the
Kruskal-Wallis and Dunn’s tests. Quartiles were assessed for differences in
characteristics and health and utilization outcomes using Dunn’s, Kruskal-Wallis, and
Fisher’s Exact tests.
3.6.5. Multilevel analyses. Using Stata statistical analysis software (StataCorp,
2017), multivariable logistic regression models were constructed to study the
association (alpha value 0.05) of multilevel attributes on patient OAT receipt during
hospitalization.
3.6.5a. Dependent and independent variables. The dependent variable (level 1)
was OAT receipt (yes/no) during hospitalization. The independent variables were
continuous, binary, or categorical variables categorized as level 1 (i.e. patient) or level 2
(i.e., hospital). Independent variable inclusion was based on the literature review,
expert opinion, prior study aims, and model fit. Level 1 and level 2 independent
variables are summarized in Table 3.7.
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Table 3.7. Independent Variables
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

Level 1: Patient and Admission Characteristics
Demographics
Age (continuous)
Male (ref. female)
Race: Non-white (ref. white)
Race: Unknown (ref white)
Ethnicity: Hispanic (ref. non-Hispanic)
Ethnicity: Unknown (ref. non-Hispanic)
Acute OUD diagnosis/infection (yes/no)
Co-occurring SUD (yes/no)
Co-occurring Mental Health disorder (yes/no)
Admission
Unintentional Overdose (yes/no)
Opioid Withdrawal (yes/no)
Length of Stay (continuous)
ICU Services Received (yes/no)
Surgical Services Received (yes/no)
Admission Source: Other (ref. outpatient)
Admission Source: Direct (ref. outpatient)
Opioid Received (yes/no)
Adjuvant Received (yes/no)
Benzodiazepine Received (yes/no)
Naltrexone Received (yes/no)
Pre-Admission
OAT Received (yes/no)
Opioid Received (yes/no)
Benzodiazepine Received (yes/no)
Naltrexone Received (yes/no)
Gabapentin/Pregabalin Received (yes/no)

1.
2.
3.
4.
5.
6.
7.

Level 2: Hospital Characteristics
Admission Volume
Acute OUD Diagnoses Relative Volume
Hospital Size-Medium (ref. small)
Hospital Size-Large (ref. small)
Census Region Midwest (ref. South)
Census Region Northeast (ref. South)
Census Region West (ref. South)

3.6.5b. Model preparation. Model preparation began with assessments for
multicollinearity among covariates using variance inflation factors (VIFs), the conditional
index, and Pearson correlation. Covariates included in the models were below
collinearity thresholds—VIF (< 10), conditional index (< 30) (Hair, Tatham, Anderson, &
Black, 1998), variance-decomposition matrix (< 0.9) (Hair et al., 1998), Pearson’s
correlation coefficient (< 0.8) (Midi, Sarkar, & Rana, 2010)—except for one covariate
with an elevated conditional index (> 30; = 33.5).
3.6.5c. Model building. Model building occurred in a stepwise approach from
simple (Model 1) to more complex (Model 2 and 3). The model equations are in Figure
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3.2 and the purpose of each of model and the equation elements are described below.

Figure 3.2. Multilevel Modeling Equations
The purpose of Model 1, the variance component model, was to describe
hospital-specific random effects (Austin & Merlo, 2017) for patient OAT receipt:
•

i = the individual admission;

•

j = the specific hospital in which the admission occurred;

•

!"#$% ("(() !*+*! 1 "-%."/*)12 = the dependent variable (patient OAT receipt);

•

344 = the level 2 intercept; and

•

-42 = the variance between hospitals (i.e., the random intercept component).
The purpose of Model 2, the intermediate model, was to test for associations

between patient characteristics and patient OAT receipt, and to describe the hospitalspecific random effects (Austin & Merlo, 2017):
•

354 is the effect of the level 1 covariate on the group specific intercept.
The purpose of Model 3, the final model, was to test for associations between

patient and hospital characteristics on patient OAT receipt and to describe the hospitalspecific random effects (Austin & Merlo, 2017):
•

354 is the effect of the individual level covariate on the group specific intercept;
and
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•

345 is the effect of the group level covariate on the group specific intercept.
Comparative model fit testing, for the nested models (Model 1 vs. Model 2 vs.

Model 3), used log-likelihood ratio test, the Akaike Information Criteria (AIC), and the
Bayesian Information Criteria (BIC). Regression coefficients, standard errors, odds ratios
with 95% confidence intervals, and the intraclass correlation coefficient (ICC)2 were also
calculated and reported for all three models.
3.6.5d. Sensitivity analysis. A sensitivity analysis was conducted to discern
whether using a narrower OAT administration definition (i.e., the exclusion of injectable
forms of methadone/buprenorphine) would change study findings. The results of this
analysis are presented in Chapter 5 (Section 5.6.4c and Appendix R).
Section 3.7. Conclusion
A mixed methods study, based on a pragmatic research paradigm, informed the
design, approach, and analyses crafted to address the three study aims of this
dissertation. The next three chapters present the study findings: Chapter 4 the
qualitative findings, Chapter 5 the quantitative findings, and Chapter 6 the synthesis and
integration of the qualitative and quantitative findings.

2

ICC =

678
:8
8
67 9
;
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Chapter 4: Presentation and Analysis of Qualitative Data
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., &
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose
epidemic: The addiction medicine consult service. Journal of Addiction Medicine,
Advance online publication. doi: 10.1097/ADM.0000000000000496.
The purpose of Aim 1 was to identify environmental and hospital supply-side
attributes that may explain, in part, the variation in care and limited use of OAT for
hospitalized patients with OUD. Four research sub-questions guided this portion of the
study:
•

Q1a: How is OAT delivered for patients with OUD in the hospital setting?

•

Q1b: Which internal and external environmental supply-side elements
facilitate hospital OAT delivery?

•

Q1c: Which internal and external environmental supply-side elements
impede hospital OAT delivery?

•

Q1d: How do hospital policies and guidance documents inform hospital OAT
delivery?

The conceptual framework, described in Chapter 2, informed Chapter 4 analyses
and the presentation of findings. Of particular note, the perspective that hospitals and
the activities within them exist is because of dynamic and complex interactions among
continuously evolving economic, cultural, political, and socially normative structures and
processes (see Table 2.2). The chapter is organized in eight sections:
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1. Section 4.1 describes the study cohort—17 key informants from 16 non-VHA
hospitals—to provide the professional and environmental context for study
findings.
2. Section 4.2. examines the shared and different organizational characteristics of
the nine established hospital AMC services.
3. Section 4.3 explores the supply-side attributes (inside and outside the hospital)
that facilitate the development and implementation of AMC services for the
nine hospitals with established services and the five hospitals with plans to
implement AMC services.
4. Section 4.4 describes the barriers (inside and outside the hospital) for the
development and implementation of AMC services and hospital OAT delivery
for all 16 hospitals.
5. Section 4.5 briefly explores the demand-side attributes (i.e., patient attributes)
that emerged during key informant interviews, although the focus of this study
was primarily on the supply-side contributions to care.
6. Section 4.6 outlines six specific emergent supply-side actions beyond the AMC
service to improve and enhance OUD-related services in the hospital context.
7. Section 4.7 summarizes hospital guidance document analyses (n = 25), which
describe the current OAT practices in non-VHA hospitals.
8. Section 4.8 links the qualitative findings to the two quantitative aims.
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Section 4.1. Study Cohort
4.1.1. Participant demographics. Interviews were completed with 17 physicians
affiliated with 16 U.S. hospitals or health systems. Participants were found through the
publicly available Addiction Medicine Fellowship program list (Addiction Medicine
Foundation, 2018). Key informants were board-certified (n = 16) or board-eligible (n = 1)
addiction medicine physicians (medical or osteopathic doctorate) from five subspecialties—family medicine, internal medicine, obstetrics and gynecology, pediatrics,
and psychiatry. The key informant mean age was 47 years. The 9 women and 8 men
were predominantly white (n = 16) and Non-Hispanic or Latino (n = 15), and most had
worked or trained in their hospital of employment for more than five years (n = 13).
4.1.2. Hospital characteristics. Hospitals were located in the West (n = 4),
Midwest (n = 4), Northeast (n = 5), and South (n = 3), and most were located in states
with Affordable Care Act Medicaid expansion (n = 12). OAT products were on all hospital
formularies for the treatment of OUD except for one, with some restrictions. Most
hospitals (n = 10) had affiliated or onsite addiction related services, such as opioid
treatment programs (OTPs) and “detox” beds. Three hospitals had OTPs and dedicated
“detox” beds, three hospitals had only OTPs, four hospitals had only dedicated detox
beds, and six hospitals had neither. Interestingly, the two hospitals without an AMC
service or plans to start one either had an affiliated OTP or “detox” beds, potentially
indicating that the types of addiction-related resources (AMC service vs. OTP vs. “detox”
beds) serve different purposes or facilitate different care production mechanisms. The
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role of the AMC service, as both an input and output of service delivery, was an
emergent and important finding that is articulated throughout this chapter.
AMC services functioned as a key care delivery mechanism for persons with
OUD. The presentation of results, therefore, begins with an assessment of the status of
AMC services (established, planning to start, or not established/no plans to start). Over
half of the hospitals, 9 of 16, had established AMC services, five hospitals planned to
start an AMC, and two hospitals had no AMC service and no plans to start one. See
Table 4.1 for a summary of hospital characteristics by region and available services.
Table 4.1. Hospital Characteristics
Hospital Type
MW
3

Region
NE
S
3
1

W
2

Affiliated/Onsite Services
OTP Detox
Both
Neither
1
2
2
4

Established AMC
Service
Starting AMC
0
1
2
2
1
1
1
2
Service
No AMC Service
1
1
0
0
1
1
0
0
Total
4
5
3
4
3
4
3
6
Table Notes. MW = Midwest; NE = Northeast; S = South; W = West; OTP = opioid treatment
program; Detox = dedicated hospital beds for detoxification from substances; Both = OTP and
dedicated hospital beds for detoxification from substances.

The following sections integrate and synthesize the evidence provided by key
informants in the interviews and from the hospital guidance documents. The
culmination of these findings provides a first glimpse into an otherwise previously
limitedly described care delivery scenario.
Section 4.2. AMC Service Design and Operations
This section describes shared practices and differences in AMC service design
and operations to address research sub-question 1a: How is OAT delivered for patients
with OUD in the hospital setting? This was assessed through the lens of the study
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conceptual framework, which focused on technology and resources (e.g., staffing,
financing) and social structures. AMC service shared practices and differences emerged
across four domains: 1) availability and coverage; 2) home department and team
composition; 3) responsibility and scope; and 4) financing. Eight of the nine established
AMC services had a dedicated consult service staffed with addiction medicine physicians
and one service was a part of the psychiatry consultation liaison service. AMC services
varied in design, specifically the availability and coverage within the hospital, team
composition, scope and responsibility of the service, and financing. The barriers and
facilitators to AMC implementation, however, were similar across programs.
4.2.1. Availability and coverage. The AMC services varied with access to
resources and staffing, because of local supply-side attributes (e.g., financing and social
structures). At the same time, many operational characteristics and challenges across
the nine services were similar. Most established AMC services (n = 8) provided in-person
consultation only during weekdays and a third of services (n = 3) provided consultation
in the emergency department. The single program with weekend service availability was
staffed by trainees who worked on the psychiatry consultation liaison service. Generally,
the limited weekday availability frustrated key informants; they felt that patients who
were admitted or discharged on weekends were not receiving life-saving addictionrelated services. As a result, care was sometimes rationed on the weekdays because of
the weekend-related staffing limitations:
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The counselors came in with 26 consult orders yesterday, on a Monday, so they
don't have time to do the assessments and to help actually find treatment beds
for patients. So, they have to prioritize it to the highest needs, people who are
directly transferring to treatment. (I1)
Key informants linked staffing constraints to limited financial resources. Staffing
deficits led to work-around clinical processes, such as taking home call or consultations
via pager. These approaches, however, did not mitigate the heavy patient caseload on
Monday mornings. Limited financing for clinical staff also constrained physically where
AMC consultation could occur (e.g., the emergency department). Key informants
believed that to be a fully operational consult service it was essential to provide services
in the emergency department.
4.2.2. Home department and team composition. The home department and
AMC service team composition varied, reflecting local social structures within each
hospital. In some programs, the AMC service was established through the departments
of family medicine or internal medicine, and in one hospital, the AMC service based in
the psychiatry and medicine departments. Eight of the nine established AMC services
were staffed with addiction medicine physicians, although physician staffing resources
varied. One well-established consult service had over 10 board-certified addiction
medicine physicians; in contrast, others were limited to one physician. Eight of the nine
consult services comprised of interprofessional teams. The most common non-physician
team members were nurse practitioners (n = 4) and social workers (n = 4) and less
common were alcohol and drug counselors (n = 2), physician assistants (n = 2),
psychologists (n = 2), and peer support providers (n = 1), see Table 4.2.
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Although not commonly a part of the AMC services, informants sought to add
peer support providers (i.e., trained persons with lived addiction experience; “peers”) to
the team. At the time of interview, only one hospital had peers on their service. The
primary responsibilities of the peer were to “…help patients stay in the hospital and help
engage them” (deidentified3) and to provide conflict de-escalation. The key informant
shared that the outcome most important to peers, which differed from the rest of the
care team, was: “relationship[s]” (deidentified). The informant noted that the inclusion
of peers on the team made other clinical staff in the hospital uncomfortable. The
informant posited that this was because peers challenged the traditional hierarchy of
clinical roles in the hospital.
In contrast to peers, medical trainees (e.g., addiction medicine fellows, resident
physicians, and medical students) were common AMC service team members.
Informants reported that trainees were a critical resource for both the standard work of
the service (e.g., trainees see the patient first) and as a mechanism for extending their
clinical staffing resources (e.g., fellows staff the consult service).
Table 4.2. Addiction Medicine Consult Service Design (n = 9)
Availability & Coverage
Weekend
ED
11%

38%

NP
50%

Peer
11%

Non-Physician Team Members
Physician Psychologist
Social
Assistant
Worker
25%
25%
50%

(n = 1)
(n = 3)
(n = 4)
(n = 1)
(n = 2)
(n = 2)
Table Notes. ED = emergency department; NP = nurse practitioner.

3

(n = 4)

Alcohol & Drug
Counselors
25%
(n = 2)

Since this was a unique property, the attribution was deidentified.
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4.2.3. Responsibilities and scope of practice. AMC service responsibility and
scope of practice existed in three categories: 1) the provision of SUD-related education
to trainees, providers, and hospital staff; 2) the delivery of psychosocial and medical
services (e.g., motivational interviewing, pharmacotherapy, linkage to care); and 3)
hospital guidance document development (e.g., order sets, guidelines, and protocols).
4.2.3a. Education. Hospital-wide education related to SUD treatment was an
important responsibility of the AMC service:
We teach an addiction mini-course in the second-year medical student
curriculum. It is a required course at our university. It is not a long course…but we
are one of the few medical schools who do that from my understanding…[our]
residential treatment facility and detox center…is a clinical training site for third
year medical students, as well as psychiatry residents…we have a Project
Echo…and we do a lot of addiction medicine education to primary care,
psychiatrists, case managers and counselors. (M1)
Further, the AMC services sought to inspire hospital culture change through their
educational initiatives. The presence of the AMC service, moreover, enhanced
understanding among hospital staff about the need to address OUD within the medical
context. Informants perceived that the AMC service provided other benefits such as
decreasing provider burnout, decreasing provider stigma, and improving the culture and
the clinical practice for SUDs: “By having the right teams in place in the hospital we can
really change the hospital experience not just for patients but for the providers” (A2)
and “I think there is a morale booster, both for us and our colleagues. And then it just
raises the profile of addiction in general when there is a consult service identified with
it” (K1).
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4.2.3b. Service delivery. Generally, AMC services were responsible for five core
services: 1) mental health and SUD assessments; 2) psychosocial intervention; 3) the
medical management of SUDs (e.g., clinical activities related to OAT initiation,
continuation, and discontinuation, the management of benzodiazepine and alcohol
withdrawal); 4) the medical management of pain; and 5) linkage to care (e.g., referrals
to treatment, bridge scripts, care pathways). Variation in team composition was
associated with the different psychosocial techniques used by the service (i.e., brief
intervention; cognitive behavioral therapy; dialectal behavioral therapy; and
motivational interviewing) and harm reduction interventions (i.e., naloxone kit
distribution; overdose education; counseling on syringe exchange; and allowing patients
to smoke).
Informants emphasized that linkage to care was an essential and distinctive AMC
service responsibility and they described four linkage to care modalities: 1) writing a
bridge script; 2) referring to community-based services; 3) admitting to a transition
program; and 4) transferring to another health system’s bridge clinic. Bridge scripts
were the most common linkage approach and occurred when an inpatient physician
wrote a prescription for buprenorphine/naloxone to “bridge” the patient until they
established care with a community-based provider. Other linkage to care approaches
included providing referral to community-based services (e.g., direct transitions into
residential treatment), which was primarily the responsibility of the case manager and
social workers.
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Other less commonly used linkage approaches were the use of transition
programs and bridge clinics. Informants described transition programs as “rapid access”
and “reach-in” interventions, meaning that a community-based provider visited patients
during hospitalization to prepare them for direct discharge to their outpatient program.
Further, only one hospital had an operational bridge clinic at the time of interview. The
bridge clinic transitioned patients, over a two-week window, to an outpatient
community-based OAT provider. Both types of programs, transition and bridge clinics,
were developed in collaboration with external partners.
AMC service standard work was hospital specific; however, two services shared a
similar consultation process based on the different types of providers on the team. At
their hospitals, staff could request either a consult from the service’s behavioral health
provider (e.g., social worker) or from a clinical provider (e.g., physician).
4.2.3c. Policy development. The final category of AMC service responsibility, led
by physicians on the team, was the creation of hospital guidance documents;
specifically, the creation and implementation of order sets, guidelines, and protocols
related hospital-based services for patients with OUD and other SUDs. Hospital guidance
document creation was a common responsibility and the content of those polices is
explored and described further in Section 4.7 of this chapter. Typically, the AMC service
leadership worked closely with pharmacy and therapeutics (P&T) committee to ensure
that OAT was available on the hospital formulary and that standard procedures were in
place for the hospital OAT delivery: “The addiction consult service took the lead in
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partnering with the P&T committee to make sure we had access to buprenorphine,
extended-release naltrexone, and methadone, on the floors. [We] wrote protocols for
how those medications are used” (A1).
4.2.4. Financing. A common concern and activity across all services was planning
for and acquiring financial resources, which consistently constrained or facilitated AMC
service existence and operation. The fiscal environment for the services was complex
and tumultuous. Informants described service financial solvency dependent on a
patchwork of monetary streams, including: in-house financing; third-party payer
revenue; grant funding; state funding; and fellowship program funding.
Many services received in-house funding for the salaries of the clinical staff and
salaries for the addiction medicine fellows. The services procured these funds from
either a specific department (e.g., medicine or psychiatry) or from hospital operations.
In addition, some operating funds came through third-party payer billing. One informant
stated that they billed “just like any other consultant” (L1) and, other informants were
acutely aware of their reimbursement return rates: “We also do our own billing for
patients…[our] reimbursement return rate is only about 25% though, because the vast
majority of patients that we see are Medicaid or uninsured” (J1) and “Our recovery rate
was 28%, so we get paid about 28% of what we bill… When we add it all up, if a nurse is
billing at the right volume they actually pay for a lot of their salary” (K1).
Some AMC services operated as pilot programs through grant funding from the
hospital or an external entity (e.g., third-party payer or the state). One informant shared
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how a local managed health care organization was funding the salary, for a limited
duration of time, of specific service team members—the physician assistant and alcohol
and drug counselor. Informants shared that state funding for the service came from
state health care reform funds (e.g., accountable care organizations) or dedicated
indigent funds in the states that opted out of Medicaid expansion.
4.2.5. Summary. To date, prior research has not described the shared and
different organizational elements of more than one AMC service. Common design and
operational practices included weekday only service availability, the use of
interprofessional teams, the use of medical trainees, and three domains of responsibility
(i.e., education, delivery of psychosocial and medical services, and policy development).
AMC services varied by home department, the professional composition of the team,
day-to-day operations, and how the services were financed.
These analyses suggest three important conclusions. First, AMC service
responsibilities included two non-medical domains: 1) education; and 2) policy
development. This finding is not surprising because of the interprofessional nature of
the AMC service and because of the complexity of the external treatment environment
(e.g., policies and regulations). Second, the AMC service was not only a mechanism for
OAT delivery, but an intervention for shaping and changing hospitals’ social structures
through diverse responsibilities (i.e., education and policy development). Third, two
supply-side attributes influenced and mediated the AMC service design and operation—
the social structures within and outside the hospital environment, and financing.
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Section 4.3. Facilitators for AMC Service Implementation
Prior to this study, little was known about the facilitative attributes for the
creation of hospital-based addiction technologies and delivery of care for patients with
OUD. This section explores research sub-question 1b: Which internal and external
environmental supply-side elements facilitate hospital OAT delivery? A primary finding
from the qualitative aim of this study was that the AMC service was a key mechanism
for hospital OAT delivery and other OUD-related services. The service promoted and
increased the use of evidence-based services in the hospital and also catalyzed the
development of other organizational technologies, such as standard practice
documents. This section describes the hospital and environmental attributes that
facilitated AMC service establishment in 9 hospitals (n = 10) and the soon to be
established services in the 5 hospitals (n = 5). These elements existed within and outside
the hospital environment and as demand-side attributes (i.e., patient characteristics).
4.3.1. Facilitative attributes within the hospital. In the hospital environment,
AMC service development was only possible within the context of positive social
structures and appropriate technology and resources (i.e., staffing). Evidence of positive
social structures included: 1) a history of caring for persons with addiction within that
hospital or health system; 2) designated financial and clinical resources for addiction
treatment; 3) addiction medicine clinical training programs; 4) normative treatment
practices; 5) supportive clinical and administrative leadership; and 6) supportive internal
stakeholders.
145

4.3.1a. Historical support and practice. Informants noted that an institutional
history of addiction related initiatives facilitated AMC service design and operations.
Informants described prior practice as positively contributing to contemporary care
delivery environments: “I worked in the hospital where one of the founders of
Alcoholics Anonymous worked so the hospital has a long history of detox and treatment
of substance use disorder (L1)” and “A neurologist who had become interested in
addiction in the 1990s established a consult service and then there was an internal
medicine doctor who took it over…it was in many ways…almost like a labor of love” (F1).
Informants described three types of prior clinical practices that influenced service
establishment: 1) ad hoc consults; 2) “curbside consults” (M1); and 3) a buprenorphine
pager. Ad hoc consultation was the most common, present in several hospitals prior to
AMC service existence. This type of practice occurred when an addiction medicine
physician provided an informal consult on a SUD patient as a favor to a colleague:
One of my colleagues and I started doing ad hoc addiction medicine consultations
five years ago and that grew into the AMC service…We had so many patients on
the internal medicine and surgical wards with addiction issues that were really
going untreated, people knew that my colleague and I prescribed buprenorphine
and so they thought that we might be able to help…they would call us and we
would leave whatever we were doing and go do a consult. (A1)
The “curbside consult” approach, used in one hospital, occurred when an addiction
medicine physician provided informal consultation for the psychiatry consult service:
Basically, I just assist in education and curbside consult for the psychiatry consult
team. I am not billing for consults myself the psychiatry consult team is, but if he
needs my help he phones me and I provide him with, what I call a curbside
consult. (M1)
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The third approach, at another hospital, was a dedicated buprenorphine pager
staffed by a family medicine inpatient team that provided remote support on
buprenorphine initiation. The informant shared that “we kind of just do that on our time
on the side, to help coach providers who are interested in prescribing buprenorphine
but aren't sure how to for their hospitalized patients” (C1). The guiding philosophy
across all three strategies was the dedication of the addiction medicine physicians to the
ethical treatment and care for people with SUDs in the hospital, regardless of
compensation.
4.3.1b. Financial and clinical resources. Financial and clinical resources were
essential to AMC service establishment. Existing treatment services and research
programming for addiction often facilitated the creation of a service. From a clinical
perspective, in hospitals with addiction-related services already in existence, clinical
leaders could argue that AMC service creation was filling a gap in the SUD care
continuum. These additional services differed among hospitals and health systems, but
included established outpatient addiction medicine clinics, dedicated hospital units for
managing SUD withdrawal, intensive outpatient programming, affiliated or onsite OTPs,
and a residential halfway house. One informant commented that because of the already
in existence robust institutional addiction research program that hospital leadership
viewed addiction-issues with familiarity and positivity. In addition to physical resources,
such as clinics, dedicated beds, and research programs, informants described the
importance of the presence of human resources; specifically, addiction medicine
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physicians. Some of the informants shared that they were recruited to their institution
to start a service or fellowship program: “I was hired with the intent that I would build
this consult service and get it up and running” (I1).
4.3.1c. Clinical training programs. Finally, unsurprisingly, addiction-related
education programs and training activities facilitated an addiction-friendly hospital
environment. Informants described how the financing for their addiction medicine
fellowship was crucial for establishing a service. More than one informant described this
explicit financial connection between the service and the fellowship:
We kind of put a pitch together where we would ask for funding for the
fellowship slot and then use that for our consult service… the chair of the
department of medicine agreed to fund a fellowship slot and half of a nurse and
then we would staff it with attendings who would bill for services. (K1)
Trainee champions were another supportive element to service development.
Residents, in particular, became champions within the hospital for improving OUDrelated services:
The initial pilot program for buprenorphine induction in the hospital was the idea
of residents. And they really have taken this on. And asked to be trained, to be Xwaivered…All of the residents are being trained in buprenorphine prescribing. It
has been exciting to see how the educational aspect of this hospital has moved
things forward for everyone not just the folks who are currently in training. (C1)
These findings compliment observations from the prior section on the important
contributions of medical trainees for AMC service operation.
4.3.1d. Normative practice. AMC service development was facilitated by care
standards for SUD services within the hospital and health system. One informant
reflected on how the normative clinical practice (i.e., standard of care) of their hospital
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was that all providers from all services must “be able to provide methadone
maintenance. It is just routine standard of care.” (C1). At another hospital, this practice
was a requirement for all trainees: “We require that all our incoming interns…during
new intern orientation get buprenorphine waived” (O1).
4.3.1e. Administrative and clinical leadership. Supportive hospital
administrators, with guidance from addiction medicine clinical champions, drove AMC
service establishment. However, hospital administrators varied in their reasons for
supporting the service. Some administrators believed that addiction was a medical and
public health issue, some administrators had relevant clinical experience, but nearly all
were perceived to be moved to action by the “business case.” Addiction medicine
physicians were key leaders in developing and presenting the business case to garner
hospital administrative support. The approaches used to engage hospital administrators
included producing data on service needs and demands, including: 1) how the hospital
census had an elevated SUD prevalence; 2) how untreated SUD negatively impacts
hospital finances; 3) how other hospitals are benefiting from service implementation;
and 4) why the hospital addiction treatment gap is a care quality issue. Each of these
approaches are addressed in turn.
4.3.1e.1. Elevated SUD prevalence. Addiction medicine leaders presented either
national public health data or internal census data on the prevalence of SUD-related
admissions to their hospital: “Between 30 and 50% [of hospitalized patients] or more,
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have some co-occurring substance use problem and the inpatient [setting] is an
opportune time to try and tackle those problems” (E1). Informants shared:
We were able to collect data…we presented that to administration...they didn’t
have the awareness of the saturation of the problem and we were really able to
get buy-in from the president of the university…We basically just showed them
the data. (M1)
4.3.1e.2. Negative financial impacts. Addiction medicine leaders also presented
data illustrating how patients with untreated SUD in the hospital had increased resource
utilization and how that was negatively impacting hospital revenue. Informants noted
that readmission penalties and increased lengths of stay were persuasive arguments for
service establishment: “What we ended up doing was basically through that needs
assessment building a pretty strong business case around length of stay reduction and
also building a business case around readmission reductions” (A2). At one hospital,
administrators were convinced to implement a service because untreated SUD patients
had longer lengths of stay which was inhibiting patient flow between the emergency
department to the inpatient wards: “The emergency department was getting a lot of
pressure from the hospital to move patients quicker, lots of patients were lingering in
the emergency department that should have either been discharged or been moved to
beds on the floor” (O1).
4.3.1e.3. Success at other hospitals. Addiction medicine champions strategically
leveraged the success of other prestigious institutions that were already providing
inpatient resources for the treatment of SUD:
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In addition to the data that we had collected, it was honestly some healthy
competition. I was saying look [institution A] has one of these, [institution B] has
one of these, [institution C] has one of these, New York City is creating a city-wide
service through the health and hospitals program. It is really silly that we don't
have one. That caught their ear and they were able to look at the data a little
more. (O1)
Another informant shared how the positive press at a competing hospital pressured
hospital leadership to move more swiftly in implementing their AMC service: “The
neighboring institution started a service…a year before we did…and you know they had
positive press coverage…my hospital had fashioned itself as a leader in addiction and it
really prodded them and was useful external pressure.” (K1)
4.3.1e.4. Care quality. Informants identified and shared with leaders how
untreated SUD in the hospital setting was a care quality issue and why this issue fell
under hospital purview. One informant stated that they “had to show that the volume
of the service is really high [if] we are going to justify it [the AMC service]” (K1). Only
one informant described presenting patient care preferences to hospital administrators
when making the AMC service business case.
4.3.1f. Stakeholders. Internal stakeholders also supported AMC service
establishment (e.g., physician-based consultation services, nursing, hospital security,
and the P&T committee). Informants affiliated with large academic health centers had
access to other consult services. At some of the hospitals these other internal services
were either supportive or were an impediment to AMC service formation. The
supportive services varied and included the psychiatry consultation service, the pain
consultation service, and the cardiovascular surgical service. Long-standing partnerships
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with psychiatric consultation services were common and the services actively worked
together to delineate responsibilities, to collaborate on care for shared patients, and
produce educational activities. One informant described an uncommon collaborator—
the cardiovascular surgical service. The surgical service became involved in the
development of the AMC service at one hospital because the surgeons had decided that
they were no longer going to conduct valve transplants on patients who injected drugs.
The surgeons’ refusal to care for these patients resulted in a joint medical ethics
conference with the addiction medicine physicians, and this event inspired the surgeons
to become vocal supporters of improving care for patients with OUD, they helped to
lobby hospital administrators to launch the service.
Another informant shared the importance of working with hospital security staff
and officers, to help them better understand SUDs, because many of the service’s
patients were either currently involved with the criminal-justice system or were
participating in illegal activities while hospitalized:
The consult service slowly over time has been able to navigate that conversation
with hospital security, and use more conflict de-escalation approaches and
behavioral agreements to managing some of those behaviors with the goal of
keeping people in the hospital to complete their treatment and then engaging
them in the community for treatment afterwards rather than transitioning to jail.
(A1)
Internal collaborators (e.g., hospital administrators, the P&T committee, nursing
staff, clinicians in other departments) further bolstered the creation of other hospitalbased technologies to promote evidence-based delivery of services for patients with
OUD, and the development of hospital guidance documents: “It has been helpful to
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have support from multiple different department. The support of the obstetrics team,
our anesthesiology team, and our pharmacy” (C1).
4.3.2. Facilitative attributes outside the hospital. The external environment,
outside the hospital, positively mediated AMC service creation. Facilitative
environmental influencers included: 1) non-clinical stakeholders; 2) clinical
stakeholders; 3) a robust community-based treatment network; 4) media coverage on
the opioid overdose epidemic; 5) policies and regulations; 6) politics and political action;
and 7) financing.
4.3.2a. Non-clinical stakeholders. Non-clinical stakeholders contributed to the
introduction of and support for AMC services. Stakeholders helped by: 1) generating
new normative expectations and behaviors related to hospital addiction care; and 2)
pressuring hospital leadership to address the issue. The non-clinical organizations of
influence included the Association of American Medical Colleges (AAMC), the Office of
National Drug Control Policy (ONDCP), local governments, and the state Medicaid
programs.
4.3.2b. Clinical stakeholders. Key informants recognized the value of formal and
informal partnerships with community-based clinical providers and other local
institutions. One informant noted that: “There is no doubt that without pathways to
treatment in the community we would be hamstrung” (A2). Informants described
professional relationships with other hospitals in their community and with a peer-
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based agency. Support from colleagues at a nearby hospital facilitated service training
and development:
We are very friendly with them [the providers at another hospital] …. Our clinics
talk together the most…more than our consult services, but the…clinics are really
extensions of the consult services…The other institution is starting a fellowship so
we plan on including them in our multiprogram case conference…We are all
friends. (K1)
4.3.2c. Robust community-based treatment network. Access to communitybased treatment resources facilitated AMC service establishment in some communities.
Although the majority of informants indicated a dearth of community-based treatment
services available to their patients, a few informants perceived that their communitybased treatment network was readily accessible for their patients upon discharge:
In our state, different counties have mental health and recovery boards and
funding to support treatment for people, and the county where we are located is
very very good, they have a lot of treatment facilities and options where they pay
for people to go to treatment. So, they were very helpful to us because they
offered us pipeline warm hand off essentially for people who were seen in
consultation to be able to transition after they got out. (L1)
4.3.2d. Awareness generation through media coverage. Public awareness of the
opioid overdose epidemic, occurring primarily through local and national media
coverage, supported service creation. General awareness about the opioid overdose
crisis among hospital leadership created pressure for leadership to start a service. An
informant stated that: “What really opened up the door was the opioid epidemic. Now
hospital leaders have been paying attention” (E1), and another noted that they believed
“it has been all the attention on the opioid crisis has been getting in popular media and
dollars are starting to be direct to that” (J1). Further, local media coverage educated
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other providers within the hospital about the challenges of the opioid overdose
epidemic in their local community: “I think all of the news media coverage of the opioid
epidemic. Our providers are seeing the reality of that on the streets of our city. It has
been hugely helpful” (C1).
4.3.2e. Policies and regulations. External policies and regulations generally were
predominantly unsupportive of AMC service establishment. Despite this, informants
noted four external policies and regulations that helped: 1) the American College of
Surgeons’ trauma certification requirements; 2) Medicaid expansion; 3) the changing
telehealth laws; and 4) Medicaid coverage for SUD treatment. One informant
elaborated further:
One big positive is our state signed up for Medicaid expansion. A lot of these
patients are covered [by Medicaid] …When I talk to people in North Carolina,
they don't have that. It is hard for me to imagine you know how they can help
patients. In that regard we are fortunate that many of our patients can access
health insurance and that provides them with access to good treatment. (D1)
4.3.2f. Supportive politics and political leadership. Local political leaders
contributed to AMC service implementation. In some jurisdictions, local city leadership
explicitly called upon hospitals to act. One informant reported that: “The health
commissioner here has encouraged hospitals to get more involved” (D1). In a different
city, the leadership of the city health department scaled up the city-wide hospital opioid
overdose prevention programs and provided funding for naloxone distribution in
hospitals.
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4.3.2g. Financing. Overall, the financial landscape constrained AMC service
implementation and operations, however, in certain contexts, financing promoted
service formation. One informant shared how quality metrics and financial incentives
and penalties linked to hospital benchmarks helped to support the business case for the
existence of an AMC service. In some local contexts, state and regional capitation-based
insurance programs and their payment policies tied to readmission rates indirectly
drove hospitals to improve services for persons with SUDs, who were commonly
readmitted.
4.3.3. Summary. The synthesis of these findings helps to answer why a simple
supply-demand model is insufficient to explain AMC service development: “It is [the]
convergence of funding opportunities…greater awareness, and grassroots advocacy by
me and my colleagues here at the institution....” (E1). These analyses suggest that the
contributions of internal and external supply-side attributes were influential for
inspiring hospital innovation and creation of new care delivery mechanisms for persons
with OUD and SUD. Support attributes within the hospital context included positive
social structures for addiction-related services, historical practice, previous clinical and
resource investments in addiction related care, especially addiction medicine training
programs, normative treatment practices, and supportive internal stakeholders.
Partnerships with clinical and non-clinical stakeholders further supported service
development. Additional facilitators included access to community-based treatment
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providers, normative practices related to addiction treatment, policies and regulations,
financing, and media coverage and awareness of the problem.
Section 4.4. AMC Service Implementation Barriers
This next section explores research sub-question 1c: Which internal and external
environmental supply-side elements impede hospital OAT delivery? Informants from all
16 hospitals (n = 17) furthered the understanding of barriers to AMC service
development and hospital OAT delivery. These constraining elements existed within and
outside the hospital, providing insight as to: 1) why hospital AMC services are a relative
new mechanism of care; 2) why adoption of AMC services across the U.S. is slow; 3) why
the hospital OAT delivery is underused; and 4) the potential leverage points to decrease
barriers.
4.4.1. Barriers within the hospital. Key informants from all 16 hospitals
described internal barriers to service establishment, service planning, and the delivery
of OUD-related services. Six interdependent organizational barriers emerged: 1)
restrictive policies and regulations; 2) existence of bureaucratic processes; 3) limited
hospital-based staffing and resources related to addiction service delivery; 4) internal
stakeholders; 5) stigmatizing behavior and training gaps perpetuated by hospital staff
and administration; and 6) financial instability.
4.4.1a. Restrictive policies and regulations. In some hospitals, the inpatient
pharmacy and P&T committee would create internal policies that inhibited OAT access:
“There are certain rules you have to follow for using certain medications within the
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hospital” (L1). One hospital did not have mono-product buprenorphine and only stocked
combo-product (buprenorphine/naloxone), thereby creating issues for treating
pregnant women because first-line treatment is mono-product. In another hospital,
conversely, the hospital formulary only included the mono-product buprenorphine,
requiring patients using the buprenorphine/naloxone combination product to switch or
discontinue during the admission. Another informant gave up trying to get the
buprenorphine implant added to the hospital formulary, stating that: “[the hospital] will
road block anything” (G1). Other internal formulary and prescribing restrictions included
limitations on when providers could prescribe buprenorphine/naloxone. One hospital,
for example, restricted buprenorphine/naloxone administration only to prescribers with
a federal buprenorphine waiver. Notably, this was one of the two hospitals without an
AMC service or plans to start one.
4.4.1b. Bureaucratic processes. Barriers to service development were related to
the bureaucratic properties of large hospitals: size, staff turnover, and slow and complex
decision-making. The large size of teaching hospitals created challenges for service
development because the newly forming AMC service was just one of many
consultation services: “[there are] only so many hours in the day for you to get in front
of people's eyes” (H1). Further, more than one informant described staff turnover as
operationally problematic, creating confusion related to the service’s roles and
responsibilities. Finally, the slow, formal, and hierarchal decision-making process slowed
down service development: “There are always the process barriers in any kind of
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hospital system or university. If you present a procedure it has to go through formal
processes, formal committees, policy committee, and up to the top” (M1), and:
As far as rolling something out you got to get it cleared by a million different
people, there is like, it is like dealing with the federal government basically, you
can't just get everyone in a room really quick and here's what we are going to do.
Our size works against us. (H1)
4.4.1c. Limited staffing and resources. Limited clinical staff with addiction
medicine expertise was a common barrier for service development and operations: “We
haven't had enough qualified faculty to be able to [start the service] until recently” (N1).
In the two hospitals without an AMC service or the plans to start one, informants shared
that the primary cause was a lack of resources, stating that: “Manpower is number one”
(G1) and “It is mostly been for lack of personnel… [to] have the bandwidth to do it” (B1).
Even for those with an established AMC service, after launching, more than one
informant described issues related to access to physical resources and staffing: “I still
have no office. I still have no dedicated land line. I don't have an admin” (P1). When
asked about dedicated individual time to the AMC service one key informant responded:
“I have about 20% FTE which is not nearly enough” (J1).
4.4.1d. Unsupportive internal stakeholders. Another common barrier to service
development and operations was resistance from other hospital stakeholders. An
informant noted: “There…[are] certain individuals who are going to slow that process
down...They have some personal biases” (M1). Psychiatry consultation services were
frequently responsible for creating roadblocks. More than one informant described the
tension between the two services as a “turf war.” Some opined that the AMC service
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threatened the psychiatric consultation liaison service because of the other service’s low
volume: “Ironically it is the psychiatrists here who aren't as enthusiastic. It has been kind
of a funny turf war. People get their thing going at a hospital and they see other services
as competition” (E1). Informants also believed that the psychiatrists were reluctant to
deliver evidence-based OUD services because of stigma and limited training experience
in caring for persons with SUDs.
Hospital leadership also impeded service and addiction treatment resource
development. One informant, without a service, described how leaders at their hospital
had “no foresight” (G1) when it came to issues related to addiction. This informant
believed that unless outside forces intervened, such as an external mandate requiring
evidence-based service delivery for OUD, or for reimbursement, that hospital leadership
would never address the issue. Hospital leaders also had concerns about starting a
service without explicitly identified connections to care upon discharge:
I think there was also a lot of concern from our hospital leadership around
making sure that patients were connected to outpatient care on discharge.
Which is a complex issue because there are some patients who may or may not,
as I was saying, connect to care on discharge. (C1)
4.4.1e. Stigmatizing provider behavior and training gaps. A consistent barrier to
hospital OAT delivery across hospitals was a lack of provider education and training. This
resulted in stigmatizing behaviors and discriminatory practices by non-addiction trained
hospital providers:

160

Stigma is about lack of education...and the personal experience of the person
who is stigmatizing the patient...I encourage [other clinical providers] to
understand [addiction] through the chronic disease model and [I] just listen...
Many times, it turns out...it is a lack of information and once I provide
information the stigma sort of just melts [away]. (P1)
Limited education and training on the treatment of SUDs is based on historic and
contemporary social structures within undergraduate and graduate medical education
training programs and further enforced through other supply-side attributes (e.g.,
reimbursement and financing policies, undergraduate and graduate medical education
accrediting bodies). The confluence of these elements informed hospital culturalcognitive social structures and in turn, likely negatively impacted the care of persons
with OUD and other SUDs within the hospital. Informants frequently observed
stigmatizing and discriminatory behavior by other providers and recognized that these
actions reflected the failure of medical education to train physicians properly in
addiction:
Historically, the medical profession really has not viewed the treatment of
addiction as part of what they do. At best, people would get a referral at the end
of their hospitalization for rehab. And there would be no attempts to initiate
treatment within the hospital. Obviously, that has not worked very well. Even
when the primary reason for hospitalization was related to their substance use.
(A1)
Further, informants observed other hospital providers as having historically antiquated
and uninformed ideas about addiction:
In this area of the country there is still the perception by many people that
addiction is not an illness, but it is a spiritual deficit, or a personal, or personality
deficit. We have a lot of barriers just in terms of educating our staff to not treat
these people differently than they would treat an individual who comes in with
chest pain. (M1)
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Even more alarming was the observation that providers who interfaced most
frequently with SUD patients, orthopedic surgeons and emergency department
physicians, were particularly uninformed on OUD and SUD treatment best practices. An
informant described how the orthopedic surgical team had a culture of “just treat ‘em
and street ‘em” (H1). In the emergency department, one informant shared how she
believed that emergency services were re-traumatizing SUD patients and that it was a
missed opportunity for care. Further, another informant explained that emergency
department services were deficient because of “Ignorance...you know the kind that
many of us in the health care field have been raised with. Modeling is often…not often
very consistent...and non-therapeutic” (G1). This informant perceived that the origin of
the challenges in the emergency department was due to the department’s externally
contracted physician staffing model that resulted in limited incentives to improve care.
Another informant shared how emergency department physicians at their hospital
believed it to be illegal to provide methadone for withdrawal: “I am going to talk at the
[emergency] department meeting and explain that it is in fact legal and humane to treat
withdrawal and that is how you can do it safely. There are really big gaps in knowledge”
(A2).
Provider misunderstanding and confusion regarding OAT policies and regulations
was common across all hospitals, and not only an issue specific to the emergency
department providers. Informants frequently observed non-addiction trained providers
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misinterpreting OAT regulations and subsequently not providing care. Providers and
administrators believed it was illegal to administer OAT in the hospital:
There is still the perception on the part of many providers that somehow it is
illegal to engage in that practice [administer methadone in the hospital] …. [the]
pharmacy has been a barrier, when Suboxone® or methadone-based
maintenance and taper regimen gets ordered and the pharmacist says you can't
do that, that is illegal. (J1)
I know that because we are not certified as an OTP that there is much hesitance
around this [administering methadone]. I know that there is as you know, the 72hour rule, so you can manage withdrawal on inpatients, but it is not practiced. I
would say that generally our legal department is very conservative when it comes
to things like that. (B1)
Hospital providers, not trained in addiction medicine, often believed they had to
have a special wavier to administer OAT during hospitalization: “The perception is that a
provider making the order, even in the hospital setting, needs to have the DATA waiver
to prescribe administer a buprenorphine product for that indication” (J1). Beyond legal
confusion, informants observed that other providers had a limited understanding of
OAT efficacy. It was common in one hospital that non-addiction trained providers
believed that OAT was “substituting one drug for another” (C1).
In addition to the confusion about legality and efficacy, informants observed
more subtle forms of stigma—apathy. This was most commonly perpetuated by hospital
leadership who decided against supporting or investing AMC service resources:
They start with all the reasons it can't be done and stop there…you know people
don't want to say out loud things like "well we don't to be known for that kind of
thing." I think again that maybe they feel we don't want to draw attention to
that I would rather draw attention to our new cardiology center…so its
prejudiced. (G1)
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Hospital leadership also held AMC services to a higher productivity standard than
other services. An informant noted the hypocrisy of how the AMC service had to justify
its existence by proving financial sustainability, while other non-revenue generating
services continued to operate without the that expectation:
I think there is still a lot of embedded stigma. It is structural. To assume that
there is a good reason for why the addiction consult service is held to a different
standard than established consult services than you know...we are only going to
do it if it is good for our business. Number one public health issue that the
community is facing. Ebola didn't generate a lot of revenue but it cost a shit load
for the hospital even though we didn't have one single patient. (K1)
Finally, and importantly, an informant observed that language used within the
addiction medicine community may perpetuate stigma and mythology around the
complexity of the medical management of OUD:
The term induction is something that I don't really like a lot. I don't actually use it
myself. I just say I am starting treatment. It makes it seem like this fancy
procedure that we are doing and we are just starting someone on treatment. I
don't really see it as any different than starting any other treatment… I think
calling it induction is a barrier to starting treatment. (D1)
4.4.1f. Limited internal financing. Securing and sustaining internal financing for
the AMC service was the “the biggest barrier” (A1) and “the hardest thing” (M1). The
complex financial landscape created multiple barriers to planning, establishing, and
delivering inpatient evidence-based AMC services. First, most AMC services operated
from a cost savings model versus a revenue-generating model, making it challenging to
articulate the fiscal value of the service to hospital leadership: “No matter what…we
operate at a loss…there is not enough billing, our billing does not support the breadth of
our team” (A2). Respondents from two different hospitals stated that their hospitals had
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closed their previous AMC services because of funding issues, because of these internal
constraints, informants had to look outside the hospital for funding:
We are currently applying for grant funding to do a pilot. To get a couple [of]
years’ worth of funding to attempt to have a consult service with the hope that
the hospital will see that it is useful to them and take over funding in the future.
(C1)
4.4.2. Barriers outside the hospital. Key informants described four external
supply-side constraints to establishing an AMC service and for delivering OAT: 1) limited
access to community-based treatment resources; 2) restrictive and limiting policies and
regulations; 3) unsupportive local politics; and 4) unstable financing.
4.4.2a. Limited community-based treatment network. Informants identified that
a limited community-based treatment network constrained service delivery and design
within the hospital because of issues related to hospital discharge and transitions to
care. Informants described five barriers that could prevent a patient from successfully
transitioning: 1) the location of the resources or facilities in relation to where the
patient lives; 2) the capacity of the treatment programs (e.g., number of beds, number
buprenorphine providers, number of clinicians); 3) discriminatory organizational
practices and policies; 4) insurance barriers (e.g. programs not accepting Medicaid); and
5) a limited range of programs with the appropriate intensity of services.
The community-based treatment programs such as skilled nursing facilities and
social service and housing programs used discriminatory practices and policies to deny
admission to patients discharged from the hospital on OAT. These policies and practices
commonly hinged on the issue of the patient receiving OAT at discharge and the facility
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not wanting or having the resources to support the patient in continuing their OAT
medication. One informant shared that the skilled nursing facilities in her community
always happened to be full whenever their team tried to discharge a patient there who
had history of injection drug use. Another informant observed that treatment centers
were unwilling to invest in resources to care for persons with intravenous antibiotic
needs, resulting in patients “sitting here in the hospital for 6 weeks because no
treatment center is able to take someone with a PICC line...” (I1).
4.4.2b. Restrictive policies and regulations. Additional challenges for delivering
evidence-based services to persons with OUD in the hospital setting were related to
policies and regulations created and enforced by non-governmental (e.g., Accreditation
Council for Graduate Medical Education [ACGME]) and governmental (e.g., local, state,
and federal) bodies. Many of the described regulatory barriers were connected to OTPs.
One informant shared how state-mandated clinical assessments that had to be
completed prior to OTP placement limited the number of patients that the service could
see because they did not have enough staff to complete the multi-hour assessments for
all qualified patients. Further, federal regulations allowed OTPs to create their own
organizational policies, which can result in discriminatory practice. An OTP in one
community, for example, discharged patients from its treatment program if the patient
had a positive urine drug screen for methamphetamine. Moreover, informants
continued to be frustrated by the federally mandated buprenorphine patient panel
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limits and the strict regulations imposed by pharmacy boards, the DEA, and third-party
payers.
Forthcoming changes (academic year 2019) to educational policies may also
constrain hospital-based OAT delivery. Recently, some addiction medicine fellowship
programs were approved for accreditation through the ACGME. ACGME fellows,
however, are not allowed to bill for patient visits independently, in turn likely changing
the supervision and staffing requirements of some of the AMC services.
4.4.2c. Unsupportive politics and political leadership. Key informants discussed
the challenges of delivering evidence-based services in the hospital setting because of
an unsupportive political environment: “It is all personality, logistics, and politics
honestly” (M1). An informant practicing in a politically conservative community
described OAT barriers as existing because of a lack of political will: “We are at the
mercy of the legislature here...and so you know they are willing to spend money on the
unborn but not on anybody at birth unfortunately...we are trying to make headway
there” (N1). Further, political leaders in this jurisdiction had other uninformed opinions
about evidence-based OAT:
[The state Medicaid program does not pay for methadone]. People who are on
methadone have to pay private facilities cash in order to get methadone…I can
speculate but I think it is political. There is this stigma. They think these people
are enjoying themselves on methadone. They do not see it as therapeutic. (N1)
4.4.2d. Limited financing. Informants identified multiple financial barriers to
delivering hospital OAT:
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I think really the biggest obstacle is the money. You just got to follow the money.
If you just follow the money. I think people culturally are willing to accept that
addiction is a disease and to treat it is such. But they aren't going to do it out of
the goodness of their heart. You have to find a way to pay them. (E1)
Third-party payers imposed five external financial barriers for the AMC services:
1) a lack of reimbursement for interprofessional teams; 2) the incentivization of nonevidence-based services (e.g., funding detox beds); 3) reimbursement restrictions; 4)
prior authorizations and utilization review; and 5) limited financial incentives for
delivering evidence-based care. An informant noted that: “The hospital is not going to
turn off that revenue stream [for detox beds] just because they don't think it is the best
idea for the patient” (H1). A source of deep frustration among informants were the
third-party payer pharmacy benefit management strategies for OAT such as prior
authorizations, quantity limits, and formulary restrictions:
[Our state] requires essentially a prior authorization before basically anyone can
write Suboxone®, and each insurance company, and even each Medicaid plan.
We have [multiple] managed Medicaid plans in the state. Each one has different
guidelines on what you are allowed to write… and of course quantity limits… That
is going to be a huge barrier to doing this in the emergency room. (B1)
If we induce them in the hospital…it is always unclear to me if the insurance
company is going to approve the films or the tablets? Are they going to approve
the tablet size? Are they going to have a problem with that? I end up re-writing
prescriptions quite a bit in the hospital just to get the prior authorization
approved for a couple of days. (I1)
Another complicating financial element was third-party payer contracting. Most
hospitals in the U.S. participate in the diagnostic related grouping (DRG) billing system,
which is a contractually agreed upon payment for a specific condition or treatment
bundle. This is problematic for treating OUD and SUDs because there is no DRG specific
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to the interprofessional and comprehensive management of drug use disorders
secondary to the primary reason for admission; thus, hospitals cannot be rewarded for
comprehensively caring for patients with SUDs under this contractual structure. One
informant noted that billing barriers may also exist in the emergency department and
were told by administrators that they were prohibited from billing consultation services
in the emergency department. It is unclear if this is either a jurisdiction or hospital policy
specific issue. Finally, key informants described issues related to pharmaceutical pricing
as influencing accessibility to OAT in the hospital context. At one hospital, the hospital
only purchased mono-product, and did not stock combination-product because of costs.
4.4.3. Summary. The external supply-side barriers to AMC service establishment
and the delivery of evidence-based OUD services were extensive and prohibitive. The
socio-economic-regulatory environment in which hospitals exist was described as
inhospitable for AMC service establishment and for the effective delivery of OAT.
Barriers within the hospital setting included policies and regulations, bureaucratic
processes, limited staffing and resources, internal stakeholders, stigmatizing provider
behavior and training gaps, and limited financial resources. In the external setting, the
barriers were access to community-based resources upon discharge, external
educational and care delivery policies and regulations, and third-party financing (e.g.,
billing and reimbursement).
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Section 4.5. The Contribution of Demand-Side Attributes
Although the focus of this research, in theory and design, was on the facilitative
and constraining supply-side elements related to AMC service development and hospital
OAT delivery, informants also described contributions to care from the demand-side
(i.e., patient attributes). Informants perceived demand-side elements as primarily
increasing barriers to evidence-based services. Patients with OUD who injected drugs
were particularly challenging to serve in the hospital because of their complex medical
and social sequalae including serious infections (e.g., endocarditis), concurrent stimulant
use disorder, homelessness, criminal justice involvement, or a lack of health insurance.
Insurance status and third-party payer coverage policies also created barriers to patients
getting timely access to OAT or other OUD-related therapeutics:
Sometimes insurance can be an issue for patients getting rapid access. We may
be able to give them extended release naltrexone while in the hospital, but to
give that when they leave, it typically requires an onerous prior authorization
process, we sometimes run into the same issue with buprenorphine and can
result in gaps in treatment. (A1)
Finally, patients had their own internalized stigma about OAT:
Unfortunately, there are many patients that are not interested in maintenance
treatment and so unfortunately a lot of people end up requesting tapers and they
don't always appreciate the efficacy or understand the gravity of their problem…I
think part of it is the stigma about medication assisted treatment. I think a lot of
patients fear medication assisted treatment, they don't want to be “hooked” on
something, they don't want to be dependent on something, and I think
particularly around hospitalization many people view that as this important
moment, I am finally going to get clean. Unfortunately, they view being on
methadone or buprenorphine as not being clean. (H1)
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In contrast, the only facilitative demand-side attribute described by the
informants was pregnancy. Pregnant women were a frequent focus of efforts for
providing timely evidence-based protocol driven hospital-based services supported with
linkage to care. This model population exemplified how people with SUDs could
effectively receive care in the hospital: “Pregnancy was probably the place where all this
was standardized first...anyone who presents to the emergency department pregnant
and in withdrawal is supposed to come up the labor floor and if they want to, they get
induced and stabilized” (F1). It is possible that the consistency around care for pregnant
women with an OUD is primarily driven by the desire to decrease complications during
pregnancy, in particular premature birth, and to improve outcomes when neonates are
born to minimize the harms, and length of stay, as it relates to neonatal opioid
withdrawal syndrome.
Section 4.6. Beyond the AMC Service: Emergent Supply-Side Elements
Beyond the development and implementation of AMC services, informants
described six emergent supply-side actions to enhance OUD-related hospital services: 1)
incentivize evidence-based care; 2) increase addiction-related training requirement; 3)
create treatment organizations or programs to enhance continuity of care; 4) deliver
care through a trauma-informed and harm reduction approaches; 5) reframe the opioid
problem; and 6) review and improve treatment policies.
Informants recommended creating financial incentives for high-quality evidencebased SUD care and to disincentivize non-evidence-based care during hospitalization.
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Informants also recommended that third-party payers should not reimburse ineffective
services, such as only offering opioid withdrawal services (“detox” protocols) and that
third-party payers (i.e., CMS) should develop value-based reimbursement mechanisms
to create external financial incentives:
I think if there were more clear incentives, financial incentives, in terms of
reimbursement structure that would be the best way to mobilize doctors to pay
attention to this problem and invest in making changes systematically to help
people with substance use problems in the hospital. That is the type of thing that
requires CMS to really take the lead. (E1)
Informants recognized education as an important element for improving hospital
services for patient with OUD. An informant noted that one approach to increase the
number of hospital AMC services across the U.S. could be to require AMC service
rotation as a part of ACGME internal medicine accreditation.
Another suggestion to improve hospital services for patients with SUD was to
create dedicated healing spaces for patients to go upon discharge, such as a skilled
nursing facility with addiction medicine services. Informants reflected on the
traumatization of hospitalization and the need for trauma-informed training among
hospital staff: “I don't think I fully appreciate the amount trauma that hospitalization
really...it is so traumatizing. I think. In the power and the hierarchy…it is really intense”
(A2). Further, informants noted that internal hospital policies, such as a no smoking
policy, were not effective for supporting people with SUDs during hospitalization:
There is a policy about smoking…People aren't allowed to smoke. They aren't
allowed to even walk outside to go to smoke…There is no smoking allowed either
in or around the hospital. Sometimes people want to leave to go smoke and
sometimes they just go smoke. And that creates issues. (D1)
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One of the things I have had to learn. Is to prioritize our goals…You want to make
sure somebody isn't going to die of a heroin [over] dose when they leave, you
want to make sure they complete their antibiotic course for endocarditis. So, we
really focus on those things. And sometimes that means letting smoking slide. If
for example the thing that is keeping them in the hospital is going out and
smoking every day, you let them go out and smoke. (A1)
Informants generally perceived that hospital leadership and, subsequently,
hospital-based initiatives, overly focused on opioid delivery with not enough emphasis
on OUD treatment. In general, hospital administrators and the broader non-clinical staff
had narrowly constructed assumptions about the problem of opioid overdose and the
responsibilities of the medical community to address the opioid overdose epidemic. The
rationale was that if access to opioids is severed in the health care setting, people will
stop using prescription opioids, and the opioid overdose epidemic will end. This type of
rationale places opioids and opioid use in the category of deviant behavior, and
discredits the clinical utility of opioids as an analgesic: “Just because they have an opioid
use disorder does not mean we need to take all opioids away from them. We still need
to adequately treat their pain and do it in as safe a way as possible” (C1).
Informants suggested that policymakers interested in enhancing SUD service
delivery in the hospital, review the treatment policy barriers associated with transitions
to care, particularly for OTPs, SNFs, and the criminal justice system. One potential
intervention to improve hospital transitions to care, as discussed by informants, was to
open hospital-affiliated OTPs. An informant, however, noted how challenging this would
be: “The limitations with [OTPs] are massive. There are both state laws and city specific
laws that render it almost impossible to find a physical space in which you could open a
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new OTP” (F1). Decreasing barriers to care through the elimination or revision of
existing policies in the external setting could enhance the provision of hospital services.
Informants described a range of issues relevant to improving and enhancing the
delivery of services for patients with SUD, and particular those with OUD. They
recognized the power of money in the health system, calling for the development of
reimbursement programs that financially reward hospitals for providing evidence-based
services and penalizing hospitals that provide non-evidenced based services to patients
with SUD. Informants noted the benefits and harms of addiction medicine specialization
and also noted the constraints of community-based OUD treatment policies for
delivering effective services for patients with OUD during hospitalization and upon
discharge. Informants also described a need for creating community-based treatment
programs to enhance continuity of care and the need to provide education to hospital
providers on trauma-informed care. Finally, more broadly, informants articulated that
hospital leadership had a narrow conceptualization of the opioid overdose epidemic and
that reframing the issue around treatment could be a helpful approach for designing
effective hospital-based services.
Section 4.7. Hospital Guidance Documents and Standards of Care
This next section explores research sub-question 1d: How do hospital policies
inform OAT delivery? This was assessed through the analysis of 25 OUD-treatment
related hospital guidance documents (i.e., policies, procedures, protocols, guidelines,
quick guides, and order sets) from 10 non-VHA hospitals (see Table 4.3), and informant
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interviews. Hospital guidance documents, a type of organizational technology, are both
an output of addiction related technologies and resources within an organization (e.g.,
addition trained clinical staff) and a reflection of social structures within the hospital,
specifically cultural-cognitive structures, which are the beliefs of people within an
organization (Scott, 2003). The findings from this section provide a preliminary
understanding of how hospital OAT delivery is conceptualized and potentially practiced
in well-resourced, non-VHA hospitals; and supports prior findings that an output of the
AMC service includes the development of other hospital technologies, such as hospital
guidance documents.
4.7.1. Guidance document domains. Two overarching policy domains,
comprised of eight policy sub-domains, were observed across guidance documents: 1)
OAT management and 2) security and behavioral management (see Table 4.4). The most
common policies were in the OAT management policy domain, specifically for opioid
withdrawal (n = 6), and the second most common was OAT continuation (n = 4). Of the
nine hospitals with an established AMC service, seven (Hospitals A, D, F, H, I, J, and K)
provided documents related to the care of persons with OUD. Policies were not
provided by Hospitals E, G, L, M, O, or P. The policy summaries (33 pages of text) may be
requested from the primary researcher.
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Table 4.3. Hospital Guidance Documents: By Title
Hospital
A

AMC Status
Established

Guidance Document Titles
Preoperative and Postoperative Pain Management
Practice Guideline
2. Misalignment of Care Guideline
3. Safety Agreement Policy
4. PICC Policy
5. PICC Assessment Tool
B
None
6. Aberrant Drug Use Policy
C
Planned
7. Acute Pain Management Guideline
8. Inpatient Methadone Guideline
9. Inpatient Buprenorphine Guideline
10. Methadone Order Set
11. Buprenorphine Order Set
12. Methadone Quick Reference Guide
13. Buprenorphine Quick Reference Guide
D
Established
14. Withdrawal Management Protocol
15. Methadone Protocol
F
Established
16. Withdrawal Management Protocol
H
Established
17. Withdrawal Management Order Set
I
Established
18. OAT Guideline
J
Established
19. Aberrant Drug Use Policy
20. Withdrawal Management Order Set
K
Established
21. Leaving Against Medical Advice Policy
22. Preoperative and Postoperative Pain Guideline
23. OAT Management During Pregnancy Guideline
24. OAT Management in Non-Pregnant Adults Guideline
N
Planned
25. Withdrawal Management Protocol
Table Notes. PICC = peripherally inserted central catheter; OAT = opioid agonist therapy.
1.

Table 4.4. Hospital Guidance Documents: Content Areasa
OAT Management
Security and Behavioral Management
Acute
OAT
OAT
Opioid
Aberrant
AMA
Safety PICC
Pain
Cont.
Initiation
Withdrawal
Drug Use
Line
A*
X
.
.
.
.
X
X
X
B1
.
.
.
.
X
.
X
X
C2
X
X
X
.
.
.
.
.
D*
.
X
.
X
.
.
.
.
F*
.
.
.
X
.
.
.
.
H*
.
.
.
X
.
.
.
.
I*
.
X
.
X
.
.
.
.
J*
.
.
.
X
X
.
X
.
K*
X
X
X
.
.
X
.
.
N2
.
.
.
X
.
.
.
.
Table Notes. aGuidance documents could be categorized into more than one policy domain; *Established
AMC service; 1No AMC service without plans to start one; 2AMC service being planned; AMA= leaving the
hospital against medical advice; PICC = peripherally inserted central catheter; OAT = opioid agonist
therapy; Cont. = continuation.
Hospital
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4.7.1. Domain 1: OAT management. Informants from all hospitals provided or
described hospital-based policies and practices related to OAT management. Four OAT
policy and practice sub-domains emerged: 1) acute pain and perioperative
management; 2) OAT continuation; 3) opioid withdrawal management; and 4) OAT
initiation.
4.7.1a. Acute pain and perioperative treatment: Guidance documents. Three
hospital guidance documents (Hospitals A, C, and K) explicitly addressed OUD-related
acute pain and perioperative management approaches. The documents, all hospital
guidelines, recommended the same general practice—OAT continuation for all patients
who had previously established OAT in the outpatient setting. Hospital K differed from
the others by recommending that pregnant patients on buprenorphine, in need of
additional opioid agonists, be discontinued from buprenorphine when additional opioids
were required for pain control. Hospital C and K included recommendations for
buprenorphine and methadone, and Hospital A recommendations were for
buprenorphine only. All the guidelines recommended the use of non-opioid adjuvants to
manage pain in the pre-operative and post-operative period.
All three guidelines recommended the use of opioid agonists for breakthrough
and severe pain. Recommendations (Hospital C and K) explicitly noted that opioid dosing
would likely be higher due to tolerance. All three guidelines suggested alternative OAT
dosing approaches to manage pain. Two guidelines (Hospital A and Hospital K)
recommended increasing the buprenorphine dose and all three guidelines
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recommended increasing OAT dosing frequency. All three guidelines included action
related to discharge planning to ensure continuity of OUD treatment. Table 4.5 (after
Section 4.7.1b) summarizes and compares the care policy domains (i.e., continuation of
OAT, the use of non-opioid adjuvants, the use of opioids, alternative OAT approaches,
and discharge planning).
4.7.1b. Acute pain and perioperative treatment: Interviews. Informants that did
not have or provide analyzable documents described routine practice and care
considerations for acute pain management and perioperative management for patients
with OUD. There was a consensus among informants that daily OAT should be continued
during hospitalization and that the buprenorphine dose could be increased or split to
manage pain: “With methadone typically, we will just continue it and use a full agonist
on top of it…. I think in general we find that just continuing it [buprenorphine] is the
best policy. That is generally what we recommend” (D1) and:
We do not have an official procedure or guideline but our consult service
recommendations would vary if the patient was on methadone or buprenorphine.
For methadone we keep it on and have them add pain medication. For
buprenorphine we may keep it on and split it, or slightly increase the dose, or
hold it and just give more pain meds and then help advise them when to restart
it. (I1)
At some institutions this practice was described as occurring on a case-by-case basis:
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We treat every case individually. The degree of the pain the person is in, how
long we expect them to be in pain, what their goals are. I had a consult with a
woman with septic arthritis of her hip and severe pain. Her long-term goal was to
be on methadone maintenance which she had been on before but was not
currently on. We treated her pain with methadone in divided doses and she
needed six weeks of intravenous antibiotics. So, she went to a nursing home on
methadone for her pain and her addiction treatment. It really depends. I had
another patient with more minor pain…so we gave him buprenorphine he was
happy with that and he followed up with me in clinic. It depends on the patient.
(D1)
Informants commented that managing this clinical scenario, continuing OAT through
surgery or pain, frequently required a phone consultation or in-person consultation with
an addiction medicine expert or the AMC service:
They tend to consult us pretty frequently for that...I think there is...from the
perspective of addiction medicine we tend to recommend continuing their basal
opioid requirement and treating acute pain on top of that. I do not think that is
universally recognized way to do things and so often times they will appreciate
getting our input on that issue. (J1)
Challenges to effective pain management for patients on OAT were related to either the
limited evidence base or the limited knowledge base about OAT among hospital staff:
I think the biggest barrier is we do not have great evidence to say this is the best
way to do it. If there were great studies that we could point out that shows
definitively that this the right thing to do for this patient. We rely more on a
combination of clinical experience, observational studies, general knowledge of
pharmacology…It is hard to convince somebody this is the right way to do it when
I do not have evidence to back me up…I think that creates a lot of confusion in
this area in treating pain in people on buprenorphine. (D1)
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Table 4.5. Guidance Document Recommendations: Pain Managementa
Hospital
A

Use of
Non-Opioid Adjuvants
Pre-Operative
Acetaminophen; NSAIDs; gabapentin
Intra-Operative
Regional anesthesia; continuous infusion
catheter; ketamine, lidocaine, or
dexmedetomidine infusion

C

K

Post-Operative
Ketamine, lidocaine, or dexmedetomidine
infusion
Pre-Operative
Ibuprofen, acetaminophen, or topical
analgesics; gabapentin; tricyclic
antidepressants; serotonin and norepinephrine
reuptake inhibitors; tizanidine, baclofen, or
cyclobenzaprine; sedating serotonin reuptake
inhibitors; ketamine or dexmedetomidine;
neuraxial, regional, and local anesthesia
Post-Operative
Use multiple modalities
Pre-Operative
Multimodal management with non-opioids
(NSAIDs, acetaminophen, epidural/spinal
analgesics, and nerve blocks)

Use of
Opioids
Post-Operative
Intravenous hydromorphone or
fentanyl patient-controlled
analgesia

Alternative OAT
Approaches
Post-Operative
Increase
buprenorphine
dose or divide
daily dose to
every 6 to 8hours

Discharge
Planning
Continue inpatient pain
management and coordinate
follow-up with outpatient
buprenorphine provider

Pre-Operative
Increase opioids and consult the
pain service. If opioids are needed
will likely need to provide higher
dose and monitor closely

Pre-Operative
Split
buprenorphine
dose or dose
methadone
three times a
day

Coordinate care. Specific
accommodations for skilled
nursing facility, outpatient living
situations, and coordination with
OTP or outpatient buprenorphine
provider. Including writing a
discharge bridge script for
buprenorphine

Post-Operative
Manage similar to routine
postoperative care but may need
higher opioid dosing
Post-Operative
If opioids are required, will likely
need higher doses and they should
use patient-controlled analgesia
and discontinue oral opioids

Post-Operative The patient should receive a
Split
letter for OTP. The discharge case
buprenorphine
manager and patient may need to
dose or increase arrange for home methadone
buprenorphine
doses with OTP if they cannot
dose
receive on their day of discharge
Table Notes. aAll hospitals recommend OAT continuation; All hospitals included recommendations for pregnant and non-pregnant patients (not
summarized in this table); Recommendations were for mild, moderate, and severe pain.
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4.7.1c. OAT continuation: Guidance documents. Informants from four hospitals
(Hospitals C, D, I, and K) provided OAT continuation guidance documents. Hospitals C, I,
and K provided recommendations for buprenorphine and methadone, and Hospital D
provided methadone recommendations. The consensus of the four guidance documents
was that OAT should be continued and providers should consult with either the AMC
service or addiction experts as needed.
Policies typically required dose verification for patients taking buprenorphine. All
three guidance documents described steps for completing this task, including contacting
the pharmacy (Hospital C), reviewing the electronic health record (Hospitals C and K),
checking the prescription drug monitoring program (PDMP) (Hospitals C, I, and K),
contacting the outpatient clinic (Hospital I), and contacting the outpatient provider
(Hospital K). Two of the hospitals provided recommendations for OAT continuation
(Hospitals C and K) and two of the documents addressed pain management (Hospitals C
and K). The other care delivery recommendation domains inconsistently articulated
among the guidelines were approaches to missed doses, linkage to care, and legal
reminders. See Table 4.6 (following Section 4.7.1d) for a summary of these findings.
All four methadone continuation guidelines recommended dose verification by
contacting the patient’s OTP. One guideline recommended use of the prescription bottle
to verify dose (Hospital I). Three of the documents addressed pain management
(Hospitals C, D, and K) in particular to provide additional opioids for pain as needed.
Three of documents included instructions on methadone formulation (i.e., liquid, tablet,
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injectable) (Hospitals D, I, and K), and two of those hospitals (Hospitals D and K)
described the OAT conversion to intramuscular injection. Three hospitals described
linkage to care processes (Hospitals D, I, and K) including the operational limits of OTP
and how to ensure communication with the OTP on the last dose received. Three
hospitals provided legal reminders (Hospitals C, I and K) about methadone (e.g., do not
write an outpatient prescription for methadone). The other care delivery
recommendation domains not consistently described across the guidelines were how to
address missed doses and naloxone orders. See Table 4.7 (following Section 4.7.1d) for a
summary of these findings.
4.7.1d. OAT continuation: Interviews. Informants that did not have or provide
analyzable documents described OAT continuation practice as similar to the provided
and reviewed hospital policies. The most common approach was OAT continuation
without restrictions upon dose verification from the outside provider: “We continue it
absolutely it is an ethical and legal obligation” (H1) and “We get confirmation from their
current providers and as long as we get confirmation about their dose and that the
provider plans to continue to follow them and then we continue it [for both types of
OAT]” (L1). Dose verification was completed by different members of the team (e.g.,
nursing or pharmacy) and involved using different verification sources depending on
OAT—for buprenorphine (PDMP) or for methadone (OTP or the state substance abuse
authority). Informants described methadone dose verification as more challenging than
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buprenorphine verification, because methadone is not in the state PDMP; however, one
informant cautioned against trusting the PDMP for buprenorphine dose verification.
Key informants described OAT continuation, specifically for buprenorphine, as
being dependent on the hospital formulary. One hospital switched patients from
Suboxone® (the combination product) to Subutex® (the mono product) because of the
formulary limitations and another hospital did the opposite, switching patients arriving
on Subutex® to Suboxone®. Some key informants were unsure about general hospital
practice for this clinical scenario, stating that they did not “think there are policies right
now [stating] that we have to do certain medication protocols. As far as I know it is
physician discretion” (M1). Further, an informant noted that fear among the providers
drove discontinuation of outside methadone because providers did not understand
federal treatment regulations:
The majority of the time [patients on methadone are discontinued while
hospitalized]. Unless they have a reason, pain. I have had these discussions with
docs. They are nervous about using it for non-pain services and they are worried
that they are doing something illegal. (M1)
Another key informant described how anyone admitted to the hospital on OAT triggers
a consultation from the AMC service:
There is almost a sort of automatic trigger finger type response for most of the
hospitals to call addiction medicine for anything. If somebody comes in on
buprenorphine or methadone it is almost guaranteed they will consult us. If they
have anything in their urine at all they are going to consult us. (L1)
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Table 4.6. Guidance Document Recommendations: Buprenorphine Continuationa
Hospital
C

Formulation
•Buprenorphine
/naloxone (nonpregnant)
•Buprenorphine
(pregnant)

I

Not described

K

Use the
prescribed
outside
formulation

Dose
Verification
• Contact pharmacy
• Review electronic
health record
• Check PDMP
•Contact clinic
•Check PDMP
Institutional Clinic
• Check electronic health
record

Missed
Dose
•If a patient has not used
opioids in the interim,
provider may order full
outpatient dose
•If a patient has used
opioids in the interim use
clinical judgment
Not described
Not described

Pain
Management
Continue dose
during acute
events

Linkage
to Care
Not described

Legal
Reminder
Not described

Not described

Not described

Not described

If dose does not
provide adequate
analgesia, use
non-opioids and
opioids and
follow pain
management
protocol

On day of
discharge notify
outpatient
provider of
plans

Do not write an
outpatient
prescription
unless you
have an XOutside Clinic
waiver and the
• Contact provider
outside
• Check PDMP
provider asks
you to
a
Table Notes. All documents recommend buprenorphine continuation; OBOT = office-based outpatient treatment for patients receiving buprenorphine.
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Table 4.7. Guidance Document Recommendations: Methadone Continuationa
Hospital
C

Dose
Verification
Contact OTP

D

Contact OTP

I

Contact OTP
and/or use
prescription
bottle

K

Contact OTP

Missed
Dose
• Discuss with OTP
provider
• If OTP cannot be reached
give full dose if 1-2 days
are missed, half dose if 34 days are missed, and
restart if ³ 5 days are
missed
Not described

Pain
Management
Short-acting
opioids or split
dosing

Formulation
Not
described

Naloxone
Order
Yes

Linkage
to Care
Not described

Do not
withhold with
opioids and do
not subsite as
analgesic

If NPO, use
IM
injection

Not
described

• Do not attempt to make
up missed dose
• If >3 days of dosing
missed decrease verified
daily dose by 10% or 10
mg for each day missed
Not described

Not described

Continue
dose in
any form
(pill or
liquid)

Not
described

• Direct questions about
addiction treatment to OTP
• Prior to discharge notify
OTP of last dose amount
and date/time
• Write note for patient to
take to OTP with dose
information
• OTPs are closed on holidays
and Sundays.
• OTP should be notified
when admitted and should
receive discharge summary

Legal
Reminder
Legal to
order if
patient is
admitted
primarily for
other
medical
reason
Not
described

Outpatient
pharmacies
cannot
dispense

OAT does not
Continue
Yes
At discharge provide letter
Do not write
provide
liquid
for OTP with admission dates outpatient
analgesia, use
dose, if
and date/amount of last
prescription
non-opioids
NPO use
dose, names and dose of
and opioids for IM
other opioids given
pain
injection
Table Notes. aAll documents recommend methadone continuation; OTP = opioid treatment program; IM = intramuscular; NPO = nothing by mouth.
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4.7.1e. Opioid withdrawal management: Guidance documents. Withdrawal
management policies were received from six hospitals (Hospitals D, F, H, I, J, and N).
Similarities and differences among the protocols were observed among the
recommendations for first-line therapy, the protocol type, the protocol initiation
threshold, and the 24-hour maximum dose. Four of the six protocols specified the firstline medication for withdrawal management as one or both types of OAT. One hospital
protocol was restricted to non-OAT pharmacotherapy symptom management (i.e.,
clonidine), and one hospital used a combination non-OAT pharmacotherapy (i.e.,
clonidine) and intramuscular buprenorphine injections. All of the protocols were framed
as tapering protocols, and one protocol provided the option for OAT initiation (Hospital
I). Each protocol had a different threshold for starting their protocol, as well as different
total maximum doses for the first 24-hours. See Table 4.8 (following section 4.7.1f) for a
summary of these findings.
4.7.1f. Interviews: Opioid withdrawal management. Informants that did not
have or provide analyzable documents described a variety of practice approaches, which
included the use of OAT to manage withdrawal, the use of non-opioid adjuvants for
symptom management (i.e., clonidine), and the use of tramadol for a rapid taper. When
queried about the distinction among induction versus withdrawal versus tapering, some
informants emphasized that their approach was focused on “maintenance therapy”
(A1). Other informants shared that there was variation across their respective hospital
or health system for managing opioid withdrawal. For example, one informant stated
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that those admitted to the hospital detoxification unit received a tapering protocol that
was for 72 hours and patients who were admitted to the main part of the hospital
received a 72-hour to 120-hour tapering protocol. Another informant described little to
no management for opioid withdrawal across their institution.
Table 4.8. Guidance Document Recommendations: Withdrawal Management
Hospital
D
F

First-Line
Therapy
Sublingual
BUP-NX
Sublingual
BUP-NX

Protocol
Initiation
COWS ³ 8
COWS ³ 13

Sublingual
BUP-NX or
Methadone

COWS ³ 12

I

Methadone

J

Clonidine

Signs of
withdrawal
or opioid
craving
Not
described

H

Starting Dose
4 mg

24-Hour Maximum
Dose
Not described

Sublingual BUP-NX
4 mg/ 1 mg

Sublingual BUP-NX
8 mg

Oral or IV Methadone
5 mg (COWS 13 to 24) and
10 mg (COWS 25 to 36)
Sublingual BUP-NX
4 mg/ 1 mg

Oral or IV Methadone
40 mg oral or 20 mg IV

Oral Methadone
15 mg
Oral Methadone
5 to 10 mg

Oral Methadone
30 mg (35 mg severe)
Oral Methadone
40 mg

Clonidine Standard
0.2mg

Dependent on regimen
selected

Sublingual BUP-NX
8 mg (10 mg severe)

Clonidine Reduced
0.1 mg

N

IM
Buprenorphine
and Oral
Clonidine

COWS ³ 5

Clonidine Lowest
0.05 mg
Clonidine
0.1 mg
IM Buprenorphine
0.3 mg

Clonidine
1.2 mg (max 0.4 mg
dose every 8 hours)

IM Buprenorphine
1.5 mg (0.3 mg x 3, plus
0.6 mg dose)
Table Notes. BUP-NX = buprenorphine/naloxone; COWS = Clinical Opiated Withdrawal Scale is a tool for
assessing the severity of withdrawal symptoms using an 11-item assessment administered in either the
outpatient or inpatient setting (Wesson & Ling, 2003); IV = intravenous; IM = intramuscular.
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4.7.1g. OAT initiation: Guidance documents. Two hospitals (Hospital C and K)
provided OAT initiation hospital guidance documents in the form of guidelines,
protocols, and order sets. There were few common recommendations across the two
guidelines. For buprenorphine initiation, Hospital C and Hospital K had different
protocol initiation thresholds with differences in Clinical Opiate Withdrawal Scale
(COWS) score thresholds to initiate OAT and allowable maximum daily doses (16 mg
versus 12 mg). The first day dosing protocols were also different, in timing, dosing, and
COWS score threshold.
Hospitals C and K also had different methadone protocols including the
threshold for protocol initiation, the maximum daily dose during hospitalization (60 mg
versus 40 mg), and the first day dosing protocol. The common recommendation was the
maximum total daily dose of methadone on day 1 of the protocol, 40 mg. See Table 4.9
(following section 4.7.1h) for a summary of these findings.
4.7.1h. Interviews: OAT initiation. Informants that did not have or provide
analyzable documents disclosed a range of practice behaviors related to OAT initiation.
At some institutions the delivery environment focused on OAT initiation versus
withdrawal management:
Methadone or buprenorphine can be initiated during hospitalization, in
consultation with an addiction medicine specialist, if the patient will be detoxed
off during hospitalization or there is a clear documented plan for continuation of
OAT in the outpatient setting. (O1)
In contrast, some hospital environments were described as underdeveloped in this
practice domain: “I am unaware of anyone doing that…And I am unaware of any
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hospital policies [on this topic]” (M1). One informant described extreme frustration that
OAT initiation was not happening for hospitalized patients:
No! No! No! That pisses me off!!… So what is happening is that people are
getting withdrawal management, tapered, and then sent to a clinic, where I reinduce them…It is a source of frustration. (F1)
Informants provided insight into some of the barriers to hospital OAT initiation,
which included: 1) OTPs requiring QTc interval testing; 2) internalized stigma of patients;
and 3) providers not trained in administering OAT. OAT initiation in many hospitals was
described as primarily the responsibility of the consult service:
What I would say around that is that it is quite rare [for physicians to do
buprenorphine inductions]. I think there are some family medicine providers that
do inductions in the outpatient setting and that will do them without our consult
service. Other than that, I have not seen it. (A2)
Occasionally [physicians who are not addiction medicine specialist will induct
patients on OAT and] there will be some miscommunications and people get
started on methadone and all of a sudden, they are being discharged and how
are they going to get connected with the methadone clinic. Sometimes surgical
teams will start buprenorphine for patients, and not involve us, which is fine, but
I think it just leaves some potential for gaps in their treatment, like what if they
don't have that Suboxone® at home anymore because they missed their
appointment because they were in the hospital, should they be back on the same
dose or not? So just stuff like that will occasionally get missed. (I1)
Some informants described a preference for providing different types of OAT in the
hospital. One informant emphasized their preference for starting buprenorphine over
methadone in the hospital context: “I really prefer buprenorphine” (P1). Other
informants discussed trying to use different non-OAT opioid formulations, such as
BuTrans® patches, but were limited by the hospital formulary (E1).
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Table 4.9. Guidance Document Recommendations: OAT Initiation
Hospital

Protocol Initiation
COWS Score1

Buprenorphine
C
Dependent on patient
category

Max Total
Dose Day 1
16 mg for
both types
of patients

Max Daily Dose
During Admission
24 mg for both
types of patients

Abstinent
No opioid use in the
prior 5 days: COWS = 0
All Others
COWS ³ 8

K

• COWS ³ 5 OR;
• The presence of
signs/symptoms of
withdrawal

Methadone
C
Not described
K
COWS ³ 5 or the
presence of
signs/symptoms of
withdrawal

12 mg

16 mg

40 mg
40 mg

60 mg
40 mg

Table Notes. COWS = Clinical Opiate Withdrawal Scale.

First Day
Dose Protocol
Abstinent
• Dose 1 is 2 mg
• COWS score to be reassessed after 2 hours
• If cravings persist add another 2 mg. This may be repeated on day 1
until max is reached
All Others
• For patients with COWS < 8 or no objective withdrawal, the COWS
should be administered every 2 hours until COWS is ³ 8
• When COWS ³ 8, administer 4 mg and assess COWS in 1 hour. If
COWS is < 8 at that time, reassess every 6 hours
• Provider may give 4 mg if COWS ³ 8 at any point
• Regardless of the historic amount of opioid use start with
buprenorphine/naloxone sublingual 4/1 mg for dose 1
• Reevaluate the patient every 2 to 3 hours
• Give additional dose increments of 4/1 mg every 2 to 3 hours until
withdrawal abates (COWS < 5)
The initial dose selection should start anywhere from 10 to 30 mg
• Regardless of the historic amount of opioid use start with
methadone 20 mg solution by mouth for dose 1
• Reevaluate the patient every two to three hours
• Give additional doses increments of 5 to 10 mg every 2 to 3 hours
until withdrawal abates (COWS <5)
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4.7.2. Policy and practice domain 2: Security and behavior management. This
policy and practice domain addressed security and behavior management of patients
with OUD and other SUDs. Informants from Hospitals A, B, J, and K provided hospital
guidance documents in this policy domain. Specific protocols addressed the
management of aberrant drug use, decision-making around peripherally inserted central
catheter (PICC) lines, and patient safety and security assessment and interventions. The
hospital guidance documents emphasized interprofessional collaboration to ensure
patient safety; however, because the guidance documents varied in focus, most of the
documents were difficult to compare, except for the aberrant drug use policies, which
had enough shared properties for analysis.
4.7.2a. Guidance documents: Aberrant drug use. Aberrant drug use was defined
as the use of drugs (illegal or prescribed) in a manner or route that was incongruent
with appropriate or safe use. The policies on this topic from Hospitals B and J were
similarly structured. Recommendations advised conducting a risk assessment for
aberrant drug use; documentation of behavior and interventions protocols;
interventions for medication administration; interventions for securing the
environment; behavioral requirements for patients leaving the unit and for patient
visitors; the use of urine drug screens; the use of patient sitters; and the involvement of
campus safety. In Hospital B, the guideline was created because of a patient’s poor
outcome. Another issue related to aberrant drug use, which came up in the Hospital J
guideline and in the interviews was limited access to sitters. The informant commented
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that there had been discussions about using video to monitor patients with drug use
disorders:
This was a discussion [we had] quite recently because of increasing opioid related
admissions. We have had more of this kind of issue [aberrant drug use] … in the
hospital or people being found with paraphernalia on them and the guidance at
this point is essentially been assigning a sitter for those individuals. To observe.
There has been a discussion to use video because sitters are a finite resource and
there was getting to be issue with a little more frequency with some concern that
there may not be enough sitter availability. (J1)
At present, according to the guideline, the use of video monitoring for this patient
population is not allowed. The polices are summarized in Table 4.10
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Table 4.10. Guidance Document Recommendations: Aberrant Drug Use
Hospital

B1

Risk
Assessment

Document

Physical
findings,
patient history,
patient
behaviors, and
laboratory
findings

Document
ation of
behaviora, b

Medication
Administration

UDS

• Convert pills to
liquida
• Crush pillsa
• Change opioid
formularya
• Direct
observationa
• Oral checka

Yesa

• Direct observation
• Check for
swallowing
• Crush medication
and put it in
pudding
• Limit IV access

Yes

Visitor
Rules
Yesb

Environment
& Equipment
• Remove sharps
container from
roomb
• Move patient
room close to
nursing station
• Leave door
openb
• Application of
tamper
prevention
seals on all IV
portsb
• Remove sharps
container from
room
• Do not leave
needles/syringe
s in the room
• Re-search the
room if there is
evidence of
“contraband”

Limit
Off-Unit
Access
Yesb

Sitter

Yesb

Security/Law
Enforcement
Search room and
belongingsb

• Security should be
informed of any
substances or
paraphernalia found
• Security will
determine if police
involvement is
necessary
• Security and nursing
may search room
including patient
belongings
Table Notes.1There were two categories of intervention: primary and secondary. Primary is indicated with superscript a and secondary is indicated with
superscript b; 2There were three levels of concern: moderate, high, and confirmed use; UDS = urine drug screen; IV = intravenous.
J2

Moderate
concern, high
concern, or
confirmed use

Objective
charting
indicating
evidence
of actions
taken and
the
patient’s
response
to these
actions

Yes

Yes

Yes
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The other hospital guidance documents comprising this domain were on topics
related to decision-making for patient discharge with PICC lines and patient safety and
security assessments and interventions. Hospital A provided several hospital guidance
documents related to PICC lines and aberrant drug use, including a PICC line policy and
PICC assessment tool, an internal and externally facing behavior agreement policy, and
a care misalignment document. An informant from Hospital A described the
involvement of the hospital AMC service when behavioral issues arose, in particular for
the misuse of drugs in the hospital setting:
[This is] part of the consult services task. We incorporate that into the behavioral
agreement. It is one of the areas of culture change. Previously that had been a
deal beaker for staying in the hospital. Because we are willing to engage with the
patient…The truth is. If someone is on appropriate dosing of buprenorphine and
methadone they are not going to want to use. They use in the hospital because
they are in pain or on the wrong dose…We do not kick people out because they
use. (A1)
The Hospital A PICC Policy and PICC Assessment Tool standardized PICC related
discharge decision-making for high risk patients. The PICC Policy stated that PICC
placement is a medical decision to be determined by a physician and informed by
previous risk factors.
The Hospital A Safety Agreement Policy was an internally facing (for staff) and
externally facing (for patients) policy. The internal component addressed how to identify
a patient at risk for care misalignment, elopement, or harm to self or others; how to
prepare and implement a safety plan; how to document the plan; how to handle
conflict; and how to prepare a crisis plan. The component of the policy for patients
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communicated both behavioral expectations (e.g., no drug use) and care delivery
expectations while in the hospital (e.g., understand the role of nursing).
The Hospital A Misalignment of Care Guideline was a tool designed to support
interprofessional care plan meetings to facilitate care for patients at risk for
misalignment in their care goals or the use of force. It outlined the steps to be taken to
facilitate and implement a plan to keep at-risk patients safe.
Hospital K’s Against Medical Advice (AMA) Policy provided a clear set of steps for
action when patients leave the hospital AMA. Four steps were recommended when a
patient says they are going to leave AMA: 1) discourage leaving and explain why it is
important to stay; 2) inform the primary team; 3) if the patient still chooses to leave,
staff ask the patient to sign the AMA form and document this conversation in the
medical record; and 4) the event is documented in the patient record and filed in a
reporting system. The guidance documents from Hospital A and Hospital K were not
included in the comparison table because they were non-comparable, standalone
protocols. A full summary of each set of recommendations is available by request from
the primary researcher.
4.7.2b. Interviews: Security and behavior management. Similar to the findings
observed in the hospital guidance documents, key informants who did not provide
guidance documents from this policy domain described care scenarios and practice
issues related to aberrant drug use and PICC line safety.

195

4.7.2b.1. Aberrant drug use. Informants shared that it was the role and
responsibility of addiction medicine and the interprofessional teams when there is
ongoing aberrant drug use during hospitalization: “It certainly comes up. I get called
about it sometimes. I get providers who are concerned about it sometimes and we will
talk through it” (C1); “We get calls about people who smuggle in opioids and use them
in the shower and have taken fentanyl or something that they have smuggled in” (M1);
and “But this is another reason we sometimes we get consulted. Somebody has been
hoarding medications and then crushing their oxy and injecting it through their port. Um
friends bringing in their benzos from home” (F1).
Many informants, when asked about protocols and standard practice on
aberrant drug use, indicated that there was limited hospital-wide understanding on
what to do in these scenarios: “I am not personally aware of protocols around that. I do
know that, I have seen certain situations of patients who have used in the hospital and
they aren't automatically discharged or anything like that” (C1) and “No. No real policy.
A lot of consternation” (N1). In contrast, other informants described a no-tolerance
policy related to on-campus drug use that involved campus security:
Yeah it is obviously not allowed and security gets involved and you know it is
pretty bad. I don't think they are looking to call the police but cognizant of the
fact that this is illegal and can't go on...I think a lot of people will just AMA [leave
against medical advice]. And leave. We have had a couple of situations where it
is obvious they have called a drug dealer or something and they usually find
themselves on the wrong side of security and they end up leaving. (H1)

196

We discourage it. I think there have been times were people caught using
intravenous drugs in the hospital and you know, generally, security is sort of put
outside their room and visitors are restricted and their belongings are generally
searched. That is only if they are caught doing it. (L1)
4.7.2b.2. PICC lines. Informants discussed the role and responsibility of addiction
medicine providers to support decision-making related to PICC line insertion or removal:
“A common genre of consults is somebody with a PICC line” (F1). Hospital clinical staff
would request that the AMC service conduct a risk assessment prior to discharging a
patient with a PICC line and a history of intravenous drug use. General practice around
PICC lines included efforts to discourage patients with intravenous drug use history from
leaving the hospital with a PICC line: “No, we try not to let them leave the hospital with
a PICC line if they have a history of intravenous use. Again, I think the nurses are kind of
trained to be more vigilant in those cases” (L1).
Informants noted that addiction medicine experts were responsible for
navigating the challenges of patient placement upon discharge because a patient had an
active OUD, a need for OAT, and a PICC line:
We cannot discharge patients often times...[because] we can't get nurses to go
into a home if there is a history of substance use...and they wouldn't be
discharging a patient with a PICC line if there is a history [of use] ...I have a huge
problem with nursing homes that will subtly discriminate against patients on
methadone. This is a big issue. A big issue, right? I am just screaming for a
lawsuit from somebody. (G1)
Any patient who needs a PICC line gets a PICC line. If patient requires long-term
antibiotics (e.g., endocarditis, osteomyelitis) then patient is discharged to SNF for
duration of antibiotics. Can be challenging if patient is on OAT –however we have
worked with several area SNF who will accept patients who inject drugs with a
PICC line on OAT. (O1)
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Related to PICC line placement, one informant described the tension between
patient autonomy and hospital interventions:
There seems to be a profound concern among the PICC line insertion team that
people are going to go and use their PICC line to get high, and I was like, so
what? I mean it is their human right. It is a terrible idea and we can message
them that is a really dangerous and really bad…my sense of their concern [the
PICC line insertion team] was that they viewed the lines as their property and
god-forbid the patient ran out and used with their IV in. I was just like patients
have agency here and they are allowed to make horrible choices… we certainly
put PICCs in OUD patients, but to be honest, I am sure they are mistreated, I
know people judge them, I know people probably make remarks, probably not
even behind their back right around them, oh he is going to do something with
his PICC. Heck a PICC is safer than doing it yourself. (H1)
Informants also described other stigmatizing, and likely traumatizing behavioral
management practices (e.g., no visitors allowed policies and searching patient’s
belongings):
I initiated a policy that when I am involved [in care] there is a no visitors policy for
patients. And I say to them you cannot have visitors. I basically get their consent
to put that in place. I explain to them you are sick and I do not want someone to
bring something in to you it could put you in jeopardy and it can put the hospital
staff in jeopardy. And many times, we have security sitting outside the door…but
it is really not a problem people get it. (P1)
Behavioral issues were so common that one hospital created an
interprofessional consult service to de-escalate patients with behavioral issues.
4.7.3. Interviews: Non-evidence-based care. Throughout the interviews,
informants described a variety of non-evidence-based care practices for patients
hospitalized with OUD. These care scenarios included patients receiving no treatment
for their OUD, patients receiving incorrect or outdated care, and patients receiving
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uncommon care delivery modalities. The informants associated with these delivery
scenarios have been deidentified.
4.7.3a. No treatment. One informant shared how the standard of care on the
medical and surgical services at their hospital was to not provide any OUD-related
care—even symptom management for withdrawal, referring to a patient with
endocarditis secondary to intravenous drug use:
At the very least we will…treat their pain…But you know what we struggle with
the most is these people who have endocarditis or are septic and have to have 6
weeks of antibiotics and they are not receiving anything for withdrawal...on
some services maybe someone would write you something for pain...but that
wouldn't necessarily be for withdrawal. They could give some clonidine.
(deidentified)
4.7.3b. Incorrect or outdated care. Evidence supports the use of continued OAT
in the outpatient setting to decrease return to substance use and death (Clark et.al,
2011). Despite this, informants described the provision of OUD-related services in their
respective hospitals as focused on “detox” (i.e., withdrawing patients from opioids
instead of initiating and continuing OAT upon discharge): “We have what we call a
chemical opiate withdrawal protocol that we have been using for a number of years”
(deidentified); “Generally they will use clonidine for detoxification purposes”
(deidentified); and:
They come in, they get consulted by addiction medicine…[and] now, our
policy/procedure is to utilize tramadol to detox along with as needed medications
for all the symptoms, clonidine, muscle relaxer, something for nausea ease,
Vistaril for anxiety things like that. We generally don't use buprenorphine or
methadone anymore expect in pregnant patients we obviously start them on
Subutex®. (deidentified)
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4.7.3c. Uncommon care delivery modalities. Informants described unique
withdrawal management protocols. The protocols do not appear to be supported by
evidence, yet there is little third-party oversight in the hospital setting to ensure the use
of validated treatment protocols. One of the protocols was a rapid 72-hour taper using
tramadol, and the other was an injectable buprenorphine taper protocol. The informant
rationalized the use of the rapid tramadol taper approach because of the 72-hour rule.
She described that prior to the implementation of the tramadol protocol they had used
Suboxone® on their detoxification unit, and the consult service. She said that once
patients realized that they could only receive the medication for 72-hours they would
leave AMA, she said it created a “revolving door, they would come and get a couple of
days’ worth [of Suboxone®] and leave and come back to get more” (deidentified). She
shared that using tramadol has minimized this effect.
4.7.4. Summary. The hospital guidance documents addressed similar clinical
domains, but differences were observed within the policy sub-domains. Informants and
guidance document recommendations related to acute pain management agreed;
patients on OAT prior to admission should be continued on OAT during hospitalization.
For withdrawal management, however, there was substantial variation among the
guidance documents across almost all practice domains (i.e., first-line therapy, protocol
initiation threshold, starting dose, and 24-hour maximum dose). This variation was also
reflected in the key informant descriptions of care practices. For OAT initiation, again as
with withdrawal management, the guidance documents were discordant across
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domains (i.e., protocol initiation threshold, maximum day 1 dose, maximum total daily
dose, and first day dose protocol), and generally informants were unsure about the
existence of common practices for OAT initiation in their institutions. The variation
among the hospital guidance documents provide additional evidence of the novelty of
this practice within hospitals, that there is limited standardization because few hospitals
are doing it; thus, a national standard does not exist yet.
It was challenging to draw conclusions from the security and behavioral
management sub-policy domains because the guidance documents varied in focus. They
emphasized interprofessional collaboration to ensure patient safety. The two aberrant
drug use policies had similar recommendations for assessments, documentation,
interventions, patient and visitor requirements, the use of urine drug screening, and
campus safety involvement. However, less consistency was observed in disclosed care
practices related to aberrant drug use—most informants indicated limited hospital-wide
understanding in addressing aberrant drug use. Less common, though highly
problematic, was the existence of guidance documents and disclosures from informants
during the interviews of the delivery of non-evidenced based care to persons with OUD.
These non-evidence-based care scenarios included patients receiving no treatment for
their OUD, patients receiving incorrect or outdated care, or receiving uncommon and
untested protocols.
The findings from this section provide additional evidence to support the
assertion that hospital policies and practice vary for the delivery of OAT and treatment
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of hospitalized patients with OUD, and that the existence of said policies and normative
practices reflect specific supply-side attributes within and outside of the local hospital
environment. The variation and care discrepancy existed within the context of 16
hospitals that are well-resourced for the delivery of addiction-related services in
contrast with the average U.S. hospital without addiction medicine experts or addiction
medicine training programs.
Finally, based on the evidence presented in the previous sections, triangulated
with the observations from this section, AMC service existence is a conduit for OAT
management policy creation and implementation. Seventy-eight percent of hospitals
with established AMC services in this study had OAT management policies (n = 7) as
compared with 0% of hospitals without an AMC service and the plans to start one.
Further, 40% of hospitals with the plans to start an AMC service (n = 2) had OAT
management guidance documents.
Section 4.8. Linking Qualitative Findings to Quantitative Approach
The analyses presented in this chapter provide the conceptual rationale and
justification for continuing to explore care delivery practice, patterns, and organizational
processes for patients with OUD in Aims 2 and 3. The findings from Chapter 4 identified
care delivery patterns for the treatment of persons with OUD during hospitalization that
appear to be suboptimal and not evidence-based. Informants described care variation
within and between hospitals. The collection and analyses of hospital guidance
documents reflected and confirmed this finding. These results provide rationale and
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justification for proceeding with Aims 2 and 3 to quantitatively explore, describe, and
assess care delivery across the largest integrated health system in the U.S.—the
Veterans Health Administration (VHA).
The results of this chapter illuminate gaps in fundamental knowledge as they
relate to understanding the social and technical contributory elements that contributes
to an addiction friendly hospital. Some of the findings from this section suggest that
there are mutable social and technical attributes within and outside of a hospital that
may enhance a hospital’s ability to deliver evidence-based OUD services including:
positive social structures (i.e., behaviors, cultural-cognitive, and normative), resource
investments in addiction-related care (e.g., addiction medicine training programs or an
AMC service), normative treatment practices (e.g., guidelines), and supportive internal
stakeholders. Further, findings from this chapter illustrate the power of the local
environment to enhance or foster the internal work of the hospital such as external
stakeholders, a robust community-based referral network, external incentives through
policy, regulations, financing, education, and knowledge. This emphasizes the
theoretical underpinnings of this study that hospitals, like other organizations, do not
operate in isolation but act as dynamic, malleable structures influenced by the broader
social and professional contexts and systems. How these internal and external
contributions are measured, defined, and quantified warrants future exploration.
Moreover, the findings from this chapter inform the analytic approaches of Chapter 5,
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specifically how OAT was operationalized to include all OAT formulations of OAT and
how hospitals were categorized as either high or low performers.

204

Chapter 5: Presentation and Analysis of Quantitative Data
Aim 2 explores the variation in hospital use of opioid agonist therapy (OAT) and
other non-OAT pharmacotherapies for hospitalized patients with OUD in the Veterans
Health Administration (VHA) system. A description of the study cohort opens the
chapter and reviews patient and facility characteristics, and pharmacotherapy delivery
patterns. The Aim 2 research sub-questions analyze care delivery patterns and examine
OAT administration variability among hospitalized veterans. Aim 3 analyses expand
upon the findings of Aim 2 to further understand the multilevel drivers of hospital OAT
variation in the VHA system. Results are organized into seven sections:
1. Section 5.1 describes the facilities, patient demographics, admission
characteristics, patient health characteristics (present on admission and
during admission), and pharmacotherapy delivery patterns (pre, during, and
post-admission) of the study cohort.
2. Section 5.2 (research sub-questions 2a, 2b, and 2c) examines the differences
in the characteristics and outcomes of patients who do and do not receive
OAT when hospitalized in the VHA.
3. Section 5.3 (research sub-questions 2d, 2e, 2f) explores the differences in the
characteristics and outcomes for patients who received OAT prior to
admission and were subsequently continued or discontinued.
4. Section 5.4 reviews the distribution and frequency of hospital OAT delivery
within the study cohort. First, the distribution and frequency of hospital OAT
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and non-OAT delivery is broadly summarized (research sub-questions 2g).
Second, the associations between hospital performance quartile and specific
OAT care delivery scenarios (research sub-questions 2h) are assessed. Third,
hospital attributes associated with hospital OAT delivery (research subquestions 2i) are summarized. Fourth, differences in non-OAT
pharmacotherapy delivery associated with hospital OAT delivery quartile
performance (research sub-questions 2j) are assessed. Finally, associations
between health and health care utilization outcomes with hospital OAT
delivery rank or quartile (research sub-questions 2k) are evaluated.
5. Section 5.5 summarizes the findings from Aim 2 that frame the Aim 3
analyses.
6. Section 5.6 explores the multilevel contributions of patients and hospital
level attributes that are associated with the delivery of OAT during admission
and the delivery of OAT in the 30 days post-admission.
7. Section 5.7 summarizes the findings of this chapter.
Section 5.1. Patient, Admission, and Hospital Descriptive Statistics
This section explores the facility, patient, and admission characteristics for the
final study cohort—12,407 unique index hospitalizations from 109 VHA hospitals in the
continental U.S. during the 2017 fiscal year.
5.1.1. Hospital characteristics. Most hospitals were in either the South (n = 43;
39%) or the Midwest (n = 25; 23%). Many facilities were large hospitals with more than
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100 beds (n = 45; 41%) or medium sized hospitals with 50 to 99 beds (n = 36; 33%).
Cases occurred most commonly in large hospitals (n = 7,234; 58%) and in the South
(39%; n = 4,867). The number of patients with OUD admitted per hospital ranged from
26 to 430 with a median of 98 (IQR = 97) (see Table 5.1).
Table 5.1. VHA Hospital Characteristics
Variable
Admissions (count)
Number of Beds
Small: 1 to 49 beds
Medium: 50 to 99 beds
Large: 100+ beds
Census Region
Midwest
Northeast
South
West

Number of Facilities
(n = 109)
Median, 98; Mean, 114.0

Patient Frequency
(n = 12,407)
Range 26 - 430; IQR 97

28
36
45

12.5% (1551)
29.2% (3622)
58.3% (7234)

25
18
43
23

22.1% (2742)
16.4% (2035)
39.2% (4867)
22.3% (2763)

5.1.2. Patient characteristics. Patient characteristics across the study cohort
were similar. Most patients were male (n = 11,543; 93%), white (n = 8,880; 72%), and
non-Hispanic or Latino (n = 11,476; 93%). The median patient age was 61 years (range
21 to 90) (see Table 5.2).
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Table 5.2. VHA Patient Characteristics
Variable
Age
Gender
Male
Female
Race
American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or Pacific Islander
White
Unknown/Declined to Answer
Ethnicity
Hispanic or Latino
Non-Hispanic or Latino
Unknown

Frequency %, Count (n = 12,407)
Median 61, Mean 58.5 (21 to 90)
93.0% (11543)
6.8% (864)
1.2% (147)
< 1% (43)
21.8% (2706)
< 1% (106)
71.6% (8880)
4.2% (525)
4.8% (595)
92.5% (11476)
2.7% (336)

5.1.3. Admission characteristics. Admission-related characteristics were also
homogenous. The median length of stay was 5 days ranging from 1 to 50 days. Most
hospital admission sources were either direct admission (n = 5,616; 45%) or from
outpatient treatment (n = 6,095; 49%). One in five patients (n = 2,303; 19%) received
services in the intensive care unit (ICU) and 6% (n = 779) received surgical services
during their admission (see Table 5.3).
Table 5.3. Admission Characteristics
Variable
Length of Stay
Admission Source
Outpatient Treatment
Other Direct Admission
Other
Service Acuity
ICU Services
Surgical Services

Frequency %, Count (n = 12,407)
Median, 5; Mean 6.6 (1 - 50)
49.1% (6095)
45.3% (5616)
4.9% (696)
18.6% (2303)
6.3% (779)

5.1.4. Health characteristics during admission. Health-related characteristics
during admission and present on admission were heterogenous. The prevalence of
primary and secondary diagnosis admissions codes varied substantially with 2,150
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unique primary ICD-10 codes and 1,875 unique secondary ICD-10 codes in the study
cohort. The top ten primary ICD-10 codes, which accounted for approximately 18% of
admissions, included: 1) alcohol dependence (4%); 2) chronic obstructive pulmonary
disease with (acute) exacerbation (2%); 3) opioid dependence with withdrawal (2%); 4)
sepsis, unspecified organism (2%); 5) kidney failure, unspecified (1%); 6) alcohol
dependence with intoxication, unspecified (1%); 7) other chest pain (1%); 8) pneumonia,
unspecified organism (1%); 9) cellulitis of right lower limb (1%); and 10) unilateral
primary osteoarthritis, right knee (1%).
The top ten secondary ICD-10 codes accounted for approximately 26% of unique
admissions: 1) opioid dependence, uncomplicated (7%); 2) acute kidney failure,
unspecified (4%); 3) suicidal ideations (4%); 4) essential (primary) hypertension (2%); 5)
pneumonia, unspecified organism (2%); 6) end stage renal disease (2%); 7) human
immunodeficiency virus disease (2%); 8) hypoosmolality and hyponatremia (1%); 9)
opioid dependence, with withdrawal (1%); and 10) chronic obstructive pulmonary
disease with acute exacerbations (1%).
OUD-related infections occurred in 5.5% of admissions. The top two OUD-related
infections were osteomyelitis (2%) and bacteremia (1%). Acute OUD-related admission
diagnoses occurred in 6% of primary diagnoses, 10% of secondary diagnoses, and 15%
for either primary and/or secondary. Further, 20% of cases in the cohort had either an
OUD infection flag or a primary or secondary OUD-related diagnosis (see Table 5.4).
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Table 5.4. Health-Related Characteristics: During Admission
Variable
Frequency %, Count (n = 12, 407)
Any Acute OUD Infectiona
5.5% (691)
1. Osteomyelitis (M86.X)
2.2% (274)
2. Bacteremia (R78.81)
1.3% (158)
3. Epidural Abscess/ Diskitis (M46.4; M51.9; M50.X; M51.8)
<1% (112)
4. Septic Arthritis (M00.)
<1% (71)
5. Prosthetic Joint Infection (T84.5x)
<1% (57)
6. Endocarditis (I33.X)
<1% (46)
7. Brain Abscess (G06.X)
<1% (45)
8. Lung Abscess (J85)
<1% (38)
9. Empyema (J86)
<1% (24)
10. Candida Endocarditis (B37.6)
<1% (3)
Any OUD-Related Diagnosis Primary or Secondaryb
14.9% (1848)
Primary
5.7% (707)
Secondary
9.5% (1181)
Any OUD-Related Diagnosis or Any Acute OUD Infection
20.1% (2491)
Top 10 Primary ICD-10 Diagnosis Codes
1. Alcohol Dependence (F10.239)
4.4% (551)
2. Chronic Obstructive Pulmonary Disease with (acute)
2.3% (289)
Exacerbation (J44.1)
3. Opioid Dependence with Withdrawal (F11.23)
2.3% (281)
4. Sepsis, Unspecified Organism (A41.9)
1.7% (213)
5. Acute Kidney Failure, Unspecified (N17.9)
1.4% (174)
6. Alcohol Dependence with Intoxication, Unspecified (F10.229)
1.4% (173)
7. Other Chest Pain (R07.89)
1.3% (165
8. Pneumonia, Unspecified Organism (J18.9)
1.2% (151)
9. Cellulitis of Right Lower Limb (L03.115)
1.1% (133)
10. Unilateral Primary Osteoarthritis, Right Knee (M17.11)
1.0% (122)
Top 10 Secondary ICD-10 Diagnosis Codes
1. Opioid Dependence, Uncomplicated (F11.20)
6.8% (842)
2. Acute Kidney Failure, Unspecified (N17.9)
4.2% (526)
3. Suicidal Ideations (R45.851)
4.1% (508)
4. Essential (Primary) Hypertension (I10.)
2.1% (257)
5. Pneumonia, Unspecified Organism (J18.9)
1.6% (193)
6. End Stage Renal Disease (N18.6)
1.5% (191)
7. Human Immunodeficiency Virus [HIV] Disease (B20)
1.5% (185)
8. Hypo-Osmolality and Hyponatremia (E87.1)
1.3% (162)
9. Opioid Dependence with Withdrawal (F11.23)
1.3% (159)
10. Chronic Obstructive Pulmonary Disease with (Acute)
1.2% (147)
Exacerbation (J44.1)
Table Notes. aNecrotizing fasciitis was queried but not present; bSee Appendix H for queried
codes.

5.1.5. Co-occurring conditions present on admission. Co-occurring diagnoses
occurred within 365 days prior to the index hospitalization. Patients with chronic
cancer-related AHRQ Elixhauser flags (AHRQ, 2018) were excluded from the cohort
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because of the common clinical practice of prescribing opioids for this population
(Caraceni et al., 2012). Co-occurring mental health and SUD were present in more than
half of the study cohort—64% of cases had a mental health diagnosis and 49% had
another SUD diagnosis. The most common mental health disorders present on
admission were mood disorders (50%), PTSD (31%), and anxiety (28%). The most
common SUD diagnoses were alcohol use disorder (36%), other psychoactive use
disorders (17%), and cannabis use disorder (16%) (see Table 5.5).
Table 5.5. Health-Related Characteristics: Present on Admission
Variable
Co-Occurring Mental Healtha
1. Mood Disorder
2. PTSD
3. Anxiety Disorder
4. Non-Mood Psychotic Disorder
5. Adjustment Disorder Other
6. Self-Harm
Co-Occurring Substance Use Disordersa
1. Alcohol Use Disorder
2. Other Psychoactive Use Disorder
3. Cannabis Use Disorder
4. Stimulant Use Disorder
5. Cocaine Use Disorder
6. Nicotine Dependence
7. Sedative Use Disorder
8. Other Substance Use Disorders
9. Hallucinogen Use Disorders
10. Inhalant Related Use Disorders
Table Notes. aSee Appendix L for codes queried.

Frequency %, Count (n = 12,407)
65.2% (8094)
50.8% (6306)
31.8% (3951)
28.7% (3560)
7.7% (957)
3.2% (402)
2.9% (358)
48.6% (6024)
37.4% (4641)
17.3% (2147)
16.5% (2045)
`9.5% (1172)
6.2% (769)
3.5% (434)
2.9% (354)
1.9% (241)
<1% (66)
<1% (46)

5.1.6. Pharmacotherapy. The pharmacotherapy data were examined for the
periods of 30 days pre-admission, admission, and 30 days post-admission.
5.1.6a. Pre-admission pharmacotherapy. Nearly one in three patients (30%)
filled at least one opioid prescription in the 30 days prior to index-hospitalization. The
two most common opioid prescriptions were oxycodone (12%) and hydrocodone (10%).
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A prescription for gabapentin/pregabalin (e.g., Lyrica®) was filled in 32% of unique cases
and benzodiazepine prescriptions were present in 9% of cases (see Table 5.6).
Table 5.6. Pre-Admission: Non-OAT Pharmacotherapya
Variable
Opioid
1. Oxycodone
2. Hydrocodone
3. Morphine
4. Tramadol
5. Fentanyl
6. Codeine
7. Hydromorphone
8. Tapentadol
9. Meperidine
10. Oxymorphone
11. Butorphanol
Benzodiazepine
1. Clonazepam
2. Lorazepam
3. Diazepam
4. Alprazolam
5. Temazepam
Concurrent Opioid/Benzodiazepine
Gabapentin/Pregabalin
Naltrexone
Injection
Oral
Naloxone
b

Frequency %, Count (n = 12,407)
30.4%
11.8%
10.1%
6.6%
5.4%
1.3%
1.1%
<1%
<1%
<1%
<1%
<1%
8.8%
3.0%
2.2%
1.7%
1.5%
<1%
4.7%
32.1%
2.0%
<1%
1.7%
3.8%

(3766)
(1462)
(1256)
(822)
(675)
(158)
(133)
(109)
(3)
(2)
(1)
(1)
(1085)
(373)
(271)
(212)
(185)
(88)
(583)
(3984)
(244)
(38)
(212)
(477)

Table Notes. aSub-categories of pharmaceutical groups may equal more than the collapsed category
because patients may have received more than one drug from a given category; bDoes not include
methadone or buprenorphine formulations for pain.

OAT receipt occurred in 11% of cases (n = 1,325) in the pre-admission time
period. The most common type of OAT was buprenorphine (5%; n = 625) and the second
most common was non-specific OAT administration (4.7%; n = 557) (see Table 5.7).
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Table 5.7. Pre-Admission: OAT
Variable
Frequency %, Count (n = 12,407)
Any OATa
10.7% (1325)
Buprenorphine Onlyb
5.0% (625)
Non-Specific Administrationc
4.7% (577)
>1Type of OAT Receivedd
<1% (112)
Methadone Onlye
<1% (11)
Table Notes. aIncludes each of the 4 sub-categories in this table; bIncludes buprenorphine prescription
fills and the Healthcare Common Procedure Coding System (HCPCS) codes (J0574, J0575, J0571);
c
Includes an OTP stop code visit or the non-specific OAT administration HCPCS code (H0033); dIncludes
any patients who received more than one type of OAT during the pre-period; eIncludes the methadone
specific HCPCS code (S0109).

5.1.6b. Admission pharmacotherapy. Admission data suggested frequent opioid
administration during admission. More than half of patients (55%) had at least one
opioid delivered during admission; oxycodone (29%) and morphine (20%) were most
common. More than one in three admissions received gabapentin/pregabalin (37%) and
more than one in four admissions received benzodiazepines (30%). First or second-line
adjuvants for the symptom management of opioid withdrawal were administered in
44% of cases. The VHA’s recommended first line adjuvant for withdrawal, clonidine, was
only observed in 9% of cases; second-line adjuvants (i.e., baclofen, gabapentin,
pregabalin, or tizanidine) were present in 39% of cases (see Table 5.8).
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Table 5.8. Admission: Non-OAT Pharmacotherapya
Variable
Frequency %, Count (n = 12,407)
Any Opioidb
54.5% (6765)
1. Oxycodone
29.2% (3623)
2. Morphine
20.4% (2525)
3. Hydromorphone
18.0% (2635)
4. Hydrocodone
13.3% (1645)
5. Tramadol
8.1% (1008)
6. Fentanyl
4.4% (551)
7. Codeine
<1% (103)
8. Meperidine
<1% (17)
9. Belladonna
<1% (11)
10. Tapentadol
<1% (2)
11. Oxymorphone
<1% (1)
12. Butorphanol
<1% (1)
No Opioids and No OAT
35.6% (4418)
Any adjuvants
44.4% (5502)
First-Line Adjuvantc
8.8% (1089)
Any Second-Line Adjuvantd
39.3% (4882)
Any benzodiazepine
30.3% (3757)
1. Lorazepam
21.6% (2677)
2. Diazepam
5.3% (662)
3. Clonazepam
3.1% (383)
4. Alprazolam
1.9% (240)
5. Midazolam
1.7% (214)
6. Temazepam
1.3% (159)
Gabapentin/Pregabalin
36.7% (4556)
Naltrexone
1.4% (168)
Oral Tablet
1.3% (155)
Injectable
<1% (31)
a
Table Notes. Group sub-categories may equal more than the collapsed category because patients
can receive more than one drug from a category; bDoes not include methadone or buprenorphine
formulations; cFirst-line: clonidine; dSecond-line: baclofen, gabapentin, pregabalin, and tizanidine.

OAT was administered in 15% of cases, with methadone delivery (9%) more
common than buprenorphine (5%). Across the study population, OAT was used primarily
to manage withdrawal symptoms (7%) (i.e., the patient did not receive OAT prior to or
after admission, only during admission). The second most common OAT delivery
mechanism was OAT sustained (6%) (i.e., a patient received OAT throughout the care
continuum—in the pre, admission, and post periods). OAT initiation and linkage to care
(2%) were uncommon (i.e., OAT starting in the hospital and continued in the outpatient
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setting within 30›days of discharge). Very few patients received OAT continuation (1%)
(i.e., OAT delivery in the pre-period and during admission, but not in the post-admission
discharge period) (see Table 5.9).
Table 5.9. Admission: OAT
Variable
Frequency %, Count (n = 12,407)
Any OATa
15.4% (1914)
Methadone Onlyb
8.5% (1049)
Buprenorphine Onlyc
5.2% (639)
>1 Type of OAT Receivedd
1.1% (136)
Non-Specific Administration Onlye
<1% (90)
OAT by Care Delivery Scenario
OAT Withdrawalf
6.8% (844)
OAT Sustainedg
5.8% (722)
OAT Initiation and Linkageh
1.6% (203)
OAT Continuedi
1.2% (145)
OAT Administered with Other Pharmacotherapy
With Any Adjuvant
7.2% (893)
With Second-Line Adjuvant
6.2% (766)
With Opioid
5.6% (690)
With First-Line Adjuvant: Clonidine
2.2% (271)
With Naltrexone
<1% (9)
a
b
Includes each of the 4 OAT sub-categories in this table; Includes the methadone specific Healthcare
Common Procedure Coding System (HCPCS) code (S0109); cIncludes buprenorphine prescription fills
and HCPCS codes (J0574, J0575, J0571); dIncludes any patients who received more than one type of
OAT during admission; eIncludes an OTP stop code visit or the non-specific OAT administration HCPCS
code (H0033); fOAT received during admission, but not in pre or post period; gOAT received in the pre,
admission, and post periods; hOAT received during admission and the post period, but not the pre
period; iOAT received in the pre and admission periods, but not the post period.

5.1.6c. Post-admission pharmacotherapy. Over one third of the patients (34%)
in the study cohort filled one or more opioid-related prescriptions in the 30 days after
hospital discharge. The most commonly filled prescriptions were oxycodone (17%) and
hydrocodone (10%). Compared with the pre-admission data, the proportion of cases
with gabapentin/pregabalin (26%) and benzodiazepine (8%) prescriptions was lower.
Compared with the pre-admission data, the proportion of cases prescribed naloxone
(6%) post-admission was more common than pre-admission (4%) (see Table 5.10).
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Table 5.10. Post-Admission: Non-OAT Pharmacotherapya
Variable
Frequency %, Count (n = 12,407)
Any Opioidb
34.3% (4250)
1. Oxycodone
17.0% (2112)
2. Hydrocodone
9.9% (1229)
3. Morphine
6.1% (759)
4. Tramadol
5.2% (650)
5. Hydromorphone
1.6% (196)
6. Fentanyl
1.2% (150)
7. Codeine
<1% (108)
8. Tapentadol
<1% (2)
9. Meperidine
<1% (2)
10. Oxymorphone
<1% (1)
11. Belladonna
<1% (1)
Any Benzodiazepine
7.7% (949)
1. Clonazepam
2.3% (317)
2. Lorazepam
2.2% (267)
3. Diazepam
1.5% (188)
4. Alprazolam
1.1% (140)
5. Temazepam
<1% (66)
6. Midazolam
<1% (3)
Concurrent Opioid & Benzodiazepine
3.9% (483)
Gabapentin/Pregabalin
26.3% (3263)
Naltrexone
2.8% (341)
Oral Tablet
2.3% (289)
Injectable
<1% (68)
Naloxone
6.2% (765)
Table Notes. aSub-categories of pharmaceutical groups may equal more than the collapsed
category because patients may have received more than one drug from a given category;
b
Does not include methadone or buprenorphine formulations for pain.

OAT receipt during the post-admission period occurred in 11% of cases, with a
nearly even distribution of use between buprenorphine (5%) and non-specific
administration (5%) (see Table 5.11).
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Table 5.11. Post-Admission: OAT
Variable
Frequency %, Count (n = 12,407)
Any OATa
11.4% (1420)
Buprenorphine Onlyb
5.1% (633)
Non-Specific Administration Onlyc
5.1% (628)
>1 Type of OAT Receivedd
1.1% (142)
Methadone Onlye
<1% (17)
Table Notes. aIncludes each of the 4 sub-categories in this table; bIncludes buprenorphine prescription
fills and the Healthcare Common Procedure Coding System (HCPCS) codes (J0574, J0575, J0571);
c
Includes an OTP stop code visit or the non-specific OAT administration HCPCS code (H0033); dIncludes
any patients who received more than one type of OAT during admission; eIncludes the methadone
specific HCPCS code (S0109).

5.1.7. Admission-related outcomes. The admission-related outcomes were
assessed during hospitalization or within the 30 days post-admission. In-hospital
mortality (1%), post-admission death (<1%), and leaving against medical advice (6%)
were uncommon outcomes across the study cohort. In contrast, it was common for
patients to need additional acute care services during the post-admission period. More
than one quarter of patients (28%) in the sample had an emergency department visit,
and re-admissions occurred for 13% of patients (see Table 5.12).
Table 5.12. VHA Study Cohort Outcomes
Variable
Admission
Left Against Medical Advice
In-Hospital Mortality
Post-Admission
Death
Emergency Department Visit
Hospital Readmission

Frequency %, Count (n = 12,407)
5.7% (701)
1.0% (119)
<1% (112)
27.7% (3436)
13.1% (1630)

5.1.8. Summary. This section explored the supply-side and demand-side
attributes, care delivery patterns, and outcomes for the entire study cohort. The study
cohort characteristics were homogenous for the supply-side (i.e., hospitals) and
heterogenous for demand-side attributes (i.e., patients). Most admissions were for
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elderly white men, with co-occurring mental health conditions, in large hospitals. In
contrast, the clinical reasons for admission varied among patients. Interestingly, most
admissions were not OUD-related by primary or secondary diagnosis or by OUD-related
infection codes.
These descriptive analyses begin to depict care patterns for patients with OUD
that are potentially problematic. In all three time periods (pre, admission, post), opioid
prescription or administration frequency was higher than OAT delivery. When OAT was
delivered in the hospital setting, it was primarily administered for withdrawal
management. The most effective approaches to care (i.e., OAT sustaining, continuing,
initiating and linkage to care) occurred infrequently. An additional indicator of poor care
or lower quality care delivery in the hospital setting was the elevated use of the
emergency department in the post-admission period. This measure has not been
studied in the VHA system; however, a 30-day hospital readmission rate for the VHA
system has been reported at 18% (Vincent, Wiitala, Burns, Iwashyna, & Prescott, 2018),
and a previous hospitalization (OR, 2.5; 95% CI [2.3, 2.7]) is associated with increased
risk of an emergency department visit (Hastings et al., 2011).
Section 5.2. OAT vs. No OAT Received During Admission
To expand upon the observations of the prior section, this section explored
potential differences between patients who received or did not receive OAT based on
clinical and admission characteristics, care delivery patterns, and outcomes. This section
addressed the following research sub-questions:
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•

2a: Do the characteristics of the patients who received OAT differ from those
who do not receive OAT while hospitalized?

•

2b: Does non-OAT pharmacotherapy delivery differ for patients who received
OAT and for those who did not receive OAT while hospitalized?

•

2c: Do outcomes differ for patients who received OAT and for those who did
not receive OAT while hospitalized?

5.2.1. Patient characteristics. Patients who received OAT differed statistically (p
< 0.05) from those who did not receive OAT during admission. OAT patients were one
year younger (mean = 57 years of age vs. 58 years of age) and were less likely to be
women (5% vs. 7%). Patients who received OAT had a statistically significant different
distribution of racial categories with more Black patients (27% vs. 21%) and fewer White
patients (68% vs. 76%). Patients administered OAT during hospitalization were also
more likely to have comorbid SUDs (51% vs. 48%) and to have mental health disorders
(67% vs. 65%). Although the two groups differed statistically on most characteristics, the
differences do not appear to be clinically significant; rather they reflect the study’s large
sample size (see Table 5.13).
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Table 5.13. Patient Characteristics: OAT Received vs. Not Received
Characteristics
Age***

Race***
American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or Pacific Islander
Unknown/Declined to Answer
White
Ethnicity
Hispanic or Latino
Non-Hispanic or Latino
Unknown
Gender***
Male
Female
Comorbidities
SUD*

OAT Received
(15%, 1,914)
Median, 60.0 years
Mean, 57.1
(SD = 12.4; 23-90)

No OAT Received
(85%, 10,597)
Median, 61.0 years
Mean, 58.8
(SD = 13.4; 21-90)

Difference
1 year

<1% (12)
<1% (7)
27.0% (516)
<1% (12)
3.4% (65)
68.0% (1302)

1.3% (135)
<1% (36)
21.0% (2190)
<1% (94)
4.3% (460)
75.7% (7578)

»
»
»
»
»
»

5.5% (105)
91.8% (1758)
2.6 % (51)

4.7% (490)
92.6% (9718)
2.8% (285)

» <1%
» <1%
» <1%

X2 = 2.3663
df = 2
p > 0.05

95.5% (1827)
4.6% (87)

92.6% (9716)
7.4% (777)

» 2%
» 3%

X2 19.99
df = 1
p < 0.05c

51.4% (983)

48.0% (5041)

» 3%

<1%
<1%
6%
<1%
<1%
7%

Test
Statistic
W = 10675000
p < 0.05a

X2 = 42.56
df = 5
p < 0.05b

X2 = 6.9972
df = 1
p < 0.05c
Mental health condition**
67.4% (1290)
64.8% (6804)
X2 = 4.5472
» 2%
df = 1
p < 0.05c
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); bPearson chi-square test; cPearson chi-square test with
Yates’ continuity correction; p < 0.05*; p < 0.01**; p < 0.001***.
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5.2.2. Admission characteristics. The two groups had statistically significant
differences for length of stay, admission source, acuity of services received (ICU and
surgical), OUD diagnoses, and OUD infection diagnoses. Although, again, most observed
differences between the two groups were likely trivial, findings with substantive
relevance were likely for three characteristics. Patients who received OAT had a longer
length of stay (5 days vs. 4 days) and were more likely to have a primary or secondary
OUD diagnosis (29% vs. 12%) or an OUD diagnosis/and or an OUD-related infection (37%
vs. 17%) (see Table 5.14).
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Table 5.14. Admission-Related Characteristics: OAT Received vs. Not Received
Admission-Related
Variables
Length of Stay***

OAT Received
(15%, 1,914)
Median, 5 days
Mean, 7.53
(SD 7.05; 1 – 50)

No OAT Received
(85%, 10,597)
Median, 4 days
Mean, 6.44
(SD 6.23, 1- 50)

1 day

46.0% (880)
49.3% (942)
4.8% (91)

49.7% (5215)
44.5% (4673)
5.8% (605)

» 4%
» 4%
» 1%

X2 = 13.533
df = 2
p < 0.05b

16.3% (312)

19.0% (1991)

» 3%

Surgical Services*

5.2% (100)

6.5% (679)

» <1%

X2 = 7.4787
df = 1
p < 0.05c
X2 = 4.0638
df = 1
p < 0.05c

Acute OUD or Infection Diagnosis
Acute OUD Diagnosis***

29.0% (560)

12.3% (1288)

» 17%

Admission Source***
Outpatient Treatment
Other Direct Admission
Other
Type of Services Received
ICU Services**

Difference

Test
Statistic
W = 8758700
p < 0. 05a

X2 = 366.98
df = 1
p < 0.05c
OUD Infection Diagnosis ***
8.3% (158)
5.1% (533)
X2 = 30.434
» 3%
df = 1
p < 0.05c
Acute OUD or Infection Diagnosis****
36.5% (698)
17.1% (1793)
X2 = 377.7
» 20%
df = 1
p < 0.05c
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); bPearson chi-square test; cPearson chi-square test
with Yates’ continuity correction; p < 0.05*; p < 0.01**; p < 0.001***.
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5.2.3. Care delivery during admission. Care delivery processes during admission
differed significantly for patients who received OAT and for those who did not. Patients
who received OAT were less likely to receive opioids (36% vs. 58%), benzodiazepines
(28% vs. 31%), or naltrexone (<1% vs. 2%). They were also more likely to receive
withdrawal management adjuvants (48% vs. 44%), or first-line adjuvants (14% vs. 8%).
The differences in opioid administration between the two groups were likely
meaningful, although, generally, the remainder of the statistical differences appeared to
have minimal clinical relevance (see Table 5.15).
Table 5.15. Admission Non-OAT Pharmacotherapy: OAT Received vs. Not Received
Care Delivery
Variables
Non-OAT Opioid***

OAT Received
(15%, 1,914)
36.1% (690)

No OAT Received
(85%, 10,597)
57.9% (6075)

Difference

Test
Statistic
X2 = 310.67
» 22%
df = 1
p < 0.05c
Any Adjuvant***
48.0% (919)
43.7% (4583)
X2 = 12.167
» 4%
df = 1
p < 0.05c
First-Line Adjuvant:
14.2% (271)
7.8% (818)
X2 = 81.064
» 7%
Clonidine***
df = 1
p < 0.05c
Second-Line Adjuvant
40.0% (766)
39.2% (4116)
X2 = 0.39576
» <1%
df = 1
p > 0.05c
Benzodiazepine***
27.6% (528)
30.8% (3229)
X2 = 7.6361
» 3%
df = 1
p < 0.05c
Naltrexone***
<1% (9)
1.5% (159)
X2 = 12.465
» 1%
df = 1
p < 0.05c
Table Notes. cPearson chi-square test with Yates’ continuity correction; p < 0.05*; p < 0.01**;
p < 0.001***.

5.2.4. Health and utilization outcomes. Compared to patients who did not
receive OAT, patients who received OAT were significantly less likely to leave against
medical advice (4% vs.6%), and to receive post-admission prescriptions for opioids (16%
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vs. 38%), benzodiazepines (5% vs. 8%), concurrent opioids and benzodiazepines (<1% vs.
4%), and naltrexone (<1% vs. 3%). The differences were small and likely have little
clinical importance; however, two of the differences had apparent clinical significance:
filled opioid prescriptions post-admission and OAT receipt post-admission (see Table
5.16).

224

Table 5.16. Outcomes: OAT Received vs. Not Received
Outcome
Variables

OAT Received
(15%, 1,914)

No OAT Received
(85%, 10,493)

Difference

Admission
In-Hospital Mortality

<1% (15)

1.0% (104)

» <1%

Left Against Medical Advice***

3.5% (68)

6.0% (633)

» 2%

Post-Admission
Death

<1% (18)

<1% (94)

» <1%

Test Statistic

X2 = 0.53115
df = 1
p > 0.0
X2 = 18.211
df = 1
p < 0.05

X2 = 0.00343
df = 1
p > 0.05
Emergency Department Visit
26.1% (499)
28.0% (2937)
X2 = 2.8819
» 2%
df = 1
p > 0.05
Hospital Readmission
12.8% (245)
13.2% (1385)
X2 = 0.19206
» <1%
df = 1
p > 0.05
Non-OAT Opioid***
16.3% (312)
37.5% (3938)
X2 = 322.98
» 22%
df = 1
p < 0.05
Benzodiazepine ***
5.4% (103)
8.1% (846)
X2 = 16.095
» 3%
df = 1
p < 0.05
Naloxone***
11.2% (214)
5.3% (551)
X2 = 97.351
» 6%
df = 1
p < 0.05
Gabapentin/Pregabalin
25.8% (493)
26.4% (2770)
X2 = 0.31084
» <1%
df = 1
p > 0.05
Naltrexone***
<1% (17)
3.2% (324)
X2 = 28.483
» 3%
df = 1
p < 0.05
Concurrent Opioid/
<1% (34)
4.3% (449)
X2 = 26.562
» 4%
Benzodiazepine***
df = 1
p < 0.05
OAT***
48.3% (925)
4.7% (495)
X2 = 3033.3
» 43%
df = 1
p < 0.05
b
Table Notes. Pearson chi-square test; p < 0.05*; p < 0.01**; p < 0.001***; Post-admission event within
30 days of discharge from index hospitalization.
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5.2.5. Summary. Most of the statistically significant findings were based on small
relative differences that were likely not clinically significant but reflected the large study
sample size. Four findings from this section stood out and warrant further discussion
and exploration. First, patients who received OAT were more likely to have an OUD
diagnosis and/or an OUD-related infection. This suggests that treatment processes and
services differed between patients with an acute OUD-related issue during admission as
compared with patients with a chronic OUD presentation. Second, patients who
received OAT had a lower frequency of opioid administration during hospitalization.
Determining whether this is appropriate or inappropriate care is challenging without
further granularity on each case. The qualitative analyses in Chapter 4 suggested that
patients who received OAT in the hospital setting may require additional opioids to
manage pain when OAT administration alone is insufficient to manage moderate to
severe pain. Lower opioid administration for this patient population during
hospitalization, therefore, may be inappropriate. Third, patients who received OAT had
less post-admission opioid prescriptions filled suggesting that prescribers may be
assessing opioid risk more carefully among patients who received OAT. However, 16% of
these patients were still receiving non-OAT opioids in the post-admission period. Fourth,
patients who received OAT were more likely to receive OAT in the 30-day discharge
period suggesting that OAT delivery in the hospital setting is part of a broader pathway
and continuum of care for treating patients with OUD in the VHA system.
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Section 5.3. OAT Discontinuation vs. OAT Continuation Upon Admission
There were 1,325 patients in the sample receiving OAT prior to hospital
admission. Of those patients, 65% (n = 867) continued OAT during admission, and 35%
(n = 458) were discontinued from OAT during admission. Of the patients who continued
OAT during admission, most (83%) were continued in the post-admission period (n =
722; the OAT sustained variable). Of those who were discontinued upon admission, 64%
of those patients (n = 295; the OAT discontinued with restart variable) were restarted
upon discharge in the post-admission period. Post-hospitalization approximately 23% of
patients (n = 308, the OAT interrupted variable) who had received OAT prior to hospital
admission (regardless of care received during admission) had their OAT care interrupted
by hospitalization, and did not return to OAT in the 30 days post-admission. Section 5.3
addresses the following research sub-questions:
•

2d: Do the characteristics of the patients who were discontinued from OAT
differ from those who were continued on OAT at admission?

•

2e: Does non-OAT pharmacotherapy delivery differ for patients who received
OAT and for those who did not receive OAT while hospitalized?

•

2f: Do outcomes differ for patients who received OAT and for those who did
not receive OAT while hospitalized?

5.3.1. Patient characteristics. Patients who were discontinued on OAT upon
admission (n = 458) and patients who continued OAT during admission (n = 867)
differed. The discontinued patients were younger (mean of 54 years of age vs. 56 years
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of age) and more likely to be women (9% vs. 4%). The observed differences were not
large, and are not clearly clinically significant, but may reflect some combined
demographics or a sub-population not otherwise discernable in the bivariate analysis
(see Table 5.17).
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Table 5.17. Patient Characteristics: OAT Continued vs. Discontinued
Characteristics
Age**

Race
American Indian/Alaska Native
Asian
Black/African American
Native Hawaiian/Pacific Islander
Unknown/Declined to Answer
White
Ethnicity
Hispanic or Latino
Non-Hispanic or Latino
Unknown
Gender***
Male
Female

OAT Discontinued
(n = 458)
Median, 59.0 years
Mean, 54.0
(SD = 13.2; 24 -81)

OAT Continued
(n = 867)
Median, 60.0 years
Mean, 56.2
(SD = 12.4; 23-87)

Difference
1 year

Test
Statistic
W = 216700
p < 0.05a

<1% (1)
<1% (2)
22.3% (102)
<1% (2)
2.8% (13)
73.8% (338)

<1% (3)
<1% (3)
28.1% (244)
<1% (6)
2.8% (24)
67.7% (587)

» <1%
» <1%
» 6%
» <1%
No diff.
» 6%

X2 = 6.108
df = 5
p > 0.05b

4.6% (21)
92.8% (425)
2.6 % (12)

5.7% (49)
91.7% (795)
2.7% (23)

» 1%
» 1%
» <1%

X2 = 0.68579
df = 2
p > 0.05

91.3% (418)
8.7% (40)

96.0% (832)
4.0% (35)

» 5%
» 5%

X2 = 11.516
df = 1
p < 0.05c

Comorbidities
Co-Occurring Substance Use Disorder

58.1% (266)

61.7% (535)

» 3%

X2 = 1.5021
df = 1
p > 0.05c

Co-Occurring Mental Health

74.2% (340)

76.4% (662)

» 2%

X2 = 0.61981
df = 1
p > 0.05c
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); b Pearson chi-square test; cPearson chi-square test with
Yates’ continuity correction; p < 0.05*; p < 0.01**; p < 0.001***.
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5.3.2. Admission characteristics. The OAT-discontinued and OAT-continued
groups differed on two admission-related characteristics: length of stay and receipt of
surgical service. Length of stay was likely the only clinically meaningful difference.
Discontinued OAT patients had a median stay of three days while OAT-continued
patients had a median stay of five days. There were also important similarities between
the groups, specifically: 1) the two groups did not differ on source of admission; 2)
patients did not differ in acuity of services (e.g., ICU use); and 3) there were no
differences in frequency of acute OUD diagnoses and or/OUD-related infections (see
Table 5.18). These findings suggest other unmeasured sources were contributing to the
differences in care.
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Table 5.18. Admission-Related Patient Characteristics: OAT Continued vs. Discontinued
Characteristics

OAT Discontinued
(n = 458)
Median, 3 days
Mean, 4.46
(SD 4.84; 1 – 43)

OAT Continued
(n = 867)
Median, 5 days
Mean, 6.65
(SD 5.88, 1- 47)

2 days

48.0% (220)
46.5% (213)
5.4% (25)

45.6% (395)
49.9% (433)
4.5% (39)

» 2%
» 2%
» 1%

X2 = 1.6934
df = 2
p > 0.05b

15.9% (73)

15.9% (138)

No diff.

Surgical Services**

10.3% (47)

5.4% (47)

» 5%

X2 = 7.2 X 10-30
df = 1
p =1c
X2 = 9.934
df = 1
p < 0.05c

OUD or Infection Diagnosis
Primary or Secondary OUD Diagnosis

26.6% (122)

27.2% (236)

» <1%

Length of Stay***

Admission Source
Outpatient Treatment
Other Direct Admission
Other
Type of Services Received
ICU Services

Difference

Test
Statistic
W = 266920
p < 0. 05a

X2 = 0.026289
df = 1
p > 0.05c
OUD Infection Diagnosis
5.0% (23)
6.3% (55)
X2 = 0.72166
» 1%
df = 1
p > 0.05c
OUD Diagnosis or Infection Diagnosis
31.2% (143)
32.9% (285)
X2 = 0.30117
» 2%
df = 1
p > 0.05c
a
b
c
Table Notes. Mann-Whitney U Test (Wilcoxon rank sum test with continuity correction); Pearson chi-square test; Pearson chi-square test with
Yates’ continuity correction; p < 0.05*; p < 0.01**; p < 0.001***.
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5.3.3. Care delivery during admission. Medications provided during admission
differed statistically for patients who discontinued or continued OAT for opioid
administration, any adjuvant administration, and second-line adjuvant administration.
Of these observed differences, only one of the care delivery processes was likely
clinically meaningful: OAT discontinued patients were more likely to receive non-OAT
opioids during admission (44% vs. 26%) (see Table 5.19).
Table 5.19. Admission Non-OAT Pharmacotherapy: OAT Continued vs. Discontinued
Characteristics

OAT Discontinued
(n = 458)
43.9% (201)

OAT Continued
(n = 867)
26.2% (227)

Difference

Test
Statistic
Non-OAT Opioid***
X2 = 42.15
» 18%
df = 1
p < 0.05c
Any Adjuvant*
37.3% (171)
43.7% (379)
X2 = 4.7615
» 7%
df = 1
p < 0.05c
First-Line
10.3% (47)
9.7% (84)
X2 = 0.055607
» <1%
Adjuvant: Clonidine
df = 1
p > 0.05c
Second-Line
31.2% (143)
39.1% (339)
X2 = 7.6988
» 8%
Adjuvant**
df = 1
p < 0.05c
Benzodiazepine
23.6% (108)
23.5% (204)
X2 = 5.5 X 10-29
» <1%
df = 1
p = 1c
Naltrexone
<1% (2)
<1% (2)
X2 = 0.01527
» <1%
df = 1
p > 0.05c
c
Table Notes. Pearson chi-square test with Yates’ continuity correction; p < 0.05*; p < 0.01**;
p < 0.001***.

5.3.4. Outcome characteristics. Compared with the OAT discontinued patients,
the OAT continued patients were statistically less likely to leave the hospital against
medical advice (3% vs. 10%), less likely to receive post-admission opioid prescriptions
(12% vs. 27%), and were more likely to receive OAT upon discharge in the postadmission period (83% vs. 64%) (see Table 5.20).
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Table 5.20. Outcomes: OAT Continued vs. Discontinued
Characteristics

Admission
In-Hospital Mortality
Left Against Medical
Advice***
Post-Admission
Death

OAT
Discontinued
(n = 458)

OAT Continued
(n = 867)

Difference

<1% (1)

1.0% (5)

» <1%

10.0% (46)

3.0% (26)

» 7%

10.0% (5)

3.0% (7)

» 7%

Test
Statistic

X2 = 0.24386
df = 1
p > 0.05
X2 = 27.589
df = 1
p < 0.05

X2 = 0.046088
df = 1
p > 0.05
Emergency
29.5% (135)
26.2% (227)
X2 = 1.4757
» 4%
Department Visit
df = 1
p > 0.05
Hospital Readmission
12.9% (59)
11.8% (102)
X2 = 0.25637
» 1%
df = 1
p > 0.05
Non-OAT Opioid***
26.9% (123)
12.0% (104)
X2 = 45.576
» 15%
df = 1
p < 0.05
Benzodiazepine
6.3% (29)
4.7% (41)
X2 = 1.2352
» 1%
df = 1
p > 0.05
Naloxone
8.1% (37)
8.7% (75)
X2 = 0.063547
» <1%
df = 1
p > 0.05
Gabapentin/Pregabalin
28.8% (132)
26.3% (228)
X2 = 0.84105
» 2%
df = 1
p > 0.05
Naltrexone
2.0% (9)
<1% (6)
X2 = 3.2764
» 2%
df = 1
p > 0.05
Concurrent Opioid &
2.0% (9)
1.2% (10)
X2 = 0.88162
» 1%
Benzodiazepine
df = 1
p > 0.05
OAT***
64.4% (295)
83.3% (722)
X2 = 58.272
» 19%
df = 1
p < 0.05
b
c
Table Notes. Pearson chi-square test; Pearson chi-square test with Yates’ continuity correction;
p < 0.05*; p < 0.01**; p < 0.001***.
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5.3.5. Summary. This section provides insights about a special subset of patients
from the study cohort—patients receiving OAT in the 30 days prior to their hospital
admission. Several findings stand out. First the difference in OAT receipt during the 30
days after hospital discharge (i.e., the post-admission period) for patients who were
either continued (83%) or discontinued (64%) on OAT during the admission was
significant. This difference illustrates the importance of hospital-based continuation of
OAT. Further, this suggests that care pathways or care transition plans may exist for
patients in the VHA system who are on OAT prior to admission.
Second, there were differences in patient-and admission-related characteristics.
Patients discontinued from OAT had substantially shorter lengths of stay (3 days vs. 5
days) suggesting that something may be characteristically different about this patient
population, and the primary reason for their hospitalization. The causes of a shorter
length of stay cannot be explicitly determined and there are a variety of factors that
could explain this difference. One explanation is that shorter stays are related to a
higher occurrence of leaving against medical advice (AMA) in the discontinuation
population (10% vs. 3%). Another explanation is that because the patient has a shorter
length of stay, due to non-OUD related factors, it is possible that a patient’s withdrawal
symptoms were not identified. This misidentification could be due to withdrawal
masking because non-OAT opioids were administered during admission. OAT
discontinued patients were more likely to receive non-OAT opioids (44% vs. 26%). The
elevated rate of opioid use could also indicate the converse -- the identification of
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withdrawal and the use of non-FDA approved opioids to manage withdrawal. Shortacting opioids in this patient population were frequently continued post-admission.
Patients discontinued from OAT had increased opioid use post-admission (27% vs. 12%),
suggesting that discontinuing OAT in the hospital setting increases the opportunity for
OUD treatment disruption and the propagation of non-evidence-based care.
There were important non-statistically significant findings from this sub-group
analysis. First, the two sub-groups did not differ in hospitalization acuity (ICU services)
or types of services received (surgery). These are both potential clinical reasons as to
why a patient could be discontinued from OAT. Second, there were no differences
between the two groups in the frequency of acute OUD diagnoses and or/OUD-related
infections. This is a relevant finding because patients with an acute OUD diagnosis may
have more obvious needs for OAT continuation. These non-significant findings indicate
that the differences in OAT continuation may be explained by other unmeasurable
elements, such as the care delivery environment.
Section 5.4. Hospital OAT Delivery Distribution and Performance Quartiles
To expand upon previous observations that patient and hospital characteristics
may contribute to hospital OAT delivery variation, this section further investigates
hospital OAT care variation across the VHA system. This section addresses the following
research sub-questions:
•

2f: Do outcomes differ for patients who received OAT and for those who did not
receive OAT while hospitalized?
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•

2g: Are specific OAT care scenarios associated with hospital OAT delivery
quartile?

•

2h: Which hospital attributes associated with hospital OAT delivery?

•

2i: Are non-OAT pharmacotherapy services associated with hospital OAT delivery
quartile?

•

2j. Were outcomes associated with hospital OAT delivery performance?
The relative OAT delivery frequency (the number of admissions with OAT

delivered divided by total number of admissions at that facility) was calculated for each
facility (n = 109). The median relative frequency was 11%, with a standard deviation of
0.10, and a range from 0% to 43%, confirming variation in hospital OAT delivery across
the VHA system. An assessment of specific OAT delivery mechanisms found that the
most common OAT delivery scenarios were withdrawal management (39%) and OAT
sustained (33%); OAT initiation and linkage to care (9%) and OAT continuation (7%) were
uncommon (see Table 5.21 and Figure 5.1).
Table 5.21. Hospital OAT Delivery Mechanisms
OAT Delivery
Rel.
Median Range
IQR
Skew
Kurtosis
Scenarios
Frequency
Any OAT
100%
0.12
0, 0.43
0.11
1.10
0.77
(n = 1914)
Withdrawal Managementa
38.6
0.05
0.0, 0.39
0.06
1.32
1.99
(n = 844)
OAT Sustainedb
33.0%
0.04
0.0, 0.23
0.06
1.38
-1.24
(n = 722)
OAT Initiation & Linkagec
9.2%
0.005
0.0, 0.08
0.02
1.77
3.13
(n = 203)
OAT Continuedd
6.6%
0.006
0..0, 0.06
0.02
1.38
1.37
(n = 145)
Table Notes. aOAT received during admission period, but not in pre or post period; bOAT received
in the pre, admission, and post periods; cOAT received during admission and the post period, but
not the pre period; dOAT received in the pre and admission periods, but not the post period.
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Figure 5.1. Relative OAT Frequency for Each Hospital by Quartile

Figure Notes. *Two hospitals had 0 OAT delivery admissions and are not plotted in the graph.
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Based on the relative OAT delivery frequency (of any OAT delivery scenario),
facilities were categorized into hospital OAT delivery performance quartiles: Q1 (0 to
6.0%), Q2 (7.0 to 11.0%), Q3 (12.0 to 18.0%), and Q4 (18.1 to 42.0%). The data had a
non-normal distribution skewed towards lower performance (see Table 5.22 and Figure
5.2.).
Table 5.22. Any OAT Received: By OAT Performance Quartilea
Performance
No. of
Median
Range
IQR
Skew
Kurtosis
Quartile
Obs.
All (n = 109)
12,407
0.12
0.0, 0.43
0.11
1.05
0.73
Q4 (n = 28)
3,944
0.27
0.18, 0.43
0.12
0.51
-0.97
Q3 (n = 26)
2,767
0.15
0.12, 0.18
0.03
0.21
-1.28
Q2 (n = 28)
2,836
0.10
0.07, 0.12
0.03
-0.05
-1.57
Q1 (n = 27)
2,860
0.05
0 .0, 0.07
0.03
-0.78
-0.33
a
Table Notes. Q4 is the highest performing group and Q1 is the lowest performing group; No. of Obs
= The total number of cases in each quartile with and without OAT delivered.
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Figure 5.2. Relative OAT Frequency Distribution by Hospital (n = 109)

5.4.1. Performance quartiles: OAT delivery. Hospital OAT performance delivery
quartiles differed for all OAT care delivery scenarios. For any OAT received, each quartile
differed statistically from each other (alpha = 0.05), indicating that quartiles provided a
meaningful distinction of OAT performance. Generally, facilities in Quartile 4 were more
likely to use OAT to manage withdrawal symptoms, to sustain OAT through the care
delivery continuum, to continue OAT, and to initiate OAT and link patients to care. The
median delivery of OAT in this quartile (27%), however, suggests that most patients,
even in the highest performing hospitals, did not receive OAT. Even the highest perform
OAT hospitals in the VHA did not appear to meet current standards of care for
addressing OUD (see Table 5.23).
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Table 5.23. OAT Delivery Scenarios by VHA Hospital OAT Delivery Performance Quartilea
OAT Delivery
Scenario

OAT Received***

Proportion,
Median (Range),
%
(n = 109)
12%
(0.0 -0.43)

Q1
Proportion,
Median, %
(n = 27)
5.0%d,e,f

Q2
Proportion,
Median, %
(n = 28)
9.8%d,g,i

Q3
Proportion,
Median, %
(n = 26)
14.5%e,g,h

Q4
Proportion,
Median, %
(n = 28)
27.2%f,h,i

Q4-Q1
Diff

» 22%

Test
Statisticb

X2 = 101.24
df = 3
p < 0.05c
d,e,f
d,i
eh
f,h,i
Withdrawal
5%
2.5%
5.1%
7.0%
11.0%
X2 = 53.051
» 8%
Management***
(0.0 – 0.39)
df = 3
p < 0.05c
d,e,f
d,i
eh
f,h,i
OAT Sustained***
4%
1.4%
2.6%
4.0%
9.6%
X2 = 54.929
» 8%
(0.0 – 0.23)
df = 3
p < 0.05c
OAT
<1%
0%e,f
<1%i
<1%e
1.6%f,i
X2 = 18.467
» 2%
Continued***
(0.0 -0.06)
df = 3
p < 0.05c
e,f
g,i
e,g
f,i
OAT Initiation and
<1%
0%
0%
1.4%
2.5%
X2 = 38.2776
» 3%
Linkage***
(0.0 – 0.08)
df = 3
p < 0.05c
Table Notes. aHospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT
during admission. Q1 hospitals were the lowest performers and Q4 the highest; bKruskal-Wallis Test; cDunn’s Test; dDunn’s Test results:
difference between Q1 and Q2; eDunn’s Test results: difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4;
g
Dunn’s Test results: difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results: difference
between Q2 and Q4; p < 0.05*; p < 0.01**; p < 0.001***.
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5.4.2. Performance quartiles: Hospital characteristics. Next, relationships
among hospital OAT performance quartile and supply-side characteristics (i.e., size and
region) were assessed. OAT performance delivery quartiles differed on the number of
hospital beds and the geographic location of the facility, but not for hospital volume of
acute OUD diagnoses and/or OUD-related infections. Meaningful differences appeared
to exist between Quartile 4 (highest performer) and Quartile 1 (lowest performer).
Quartile 4 included fewer small hospitals (4% vs. 26%), more large hospitals (57% vs.
37%), and a different geographic distribution of facilities. Quartile 4 included more
hospitals in the Midwest (25% vs. 15%), Northeast (32% vs. 7%), and the West (21% vs.
4%), and fewer hospitals in the South (21% vs. 74%) (see Table 5.24).
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Table 5.24. Hospital Characteristics by VHA Hospital OAT Delivery Performance Quartilea,b
Characteristics
Acute OUD
Diagnosis Volume
Admission Volume

All
(n = 109)
Median, 0.32
Range
0.13, 0.83

Quartile 1
(n = 27)
Median, 0.34
Range
0.22, 0.56

Quartile 2
(n = 28)
Median, 0.33
Range
0.21, 0.55

Quartile 3
(n = 26)
Median, 0.29
Range
0.18, 0.45

Quartile 4
(n = 28)
Median, 0.28
Range
0.13, 0.83

Median, 98
Range
26, 430

Median, 78
Range
33, 430

Median, 97.5
Range
26, 221

Median, 104
Range
30, 213

Median, 136
Range
35, 294

Q4-Q1
Diff
0.6

Test
Statistic
X2 = 3.818
df = 3
p > 0.05d
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X2 = 5.206
df = 3
p > 0.05d

Hospital Size*
Small
25.7% (28)
25.9% (7)
39.3% (11)
23.1% (6)
3.6% (1)
p < 0.05c
» 22%
Medium
33.0% (36)
37.0% (10)
25.0% (7)
30.8 (8)
39.3% (11)
» 2%
Large
41.3% (45)
37.0% (10)
35.7% (10)
46.2% (12)
57.1% (16)
» 20%
U.S. Region**
Midwest
22.9% (25)
14.8% (4)
28.6% (8)
23.1% (6)
25.0% (7)
p < 0.05c
» 10%
Northeast
16.5% (18)
7.4% (2)
10.7% (3)
15.4% (4)
32.1% (9)
» 25%
South
39.4% (43)
74.1% (20)
25.0% (7)
38.5% (10)
21.4% (6)
» 52%
West
21.1% (23)
3.7% (1)
35.7% (10)
23.1% (6)
21.4% (6)
» 17%
Table Notes aHospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT during
admission. Q1 hospitals were the lowest performers and Q4 the highest; bQuartile percentages were calculated by row; cFisher’s Exact Test was used
because some of the cell values were less than 5; dKruskal-Wallis Rank Sum Test; Small hospital = 1-49 beds; Medium hospital = 50-99 beds;
Large hospital = > 99 beds; p < 0.05*; p < 0.01**; p < 0.001***.
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5.4.3. Performance quartiles: Non-OAT pharmacotherapy. OAT performance
quartiles differed statistically for the delivery of non-OAT opioids, any withdrawal
management adjuvant, and second-line adjuvant. Quartile 4 facilities were significantly
less likely to administer opioids compared with the other OAT performance quartiles
(Q1, Q2, and Q3). Quartile 4 hospitals also had lower use of adjuvant and second-line
adjuvant administration versus the bottom quartile (Q1). There were no statistically
significant differences among quartiles for use of benzodiazepines, which across the
study population was relatively high (median – 32%; range 13% to 83% of admissions),
and for naltrexone which across the study population was relatively low (median <1%;
range 0% to 8%) (see Table 5.25).
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Table 5.25. Non-OAT Pharmacotherapy Delivery by VHA Hospital OAT Delivery Performance Quartilea
Care
Delivery
Scenario
Opioid**

Prop.,
Median %
(Range)
53.8%
(0.2, 0.83)

Q1
(n = 27)
Prop., Median %
56.5%f

Q2
(n = 28)
Prop., Median %
59.3%i

Q3
(n = 26)
Prop., Median %
54.1%h

Q4
(n = 28)
Prop., Median %
46.8%f,h,i

Q4-Q1
Diff
» 10%

Test
Statisticb

X2 = 15.556
df = 3
p < 0.05c
e,f
e
f
Any
44.4%
48.5%
45.2%
42.9%
41.6%
X2 = 12.085
» 6%
Adjuvant**
(0.21, 0.74)
df = 3
p < 0.05 c
1
First-Line
7.7%
7.7%
7.7%
8.2%
6.9%
X2 =
» <1%
(0.0, 0.40)
0.21976
df = 3
p > 0.05
Second39.0%
44.7%e,f
41.4%
36.2%e
36.8%f
X2 = 16.12
» 8%
Line2**
(0.16, 0.69)
df = 3
p < 0.05c
Benzo32.2%
34.0%
33.2%
29.3%
28.2%
X2 = 0.2818
» 6%
diazepine
(0.13, 0.83)
df = 3
p > 0.05c
Naltrexone
<1%
1.2%
<1%
1.2%
1.1%
X2 = 5.1653
» <1%
(0.0, 0.08)
df = 3
p > 0.05
a
Hospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT during admission. Q1
hospitals were the lowest performers and Q4 the highest; bKruskal-Wallis Test; cDunn’s Test calculated; dDunn’s Test results: difference between
Q1 and Q2; eDunn’s Test results: difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4; gDunn’s Test results:
difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results: difference between Q2 and Q4;
1
First line: clonidine; 2Second-line: baclofen, gabapentin, pregabalin, and tizanidine; p < 0.05*; p < 0.01**; p < 0.001***.

245

5.4.4. Performance quartiles: Outcomes. Of the ten health care utilization
measures, three differed statistically by OAT quartile. Opioid prescriptions in the 30 days
post-admission were less common in Quartile 4 (28%) as compared to the other
quartiles (Q1, 37%; Q2, 41%; Q3, 34%). Gabapentin/pregabalin prescriptions in the postadmission period were higher in Quartile 1 (29%) versus Quartile 3 (25%) and Quartile 4
(24%). Post-admission OAT receipt differed among each of the quartiles: Q1, 4%; Q2,
7%; Q3, 10%; and Q4, 19%. The frequency of post-admission emergency department
visits (median, 29%; range: 0% to 50%) was noteworthy but did not differ significantly.
Also, the two mortality measures (in-hospital mortality and post-admission death) were
uncommon across all quartiles (see Table 5.26).

246

Table 5.26. Outcomes by VHA Hospital OAT Delivery Performance Quartilea
Outcome
Variable

Q11
(n = 27)

Q21
(n = 28)

Q31
(n = 26)

Q41
(n = 28)

Q4Q1
Diff.

Test
Statisticb

<1%
(0.0 -0.05)

<1%

<1%

<1%

1.1%

» <1%

Left Against
5.2%
Medical
(0.0 -0.26)
Advice
Post-Admission
Death
0%
(0.0 -0.05)

5.3%

5.7%

5.3%

5.1%

» <1%

X2 = 2.1073
df = 3
p > 0.05
X2 = 0.31675
df = 3
p > 0.05

1.2%

<1%

<1%

<1%

» <1%

Emergency
Department
Visit
Hospital
Readmission

28.6%
(0.0 -0.53)

25.9%

29.6%

29.9%

27.0%

» 1%

13.1%
(0.02 -0.27)

12.0%

13.2%

12.8%

13.8%

» 2%

Opioid***

36.4%
(0.1 -0.69)

36.6%f

41.2%i

34.0%h

28.2%f,h,i

» 8%

Benzodiazepine

7.8%
(0.0- 0.22)

7.1%

8.8%

7.3%

7.6%

» <1%

Naloxone

5.0%
(0.0 - 0.31)

6.4%

4.1%

5.3%

6.8%

» <1%

Gabapentin/
Pregabalin*

26.2%
(0.13 -0.47)

28.2%e,f

26.2%

24.5%e

23.9%f

» 4%

Naltrexone

<1%
(0.0 -0. 08)

1.2%

<1%

1.2%

1.1%

» <1%

Concurrent
Opioid/
Benzodiazepine
OAT***

3.9%
(0.0-0.14)

4.0%

4.2%

3.9%

3.4%

» <1%

8.4%
(0.0-0.38)

3.5%d,e,f

6.8%d,g,i

10.3%e,g,h

18.5%f,h,i

» 15%

Admission
In-Hospital
Mortality

Prop.
Median
(Range)

X2 = 0.83801
df = 3
p > 0.05
X2 = 1.5277
df = 3
p > 0.05
X2 = 1.1666
df = 3
p > 0.05
X2 = 16.707
df = 3
p < 0.05c
X2 = 5.9958
df = 3
p > 0.05
X2 = 4.2447
df = 3
p > 0.05
X2 = 10.161
df = 3
p < 0.05c
X2 = 5.1653
df = 3
p > 0.05
X2 = 3.3905
df = 3
p > 0.05

X2 = 55.252
df = 3
p < 0.05c
1
a
Table Notes. Median proportion in percent per quartile; Hospitals were categorized into OAT delivery
performance quartiles based on the proportion of cases at a hospital with OAT during admission; bKruskalWallis Test; cDunn’s Test; dDunn’s Test results: difference between Q1 and Q2; eDunn’s Test results:
difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4; gDunn’s Test results:
difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results:
difference between Q2 and Q4; p < 0.05*; p < 0.01**; p < 0.001***.
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5.4.5. Summary. OAT delivery in the hospital setting varied across the VHA
system, with statistically significant differences observed across hospital performance
quartiles. Underperformance across the system was consistent. The highest performing
hospitals, in Quartile 4, provided OAT to less than half of their patients with a current or
prior OUD diagnosis. The most common OAT delivery scenarios across the VHA system
were withdrawal management and sustaining OAT through the VHA care continuum.
Hospital OAT performance quartiles differed statistically by the number of hospital beds
and the geographic location of the facility, but not for hospital volume of acute OUD
diagnoses or OUD-related infections. Hospitals also differed among quartile
performance for the delivery of non-OAT opioids, withdrawal management adjuvants,
and second-line adjuvants. Finally, of the ten outcome measures, only three differed
statistically by OAT quartile: 30-day opioid prescription fills (lowest in Q4), 30-day
gabapentin/pregabalin prescription fills (highest in Q1 and lowest in Q4), and 30-day
OAT receipt (highest in Q4 and lowest in Q1). The remaining seven health care
utilization outcome measures did not differ by quartile. These preliminary and
exploratory analyses suggest that contextual attributes within the hospital or the local
environment influence OAT and non-OAT care delivery performance and subsequent
outcomes for discharged patients.
Section 5.5. Aim 3 Justification
The findings from Aim 2 support continuing to explore these phenomena
through additional contextual analyses in Aim 3. Aim 3 tests associations between
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multilevel attributes and the delivery of OAT during admission for patients hospitalized
with OUD-related diagnoses in VHA hospitals.
Aim 2 analyses suggested potentially problematic care patterns for patients with
OUD across the VHA system, specifically, that patients frequently received opioids and
gabapentin/pregabalin, and not OAT. In all three time periods (pre, admission, post),
opioid prescription or administration frequency was higher than OAT delivery.
Withdrawal management was the predominant OAT delivery mechanism, which is not
the most effective way to treat OUD and not the current standard of care. Additionally,
although 21st century harm reduction practices recommend co-prescribing of naloxone
with opioid prescriptions or for patients with OUD, few VHA patients received naloxone.
It is possible that patients had already been prescribed naloxone 31 days prior to
admission and thus already had naloxone in their possession.
Although the study cohort was homogenous for many demand-side attributes
(i.e., patient characteristics), the clinical reasons for hospital admission varied. Most
admissions were not OUD related (by primary or secondary diagnosis or by OUD-related
infection codes). A comparison of those who received and did not receive OAT during
admission found that more patients who received OAT had an acute OUD diagnosis and
OUD-related infections. However, overall, 60% of patients who received OAT did not
have a primary or secondary OUD diagnosis or an OUD-related infection suggesting
unexplained influencers may contribute to OAT delivery during admission.
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Finally, a wide range of OAT administration during hospitalization persisted—
some hospitals delivered no OAT (n = 2) and some hospitals delivered OAT to 43% of
their patients with OUD (n = 2). The frequency of the type of OAT mechanism varied
across hospital OAT performance quartile, suggesting that measured (hospital size,
geographic location, and hospital OAT performance quartile) and unmeasured supplyside attributes influenced OAT care delivery and performance. Observed differences
existed for hospital size, geographic location, and OAT performance quartile, but not for
acute OUD case volume. Other elements may drive care delivery variation. Differences
existed among hospital OAT performance quartiles for non-OAT care delivery
mechanisms, specifically, opioid delivery during and in the 30 days after hospital
discharge. Although statistical differences did not exist for most outcomes, one nonsignificant finding stands out: nearly one third of patients received services in the
emergency department within 30 days of hospitalization which suggests unresolved
care issues post-hospitalization for this patient population.
The Aim 2 descriptive and bivariate analyses justify the continued exploration
and understanding of OAT delivery for exploration of Aim 3. Proceeding with Aim 3 is
warranted because the current care delivery practices were observed to be sub-optimal,
demand-side (patient) and supply-side (hospital) attributes were associated with the
receipt of OAT, and hospital OAT delivery varied significantly across the VHA system.
Aim 3 explores the unexplained differences among those who receive and do not
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receive OAT when hospitalized in the VHA system and the contributions of patient and
hospital-level attributes to OAT delivery using multilevel models.
Section 5.6. Multilevel Model Output
This section explores the associations of patient and hospital attributes on the
receipt of OAT during hospitalization through multilevel modeling. The multilevel model
uses the same study cohort as Aim 2, with 12,407 unique index hospitalizations from
109 VHA hospitals within the continental U.S. during the 2017 fiscal year. This section
addressed research sub-questions:
•

3a: How much of the variation in OAT delivery is attributable to the
hospitals?

•

3b: How do level 1 and level 2 attributes affect hospital OAT delivery?

5.6.4. Multilevel logistic regression model. A multilevel logistic regression model
was used to test for associations at the 0.05 alpha value in this study cohort. A patient
hospitalized in an average VHA hospital, without controlling for patient-level or hospitallevel covariates, had a 12% chance of OAT administration.4
5.6.4a. Testing for hospital variation. The first model, Model 1, was the variance
component model. This model did not include any covariates and only included the
intercept. The intraclass correlation statistic (ICC) for Model 1 was 0.14, meaning that
approximately 14% of the variability of receiving OAT during admission was explained by

4

The probability of receiving OAT in an 'average' VHA facility were estimated as exp(-1.97) =
0.139 with the calculated probability of 0.14/(1+0.14) = 0.12.
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between-hospital differences (e.g., hospital level characteristics). Subsequently, withinhospital differences (e.g., patient level characteristics) explained the other 86% of the
variability for receiving OAT during admission (see Table 5.27).
The second model, Model 2, was the level 1 intermediate model. This model
included the intercept and the patient covariates. In this model, there was a decrease in
the ICC from Model 1, going from 0.14 to 0.10, suggesting that some of the variation in
OAT delivery across the study cohort may be due to the differences in patient
population characteristics among hospitals (e.g., differences in average age or gender
distribution). In this model, level 1 covariates collectively accounted for 4% of OAT
delivery variation (see Table 5.27).
The third model, Model 3, was the final model, which included the intercept,
patient characteristics, and hospital covariates. When compared with Model 2, the ICC
statistic in this Model decreased from 0.10 to less than 0.06, respectively, indicating that
the inclusion of the available and selected hospital level variables, in part, explained
variation between hospitals. However, with an additional 6% still unexplained by the
model, this suggests that additional unexplored or unmeasured level 2 covariates may
further explain variation hospital OAT delivery in the VHA system (see Table 5.27).
Table 5.27. Testing for Variation in Hospital OAT Delivery Across the VHA

Constant
ICC

Model 1: Without
Covariates
B
SE
95% CI
0.52
0.09
0.37, 0.72
0.14
0.02
0.10, 0.18

Model 2: Patient
Covariates
B
SE
95% CI
0.38
0.07
0.26, 0.56
0.10
0.18
0.07, 0.14

Model 3: Patient and
Hospital Covariates
B
SE
95% CI
0.02
0.05
0.13, 0.34
0.06
0.13
0.04, 0.09
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5.6.4b. Testing for associations among covariates and OAT delivery. In Model 2,
the model with only patient characteristics, 12 covariates were associated with either
increased or decreased odds of OAT delivery during admission. Six covariates increased
the odds of OAT delivery, while holding the other level 1 covariates constant: 1) preadmission OAT receipt (OR [Odds Ratio] 15.3; 95% CI [13.2, 17.8]); 2) the presence of an
OUD diagnosis or infection (OR 2.30; 95% CI [1.99, 2.67]); 3) male gender (OR 1.52; 95%
CI [1.15, 2.00]); 4) an opioid withdrawal diagnosis (OR 1.46; 95% CI [1.12, 1.91]); 5)
admission adjuvant receipt (OR 1.53; 95% CI [1.33, 1.76]); and 6) an increased length of
stay (OR 1.04; 95% CI [1.04, 1.05]) (see Table 5.28).
Six covariates were associated with decreased odds of OAT delivery during
hospitalization, while holding the other level 1 covariates constant: 1) pre-admission
naltrexone receipt (OR 0.27; 95% CI [0.13, 0.57]); 2) unintentional overdose diagnosis
(OR 0.29; 95% CI [0.16, 0.52]); 3) admission naltrexone receipt (OR 0.30; 95% CI [0.14,
0.65]); 4) pre-admission non-OAT opioid receipt (OR 0.49; 95% CI [0.41, 0.58]); 5)
admission non-OAT opioid receipt (OR 0.53; 95 CI [0.46, 0.61]); and 6) co-occurring SUD
diagnosis (OR 0.77; 95% CI [0.67, 0.88]) (see Table 5.28).
In Model 3, which included both patient and hospital characteristics, the 12
patient covariates associated with either increased or decreased odds of hospitalized
OAT delivery in Model 2 did not qualitatively change with regard to direction or
statistical significance. One hospital covariate decreased the odds of OAT delivery
slightly, increased hospital acute diagnosis relative volume (OR 0.98; 95% CI [0.97,
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0.99]). Four of the hospital-level covariates increased the odds of OAT delivery: size and
location. The medium (OR 1.90; 95% CI [1.33, 2.70) and large sized hospitals (OR 2.04;
95% CI [1.39, 3.00]) had increased odds of OAT delivery during admission compared to
small hospitals. Hospitals located in the Northeast (OR 1.80; 95% CI [1.30, 2.49]) and
West (OR 1.62; 95% CI [1.19, 2.22]) had increased odds of OAT receipt compared to
hospitals located in the South (see Table 5.28).
5.6.4c. OAT sensitivity analysis definition. A sensitivity analysis examined if
there were differences in the study results if the definition of hospital OAT delivery was
narrowed (Definition 2). The two definitions were: 1) Definition 1: Any type of OAT
regardless of FDA-approval of that formulation (e.g., intramuscular/intravenous
methadone or buprenorphine); 2) Definition 2: Only FDA-approved formulations of OAT
(e.g. oral/sublingual methadone and buprenorphine). When comparing results of the
two models, there was only one difference observed for one of the 18 statistically
significant covariates. In the model built with Definition 2, the narrower OAT definition,
the variable surgical services (a patient covariate) was no longer statistically significant.
Otherwise, there were no observed differences in the statistical significance of any of
the other 17 covariates or the directionality of the parameters. This suggests that the
findings from Aim 1 that non-FDA approved versions of buprenorphine/methadone are
used in the hospital setting, may be true. See Appendix R for additional details.
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Intercept
Level 1: Age
Level 1: Gender: Male (ref. female)
Level 1: Race: Non-white (ref. white)
Level 1: Race: Unknown (ref. white)
Level 1: Ethnicity: Hispanic (ref. non-Hispanic)
Level 1: Ethnicity: Unknown (ref. non-Hispanic)
Level 1: Acute OUD Diagnosis/Infection
Level 1: Co-Occurring SUD
Level 1: Co-Occurring Mental Health
Level 1: Unintentional Overdose
Level 1: Opioid Withdrawal
Level 1: Length of Stay
Level 1: ICU Services
Level 1: Surgical Services
Level 1: Pre-Admission: OAT
Level 1: Pre-Admission: Non- OAT Opioid
Level 1: Pre-Admission: Benzodiazepine
Level 1: Pre-Admission: Naltrexone
Level 1: Pre-Admission: Gabapentin
Level 1: Admission Source: Other (ref. outpatient)
Level 1: Admission Source: Direct (ref. outpatient)
Level 1: During Admission: Non-OAT Opioid
Level 1: During Admission: Adjuvant
Level 1: During Admission: Benzodiazepine
Level 1: During Admission: Naltrexone

Model 2: Patient Covariates
B
SE
OR
95% CI
-2.79***
0.22 0.06
0.04
0.00
0.00
1.00
1.00
0.42**
0.14 1.52
1.15
-0.07
0.08
0.94
0.80
-0.17
0.18
0.85
0.60
0.06
0.14
1.06
0.80
0.18
0.21
1.20
0.79
0.83***
0.07 2.30
1.99
-0.26***
0.07 0.77
0.67
-0.04
0.07
0.96
0.84
-1.24***
0.30 0.29
0.16
0.38**
0.14 1.46
1.12
0.04***
0.00 1.04
1.04
-0.12
0.08
0.88
0.75
-0.27
0.14
0.76
0.58
2.73***
0.08 15.3
13.2
-0.72***
0.09 0.49
0.41
0.04
0.12
1.04
0.81
-1.31**
0.38 0.27
0.13
-0.12
0.08
0.89
0.76
-0.16
0.14
0.85
0.64
-0.01
0.08
0.99
0.85
-0.63***
0.07 0.53
0.46
0.42***
0.07 1.53
1.33
-0.11
0.07
0.90
0.78
-1.19**
0.39 0.30
0.14
0.09
1.01
2.00
1.09
1.20
1.41
1.80
2.67
0.88
1.11
0.52
1.91
1.05
1.04
1.00
17.8
0.58
1.32
0.57
1.03
1.12
1.16
0.61
1.76
1.04
0.65

Model 3: Patient/ Hospital Covariates
B
SE
OR
95% CI
-2.78***
0.00
0.04
0.03
0.13
0.00
0.08
1.00
1.00
1.01
0.42**
0.18
1.52
1.16
2.01
-0.05
0.14
0.95
0.82
1.11
-0.18
0.21
0.84
0.59
1.19
0.02
0.07
1.02
0.77
1.34
0.17
0.07
1.20.80
1.81
0.83***
0.07
2.30
1.99
2.66
-0.26***
0.30
0.77
0.67
0.88
-0.04
0.14
0.97
0.84
1.11
-1.24***
0.00
0.29
0.16
0.52
0.38**
0.08
1.47
1.12
1.92
0.04***
0.14
1.04
1.03
1.05
-0.13
0.14
0.88
0.74
1.03
-0.29*
0.08
0.75
0.57
0.99
2.73***
0.12
15.3
13.1
17.7
-0.72***
0.38
0.49
0.41
0.58
0.03
0.08
1.03
0.81
1.32
-1.33***
0.00
0.26
0.12
0.56
-0.12
0.14
0.89
0.77
1.04
-0.13
0.07
0.88
0.66
1.16
-0.01
0.07
0.99
0.85
1.15
-0.64***
0.07
0.53
0.46
0.61
0.42***
0.39
1.52
1.32
1.75
-0.08
0.08
0.92
0.80
1.06
-1.17**
0.09
0.31
0.14
0.66

Table 5.28. Logistic Regression Models Testing for Multilevel Characteristic Associations with Hospital OAT Delivery
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Model 2: Level 1 Characteristics
SE
OR
95% CI

Level 2: Acute OUD Diagnoses Volume
----Level 2: Hospital Size: Medium (ref. small)
----Level 2: Hospital Size: Large (ref. small)
----Level 2: Census Region: Midwest (ref. South)
----Level 2: Census Region: Northeast (ref. South)
----Level 2: Census Region: West (ref. South)
----Level 2: Admission Volume
----Table Notes. Bold indicates statistical significance; p < 0.05*; p < 0.01**; p < 0.001***

B

Table 5.28. Continued

0.01
0.18
0.20
0.16
0.17
0.16
0.00

0.98
1.90
2.04
1.27
1.80
1.62
1.00

0.97
1.33
1.39
0.93
1.30
1.19
1.00

0.99
2.70
3.00
1.72
2.49
2.22
1.00

Model 3: Levels 1 and 2 Characteristics
SE
OR
95% CI

-0.02**
0.64***
0.71***
0.24
0.59***
0.48**
0.00

B

5.6.5. Summary. The multilevel model provided another perspective of how OAT
delivery varied across the VHA system with two primary findings. First, unexplained
variation was attributable to both the differences between hospitals (14%) and
differences within hospitals (86%). In the final model, the between-hospital difference
dropped to 6%, but not 0%, indicating that the patient and hospital characteristics
included in the model did not fully explain between-hospital variation. Second, as
hypothesized, several patient and hospital covariates were associated with differing
odds of OAT receipt during admission. These findings reveal mutable and nonmutable
characteristics for future exploration for patients, hospitals, and health systems. Patient
receipt of OAT prior to hospitalization enhanced the odds of OAT during hospitalization
indicating the importance of establishing OAT care in the outpatient setting prior to
hospitalization and further, establishing care transition processes that enhanced care
coordination for patients with OUD across the care delivery continuum. Specific
immutable characteristics about the hospital, such as the geographic location and the
size, likely reflected other unmeasurable attributes or resources within each respective
hospital that influence the delivery of OAT.
A perplexing finding was that patients with acute opioid overdose diagnoses had
lower odds of receiving OAT. One reason commonly used to explain the undertreatment
of OUD in certain care delivery contexts is under diagnosis. In this study, however,
patients with a primary or secondary overdose diagnosis had decreased odds of
receiving this life-saving medication. The providers knew that these patients had an
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acute OUD issue; thus, the reasons for not providing OAT must be explained by
something else (e.g., resources, training, culture, stigma).
Section 5.7. Conclusion
The primary hypotheses of this study, explored through qualitative methods and
further addressed through quantitative approaches, were that care variation would exist
for OAT delivery during hospital admission and that multilevel attributes (patient and
hospital) would contribute to OAT delivery and OAT delivery variation between and
within hospitals. Overall, the findings from Aim 2 and Aim 3 supported and extended the
qualitative findings from Aim 1: 1) variability in OAT delivery existed in an integrated
health system; 2) a severe care deficit existed for this patient population; and 3)
mutable and nonmutable characteristics of patients and hospitals contribute to the
delivery of OAT in the hospital setting. The final chapter, Chapter 6, presents an
integrated synthesis of the qualitative and quantitative findings.
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Chapter 6. Discussion, Health System and Policy Implications, and Conclusions
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., &
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose
epidemic: The addiction medicine consult service. Journal of Addiction Medicine,
Advance online publication. doi: 10.1097/ADM.0000000000000496.
The final chapter of this dissertation integrates the results from the analysis of
the data supporting the three study aims with the overarching purpose of informing
future research, practice, and policy. The study findings are timely and relevant as the
U.S. struggles with the 21st century opioid overdose epidemic. Prior to this dissertation,
analyses describing care delivery for patients with an opioid use disorder (OUD) in the
hospital were limited and there were no multi-site or system-wide assessments of the
delivery patterns and practices for hospitalized patients with OUD. This study provides
the first description of system-wide opioid agonist therapy (OAT) delivery and an
exploration of the contextual attributes, inside and outside the hospital, associated with
the delivery of services for hospitalized patients with OUD. The research question for
this study asked: How do supply-side attributes influence hospital OAT delivery, health
outcomes, and health services utilization for persons hospitalized with OUD?
To answer questions about complex social phenomena, such as hospital OAT
delivery, the analysis drew on a diverse and complementary array of scholarship from
the domains of public health, health policy, sociology, organizational behavior, systems
science, and economics. The mixed methods study, grounded in a pragmatic research
philosophy, addressed multiple OUD-related care delivery issues. The study provides a
system wide quantitative analysis of the Veterans Health Administration (VHA) hospital
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services (n = 109 hospitals; n = 12,407 patients) and a multisite qualitative assessment of
non-VHA hospitals (n = 16 non-VHA hospitals; n = 17 addiction medicine physicians) on
the topic of hospital-based services for patients with OUD.
This final chapter includes a synopsis of the seven primary study findings, a
presentation of the modified study conceptual framework, a discussion of research
limitations, final conclusions, and the implications for health systems and policy:
1. Section 6.1 integrates the qualitative and quantitative results and concludes
that OAT is underused in the hospital (Finding 1).
2. Section 6.2 outlines the evidence from the three study aims suggesting that
OAT delivery varies across hospitals and health systems (Finding 2).
3. Section 6.3 describes how OAT is ineffectively used (e.g., withdrawal
management) in hospitals inside and outside the VHA (Finding 3).
4. Section 6.4 illustrates how and which non-OAT modalities (e.g., short-acting
opioid substitutes) are inappropriately used during and after hospitalization
(Finding 4).
5. Section 6.5 provides evidence of specific attributes inside and outside the
hospital facilitating or impeding AMC service development and OAT delivery
(Finding 5).
6. Section 6.6 details patient attributes that impact hospital OAT delivery
(Finding 6).
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7. Section 6.7 asserts, with evidence from this study, that the hospital is an
important part of the OUD care continuum (Finding 7).
8. Section 6.8 presents the modified and updated study conceptual framework,
based upon the study findings.
9. Section 6.9 outlines the limitations associated with the qualitative,
quantitative, and integrative approaches.
10. Section 6.10 proposes health system and policy interventions related to
education and service delivery to promote OAT use for hospitalized patients
with OUD, and the removal of policies creating barriers to OAT access.
11. Section 6.11 outlines future research and policy questions.
12. Section 6.12 states the dissertation’s final conclusions.
Section 6.1. Finding 1: OAT is Underused in the Hospital
Hospital OAT delivery for patients with OUD is essentially undescribed in the
peer-reviewed literature; in contrast, OAT delivery in the community setting is wellstudied, and it is established that OAT is underused in that context (Knudsen & Roman,
2012). The studies describing the hospital care delivery environment use discharge
prescribing and referral data to assert potential hospital OAT underuse (Ali & Mutter,
2016; Frazier et al., 2017; Naeger, Ali, et al., 2016; Rosenthal et al., 2015). To date, a
multi-site or system-wide study has not been conducted to assess hospital OAT delivery.
The findings from this study, therefore, are a novel contribution, confirming and
expanding prior assertions that OAT is likely underused in the hospital.
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6.1.1. Qualitative evidence. Semi-structured interviews with 17 addiction
medicine physicians, in non-VHA hospitals, documented OAT underutilization even in
the hospitals with addiction medicine-related resources (e.g., addiction medicine
trained physicians, or AMC services, or addiction medicine fellowships). OAT initiation
(i.e., starting a patient on OAT who was not already on it prior to hospitalization), as
federal guidance suggests (SAMHSA, 2018), should be offered by medical staff as the
first-line treatment option for patients not already on OAT. In this study, informants
perceived this practice, outside the AMC services, to be either uncommon or not
occurring in non-VHA hospitals. One informant stated that their non-VHA hospital
typically did not provide any OUD-related care, including symptom management for
withdrawal.
6.1.2. Quantitative evidence. Across the VHA study cohort (n = 12,407) the vast
majority of patients did not receive OAT during admission (85%) or in the 30 days post
admission (89%). In this study cohort, a patient with an OUD who was hospitalized in a
VHA hospital had a 12% chance of OAT administration during hospitalization, without
controlling for patient or hospital characteristics. Hospital care practices across the VHA
system reflected a lower than desired performance even in the highest performing
hospitals. On average, less than one third of patients with OUD received OAT when
treated in the highest OAT performing hospitals.
6.1.3. Summary. Evidence from the qualitative and quantitative analyses
suggests that OAT is underused in the hospital context. This finding is supported by the
262

perspectives of expert addiction medicine physicians in non-VHA hospitals and from the
VHA health care administrative data. Further, there is outside evidence to suggest that
the VHA system has enhanced hospital care quality as compared with non-VHA
hospitals. VHA hospitals out-performed non-VHA hospitals on 14 of 15 care quality
metrics (Weeks & West, 2018). This may suggest that non-VHA hospitals have worse
performance in this care delivery domain.
Section 6.2. Finding 2: OAT Delivery Varies Across Hospitals and Health Systems
There is a long-standing interest in identifying and explaining variation in health
services delivery across communities (Glover, 1938). Low variation in health services
delivery should occur for highly effective and inexpensive treatments (Chandra &
Skinner, 2012; Skinner, 2011; Wennberg et al., 2002), such as OAT. Variation in OAT use
in the community setting, however, is associated with a variety of patient and structural
elements (Ducharme, Knudsen, & Roman, 2006; Mark, Lubran, McCance-Katz, Chalk, &
Richardson, 2015). Within the VHA system, in previous research, decreased OAT access
was associated with older age, urban residence, and race (Manhapra, Quinones, &
Rosenheck, 2016). Variation in hospital OAT delivery within, among, or across health
systems has not been assessed.
6.2.1. Qualitative evidence. Analysis of the hospital guidance documents
received from the study’s informants revealed variation in OAT delivery approaches
across hospital contexts with modest similarities in practice. The withdrawal
management hospital guidance documents differed in practice domains, specifically:
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which medication was first-line (i.e., methadone vs. buprenorphine vs. clonidine);
severity of withdrawal symptoms (e.g., COWS score ³ 5 or ³ 8 or ³ 12 or ³ 13); initial
dose (e.g., methadone 5 mg, 10 mg, or 15 mg); and the 24-hour maximum dose (e.g., 30
mg or 40 mg of methadone). Similarly, variation was observed in the OAT initiation
guidance documents (e.g., protocol initiation threshold, maximum total daily dose). In
contrast, there was clear practice consensus for the acute management and non-acute
pain management for patients on OAT prior to hospitalization. This was reflected in the
guidance documents and the informant interviews. The consensus was that, in most
circumstances, daily OAT should be continued in the hospital and that buprenorphine
doses could be increased or split to help manage pain.
6.2.2. Quantitative evidence. The quantitative findings echo the qualitative
findings. OAT delivery performance varied across the VHA health system. Hospital OAT
delivery in this integrated health system ranged from 0% of admissions, in the lowest
performing hospitals, to 43% of admissions, in the highest performing hospital. Hospital
OAT delivery performance differed significantly across four hospital performance
quartiles (Q4, Q3, Q2, and Q1). The median performance in the highest performing
quartile (Q4) was 27% and the lowest performing quartile was 5%, a five-fold difference
in median care practices between the highest and lowest quartiles.
6.2.3. Summary. Evidence from the qualitative and quantitative analyses
suggests that OAT delivery varies across hospitals and health systems in well-resourced
non-VHA hospitals and within an integrated health system. Hospital OAT delivery
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variation within the VHA system is not surprising as it reflects previous OAT delivery
research in the VHA’s community-based treatment system (Finlay et al., 2018). In 2017,
the overall rate for OUD pharmacotherapy delivery across the VHA was 41% (n =
22,179), with facility performance varying between 2% to 76% (Finlay et al., 2018); in
this study, the median delivery across hospitals was 12%, with hospital performance
varying between 0% to 43% (n = 109 hospitals; n = 12,407 patients). It is possible that
hospitals and health systems outside this study sample have OAT delivery variation, in
particular low resourced hospitals (e.g., no addiction medicine physicians) and hospitals
not affiliated with an integrated health system.
Section 6.3. Finding 3: Less Effective OAT Approaches Are Used
To date, the peer-reviewed literature has not described or distinguished the
different types of OAT delivery scenarios that could occur during hospitalization. This
dissertation provides the first description and assessment of different types of hospital
OAT scenarios, specifically: OAT continued; OAT initiation and linkage to care; OAT
withdrawal management; and OAT sustained.
6.3.1. Qualitative evidence. The non-VHA key informants described OAT delivery
in their respective hospitals as broadly focused on “detox” (i.e., withdrawing patients
from opioids instead of initiating or continuing OAT) outside the care delivered by AMC
services. The focus of OUD-related hospital technologies (e.g., hospital guidance
documents) on withdrawal management in non-VHA hospitals supported this finding.
Six of the non-VHA hospitals had guidance for OAT withdrawal management; in
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contrast, only three had OAT initiation guidance documents and four had OAT
continuation guidance. One non-VHA hospital protocol was restricted to adjuvant
symptom-only management (i.e., clonidine to minimize the severity of opioid
withdrawal). This suggests that across non-VHA hospitals, even in the presence of
addiction medicine experts, there may be a need for education on how to most
effectively care for people with OUD during hospitalization to match contemporary
research and federal guidance (SAMHSA, 2018). Medical withdrawal, unless it is patient
preference, is contrary to known best practices for OUD treatment (Clark, Samnaliev,
Baxter, & Leung, 2011). Federal guidance suggests “offering maintenance therapy with
medication, not short-term medically supervised withdrawal” (SAMHSA, 2018, pp. 3-44)
and states that it is “essential for the patient to continue receiving OUD medication
while hospitalized” (SAMHSA, 2018, pp. 3-101). Federal guidance further recommends
that providers should not “force patients to withdraw from opioid agonist therapy in the
hospital” (SAMHSA, 2018, pp. 3-104).
6.3.2. Quantitative evidence. The VHA quantitative findings corroborate the
non-VHA qualitative findings that articulated the common use of withdrawal
management. When OAT delivery occurred in the VHA system (in only 15% of hospital
admissions), it was most commonly delivered as withdrawal management (39%), which
is not the recommended first-line approach to OUD management (SAMHSA, 2018).
When separated into high and low OAT performance quartiles, the highest performing
hospitals (Q4) were more likely than the other quartiles to use the other more effective
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OAT delivery approaches (e.g., OAT continued, OAT initiation and linkage, and OAT
sustained). Nonetheless, the occurrence of these approaches was still infrequent in the
Quartile 4 hospitals. Median performance in Quartile 4 was 10% for OAT sustained, 3%
for OAT initiated and linkage to care, and 2%, for OAT continued.
6.3.3. Summary. Evidence from the qualitative and quantitative analyses of this
study suggests that less effective OAT approaches are used during hospitalization. This
dissertation is the first study to attempt to distinguish four different hospital-based OAT
delivery care scenarios: 1) OAT continued; 2) OAT initiated and linkage; 3) OAT
sustained; and 4) OAT withdrawal management. It is possible that there are other OAT
scenarios not captured in this study. These designations may serve as the beginning of a
foundational conversation about hospital OAT delivery quality.
Section 6.4. Finding 4: Non-OAT Pharmacotherapies are Used
An additional care delivery concern related to the treatment of patients with
OUD in the hospital is the possibility that other less effective non-OAT
pharmacotherapies (e.g., short-acting non-OAT opioids) are used as a substitute for
OAT. Research does not exist describing this explicit concern. Prior research, however,
suggests that prescription non-OAT opioid use and other non-OAT medications (e.g.,
benzodiazepine) post-hospital discharge are common for patients with OUD (Larochelle
et al., 2016; Naeger, Ali, et al., 2016). This study confirms these previously established
findings and expands upon a literature gap to describe the frequent use of non-OAT
opioid pharmacotherapy in the hospital for patients with OUD.
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6.4.1. Qualitative evidence. Since all of the key informants were addiction
medicine experts, the use of non-OAT modalities as substitutes for OAT was not
commonly described. Two informants, however, shared that their hospital withdrawal
management protocols used non-OAT approved opioids, specifically: a rapid 72-hour
taper using tramadol and an injectable buprenorphine taper protocol.
6.4.2. Quantitative evidence. Three findings from the VHA cohort suggest the
potential use of non-OAT pharmacotherapies for the treatment of OUD. First, non-OAT
opioid prescription or administration occurred more often than OAT delivery in all three
time periods: 30 days prior to index hospitalization (30% vs. 11%); during index
hospitalization (55% vs. 15%); and 30 days post-hospital admission (34% vs. 11%).
Second, patients who were discontinued from their OAT during hospitalization were
more likely to receive non-OAT opioids during admission (44% vs. 26%) and at discharge
(27% vs. 12%) when compared with patients who were continued on their pre-OAT
during hospitalization. Discontinuing OAT during hospitalization not only disrupted OUD
treatment but appeared to promote the use of non-evidence-based care (i.e., the
substitution of non-OAT opioids). Third, there were other potentially problematic
prescribing trends post-admission, including: gabapentin/pregabalin (26%),
benzodiazepine (8%), and concurrent benzodiazepine and opioid prescribing (4%).
6.4.3. Summary. Evidence primarily from the quantitative analyses suggest that
non-OAT pharmacotherapies, specifically, non-OAT opioids, may be administered and
prescribed frequently within the VHA system. Post-admission opioid prescription
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frequency in the VHA cohort was higher (34%) than previously reported findings within
a non-VHA population, which had 22% of patients (n = 8,225) fill a non-OAT opioid
prescription in the 30 days after hospital discharge (Naeger, Ali, et al., 2016). These
findings suggest either clinician misidentification of patients with an OUD or provider
training deficits. In most clinical scenarios, patients with OUD should not receive nonOAT opioid prescriptions upon discharge because non-OAT opioid continuation after a
hospitalization is associated with higher risk for a subsequent overdose (Larochelle et
al., 2016).
Section 6.5. Finding 5: Contextual Hospital Attributes Inform OUD-Related Services
Hospitals are socially constructed entities comprised of physical, technological,
cultural, and social milieu (Scott, 2003). The internal social structures of organizations
are comprised of normative, patterned, formal and informal interactions (Scott, 2003).
Social structures within an organization impart explicit and implicit values, norms, and
role expectations (Davis, 1949; Scott, 2003). These expectations are promulgated
through reward systems for specific behavior and enacted through socialization,
mentoring, group dynamics, decision-making, communication, influence, and leadership
(Kinicki & Kreitner, 2009; Ostroff et al., 2003). Organizations exist as coordinated
systems embedded within broad complex networks (Meyer & Rowan, 1977), dependent
on external relationships (Scott, 2003).
In the health care context, a hospital exists as a functional unit within the nested
context of a larger health services delivery production system and comprised of smaller
269

units (patients, units, divisions, departments) (Ferlie & Shortell, 2001; Perrow, 1986). A
product of this phenomenon is the continuous evolution and interaction within each
level of the nested context and the influence of external factors, such as other hospitals
(DiMaggio & Powell, 1983), the prior training and socialization of hospital employees
(Scott, 2003), financial incentives or disincentives promoted through external contracts
(Alchian & Demsetz, 1972; Eisenhardt, 1989; Jensen & Meckling, 1976; Zeckhauser &
Pratt, 1985), or the enforcement of contracts (North, 1990; Zeckhauser & Pratt, 1985).
This theoretical foundation provides the rationale and justification for exploring how
attributes within and outside the hospital influence and shape the delivery of evidencebased OUD services. This study is the first to explore the attributes that facilitate or
impede care for patients hospitalized with OUD.
6.5.1. Qualitative evidence. The analysis of the non-VHA key informant
interviews found six internal facilitators, six internal barriers, seven external facilitators,
and four external barriers to AMC service establishment and hospital OAT delivery. A
primary finding was that the AMC service, a hospital characteristic, was both an output
of a supportive hospital environment and a modifier for service delivery and the
development of other addiction-related technologies. A supportive hospital
environment was generated through positive social structures and technology and
resources allocated to addiction-related service activities. Fifteen key informants
described six supports provided at the 14 non-VHA hospitals with established or
planned AMC services:
270

•

Historic precedent and investment in addiction service delivery, education,
and research;

•

Dedicated resources for addiction services, research, and education;

•

Creation or existence of an addiction medicine clinical training program;

•

Use of evidence-based addiction treatment practices;

•

Leadership supportive of addiction treatment; and

•

Internal stakeholders supportive of addiction treatment.

Key informants (n = 17) from all 16 non-VHA hospitals described AMC
establishment and hospital OAT service delivery barriers. Informants most commonly
cited barriers related to resources and staffing, social structures, and financing:
•

Restrictive hospital policies and regulations that inhibited or prevented
hospital OAT delivery;

•

Bureaucratic processes slowing AMC service development, OUD-service
delivery, and education;

•

Limited staffing and resources for addiction-related treatment and
education;

•

Unsupportive internal stakeholders;

•

Knowledge gaps within hospital leadership and clinical staff that
promulgated discriminatory behavior towards patients with OUD; and

•

Unstable internal financial environment jeopardizing AMC service
sustainability.
271

Each of the internal barriers and facilitators to AMC service and OAT delivery,
except for historic precedent, are mutable properties of a hospital or health services
delivery organization that could be changed through strategic interventions.
Key informants in hospitals with established or planned AMC services described
seven external influencers that positively mediated AMC service establishment and
subsequently enhanced OAT delivery:
•

Elevation and prioritization of this issue by non-clinical stakeholders;

•

Development of formal and informal partnerships with external clinical
stakeholders;

•

Access to a robust community-based treatment network;

•

Media coverage of the opioid overdose epidemic;

•

Policies and regulations enhancing OAT access;

•

Supportive political leadership and political action; and

•

Supportive financial incentives.

Four external barriers were also described by informants:
•

A limited community-based treatment network;

•

Policies and regulations impeding OAT access;

•

Unsupportive political leadership and political action; and

•

Financing and funding limitations.

These external facilitators and barriers were all mutable. Unlike interventions
targeted at the hospital environment, however, hospital leadership and staff had limited
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control and influence to change these external elements. Changing, removing,
increasing, promoting, or enhancing external elements is possible but likely a more
challenging and long-term endeavor.
6.5.2. Quantitative evidence. The quantitative analyses did not support a
nuanced assessment of organizational characteristics or the external hospital
environments. Each hospital’s OAT delivery performance, however, was compared to
the other hospitals within the VHA system (n = 109) to discern hospital-level
characteristics contributing to variation. The characteristics observed to enhance OAT
delivery included hospital size and geographic location. An impediment to OAT delivery
was an elevated rate of acute OUD admissions in the hospital. Statistically significant
differences in hospital size and region were also observed among the hospital OAT
performance quartiles. There were more small hospitals (26%; n = 7) in the lowest
performing quartile as compared with the hospitals in the highest performing quartile
(3%; n = 1). Most hospitals (74%; n = 20) in the lowest performing quartile were in the
South as compared with the highest performing quartile (21%; n = 6).
Further, when patient and hospital characteristics were controlled for in the
multilevel logistic regression model, specific hospital characteristics increased the odds
of patient OAT receipt during admission: the medium (OR 1.90; 95% CI [1.33, 2.70]) and
large hospital sizes (OR 2.04; 95% CI [1.39, 3.00]), as compared to the small hospitals,
and hospitals located in the Northeast (OR 1.80; 95% CI [1.30, 2.49]) or the West (OR
1.62; 95% CI [1.19, 2.22]), as compared to the South. In contrast, elevated acute OUD
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diagnosis volume in a hospital decreased the odds of individual OAT receipt (OR 0.98;
95% CI [0.97, 0.99]). Although the size or location of a VHA hospital is essentially
immutable, these characteristics likely represent potentially modifiable organizational
and environmental characteristics. The fully specified multilevel model accounted for
only 6% (ICC value) of the contributions to performance variation in the VHA dataset.
This suggests that there were other unmeasured organizational attributes contributing
to OAT delivery variation within the VHA system.
6.5.3. Summary. Evidence from this study’s qualitative and quantitative analyses
suggests that internal and external supply-side elements likely influence both the
establishment of AMC services and hospital OAT delivery. Research in the outpatient
and community-based settings suggests a variety of reasons for OAT underuse (e.g.,
financial, regulatory, geographic, and health care professional attitudinal factors)
(Sharma et al., 2017). This study is the first to describe these phenomena in the hospital
setting.
Section 6.6. Finding 6: Patient Attributes Facilitate or Deter Hospital OAT Delivery
There is a limited evidence base suggesting that patients who are hospitalized
with OUD or SUD would like to receive treatment for their drug use disorder. A
qualitative analysis of 32 hospitalized adults with SUD, the majority of whom had
moderate-to-high-risk use of opioids (65%), concluded that current hospitals practice
was not meeting their needs and that care could be greatly improved if life stressors,
trauma, or basic needs were addressed (Velez et al., 2017). Patients articulated a need
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for supported, coordinated, and timely care upon hospital discharge (Velez et al., 2017).
Studies of patient attributes that enhance or deter hospital OAT delivery have not been
reported. This study builds on the findings that patient attributes contribute to hospital
OAT delivery.
6.6.1. Qualitative evidence. In the interviews from non-VHA hospitals,
informants perceived specific patient characteristics that were an impediment to OAT
access. Informants described patients with OUD who inject drugs as particularly
challenging to serve in the hospital because of their complex psychosocial
characteristics (e.g., uninsured, homeless, criminal justice involvement) and ongoing
medical issues (e.g., serious infections, polysubstance use). Patients with these
challenges, specifically those with a need for long-term antibiotics, were also generally
not accepted in transitional and lower acuity facilities, creating barriers for discharge.
The common barriers to OAT, from this perspective, included insurance status, care
disruption by the criminal justice system, the creation of a non-therapeutic atmosphere
with law enforcement involvement, and the patient’s own internalized stigma about
OAT. In contrast, only one specific demographic characteristic emerged qualitatively to
enhance OAT delivery—pregnancy. Pregnant patients had enhanced access to
treatment because hospitals’ efforts focused on providing protocol driven hospitalbased services with supported linkages to prevent premature births linked to maternal
opioid withdrawal.
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6.6.2. Quantitative evidence. Associations between patient characteristics and
hospital OAT delivery were observed in the VHA. The findings from the fully-specified
multilevel logistic regression showed that patient demographics and the receipt of
specific types of care before and during admission, were either positively or negatively
associated with hospital OAT delivery. The positively associated patient characteristics
included:
•

An OUD diagnosis or infection during admission (OR 2.30; 95% CI [1.99,
2.66]);

•

Male gender (OR 1.52; 95% CI [1.16, 2.01]); and

•

An opioid withdrawal diagnosis (OR 1.47; 95% CI [1.12, 1.92]).

The other care delivery scenarios positively associated with hospital OAT delivery
included:
•

Pre-admission OAT receipt (OR 15.3; 95% CI [13.2, 17.7]);

•

Admission adjuvant receipt (OR 1.52; 95% CI [1.32, 1.75]); and

•

An increased length of hospital stay (OR 1.04; 95% CI [1.03, 1.05]).

The negatively associated patient characteristics included:
•

An unintentional overdose diagnosis (OR: 0.29; 95% CI [0.16, 0.52]); and

•

Having a co-occurring SUD diagnosis during admission (OR: 0.77; 95% CI
[0.67, 0.88]).

The other care delivery scenarios negatively associated with hospital OAT delivery
included:
276

•

Pre-admission non-OAT opioid receipt (OR 0.49; 95% CI [0.41, 0.58]);

•

Admission non-OAT opioid receipt (OR 0.53; 95 CI [0.46, 0.61]);

•

Pre-admission naltrexone receipt (OR 0.26; 95% CI [0.12, 0.56]); and

•

Admission naltrexone receipt (OR 0.31; 95% CI [0.14, 0.66]).

6.6.3. Summary. Evidence from this study’s qualitative and quantitative analyses
confirms and expands upon previous findings (Velez et al., 2017) that specific patient
characteristics may facilitate or deter hospital-based OAT access. Demographic
characteristics described as relevant to OAT access in the qualitative findings were
either not assessed (e.g., criminal justice involvement, homelessness), not relevant to
the veteran patient population (e.g., insurance status), or not common among patients
in the VHA (e.g., pregnancy).
Section 6.7. Finding 7: The Hospital has an Important Role in the OUD Care Continuum
There is a growing evidence base exploring the influence of hospital service
delivery on patient outcomes upon discharge. Retrospective analyses of AMC services
(Nordeck et al., 2018; Suzuki, 2016), prospective single-site studies (Trowbridge et al.,
2017; Wakeman et al., 2017), and one randomized control trial (Liebschutz et al., 2014)
suggest the provision of OUD-related services in the hospital context is associated with
either discontinued or continued OAT upon discharge. Further, a recent study by
Moreno et al. (2019) observed that 30-day and 90-day hospital readmissions were
reduced for patients who received buprenorphine during their index hospitalization
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suggesting that care in the inpatient setting has implications post-discharge. The
findings from this study build and expand on these previous findings.
6.7.1. Qualitative evidence. Data from the semi-structured interviews suggest
that hospitals had a role in either disrupting, starting, or continuing care for patients
with OUD. Hospital involvement was dependent on the existence of addiction-related
resources, specifically the AMC service. Key informants, from non-VHA hospitals, shared
that the AMC services were primarily responsible for OAT initiation. They observed that,
when OAT initiation was managed by non-AMC providers, treatment gaps frequently
occurred because of the providers’ limited knowledge of how to link patients to care
upon discharge. Care disruption was also attributed to restrictive internal policies
related to OAT delivery and provider training gaps and confusion about OAT federal
regulations. Providers and administrators commonly believed it was illegal to administer
OAT in the hospital or that a provider had to have a special wavier.
6.7.2. Quantitative evidence. The VHA dataset illustrates how hospitals serve an
important role in the broader OUD care continuum. There were 1,325 patients in the
study cohort who received OAT prior to hospital admission, two-thirds (65%; n = 867) of
these patients were continued on OAT during admission. This is a positive finding but
also reflects room for improvement, as OAT discontinuation in the hospital setting
should be a rare occurrence (e.g., patient preference). Of the 1,325 patients who
received OAT prior to admission, 23% (n = 308) did not receive OAT within 30 days of
hospital discharge and their OAT was interrupted because of hospitalization. Of the 308
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patients whose OAT engagement was interrupted post-hospitalization, 53% had their
OAT discontinued upon admission (n = 163), and 47% had their OAT continued during
admission (n = 145). Further, patients who were continued on OAT were statistically less
likely to leave the hospital against medical advice (3%; n = 26) as compared to those
who were discontinued on their OAT (10%; n = 46). Further, for patients who received
any type of OAT during admission were statistically more likely than those who did not
receive any OAT during hospitalization to receive OAT in the post-admission period (48%
vs. 5%; p < 0.05). These observations suggest that hospitalization disrupts ongoing
outpatient OAT delivery, inpatient medical management of the patient’s primary issue,
and OAT receipt upon hospital discharge.
6.7.3. Summary. Evidence from the study’s qualitative and quantitative findings
suggests that hospitals play an important organizational role in the OUD care
continuum, either disrupting, starting, or continuing care. This perspective is reflected in
the efforts of leadership at the Centers for Medicare & Medicaid Services [CMS]). CMS
requires the use of the ASAM levels of care (ASAM. 2018b) for §1115 waivers to address
the opioid overdose epidemic (CMS, 2017), emphasizing care coordination among the
different ASAM levels of care, including acute care hospitals (Level 4.0).
Section 6.8. Modified Conceptual Framework.
The original study conceptual framework, presented in Chapter 2 (Figure 2.1),
guided research design, and analysis, through the integrated conceptualization of the
contributions of the dynamic, evolving, organizational and socio-economic forces that
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influence the delivery of hospital-based OAT. Based on the results of the dissertation,
the conceptual framework was updated and refined (see Figure 6.1). The most
substantial modifications include: 1) visualizing the hospitalization of the patient as a
dynamic interaction and exchange; 2) drawing attention to an organizational outcome—
the establishment of an AMC service—that influences the OUD-related care delivered
during hospitalization; 3) distinguishing different types of service delivery for patients
with OUD; and 4) refining the broader categories of the contextual attributes.
In addition to these changes, the modified conceptual framework became more
granular through the incorporation of the specific findings from this study (i.e., how the
hospital, the events of hospitalization, the patient demand-side attributes, and the
external environment influence hospital OAT delivery, and AMC service establishment).
The modified conceptual framework may help researchers and policymakers visualize
the complex and interdependent contributions affecting the production and delivery of
evidence-based services for hospitalized patients with OUD. The positive and negative
contributions are included in the updated conceptual model. The (+) symbol identifies
variables that enhance OAT delivery and support AMC services, and the (-) symbol
reflects elements that inhibit OAT delivery and development of AMC services. The
elements written in italics were quantitative findings and the non-italicized words were
the qualitative findings. It is possible for an element to have both facilitative and
impeding contributions and that contextual elements may fit into more than one
category.
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Figure 6.1. Updated Conceptual Framework
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Section 6.9. Research Limitations
The interpretation and conclusions generated from the findings of this
dissertation are limited because of the study focus and the qualitative and quantitative
methodological approaches.
6.9.1. Study scope limitations. This study was focused primarily on
understanding and exploring supply-side contributions (i.e., the hospital) and not the
demand-side contributions (i.e., the patient). This is a study finding limitation because
health care access and delivery occurs through the dynamic interaction of the supplyside and demand-side (Levesque et al., 2013). The qualitative and quantitative datasets
were limited to primarily exploring supply-side factors, aside from patient
demographics. This was due to the choices made on how to reasonably scope this study,
which included deciding on who to include in the qualitative study cohort. The study
was limited to querying addiction medicine physician experts to ensure a narrower and
more focused sampling frame to ensure timely completion of the dissertation. The
inclusion of the patient perspective would have complicated the study design and
methods (e.g., creation of patient survey, different sampling approach).
6.9.1. Qualitative limitations. The main limitation of this study was
transferability, which is inherent to findings from qualitative research. Findings from the
interviews with addiction medicine experts in large well-resourced institutions may not
be applicable to hospitals with more limited resources (e.g., the organizational and
internal environmental attributes that facilitate AMC establishment and hospital OAT
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delivery). This study does not provide an understanding of the challenges faced in
lower-resourced hospitals. Indeed, the proposed solution—the creation of AMC
services—may not be possible in these contexts. Sixteen of the 17 informants were from
hospitals not affiliated with an integrated delivery system, meaning that the
organizational challenges particularly around care continuation differ from those
working in a VHA type system. Further, this study cohort included perspectives from
addiction medicine physicians at relatively well-resourced hospital with regards to
addiction-related services.
Another limitation in this study was the variation in the amount of involvement
that the key informants had with establishing or running their respective AMC
services—some informants were observers, some were creators, and some worked on
the service. This was a limitation because systems may be perceived differently based
on the positionality of “the perceiver” (Lendaris, 1986). However, the quantitative
analyses provided additional perspectives on the use of OAT among hospitalized
patients that could more broadly translate to larger and smaller hospitals in rural and
urban communities that serve a spectrum of patients. Finally, and importantly, this
study did not include the patient perspective, which would have strengthened the study
because patients would have identified relevant practice and policy issues unobserved
in this study.
6.9.2. Quantitative limitations. There are also inherent limitations associated
with retrospective secondary analyses of administrative health services data. First, as an
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observational retrospective cohort study, causal relationships cannot be established.
Second, there were limitations to the generalizability of the results because of the study
cohort (veterans) and the health services system design (the VHA). This was a study of
VHA administrative data, and primarily applicable to the U.S. veteran population (older,
white, and male). Further, the VHA is an integrated health payer and health system;
thus, its linkages to care and organizational facilitators and barriers may differ from nonVHA hospitals, as was reflected in the sustained OAT data analyses. This is an important
point because it means that third-party health insurance, the revenue generated
through billing, and the formulary, which is the same across the VHA system, are not the
external and internal environmental attributes contributing to deficiencies and
variations in hospital OAT. Rather, other factors were contributing to variation in the
VHA. In addition, patient inclusion criteria for quantitative aims included an OUD
diagnosis in the year prior to (and including) index hospitalization. However, OUD may
not have been a focus of treatment during hospitalization. Care practices may vary from
what was observed in the current study when OUD-related complications are the
primary reason for hospitalization. Finally, the study data are from the year 2017, a
specific moment in time, and do not capture potential changes in practice over time.
Nevertheless, the qualitative interviews with addiction medicine experts in non-VHA
hospitals help balance the limitations in the quantitative analysis. The interviews offer
insight into emerging standards of care and provide detail on how and why OAT is used
for patients with OUD.
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The study cohort was also limited by the true denominator prevalence issue as
described by Harris (2016). When using a diagnosis-based denominator—the number of
persons hospitalized with OUD—to compare hospital delivery performance, it is possible
that hospital delivery performance differences may be a result of a hospital’s and clinical
staff’s ability to identify, diagnose, and document OUD. The findings from this study
suggest that the contributions from these phenomena are likely minimal. Differences
were not observed in the bivariate analyses of acute OUD diagnosis volume and OUD
admission volume among hospital OAT performance quartiles. The true denominator
prevalence issue is most problematic when the denominator affects performance
measures. Selective identification of patients can enhance or suppress measures of
hospital performance. The measures used in the quantitative analysis were not being
used as quality measures and have no affect on hospital finances.
Another limitation is related to the construction of study variables, specifically,
the health services utilization variables. The study was restricted to a 30-day period of
observation post-index hospitalization. Previous research on opioid overdose deaths
post-hospitalization used a time period longer than 30 days (Larochelle et al., 2018;
Larochelle et al., 2016). A longer-term observation period (> 30 days) may provide
additional information about risks of hospitalization and the OAT care delivery
continuum. It is also possible that this study has underreported acute care delivery
utilization in the 30-day period post-index hospitalization, as the 30-day ED and
readmission flags only included readmissions and visits to VHA facilities. Finally, the
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study was likely underpowered to effectively assess the impact of infrequently occurring
outcomes (e.g., 30-day death rate and in-hospital mortality).
6.9.3. Mixed methods integration limitations. There were several limitations to
integrating the qualitative and quantitative findings for this mixed methods study. Key
informants, and hospital guidance documents, were all from outside the VHA system.
The quantitative data were from the VHA system. However, OAT care practice
approaches outside the VHA informed the design of OAT practice variables and
informed the selection of covariates included in the quantitative data. Unfortunately,
data on the existence of AMC services or the presence of addiction-related hospitalbased services were not available for the VHA facilities, limiting the ability to connect
VHA outcomes to VHA addiction-related hospital services. Nevertheless, mixing
quantitative and qualitative data strengthened the conclusions of this research study.
The final presentation and synthesis of study findings were enhanced because of the
mixed methods approach used in this study. Importantly, the qualitative findings
contextualized the quantitative findings, providing richer and policy and practice
relevant applications. Further, the two sets of data were complimentary, confirmatory,
and also provided insights that would not have emerged in isolation.
Section 6.10. Health Systems and Policy Implications
This section explores potential policy tools and health systems interventions that
could enhance and promote health system and hospital services for patients with OUD.
The evidence, provided by prior research paired with the findings from this study,
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suggests that OAT is not reaching the majority of hospitalized patients with an OUD and
that systems-level attributes and policies inhibit hospital OAT delivery. This section
proposes interventions for policymakers, health system and hospital leaders, clinicians,
and researchers who are interested in improving services for patients hospitalized with
OUD.
Policy tools are incentives or rules (Stone, 2011) that promote regulative or
allocative action on policy targets (Dunn, 2012). Regulative policy action ensures
compliance with certain standards or procedures, and allocative policy actions require
the input of time, money, personnel, and equipment (Dunn, 2012). Policy tools may be
distributive or redistributive (Lowi, 1964) and may target different actors responsible for
action within a system. Health and social service policies are supposed to promote the
non-punitive treatment for persons with SUDs (Babor et al., 2010). These policies affect
treatment access through planning, financing, developing the professional workforce,
and shaping the structural resources available to treat SUDs (e.g., number of facilities)
(Klingemann et al., 1993; Klingemann & Klingemann, 1999).
The findings from this study could inspire policy interventions inside and outside
the hospital targeting a variety of actors to address OAT underuse, including: variation
of OAT delivery across systems; the use of less effective treatment approaches; the
frequent use of non-OAT modalities; the mutable internal and external environmental
attributes impeding or facilitating hospital OAT delivery; the specific patient attributes
that facilitate or impede OAT delivery; and the recognition that the hospital is an
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important component in the OUD care continuum. The suggested policy and health
system interventions fall into three broad domains: 1) education; 2) service delivery;
and 3) policy modifications.
6.10.1. Education interventions. An important observation from the non-VHA
hospital informant interviews was the consensus across the study cohort that most
hospital providers, in particular physicians, had knowledge gaps in their understanding
of how to care for patients with OUD. Knowledge gaps included a lack of awareness of
evidence-based practices for OUD treatment, misconceptions and discriminatory beliefs
about people with SUDs, and a misunderstanding of federal OAT policies. There are at
least two education-related strategies that may support the amelioration of knowledge
gaps related to OUD and OAT service delivery: 1) targeted educational campaigns; and
2) educational requirements.
6.10.1a. Strategy 1: Targeted OAT educational campaigns. To reduce confusion
related to federal OAT policies in the hospital setting, stakeholders could engage in
educational initiatives to debunk common myths and to increase awareness about the
legality and efficacy of providing OAT to hospitalized patients with OUD. SAMHSA could
include specific information about these policies in its buprenorphine waiver training
courses or create a special training and educational platform for hospital-based
providers. Further, the DEA could improve messaging about the legality of treating
patients with OAT during hospitalization and include this information in any
documentation or re-licensing information related to a provider’s general DEA license.
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Specific groups of providers could be targeted for intervention. Medical
societies, in particular ASAM, could partner with the Society of Hospital Medicine and
the American Hospital Association (AHA) to launch an educational campaign for
hospital-based physicians. Further, orthopedic surgeons and emergency medicine
physicians were particularly noted as having challenges in caring for patients with OUD.
These specific groups could be a direct focus for policy initiatives and educational
campaigns led by their respective medical societies: The American Board of Orthopaedic
Surgeons and the American Academy of Emergency Medicine.
6.10.1b. Strategy 2: Educational requirements. There may also be opportunities
for medical education regulatory and accrediting bodies (e.g., Association of American
Medical Colleges, the Liaison Committee for Medical Education, Commission on
Osteopathic College Accreditation, the American Osteopathic Association, and the
Accreditation Council for Graduate Medical Education [ACGME]) to mandate evidencebased addictions training for both undergraduate and graduate medical education. The
groups could incorporate training in addiction services into the learning competency
requirements at each stage of medical training, and reinforce this learning with the
inclusion of addiction medicine related questions in national medical licensing
examinations.
Moreover, ACGME and physician specialty boards could leverage and expand
upon programmatic requirements. Internal medicine residents, for example, are
required to rotate at a hospital with a general medical consult service. This requirement
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means that general medical consult services must exist in hospitals that seek to employ
internal medicine residents. Similarly, all internal medicine residents could be required
to rotate on an AMC service. Another leverage point could be to require residents and
medical students to obtain a buprenorphine waiver as a graduation requirement. This is
being tested at the Brown University School of Medicine with support from state
legislation (Arditi, 2017). This will likely become more common because the federal
2018 SUPPORT for Patients and Communities Act created a pathway for medical
trainees to obtain a waiver to prescribe buprenorphine immediately upon entering
practice (J. W. Frank, Wakeman, & Gordon, 2018).
6.10.2. Service delivery interventions. There are at least four potential
strategies to guide and enhance initiatives to improve OUD care in health systems and
hospital settings: 1) guidance documents; 2) regulatory requirements; 3) statutory
requirements; and 4) financial incentives.
6.10.2a. Strategy 1: Guidance documents. First, health systems and hospitals
could implement standardized guidance documents to promote and enhance care
delivery standards for hospital OAT delivery. Organizations can use guidance documents
to address care variation to support standard practice in clinical scenarios with high
levels of certainty, clinical agreement, and definitive science (Institute of Medicine
Committee on Quality of Health Care in America, 2001). This intervention is proposed
because significant variation was found in the quantitative and qualitative analyses. The
clinical addiction medicine community could develop or endorse standard protocols and
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share these documents nationwide. AHA and ASAM could partner as initiative leaders to
either create new materials or endorse the use of other materials already existence,
such as the Project Support for Hospital Opioid Use Treatment (SHOUT) tools (Project
SHOUT, 2018) or the recently published federal treatment guidance documents
(Substance Abuse and Mental Health Services Administration, 2018). It is likely that the
voluntary adoption of these guidance documents will be limited to the innovators and
early adopters (Rogers, 2003); thus, the use of external coercive policies to adopt these
guidelines may be necessary through the Joint Commission (see strategy 2 below).
6.10.2b. Strategy 2: Regulatory requirements. A second strategy to enhance
OAT delivery may include the use of external coercive policies to require hospitals to
deliver OAT by leveraging the power of hospital-related accrediting and professional
regulatory bodies (e.g., the Joint Commission or American College of Surgeons [ACS]).
The Joint Commission designates hospital accreditation requirements and ensures
hospitals are meeting those standards. At present, there are no requirements related to
the care of persons with OUD and SUDs in the hospital context. In 2008, the Joint
Commission created optional performance metrics for alcohol screening and
pharmacotherapy for persons with SUDs, including OUD (Joint Commission, 2015). It is
within the authority of the Joint Commission to require reporting and performance
measurement for OAT and mandate addiction-related technologies for hospital
accreditation (e.g., presence of addiction medicine physicians or consult services).

291

ACS is another regulatory body with the power to influence hospital practice,
particularly at large tertiary care centers, or any hospital that strives to maintain or
become trauma center certified. ACS specifically requires that all trauma patients
admitted for more than 24 hours must be screened for alcohol use disorders (American
College of Surgeons, 2018). The current policy could be expanded to include other SUDs
or could be modified to require a consultation with a board-certified addiction medicine
physician, which would require hospitals to have trained addiction medicine physicians
on staff.
6.10.2c. Strategy 3: Statutory requirements. Third, local jurisdictions could enact
coercive policies to improve hospital practices. An excellent example of this occurred
recently in Massachusetts. In August 2018, the Massachusetts legislature passed House
Bill 4866, Prevention and Access to Appropriate Care and Treatment of Addiction,
comprehensive legislation focused on addressing the opioid overdose epidemic (WBUR
News & Wire Services, 2018). The legislation requires Massachusetts’s emergency
departments to offer and provide OAT for patients with an opioid overdose, and to link
them to care upon discharge (WBUR News & Wire Services, 2018). Similar legislation in
other states could be proposed and expanded to require offering of OAT during hospital
admission. Garnering the support necessary to pass this type of legislation would likely
entail the creation of a broad coalition of patients, health care professionals, and
legislators. An important consideration for this strategy is that there will be differences
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in how the statute is implemented and enforced in different jurisdictions, dependent on
local governance structures among state health, mental health, and SUD agencies.
6.10.2d. Strategy 4: Financial incentives and penalties. Another strategy may be
to create financial motivators for hospital performance related to OUD service delivery.
Public payers, such as Medicaid, could incentivize appropriate hospital care through the
Delivery System Reform Incentive Payment (DSRIP) program through the §1115 waiver
mechanism (MACPAC, 2018). Through this program mechanism, policymakers could test
reimbursement strategies, the design of interprofessional teams, penalties for delivering
non-evidence-based services (e.g., funding detox beds), and financial incentives for
evidence-based services. To make this a reality, CMS would need to explicitly outline
these approaches in program notices for future demonstration opportunities.
Cities are also investing local dollars to create hospital AMC services. New York
City Health & Hospitals launched the Consult for Addiction Treatment and Care in
Hospitals Program (CATCH). Funded in part by more than $7.5 million from Mayor de
Blasio’s Healing NYC Initiative, the CATCH program is implementing AMC services at six
New York public hospitals over the next one and a half years (NYC Health & Hospitals,
2018). Replicating this citywide initiative in other jurisdictions is likely possible with the
right coalition and project champions; however, similar to the variation in state law
implementation and enforcement, a one-size-fits-all strategy might not be possible
because of local differences in city and county health agency relationships, operations,
and governance structures.
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Finally, the delivery of hospital-based OAT could be included in CMS pay-forperformance hospital programming such as Medicare’s Hospital Value-Based Purchasing
Program. This program uses value-based purchasing to redistribute funds to
participating hospitals based on performance (CMS, 2018b) The metrics for this program
could be updated to include care processes related to OAT delivery. Another potential
CMS program that could incentivize OAT delivery during hospitalization is the Hospital
Readmission Reduction Program (CMS, 2018a), which reduces hospital payments based
on excessive readmissions. Conditions that are currently tracked do not include OUD
and or OUD-related infection, and these could be added to the program. Summaries of
the education and service delivery policy interventions are provided in Table 6.1, on the
following page.
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Table 6.1. Interventions to Enhance OUD Services During Hospitalization
Policy Tool
and Strategy
Education
Targeted OAT educational
campaigns
Mandate addiction medicine
training as a core clinical
competency
Mandate addiction medicine
exam questions into licensing
exams
Mandate rotation on an AMC
service

Policy
Action
N/A

Responsible
Actors

Target
Actors

SAMHSA; DEA;
medical societies
UME regulatory
bodies1; GME
regulatory bodies2
NBME

Hospital
physicians
UME and GME
programs

Regulative

GME regulatory
bodies2

Mandate
buprenorphine/naloxone training
for medical trainees
Service Delivery
Create national hospital OAT
guidance documents and
mandate adoption
Mandate AMC service existence

Regulative

UME regulatory
bodies1; GME
regulatory bodies 2

GME programs;
health systems
and hospitals
Medical trainees

Regulative
Regulative

ASAM, AHA, Project
SHOUT, SAMHSA, Joint
Commission
Joint Commission; ACS

Mandate hospital OUD care
quality reporting
Mandate hospital OAT provision

Regulative

Joint Commission; ACS

Regulative

State or local public
health department
CMS

Regulative
Regulative

Medical trainees

P&T committees,
hospital legal
departments
Health systems
and hospitals
Health systems
and hospitals
Health systems
and hospitals
Health systems
and hospitals
Health systems
and hospitals
State Medicaid
program

Include OAT in the Hospital Value- Allocative
Based Purchasing Program
Include OUD in the Hospital
Allocative
CMS
Readmission Reduction Program
Incentivize hospital OUD
Allocative
CMS
treatment innovation with DSRIP
and §1115 waiver mechanism
Allocate local funds to pay for
Allocative
Local jurisdictions
Health systems
AMC service
and hospitals
Table Notes. SAMHSA = Substance Abuse and Mental Health Service Administration; DEA = Drug
Enforcement Administration; UME = undergraduate medical education; GME = graduate medical
education; NBME = National Board of Medical Examiners; AMC = addiction medicine consult service;
ASAM = American Society of Addiction Medicine; AHA = American Hospital Association; ACS =
American College of Surgeons; CMS = Centers for Medicare and Medicaid Services; DSRIP = Delivery
System Reform Incentive Payment; 1American Association of Medical Colleges, the Liaison Committee
on Medical Education, the American Osteopathic Association; 2Accreditation Council for Graduate
Medical Education and other medical specialty organizations.
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6.10.3. Policy reform. Treatment policies, inside and outside non-VHA hospitals,
were identified by key informants as creating OAT delivery barriers. Within the hospital,
informants observed internal policies creating barriers through hospital formulary
limitations, restrictive OAT prescribing and administering policies, and the absence of
hospital-wide guidance documents for OUD-related services. The absence of guidance
documents was perceived to complicate OUD care management issues because hospital
standards of care for this patient population were unknown.
Policies creating barriers to hospital OAT access were created by third-party
payers (e.g., coverage policies), OTPs (e.g., state assessment requirements), and federal
drug treatment regulators (e.g., buprenorphine patient panel limits). Frequently, these
policies negatively constrained outpatient OAT access, which in turn influenced the
potential care delivery options in the hospital setting. Informants believed that
streamlined access to outpatient services was necessary for establishing an AMC service
(see Table 6.2).
Table 6.2. Policies for Reform Suggested by Informants
Hospital
• Formulary restrictions on OAT
• Only allowing providers with DATA
waivers to prescribe
buprenorphine/naloxone

Outside the hospital
Third-Party Payer Polices
• No methadone coverage
• Prior authorization for buprenorphine
• Utilization review for buprenorphine
• Formulary restrictions for buprenorphine
OTP Policies
• State assessment requirements prior to placement
• Disallow concurrent polysubstance use
Federal Drug Treatment Policies
• Buprenorphine panel limits
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In addition to the suggestions for policy revision from informants, hospital
policies such as behavioral management, visitor and room searches, and smoking
policies could become more trauma-informed. Further, the removal of the 72-hour rule,
which limits the use of OAT for three days for patients admitted with opioid withdrawal,
may eliminate much of the confusion held by hospital providers on the legality of
providing OAT in the hospital. More broadly, policymakers could consider removing the
special regulatory oversight system currently governing OAT, specifically the OTP
regulations and buprenorphine/naloxone wavier system (Fiscella, Wakeman, & Beletsky,
2018; J. W. Frank et al., 2018). Canada, for example, has discontinued its federal waiver
and provider enrollment requirements for methadone to decrease administrative
barriers to care (Priest et al., 2019). Despite decreasing federal government
involvement, all the provinces still require or strongly suggest that providers who
prescribe OAT participate in additional training (CRISM-ICRAS, 2018), which may still
create barriers to OAT prescribing. Another international model with considerable
success in increasing OAT access is the French system, which since 1996 has allowed
providers to prescribe buprenorphine without any additional training or registration
requirements (Auriacombe, Fatséas, Dubernet, Daulouede, & Tignol, 2004). The U.S.
could implement one of these approaches or a hybrid approach, either shifting
responsibility to states or using the already existing federal regulatory system that
oversees the distribution and prescription of scheduled pharmaceutical products (i.e.,
the FDA and the DEA).
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Section 6.11. Future Research Questions and Areas for Exploration
Several future research questions and areas for exploration were generated from
study findings. Potential lines of inquiry include: extending and expanding upon this
study; confirming the study’s quantitative findings in non-VHA health systems and
hospitals; confirming the study’s qualitative findings in hospitals and health systems
without an addiction medicine fellowship or in rural hospitals; operationalizing hospital
OAT care quality; exploring barriers to provider knowledge; exploring demand-side
issues from the patient perspective; and continuing research on AMC service design and
operations.
6.11.1. Continue research with VHA hospitals. Future research could explore
why hospital OAT variation exists across the VHA system. These explorations could
include the addition of other information not in the original dataset, such as the
existence of VHA affiliated community-based addiction-related services. Questions from
this line of inquiry could include:
•

What are the organizational or environmental (i.e., policy, regulatory, other
organizations) factors that contribute to high performing VHA hospitals?

•

What are the organizational or environmental (i.e., policy, regulatory, other
organizations) factors that contribute to low performing VHA hospitals?

Additional areas for exploration could involve a chart review to better understand why
some patients were sustained or discontinued on OAT during hospitalization. This
review could also include an investigation into hospital performance trends on
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sustaining OAT through a hospitalization. Another approach would be to see if different
findings exist when the study population is narrowed to only patients hospitalized with
opioid overdose or other OUD-related complications. Finally, different outcome
measures related to OAT administration could be assessed through multilevel modeling
including: in-hospital mortality, 30-day readmission, 30-day emergency department
visit, 30-day death, and leaving the hospital against medical advice.
6.11.2. Confirm and expand study findings in non-VHA hospitals. The
quantitative findings from this study could be confirmed outside the non-VHA system,
specifically: Do the study’s findings of OAT underuse, OAT variation, and the use of nonOAT pharmacotherapies persist in non-VHA hospitals and health systems, both in the
U.S. or internationally? To answer this question, policymakers and researchers need to
explore data access issues. One of the primary challenges to studying hospital OAT
delivery is the widespread use of diagnosis-related groupings (DRG) in hospital billing.
The DRG billing system allows hospitals to bill payers through a bundled payment
algorithm to account for illness acuity (Quinn, 2008). Although DRG billing minimizes
administrative billing processes, it unfortunately masks the ability for researchers and
payers to determine if OAT was delivered during hospitalization, a conundrum for
studying most pharmacotherapy administered during hospitalization. Another potential
line of inquiry that bypasses the DRG billing complication could be to assess OAT
delivery in the international hospital setting to determine if this care deficit exists in
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other care contexts or in other domestic integrated health systems (e.g., Kaiser
Permanente).
6.11.3. Confirm and expand study findings in hospitals without addiction
medicine fellowships. The qualitative findings, in particular the barriers to AMC service
establishment and the delivery of evidence-based care, could be confirmed in hospitals
without addiction medicine fellowship affiliation and hospitals in rural settings.
Questions for this avenue of research could include:
•

Are there different contextual attributes that facilitate or impede AMC
service establishment and OAT delivery in hospitals without an addiction
medicine fellowship? Or in rural hospitals?

•

Are the OAT and non-OAT practices different in hospitals without an
addiction medicine fellowship? Or in rural hospitals?

6.11.3. Operationalize hospital OAT care quality. The findings from this study
could lead to future lines of inquiry about how hospital OAT delivery quality could be
defined and measured from a care quality perspective. Future questions could ask:
•

Is the delivery of OAT during hospitalization enough or does linkage to care need
to happen? What about patients who are already on OAT?
6.11.4. Explore barriers to provider knowledge. The findings from this study also

inspire questions related to the knowledge base and training of health care
professionals, in particular physicians. Future research could focus on exploring hospital
provider understanding of contemporary best practices for OUD treatment and OAT
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regulations. A specific question that could be explored in the VHA setting is to assess
why patients on OAT prior to hospitalization are being discontinued from OAT and being
managed on short-acting opioid agonists. As was described in the qualitative findings,
the continuation of OAT supplemented with short-acting opioids is the recommended
approach to managing pain for patients with OUD (SAMHSA, 2018).
6.11.5. Explore demand-side perspectives. This study was designed to focus on
supply-side barriers and facilitators; as such, future research could focus on the barriers
to patient access to hospital OAT. This could be done by inviting the patient’s
perspective. Further, research could include and consider patient-informed harm
reduction approaches and the impacts of hospitalization trauma. Recent research on
hospitalized patients, not specific to patients with SUDs, suggests that the trauma of
hospitalization itself is associated with increased access to acute care delivery services
(ED visits and 30-day readmission) in the 30 days post discharge (Rawal et al., 2018).
Based on the findings of this study and prior research (Velez et al., 2017), the trauma of
hospitalization could disproportionately impact patients hosptialized with SUDs.
6.11.6. Continue research on AMC service design and operations. Beyond this
study, little is known about the design and operations of AMC services. Future research
could build on study findings by developing an AMC service design survey that could be
administered by the AHA. This survey could further quantify the potential barriers to
AMC service operations (e.g., questions related to hospital formulary), the prevalence of
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AMC services (e.g., does your hospital have an AMC service), and design elements (e.g.,
availability and coverage).
Section 6.12. Study Conclusions and Future Challenges
Addictions cannot be understood as merely the behavior patterns of individuals,
as if they were the product of personal choices or personality characteristics
alone, but also must be conceptualized as collective probabilities that are woven
into the social fabric. (Reinarman & Granfield, 2014, p. 16)
This study began the process of describing and exploring the dynamic, evolving,
organizational and socio-economic phenomena influencing the delivery of hospitalbased services for patients with OUD. There are seven primary findings from this mixed
methods study that confirm and expand upon prior research and also provide novel
contributions. The quality of care for this patient population appears to be suboptimal
(Findings 1, 2, 3, and 4). This study provides the first description of specific contextual
attributes inside and outside the hospital that facilitate or impede AMC service
development and hospital OAT delivery (Finding 5). This study builds upon a growing
evidence base suggesting that patient attributes impede or facilitate hospital OAT
delivery (Finding 6), and also provides a first look into the important role of the hospital
in the broader OUD care continuum (Finding 7). The findings from this study suggest it is
likely that many U.S. hospitals, particularly those without addiction medicine expertise,
fail to provide adequate care for patients with OUD during hospitalization.
Although the study findings are primarily negative, there are a variety of ways in
which hospitals, health systems, and policymakers may improve care for patients with
OUD in the hospital setting. The proposed policy and system interventions have the
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potential to minimize harm and enhance support for people seeking treatment for their
drug use. Resources should be allocated to these initiatives. There is, however, a
significant challenge: the U.S. health services delivery system exists within the U.S.
contemporary drug policy regime. The U.S. drug policy regime does not exist to
minimize harm to persons who use drugs. It is grounded in a historical and social
context that views persons with SUDs as morally deficient and incapable of making
sound decisions. The construction of these views, embodied and normalized through
over a century of policy and practice, run counter to the public health model of
promoting human health and mitigating disease. A true public health approach to caring
for persons with SUDs requires an overhaul of the U.S. drug policy regime. The current
framework for addressing harmful drug use centers on the false notion that people who
use drugs are immoral and must face criminal consequences for their behaviors. Until
these antiquated views are stripped from federal and local policies, people with SUDs in
the U.S. will continue to die and suffer unnecessarily.
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Appendix A: The DSM 5 Opioid Use Disorder Diagnostic Criteria
From the American Psychiatric Association (2013):
“A problematic pattern of opioid use leading to clinically significant impairment or distress, as
manifested by at least two of the following, occurring within a 12-month period:
1. Opioids are often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use.
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid,
or recover from its effects.
4. Craving, or a strong desire or urge to use opioids.
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school,
or home.
6. Continued opioid use despite having persistent or recurrent social or interpersonal
problems caused or exacerbated by the effects of opioids.
7. Important social, occupational, or recreational activities are given up or reduced
because of opioid use.
8. Recurrent opioid use in situations in which it is physically hazardous.
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or
psychological problem that is likely to have been caused or exacerbated by the
substance.
10. Tolerance, as defined by either of the following: A need for markedly increased amounts
of opioids to achieve intoxication or desired effect; or a markedly diminished effect with
continued use of the same amount of an opioid. *This criterion is not considered to be
met for those taking opioids solely under appropriate medical supervision.
11. Withdrawal, as manifested by either of the following: The characteristic opioid
withdrawal syndrome (refer to Criteria A and B of the criteria set for opioid withdrawal,
pp. 547–548); or opioids (or a closely related substance) are taken to relieve or avoid
withdrawal symptoms. *This criterion is not considered to be met for those individuals
taking opioids solely under appropriate medical supervision.
Specify if:
In early remission: After full criteria for opioid use disorder were previously met, none of the
criteria for opioid use disorder have been met for at least 3 months but for less than 12 months
(with the exception that Criterion A4, “Craving, or a strong desire or urge to use opioids,” may
be met).
In sustained remission: After full criteria for opioid use disorder were previously met, none of
the criteria for opioid use disorder have been met at any time during a period of 12 months or
longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use opioids,”
may be met).
On maintenance therapy: This additional specifier is used if the individual is taking a prescribed
agonist medication such as methadone or buprenorphine and none of the criteria for opioid use
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disorder have been met for that class of medication (except tolerance to, or withdrawal from,
the agonist). This category also applies to those individuals being maintained on a partial
agonist, an agonist/antagonist, or a full antagonist such as oral naltrexone or depot naltrexone.
In a controlled environment: This additional specifier is used if the individual is in an
environment where access to opioids is restricted.
Coding based on current severity: Note for ICD-10-CM codes: If an opioid intoxication, opioid
withdrawal, or another opioid-induced mental disorder is also present, do not use the codes
below for opioid use disorder. Instead, the comorbid opioid use disorder is indicated in the 4th
character of the opioid-induced disorder code (see the coding note for opioid intoxication,
opioid withdrawal, or a specific opioid-induced mental disorder). For example, if there is
comorbid opioid-induced depressive disorder and opioid use disorder, only the opioid-induced
depressive disorder code is given, with the 4th character indicating whether the comorbid
opioid use disorder is mild, moderate, or severe: F11.14 for mild opioid use disorder with opioidinduced depressive disorder or F11.24 for a moderate or severe opioid use disorder with opioidinduced depressive disorder.
305.50 (F11.10) Mild: Presence of 2–3 symptoms.
304.00 (F11.20) Moderate: Presence of 4–5 symptoms.
304.00 (F11.20) Severe: Presence of 6 or more symptoms.”
(American Psychiatric Association, 2013)
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Appendix B: OHSU IRB Approved Informational Sheet
TITLE: Opioid Agonist Treatment in Hospitals
PRINCIPAL INVESTIGATOR: Dennis McCarty, PhD (503) 494-1177
CO-INVESTIGATOR: Kelsey Priest, MPH
FUNDED BY: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
PURPOSE:
You have been invited to be in this research study because you are either a national hospital
addiction medicine expert (e.g., physician, pharmacist, nurse, social worker, hospital
administrator, health services researcher, or government official), a member of a hospital
pharmacy and therapeutics committee for at least 6 months (e.g., nursing, physician,
pharmacist, hospital administrator), or a health professional (e.g., nursing, physician,
pharmacist, hospital administrator) who works on a hospital addiction consult service.
The purpose of this interview is to explore your perspectives about your organization’s hospital
opioid use disorder care delivery policies, procedures, and practice, specifically:
1. Hospital OUD care delivery policies, procedures, and practice.
2. Barriers and facilitators to hospital OUD treatment and OAT delivery.
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery.
PROCEDURES:
This study requires one 45-to 60-minute telephone (or in-person) audio recorded interview. If
you mention a specific hospital policy during the course of the interview I will request a copy
and I may follow-up with clarifying questions.
We are recruiting approximately 30 key informants to participate in this study who are
professionals identified from across the United States as hospital-based OUD treatment experts.
The recordings of the interviews will be professionally transcribed (meaning that what is said
will be written down exactly as stated), reviewed, summarized, and entered into a software
program that is designed to facilitate analysis of the interviews. Notes will be taken during the
interviews and entered into the same software program. All data from the interviews will be deidentified and coded with a special number when entered and stored in the software program.
If you have any questions, concerns or complaints regarding this study now or in the future, or
you think you may have been injured or harmed by the study, contact Dr. Dennis McCarty (503)
494-1177 or mccartyd@ohsu.edu.
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RISKS:
Although we have made every effort to protect your identity, there is a minimal risk of loss of
confidentiality. The recording of the interview will be stored on OHSU encrypted and passwordprotected servers for no longer than 3 years after study completion. Access to the data will be
granted only to the study researchers. All of the data kept in notes, recordings, and
transcriptions related to the research will be destroyed as soon as the research is complete.
BENEFITS:
You will not benefit from being in this study. However, by serving as a participant, you may help
us learn how to benefit patients with opioid use disorder in the future.
CONFIDENTIALITY:
We will take steps to keep your personal information confidential, but we cannot guarantee
total privacy. All NIDA sponsored studies have an automatic federal certificate of confidentiality
to help protect the confidentiality of the data.
PARTICIPATION:
This research is being overseen by an Institutional Review Board (“IRB”). You may talk to the
OHSU IRB at (503) 494-7887 or irb@ohsu.edu if:
• Your questions, concerns, or complaints are not being answered by the research team.
• You want to talk to someone besides the research team.
• You have questions about your rights as a research subject.
• You want to get more information or provide input about this research.
You may also submit a report to the OHSU Integrity Hotline online at
https://secure.ethicspoint.com/domain/media/en/gui/18915/index.html or by calling toll-free
(877) 733-8313 (anonymous and available 24 hours a day, 7 days a week).
You do not have to join this or any research study. If you do join, and later change your mind,
you may quit at any time. If you refuse to join, or withdraw early from the study, there will be
no penalty or loss of any benefits to which you are otherwise entitled.
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Appendix C: OHSU IRB Approved Email Recruitment Script
Subject Line: OHSU Research Study: Opportunity for Participation
Email Primary Contact

“Dear ___________,
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health & Science
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public
Health in the Health Systems and Policy program. I am contacting you in connection with a
research study (OHSU IRB approval #STUDY00018092) that I am conducting as part of my
dissertation, under the supervision of Dr. Dennis McCarty who is the chair of my dissertation
committee. This project seeks to learn more about the health care service patterns of opioid
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder.
I am seeking to speak with an expert from your hospital on hospital-based practices and policies
related to the treatment of persons with opioid use disorder. Preferably this will be someone
who has worked on opioid use disorder related initiatives for several years and/or has seen the
implementation of programs, like an addiction consult services over time. The purpose of the
interview is to capture this expert’s perspectives about your organization’s hospital opioid use
disorder care delivery policies, procedures, and practice, specifically:
1.
2.
3.

Hospital OUD care delivery policies, procedures, and practice.
Barriers and facilitators to hospital OUD treatment and OAT delivery.
Ideas or solutions for enhancing hospital OUD treatment and OAT delivery.

I am emailing to see if you would be interested in participating as a key informant in our
research study or if you could refer me to someone at your hospital who you think would be
better able to answer these questions.
In either case, please respond to this email with either your recommended contact or indicate
whether or not you are interested in participating.
If you are interested in participating, I will arrange a time over email for us to have a 45 to 60minute confidential phone interview (or in-person meeting) to talk at your convenience.
If you are recommending a colleague, I will reach out to them directly.
If you have concerns about this research please contact Dr. Dennis McCarty at (503) 494-1177
and mccartyd@ohsu.edu.If you have questions about your rights as a research subject or
research-related injuries, you can call the OHSU Research Integrity Office at 503-494-7887.
Email Secondary Contact
“Dear ___________,
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health& Science
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public
Health in the Health Systems and Policy program. I am contacting you in connection with a
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research study (OHSU IRB approval #STUDY00018092) that I am conducting as part of my
dissertation, under the supervision of Dr. Dennis McCarty who is the chair of my dissertation
committee. This project seeks to learn more about the health care service patterns of opioid
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder.
I am seeking to speak with an expert from your hospital on hospital-based practices and policies
related to the treatment of persons with opioid use disorder. Preferably this will be someone
who has worked on opioid use disorder related initiatives for several years and/or has seen the
implementation of programs, like an addiction consult services over time. The purpose of the
interview is to capture this expert’s perspectives about your organization’s hospital opioid use
disorder care delivery policies, procedures, and practice, specifically:
1.
2.
3.

Hospital OUD care delivery policies, procedures, and practice.
Barriers and facilitators to hospital OUD treatment and OAT delivery.
Ideas or solutions for enhancing hospital OUD treatment and OAT delivery.

You have been identified by [references name] as an expert in hospital-based practices and
policies related to the treatment of persons with opioid use disorder at your hospital.
I am emailing to see if you would be interested in participating as a key informant in our
research study. If you are interested please respond to this email, and I will arrange a time for us
to have a 45 to 60-minute confidential phone interview (or in-person meeting) to talk at your
convenience.
If you have concerns about this research please contact Dr. Dennis McCarty at (503) 494-1177
and mccartyd@ohsu.edu.
If you have questions about your rights as a research subject or research-related injuries, you
can call the OHSU Research Integrity Office at 503-494-7887.
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Appendix D: OHSU IRB Approved Key Informant Demographic Survey
What is your age?
• <25
• 25-29
• 30-34
• 35-39
• 40-44
• 45-49
• 50-54
• 55-59
• 60-64
• 65-69
• 70 or older
•
With what gender do you identity?
• Woman
• Man
• Other __
• Decline to Answer
How do you racially identify?
• American Indian/Alaska Native
• Asian
• Native Hawaiian or Other Pacific Islander
• Black or African American
• White
• More than one race
• Decline to Answer
What ethnicity best describes you? [pick one]
• Hispanic or Latino
• Not Hispanic or Latino
• Decline to Answer
What health professional degree(s) do you have? And what year did you graduate from each
program(s)?
Which profession best describes your current work?
• Hospital administrator/manager
• Nurse
• Pharmacist
• Physician
o Specialty:
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•
•
•
•

o Addiction Medicine Board Certification? (y/n)
Social worker
Behavioral health specialist
Legal counsel
Other___

For how many years have you worked at your respective hospital?
• <1
• 1-2
• 3-5
• more than 5
For how many years have you been the fellowship program director?
• <1
• 1-2
• 3-5
• more than 5
For how many years have you worked on the addiction consult service (if applicable)?
• <1
• 1-2
• 3-5
• more than 5
Does your hospital have methadone on the formulary for treatment of OUD?
• Yes
• No
• Unknown
Does your hospital have buprenorphine on the formulary for treatment of OUD?
• Yes
• No
• Unknown

336

Appendix E: OHSU IRB Approved Semi-Structured Interview Guide
ID #:

Date:

Introduction
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health & Science
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public
Health in the Health Systems and Policy program. As part of the requirements of the doctoral
program, I am conducting dissertation research to study the treatment of persons with opioid
use disorder (OUD) in the hospital setting. As the [position of research participant] for the
[hospital name], you have been identified as knowledgeable about the treatment of persons
with opioid use disorder at [hospital name].
This project is an opportunity to learn more about the health care service patterns of opioid
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder. The
purpose of this interview is to capture your perspectives about your organization’s hospital
opioid use disorder care delivery policies, procedures, and practice, specifically:
1. Hospital OUD care delivery policies, procedures, and practice.
2. Barriers and facilitators to hospital OUD treatment and OAT delivery.
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery.
The interview will last between 45 and 60 minutes, depending on the length of your answers. If
you describe any hospital-based policies during the interview I will follow-up via email after the
interview with a request to see them with your permission and I may also follow up with
additional clarifying questions.
Consent
I have provided the consent form ahead of time, and I want to ensure that you are clear on the
expectations of participation. I assume that your presence here today indicates you have read
the consent form. Do you have any questions about your participation in this research study? I
would now like to receive verbal consent to participate from you.
<Obtain verbal consent>
Audio Recording Instructions
With your permission, I will take notes and record the interview. Your participation in this
interview is voluntary; you do not have to answer any question that you do not want to answer
and you may stop the interview at any time. All individual responses will be kept confidential.
The recording and my notes will help me to accurately represent our discussion; no one else will
ever hear the recordings or see the written transcripts. If there are things that you tell me that
you do not wish repeated, please indicate this so that I do not include those comments in any
summaries or reports that I develop from this interview.

337

Similarly, if at any time you would like me to stop recording, please indicate this and I will turn
off the recorder. Findings will be reported in the aggregate with larger themes identified within
and across hospitals. Quotes will be selected to illustrate these broader themes and will be
presented without attribution to individuals. Do I have your permission to record this interview?
<Obtain verbal consent, and turn on the recording device>
At this time, do you have any other questions or concerns?
<After addressing any questions and/or concerns>
Then let us begin.
Questions
1. We will start with a brief demographic survey.
<Reads questions from key informant demographic survey>
2. Role and Introductions. Please tell me briefly about your role at your institution and
within the hospital.
3. Responsibility of Care. Who (what service) within the hospital is responsible for the
clinical management of an OUD during hospitalization?
a. Probe: Dependent on clinical scenario (e.g., surgical vs. non-surgical or acuity).
4. Care Delivery Mechanisms. Does your hospital have an addiction consult service?
a. If yes, when did the service start? What was the context or catalyst for this
change?
i. Probe: Since that time, what shifts in culture and/or stigma of persons
with OUD or other addictive disorders have occurred?
ii. Probe: How have hospital policies, procedures, or guidelines changed
over time related to care for persons with OUD since the establishment
of the service?
iii. Probe: What were the facilitators for starting the service?
1. Probe: Within the organization?
2. Probe: Outside the organization?
iv. Probe: What were the barriers to starting the service?
1. Probe: Within the organization?
2. Probe: Outside the organization?
b. If no, is this something that is being considered? If not, why do you think that is?
5. Addiction Consult Service Structure and Design. What is the current design of the
addiction consult service?
a. Probe: Describe the team composition (e.g., what professionals are on the
team).
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b. Probe: Describe the services provided by the consult service (e.g., medication
management, pain consultation, harm reduction).
c. Probe: Describe the availability of the service (e.g., weekdays only, 24-7
coverage).
6. Current Policies. What are your hospital’s current policies and procedures (e.g.,
guidelines) for OUD management and/or withdrawal?
a. Probe: Specifically, does your hospital have policies or procedures on the
continuation of methadone or buprenorphine for OUD treatment during
hospitalization?
i. If so, please describe the policies.
ii. Have these changed over time? If yes, how so?
b. Probe: Does your hospital have any policies or procedures on the induction of
methadone or buprenorphine during hospitalization?
i. If so, please describe the policies
ii. Have these changed over time? If yes, how so?
c. Probe: Does your hospital have any policies or procedures on the use of
buprenorphine or methadone to manage withdrawal?
i. If so, please describe the policies.
ii. Have these changed over time? If yes, how so?
d. Probe: If applicable, do these policies or procedures reflect practice generally?
7. Organizational Barriers. What do you think are some of the organizational barriers to
implementing policies and procedures for caring for persons with OUD at your hospital?
a. Probe: Physical environment/location?
b. Probe: Leadership?
c. Probe: Resources and staffing?
d. Probe: Policy implementation process?
e. Probe: Hospital culture and understanding of OUD?
8. External Barriers. What do you think are some of the external barriers to implementing
policies and procedures for caring for persons with OUD at your hospital?
a. Probe: Federal or local policies? (e.g., federal regulations or insurance
regulations)
b. Probe: System service delivery issues (e.g., care transitions)?
c. Probe: Other local hospitals?
9. Organizational Facilitators. What do you think are some of the organizational
facilitators for implementing policies and procedures for caring for persons with opioid
use disorder at your hospital?
a. Probe: Physical environment/location?
b. Probe: Leadership?
c. Probe: Resources and staffing?
d. Probe: Policy implementation process?
e. Probe: Hospital culture and understanding of OUD?
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10. External Facilitators. What do you think are some of the external facilitators for
implementing policies and procedures for caring for persons with opioid use disorder at
your hospital?
a. Probe: Federal or local policies?
b. Probe: System?
c. Probe: Other local hospitals?
11. Is there anything else that we have not discussed about the treatment of OUD in your
hospital?
Closing the Interview
Thank you for participating in this interview, and for your thoughtful comments, insights and
candor. I am meeting with approximately 19 other key informants from other hospitals across
the United States. I will be analyzing and synthesizing the key themes and issues that emerge
over the course of the study. If you think of anything else, please contact me. Findings from the
interviews will be included in my dissertation and read by the OHSU-PSU School of Public Health
faculty serving on my dissertation committee. At the conclusion of the study, I would be happy
to share a report of the aggregated findings with you. May I contact you if I have any follow up
questions? Again, thank you for your time and willingness to participate.
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Appendix F: Final Qualitative Analyses Codebook & Code Distribution

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

Category (code)
Addiction Consult Service: Elements related to AMC service
Culture and Practice Shift
Design
Historical Context
Policy Influence
Team Composition
Care Delivery Topics: Elements related to OUD treatment within hospital
Criminal Justice
Culture Change
Education
Electronic Health Record
Emergency Department
Endocarditis
Formulary
Harm Reduction
Injectable Naltrexone
Linkage to Care
Naloxone
Non-evidence-based care
Nursing involvement/initiative
Pain Consult
Peers
Psychiatry Consult
Script on DX
Security and Public Safety
Stigma
Stimulant Use
Tobacco/Nicotine
Trainees
Trauma
Demand-Side Attributes: Elements related to patient characteristics
Patient Characteristics
External Environment: Elements external to the hospital influencing care
delivery
External Treatment Organizations
Media Coverage
Normative social structure
Policies and Regulations
Politics and Political Leadership
Quality Metrics
Hospital Policy: Policy and practice related to the treatment of OUD
Aberrant Drug Use/Behavioral Agreement
BYOD
Induction
OAT continuation
PICC

Code
Count
239
9
44
77
2
32
217
5
8
34
8
30
11
20
12
2
63
11
24
10
12
19
36
8
5
43
5
4
61
2
27
29
66
49
12
12
19
24
9
205
25
1
43
23
17
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46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.

Pain Management
Policy Frame
Policy Process
Pregnancy
Security
Withdrawal Management
Hospital Supply-Side Attributes: Elements within the hospital influencing
care
Leadership
Location/Geography
Misunderstanding of Policy
Normative Social Structures
Research, Evaluation, Data
Resources and Staffing
Stakeholders
Other Models of Care
Ad Hoc Consults
Bridge Clinic
Detox
Longitudinal Care (within the same institution)
OTP
Service or Policy Design Lever
Financing: Elements related to financing care and delivery of services for
persons with OUD

24
5
22
16
6
47
92
44
3
13
18
22
71
8
62
13
6
20
4
33
21
97
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Appendix G: RStudio Packages
dunn.test
Dinno, A. (2017). Dunn.test: Dunn's Test of multiple comparisons using rank sums.
Retrieved from https://CRAN.R-project.org/package=dunn.test
car

Fox, J., & Weisberg, S. (2011). Car. Thousand Oaks, CA: SAGE Publications. Retrieved
from http://socserv.socsci.mcmaster.ca/jfox/Books/Companion
psych

Revelle, W. (2018). Psych: Procedures for personality and psychological research.
Evanston, IL: Northwestern University. Retrieved from https://CRAN.Rproject.org/package=psych
icd

Wasey, J. O. (2018). icd: Comorbidity calculations and tools for ICD-9 and ICD-10 codes.
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Appendix H: OUD Diagnosis Codes Queried
ICD-10-CM
Code
F11.10
F11.11
F11.120
F11.121
F11.122
F11.129
F11.14
F11.150
F11.151
F11.159
F11.181
F11.182
F11.188
F11.19
F11.20
F11.220
F11.21
F11.221
F11.222
F11.229
F11.23
F11.24
F11.250
F11.251
F11.259
F11.281
F11.282
F11.288
F11.29
F11.90
F11.920
F11.921
F11.922
F11.929
F11.93
F11.94
F11.950
F11.951
F11.959

ICD-10-CM Description
Opioid abuse, uncomplicated
Opioid abuse, in remission
Opioid abuse with intoxication, uncomplicated
Opioid abuse with intoxication delirium
Opioid abuse with intoxication with perceptual disturbance
Opioid abuse with intoxication, unspecified
Opioid abuse with opioid-induced mood disorder
Opioid abuse with opioid-induced psychotic disorder with delusions
Opioid abuse with opioid-induced psychotic disorder with hallucinations
Opioid abuse with opioid-induced psychotic disorder, unspecified
Opioid abuse with opioid-induced sexual dysfunction
Opioid abuse with opioid-induced sleep disorder
Opioid abuse with other opioid-induced disorder
Opioid abuse with unspecified opioid-induced disorder
Opioid dependence, uncomplicated
Opioid dependence with intoxication, uncomplicated
Opioid dependence, in remission
Opioid dependence with intoxication delirium
Opioid dependence with intoxication with perceptual disturbance
Opioid dependence with intoxication, unspecified
Opioid dependence with withdrawal
Opioid dependence with opioid-induced mood disorder
Opioid dependence with opioid-induced psychotic disorder with delusions
Opioid dependence with opioid-induced psychotic disorder with hallucinations
Opioid dependence with opioid-induced psychotic disorder, unspecified
Opioid dependence with opioid-induced sexual dysfunction
Opioid dependence with opioid-induced sleep disorder
Opioid dependence with other opioid-induced disorder
Opioid dependence with unspecified opioid-induced disorder
Opioid use, unspecified, uncomplicated
Opioid use, unspecified, with intoxication, uncomplicated
Opioid use, unspecified, with intoxication delirium
Opioid use, unspecified, with intoxication with perceptual disturbance
Opioid use, unspecified, with intoxication, unspecified
Opioid use, unspecified with withdrawal
Opioid use, unspecified with opioid-induced mood disorder
Opioid use, unspecified with opioid-induced psychotic disorder with delusions
Opioid use, unspecified with opioid-induced psychotic disorder with
hallucinations
Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
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F11.981
F11.982
F11.988
F11.99
T40.0X1A
T40.0X1D
T40.0X1S
T40.0X4A
T40.0X4D
T40.0X4S
T40.0X5A
T40.0X5D
T40.0X5S
T40.1X1A
T40.1X1D
T40.1X1S
T40.1X4A
T40.1X4D
T40.1X4S
T40.2X1A
T40.2X1D
T40.2X1S
T40.2X4A
T40.2X4D
T40.2X4S
T40.2X5A
T40.2X5D
T40.2X5S
T40.3X1A
T40.3X1D
T40.3X1S
T40.3X4A
T40.3X4D
T40.3X4S
T40.3X5A
T40.3X5D
T40.3X5S
T40.4X1A
T40.4X1D
T40.4X1S
T40.4X4A
T40.4X4D
T40.4X4S
T40.4X5A

Opioid use, unspecified with opioid-induced sexual dysfunction
Opioid use, unspecified with opioid-induced sleep disorder
Opioid use, unspecified with other opioid-induced
Opioid use, unspecified with unspecified opioid-induced disorder
Poisoning by opium, accidental (unintentional), initial encounter
Poisoning by opium, accidental (unintentional), subsequent encounter
Poisoning by opium, accidental (unintentional), sequelae
Poisoning by opium, undetermined, initial encounter
Poisoning by opium, undetermined, subsequent encounter
Poisoning by opium, undetermined, sequelae
Adverse effect of opium, initial encounter
Adverse effect of opium, subsequent encounter
Adverse effect of opium, sequelae
Poisoning by heroin, accidental (unintentional), initial encounter
Poisoning by heroin, accidental (unintentional), subsequent encounter
Poisoning by heroin, accidental (unintentional), sequelae
Poisoning by heroin, undetermined, initial encounter
Poisoning by heroin, undetermined, subsequent encounter
Poisoning by heroin, undetermined, sequelae
Poisoning by other opioids, accidental (unintentional), initial encounter
Poisoning by other opioids, accidental (unintentional), subsequent encounter
Poisoning by other opioids, accidental (unintentional), sequelae
Poisoning by other opioids, undetermined, initial encounter
Poisoning by other opioids, undetermined, subsequent encounter
Poisoning by other opioids, undetermined, sequelae
Adverse effect of other opioids, initial encounter
Adverse effect of other opioids, subsequent encounter
Adverse effect of other opioids, sequelae
Poisoning by methadone, accidental (unintentional), initial encounter
Poisoning by methadone, accidental (unintentional), subsequent encounter
Poisoning by methadone, accidental (unintentional), sequelae
Poisoning by methadone, undetermined, initial encounter
Poisoning by methadone, undetermined, subsequent encounter
Poisoning by methadone, undetermined, sequelae
Adverse effect of methadone, initial encounter
Adverse effect of methadone, subsequent encounter
Adverse effect of methadone, sequelae
Poisoning by synthetic narcotics, accidental (unintentional), initial encounter
Poisoning by synthetic narcotics, accidental (unintentional), subsequent
encounter
Poisoning by synthetic narcotics, accidental (unintentional), sequelae
Poisoning by synthetic narcotics, undetermined, initial encounter
Poisoning by synthetic narcotics, undetermined, subsequent encounter
Poisoning by synthetic narcotics, undetermined, sequelae
Adverse effect of synthetic narcotics, initial encounter
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T40.4X5D
T40.4X5S
T40.601A
T40.601D
T40.601S
T40.604A
T40.604D
T40.604S
T40.605A
T40.605D
T40.605S
T40.691A
T40.691D
T40.691S
T40.694A
T40.694D
T40.694S
T40.695A
T40.695D
T40.695S

Adverse effect of synthetic narcotic, subsequent encounter
Adverse effect of synthetic narcotic, sequelae
Poisoning by unspecified narcotics, accidental (unintentional), initial encounter
Poisoning by unspecified narcotics, accidental (unintentional), subsequent
encounter
Poisoning by unspecified narcotics, accidental (unintentional), sequelae
Poisoning by unspecified narcotics, undetermined, initial encounter
Poisoning by unspecified narcotics, undetermined, subsequent encounter
Poisoning by unspecified narcotics, undetermined, sequelae
Adverse effect of unspecified narcotics, initial encounter
Adverse effect of unspecified narcotics, subsequent encounter
Adverse effect of unspecified narcotics, sequelae
Poisoning by other narcotics, accidental (unintentional), initial encounter
Poisoning by other narcotics, accidental (unintentional), subsequent encounter
Poisoning by other narcotics, accidental (unintentional), sequelae
Poisoning by other narcotics, undetermined, initial encounter
Poisoning by other narcotics, undetermined, subsequent encounter
Poisoning by other narcotics, undetermined, sequelae
Adverse effect of other narcotics, initial encounter
Adverse effect of other narcotics, subsequent encounter
Adverse effect of other narcotics, sequelae

(ICD10Data.com, 2018)
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Appendix I: VHA Study Cohort Consort Diagram
139 Unique Facilities
15,420 Unique Index Hospitalizations

Step 1. Exclude Puerto Rico facility
(hospitals = 1; cases = 134).
Step 2. Exclude facilities with bed category
discrepancies (hospitals = 6; cases = 141).
Step 3. Exclude cases with non-Hospital place
admissions (cases = 7) or missing place of
admission (cases = 2).

132 Unique Facilities
15,136 Unique Index Hospitalizations

Step 4. Exclude cases missing primary or
secondary admission diagnosis (n = 271).
Step 5. Exclude cases with inconsistent death
variable (cases = 4); lost a facility here
(hospitals = 1).
Step 6. Exclude cases with cancer flag (see
definition in next section) —solid tumor w/o
metastatic, metastatic cancer, and lymphoma
(cases = 2062).

130 Unique Facilities
12,669 Unique Index Hospitalizations

Step 7. Exclude cases with a length of stay >=
51 days (99th percentile) (cases = 130); lost a
facility here (hospitals = 1).

Step 8. Excluded facilities based on minimum
observations < 25 (hospitals = 21; cases =
262).

109 Unique Facilities
12,407 Unique Index Hospitalizations

(CONSORT, 2010)
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Appendix J: Patient and Hospital Study Cohort Definitions
Acronyms
CDW = corporate data warehouse; VHA = Veterans Health Administration.
Index Hospitalization
Index hospitalization was defined as the first acute hospitalization per patient with an OUD
diagnosis as defined below in the VHA 2017 fiscal year (discharge date between 10/1/2016 and
10/1/2017). Index hospitalizations were included in the study cohort for an OUD diagnosis at the
time of hospitalization in any of the “Present on Admission” fields or any number of the
diagnosis fields for that hospital stay or any OUD diagnosis for any encounter outpatient or
inpatient within the 12 months prior to index hospitalization.
OUD Diagnosis
Patients with an OUD diagnosis, from any source, inpatient or outpatient, between 10/1/2015
and 10/1/2017 in the year preceding the discharge date of index hospitalization. This could
include an OUD diagnosis during index hospitalization and the diagnosis could be at any of the
24 diagnoses positions.
Hospitalization fields searched
1. Present on admission: “Inpat.PresentOnAdmission”
2. Summary diagnoses: “Inpat.InpatientDiagnosis”
3. Discharge diagnoses: “Inpat.InpatientDischargeDiagnosis”
4. Diagnoses associated with patient transfer within the hospital:
“Inpat.PatientTransferDiagnosis”
5. Diagnoses associated with specialty transfer within the hospital:
“Inpat.SpecialtyTransferDiagnosis”
6. Fee Basis inpatient diagnoses tables
Outpatient fields searched
1. Outpatient diagnosis table
2. Fee Basis Outpatient diagnoses tables
Identification of Cancer Codes: Present on Admission
Comorbidities were identified in several sources within the CDW (Outpatient, Outpatient FEE
BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient Present
on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE BASIS). At least one ICD10
diagnosis was present for a patient to receive a flag. Conditions were identified within 365 days
prior to the index admission date. The Elixhauser classification system (Agency for Healthcare
Research and Quality, 2018) was used: LYMPH = 'Lymphoma'; METS = 'Metastatic cancer';
TUMOR = 'Solid tumor w/out metastasis.’
Hospital Selection
Included hospitals were restricted to “acute care hospitals” from a report produced internally at
the VHA, which only included hospitals with at least 500 “acute” bed days of service during fiscal
year 2017.
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Hospital Size
Hospital size was defined by the number of operating beds from a document downloaded from
the VHA Support Service Center reporting portal. Operating beds were staffed and available for
admission of patients. The operating bed count did not include unavailable beds. Occupancy
rates were determined for each facility based on current approved operating bed levels.
Further, the bed type was restricted to “acute” (e.g., internal medicine, surgery, neurology) and
did not include counts for nursing beds or hospice beds (e.g., beds that cannot accommodate
acute care patients).
Hospital Identifier
The hospital identifier, the parent facility, was created by using the VHA station number. A
variable from the VHA CDW.

349

Appendix K: Patient and Admission Definitions
Acronyms
CDW = corporate data warehouse; VHA = Veterans Health Administration; SUD = substance use
disorder; OUD= opioid use disorder.
Age
Calculated continuous variable for age of patient on the index hospitalization admission date.
Values ranged from 21 to 90. Patients aged > 90 were listed at 90.
Co-Occurring Mental Health Condition: Present on Admission
Co-occurring mental health conditions were identified in several sources within the CDW
(Outpatient, Outpatient FEE BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer
Diagnosis, Inpatient Present on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE
BASIS). At least one ICD-10 diagnosis must have been present for a patient to receive a positive
flag. See Appendix L for ICD-10 code list. Conditions were identified within 365 days prior to the
index hospitalization admission date: Adjustment disorder other; anxiety disorder; mood
disorder; non-mood psychotic disorder; post-traumatic stress disorder; and self-harm.
Co-Occurring SUD: Present on Admission
Co-occurring SUDs were identified in several sources within the CDW (Outpatient, Outpatient
FEE BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient
Present on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE BASIS). At least one
ICD-10 diagnosis must have been present for a patient to receive a positive flag. See Appendix L
for ICD-10 code list. Conditions were identified within 365 days prior to the index hospitalization
admission date: Alcohol use disorder; cannabis use disorder; cocaine use disorder; hallucinogen
use disorder; nicotine dependence; other psychoactive use disorders; other stimulant related
disorders; other substance use disorder; and sedative hypnotic disorder.
Gender
VHA variable for gender of the patient: male or female.
Ethnicity
VHA variable describing the patient’s ethnicity: Not Hispanic or Latino; Hispanic Or Latino; and
Unknown.
OUD-Related Infection: During Admission
OUD-related infections during index hospitalization were captured using the following tables
from the CDW: Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient
Present on Admission, Inpatient Specialty Transfer Diagnosis. The presence of a least one ICD-10
diagnosis in one of those tables must have been present during admission for a patient to
receive a positive flag. See Appendix M for ICD-10 code list: Endocarditis; candida endocarditis;
osteomyelitis; bacteremia; discitis; septic arthritis; brain abscess; joint infection; necrotizing
fasciitis; empyema; and lung abscess.
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OUD-Related Diagnosis: During Admission
An OUD-related diagnosis during admission occurred in either the primary or secondary
diagnosis code location for the index hospitalization from the “Inpat.InpatientDiagnosis” table.
The ICD-10 codes were transformed using the ICD Rstudio package (Wasey, 2018).
•

All OUD Codes: Primary: A variable that indicates whether an F or T code for OUD was
in the primary diagnosis position. Included codes are listed in Appendix H.

•

All OUD Codes: Secondary: A variable that indicates whether an F or T code for OUD
was in the secondary. Included codes are listed in Appendix H.

•

Any OUD Code: A primary or secondary OUD code. Included codes are listed in
Appendix H.

Primary or Secondary Diagnosis Code: During Admission
The primary or secondary diagnosis code captured the primary or secondary diagnosis codes for
the index hospitalization from the “Inpat.InpatientDiagnosis” table. The ICD-10 codes were
transformed using the ICD RStudio package (Wasey, 2018).
Race
The race variable used in this study was the “Race 1” category. The original 8 categories were
collapsed to 6 categories: Unknown; Native American; Black; Asian; Native Islander; and White.
Admission Source
The admission source variable indicated the source for the admission. These entries come from
VISTA, and each local health care system devises their own coding scheme and abbreviations.
The original 18 categories were collapsed into 3 categories: outpatient treatment; other direct
admission; and other.
ICU Services Received
The ICU variable indicated whether there was an ICU bed stay (i.e., medical, surgical, cardiac,
neurosurgery) associated with the index hospitalization.
Surgical Services Received
The surgical services variable indicated whether there was a surgery bed stay (i.e., general
surgery, cardiac surgery, surgical step-down, thoracic surgery, oral surgery, plastic surgery)
associated with the index hospitalization.
Length of Stay
The length of stay variable was calculated based on the number of days of index hospitalization.
If admitted/discharged on the same day this was represented as 1 day. The values ranged from
1 to 1652, and 90% of values were between 1 and 15 days.
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Appendix L: Co-Occurring Mental Health and Substance Use Disorder
Diagnosis Codes Queried
ICD10
Code

ICD10 Long Description

F4321

Adjustment disorder with depressed mood

F4322

Adjustment disorder with anxiety

F4323

Adjustment disorder with mixed anxiety and depressed mood

F4324

Adjustment disorder with disturbance of conduct

F4325

Adjustment disorder with mixed disturbance of emotions and conduct

F4329

Adjustment disorder with other symptoms

F438

Other reactions to severe stress

F439

Reaction to severe stress, unspecified

F4320

Adjustment disorders, unspecified

F1010

Alcohol abuse, uncomplicated

F10120

Alcohol abuse with intoxication, uncomplicated

F10121

Alcohol abuse with intoxication delirium

F10129

Alcohol abuse with intoxication, unspecified

F1014

Alcohol abuse with alcohol-induced mood disorder

F10150

Alcohol abuse with alcohol-induced psychotic disorder with delusions

F10151

Alcohol abuse with alcohol-induced psychotic disorder with hallucinations

F10159

Alcohol abuse with alcohol-induced psychotic disorder, unspecified

F10180

Alcohol abuse with alcohol-induced anxiety disorder

F10181

Alcohol abuse with alcohol-induced sexual dysfunction

F10182

Alcohol abuse with alcohol-induced sleep disorder

F10188

Alcohol abuse with other alcohol-induced disorder

F1019

Alcohol abuse with unspecified alcohol-induced disorder

F1020

Alcohol dependence, uncomplicated

F1021

Alcohol dependence, in remission

F10220

Alcohol dependence with intoxication, uncomplicated

F10221

Alcohol dependence with intoxication delirium

F10229

Alcohol dependence with intoxication, unspecified

F10230

Alcohol dependence with withdrawal, uncomplicated

F10231

Alcohol dependence with withdrawal delirium

F10232

Alcohol dependence with withdrawal with perceptual disturbance

F10239

Alcohol dependence with withdrawal, unspecified

F1024

Alcohol dependence with alcohol-induced mood disorder

F10250

Alcohol dependence with alcohol-induced psychotic disorder with delusions

F10251

Alcohol dependence with alcohol-induced psychotic disorder with hallucinations
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F10259

Alcohol dependence with alcohol-induced psychotic disorder, unspecified

F1026

Alcohol dependence with alcohol-induced persisting amnestic disorder

F1027

Alcohol dependence with alcohol-induced persisting dementia

F10280

Alcohol dependence with alcohol-induced anxiety disorder

F10281

Alcohol dependence with alcohol-induced sexual dysfunction

F10282

Alcohol dependence with alcohol-induced sleep disorder

F10288

Alcohol dependence with other alcohol-induced disorder

F1029

Alcohol dependence with unspecified alcohol-induced disorder

F10920

Alcohol use, unspecified with intoxication, uncomplicated

F10921

Alcohol use, unspecified with intoxication delirium

F10929

Alcohol use, unspecified with intoxication, unspecified

F1094

Alcohol use, unspecified with alcohol-induced mood disorder

F10950

Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions

F10951

Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations

F10959

Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified

F1096

Alcohol use, unspecified with alcohol-induced persisting amnestic disorder

F1097

Alcohol use, unspecified with alcohol-induced persisting dementia

F10980

Alcohol use, unspecified with alcohol-induced anxiety disorder

F10981

Alcohol use, unspecified with alcohol-induced sexual dysfunction

F10982

Alcohol use, unspecified with alcohol-induced sleep disorder

F10988

Alcohol use, unspecified with other alcohol-induced disorder

F1099

Alcohol use, unspecified with unspecified alcohol-induced disorder

F4000

Agoraphobia, unspecified

F4001

Agoraphobia with panic disorder

F4002

Agoraphobia without panic disorder

F4010

Social phobia, unspecified

F4011

Social phobia, generalized

F40210

Arachnophobia

F40218

Other animal type phobia

F40220

Fear of thunderstorms

F40228

Other natural environment type phobia

F40230

Fear of blood

F40231

Fear of injections and transfusions

F40232

Fear of other medical care

F40233

Fear of injury

F40240

Claustrophobia

F40241

Acrophobia

F40242

Fear of bridges

F40243

Fear of flying
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F40248

Other situational type phobia

F40290

Androphobia

F40291

Gynephobia

F40298

Other specified phobia

F408

Other phobic anxiety disorders

F409

Phobic anxiety disorder, unspecified

F410

Panic disorder [episodic paroxysmal anxiety] without agoraphobia

F411

Generalized anxiety disorder

F413

Other mixed anxiety disorders

F418

Other specified anxiety disorders

F419

Anxiety disorder, unspecified

F42

Obsessive-compulsive disorder

F1210

Cannabis abuse, uncomplicated

F12120

Cannabis abuse with intoxication, uncomplicated

F12121

Cannabis abuse with intoxication delirium

F12122

Cannabis abuse with intoxication with perceptual disturbance

F12129

Cannabis abuse with intoxication, unspecified

F12150

Cannabis abuse with psychotic disorder with delusions

F12151

Cannabis abuse with psychotic disorder with hallucinations

F12159

Cannabis abuse with psychotic disorder, unspecified

F12180

Cannabis abuse with cannabis-induced anxiety disorder

F12188

Cannabis abuse with other cannabis-induced disorder

F1219

Cannabis abuse with unspecified cannabis-induced disorder

F1220

Cannabis dependence, uncomplicated

F1221

Cannabis dependence, in remission

F12220

Cannabis dependence with intoxication, uncomplicated

F12221

Cannabis dependence with intoxication delirium

F12222

Cannabis dependence with intoxication with perceptual disturbance

F12229

Cannabis dependence with intoxication, unspecified

F12250

Cannabis dependence with psychotic disorder with delusions

F12251

Cannabis dependence with psychotic disorder with hallucinations

F12259

Cannabis dependence with psychotic disorder, unspecified

F12280

Cannabis dependence with cannabis-induced anxiety disorder

F12288

Cannabis dependence with other cannabis-induced disorder

F1229

Cannabis dependence with unspecified cannabis-induced disorder

F1290

Cannabis use, unspecified, uncomplicated

F12920

Cannabis use, unspecified with intoxication, uncomplicated

F12921

Cannabis use, unspecified with intoxication delirium

F12922

Cannabis use, unspecified with intoxication with perceptual disturbance
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F12929

Cannabis use, unspecified with intoxication, unspecified

F12950

Cannabis use, unspecified with psychotic disorder with delusions

F12951

Cannabis use, unspecified with psychotic disorder with hallucinations

F12959

Cannabis use, unspecified with psychotic disorder, unspecified

F12980

Cannabis use, unspecified with anxiety disorder

F12988

Cannabis use, unspecified with other cannabis-induced disorder

F1299

Cannabis use, unspecified with unspecified cannabis-induced disorder

F14121

Cocaine abuse with intoxication with delirium

F14122

Cocaine abuse with intoxication with perceptual disturbance

F14129

Cocaine abuse with intoxication, unspecified

F1414

Cocaine abuse with cocaine-induced mood disorder

F14150

Cocaine abuse with cocaine-induced psychotic disorder with delusions

F14151

Cocaine abuse with cocaine-induced psychotic disorder with hallucinations

F14159

Cocaine abuse with cocaine-induced psychotic disorder, unspecified

F14180

Cocaine abuse with cocaine-induced anxiety disorder

F14181

Cocaine abuse with cocaine-induced sexual dysfunction

F14182

Cocaine abuse with cocaine-induced sleep disorder

F14188

Cocaine abuse with other cocaine-induced disorder

F1419

Cocaine abuse with unspecified cocaine-induced disorder

F14220

Cocaine dependence with intoxication, uncomplicated

F14221

Cocaine dependence with intoxication delirium

F14222

Cocaine dependence with intoxication with perceptual disturbance

F14229

Cocaine dependence with intoxication, unspecified

F1423

Cocaine dependence with withdrawal

F1424

Cocaine dependence with cocaine-induced mood disorder

F14250

Cocaine dependence with cocaine-induced psychotic disorder with delusions

F14251

Cocaine dependence with cocaine-induced psychotic disorder with hallucinations

F14259

Cocaine dependence with cocaine-induced psychotic disorder, unspecified

F14280

Cocaine dependence with cocaine-induced anxiety disorder

F14281

Cocaine dependence with cocaine-induced sexual dysfunction

F14282

Cocaine dependence with cocaine-induced sleep disorder

F14288

Cocaine dependence with other cocaine-induced disorder

F1429

Cocaine dependence with unspecified cocaine-induced disorder

F14920

Cocaine use, unspecified with intoxication, uncomplicated

F14921

Cocaine use, unspecified with intoxication delirium

F14922

Cocaine use, unspecified with intoxication with perceptual disturbance

F14929

Cocaine use, unspecified with intoxication, unspecified

F1494

Cocaine use, unspecified with cocaine-induced mood disorder

F14950

Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions
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F14951

Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations

F14959

Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified

F14980

Cocaine use, unspecified with cocaine-induced anxiety disorder

F14981

Cocaine use, unspecified with cocaine-induced sexual dysfunction

F14982

Cocaine use, unspecified with cocaine-induced sleep disorder

F14988

Cocaine use, unspecified with other cocaine-induced disorder

F1499

Cocaine use, unspecified with unspecified cocaine-induced disorder

F1610

Hallucinogen abuse, uncomplicated

F16120

Hallucinogen abuse with intoxication, uncomplicated

F16121

Hallucinogen abuse with intoxication with delirium

F16122

Hallucinogen abuse with intoxication with perceptual disturbance

F16129

Hallucinogen abuse with intoxication, unspecified

F1614

Hallucinogen abuse with hallucinogen-induced mood disorder

F16150

Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions

F16151

Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations

F16159

Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified

F16180

Hallucinogen abuse with hallucinogen-induced anxiety disorder

F16183

Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)

F16188

Hallucinogen abuse with other hallucinogen-induced disorder

F1619

Hallucinogen abuse with unspecified hallucinogen-induced disorder

F1620

Hallucinogen dependence, uncomplicated

F1621

Hallucinogen dependence, in remission

F16220

Hallucinogen dependence with intoxication, uncomplicated

F16221

Hallucinogen dependence with intoxication with delirium

F16229

Hallucinogen dependence with intoxication, unspecified

F1624

Hallucinogen dependence with hallucinogen-induced mood disorder

F16250

Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions

F16251

Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations

F16259

Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified

F16280

Hallucinogen dependence with hallucinogen-induced anxiety disorder

F16283

Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)

F16288

Hallucinogen dependence with other hallucinogen-induced disorder

F1629

Hallucinogen dependence with unspecified hallucinogen-induced disorder

F1690

Hallucinogen use, unspecified, uncomplicated

F16920

Hallucinogen use, unspecified with intoxication, uncomplicated

F16921

Hallucinogen use, unspecified with intoxication with delirium

F16929

Hallucinogen use, unspecified with intoxication, unspecified

F1694

Hallucinogen use, unspecified with hallucinogen-induced mood disorder

F16950

Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions
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F16951

Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with
hallucinations

F16959

Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified

F16980

Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder

F16983

Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)

F16988

Hallucinogen use, unspecified with other hallucinogen-induced disorder

F1699

Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder

F18121

Inhalant abuse with intoxication delirium

F18129

Inhalant abuse with intoxication, unspecified

F1814

Inhalant abuse with inhalant-induced mood disorder

F18150

Inhalant abuse with inhalant-induced psychotic disorder with delusions

F18151

Inhalant abuse with inhalant-induced psychotic disorder with hallucinations

F18159

Inhalant abuse with inhalant-induced psychotic disorder, unspecified

F1817

Inhalant abuse with inhalant-induced dementia

F18180

Inhalant abuse with inhalant-induced anxiety disorder

F18188

Inhalant abuse with other inhalant-induced disorder

F1819

Inhalant abuse with unspecified inhalant-induced disorder

F1824

Inhalant dependence with inhalant-induced mood disorder

F18250

Inhalant dependence with inhalant-induced psychotic disorder with delusions

F18251

Inhalant dependence with inhalant-induced psychotic disorder with hallucinations

F18259

Inhalant dependence with inhalant-induced psychotic disorder, unspecified

F1827

Inhalant dependence with inhalant-induced dementia

F18280

Inhalant dependence with inhalant-induced anxiety disorder

F18288

Inhalant dependence with other inhalant-induced disorder

F1829

Inhalant dependence with unspecified inhalant-induced disorder

F18920

Inhalant use, unspecified with intoxication, uncomplicated

F18921

Inhalant use, unspecified with intoxication with delirium

F18929

Inhalant use, unspecified with intoxication, unspecified

F1894

Inhalant use, unspecified with inhalant-induced mood disorder

F18950

Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions

F18951

Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations

F18959

Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified

F1897

Inhalant use, unspecified with inhalant-induced persisting dementia

F18980

Inhalant use, unspecified with inhalant-induced anxiety disorder

F18988

Inhalant use, unspecified with other inhalant-induced disorder

F1899

Inhalant use, unspecified with unspecified inhalant-induced disorder

F1810

Inhalant abuse, uncomplicated

F18120

Inhalant abuse with intoxication, uncomplicated

F1820

Inhalant dependence, uncomplicated

F1821

Inhalant dependence, in remission
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F18220

Inhalant dependence with intoxication, uncomplicated

F18221

Inhalant dependence with intoxication delirium

F18229

Inhalant dependence with intoxication, unspecified

F1890

Inhalant use, unspecified, uncomplicated

F3010

Manic episode without psychotic symptoms, unspecified

F3011

Manic episode without psychotic symptoms, mild

F3012

Manic episode without psychotic symptoms, moderate

F3013

Manic episode, severe, without psychotic symptoms

F302

Manic episode, severe with psychotic symptoms

F303

Manic episode in partial remission

F304

Manic episode in full remission

F308

Other manic episodes

F309

Manic episode, unspecified

F310

Bipolar disorder, current episode hypomanic

F3110

Bipolar disorder, current episode manic without psychotic features, unspecified

F3111

Bipolar disorder, current episode manic without psychotic features, mild

F3112

Bipolar disorder, current episode manic without psychotic features, moderate

F3113

Bipolar disorder, current episode manic without psychotic features, severe

F312

Bipolar disorder, current episode manic severe with psychotic features

F3130

Bipolar disorder, current episode depressed, mild or moderate severity, unspecified

F3131

Bipolar disorder, current episode depressed, mild

F3132

Bipolar disorder, current episode depressed, moderate

F314

Bipolar disorder, current episode depressed, severe, without psychotic features

F315

Bipolar disorder, current episode depressed, severe, with psychotic features

F3160

Bipolar disorder, current episode mixed, unspecified

F3161

Bipolar disorder, current episode mixed, mild

F3162

Bipolar disorder, current episode mixed, moderate

F3163

Bipolar disorder, current episode mixed, severe, without psychotic features

F3164

Bipolar disorder, current episode mixed, severe, with psychotic features

F3170

Bipolar disorder, currently in remission, most recent episode unspecified

F3171

Bipolar disorder, in partial remission, most recent episode hypomanic

F3172

Bipolar disorder, in full remission, most recent episode hypomanic

F3173

Bipolar disorder, in partial remission, most recent episode manic

F3174

Bipolar disorder, in full remission, most recent episode manic

F3175

Bipolar disorder, in partial remission, most recent episode depressed

F3176

Bipolar disorder, in full remission, most recent episode depressed

F3177

Bipolar disorder, in partial remission, most recent episode mixed

F3178

Bipolar disorder, in full remission, most recent episode mixed

F3181

Bipolar II disorder
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F3189

Other bipolar disorder

F319

Bipolar disorder, unspecified

F320

Major depressive disorder, single episode, mild

F321

Major depressive disorder, single episode, moderate

F322

Major depressive disorder, single episode, severe without psychotic features

F323

Major depressive disorder, single episode, severe with psychotic features

F324

Major depressive disorder, single episode, in partial remission

F325

Major depressive disorder, single episode, in full remission

F328

Other depressive episodes

F329

Major depressive disorder, single episode, unspecified

F330

Major depressive disorder, recurrent, mild

F331

Major depressive disorder, recurrent, moderate

F332

Major depressive disorder, recurrent severe without psychotic features

F333

Major depressive disorder, recurrent, severe with psychotic symptoms

F3340

Major depressive disorder, recurrent, in remission, unspecified

F3341

Major depressive disorder, recurrent, in partial remission

F3342

Major depressive disorder, recurrent, in full remission

F339

Major depressive disorder, recurrent, unspecified

F341

Dysthymic disorder

F390

Unspecified mood [affective] disorder

F17203

Nicotine dependence unspecified, with withdrawal

F17208

Nicotine dependence, unspecified, with other nicotine-induced disorders

F17209

Nicotine dependence, unspecified, with unspecified nicotine-induced disorders

F17213

Nicotine dependence, cigarettes, with withdrawal

F17218

Nicotine dependence, cigarettes, with other nicotine-induced disorders

F17219

Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders

F17223

Nicotine dependence, chewing tobacco, with withdrawal

F17228

Nicotine dependence, chewing tobacco, with other nicotine-induced disorders

F17229

Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders

F17293

Nicotine dependence, other tobacco product, with withdrawal

F17298

Nicotine dependence, other tobacco product, with other nicotine-induced disorders

F17299

Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders

F200

Paranoid schizophrenia

F201

Disorganized schizophrenia

F202

Catatonic schizophrenia

F203

Undifferentiated schizophrenia

F205

Residual schizophrenia

F2081

Schizophreniform disorder

F2089

Other schizophrenia
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F209

Schizophrenia, unspecified

F22

Delusional disorders

F23

Brief psychotic disorder

F24

Shared psychotic disorder

F250

Schizoaffective disorder, bipolar type

F251

Schizoaffective disorder, depressive type

F258

Other schizoaffective disorders

F259

Schizoaffective disorder, unspecified

F28

Other psychotic disorder not due to a substance or known physiological condition

F29

Unspecified psychosis not due to a substance or known physiological condition

F4489

Other dissociative and conversion disorders

F1910

Other psychoactive substance abuse, uncomplicated

F19120

Other psychoactive substance abuse with intoxication, uncomplicated

F19121

Other psychoactive substance abuse with intoxication delirium

F19122

Other psychoactive substance abuse with intoxication with perceptual disturbances

F19129

Other psychoactive substance abuse with intoxication, unspecified

F1914

Other psychoactive substance abuse with psychoactive substance-induced mood disorder
Other psychoactive substance abuse with psychoactive substance-induced psychotic
disorder with delusions
Other psychoactive substance abuse with psychoactive substance-induced psychotic
disorder with hallucinations
Other psychoactive substance abuse with psychoactive substance-induced psychotic
disorder, unspecified
Other psychoactive substance abuse with psychoactive substance-induced persisting
amnestic disorder
Other psychoactive substance abuse with psychoactive substance-induced persisting
dementia

F19150
F19151
F19159
F1916
F1917
F19180
F19181

Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder
Other psychoactive substance abuse with psychoactive substance-induced sexual
dysfunction

F19182

Other psychoactive substance abuse with psychoactive substance-induced sleep disorder

F19188
F1919

Other psychoactive substance abuse with other psychoactive substance-induced disorder
Other psychoactive substance abuse with unspecified psychoactive substance-induced
disorder

F1920

Other psychoactive substance dependence, uncomplicated

F1921

Other psychoactive substance dependence, in remission

F19220

Other psychoactive substance dependence with intoxication, uncomplicated

F19221

Other psychoactive substance dependence with intoxication delirium

F19222

Other psychoactive substance dependence with intoxication with perceptual disturbance

F19229

Other psychoactive substance dependence with intoxication, unspecified

F19230

Other psychoactive substance dependence with withdrawal, uncomplicated

F19231

Other psychoactive substance dependence with withdrawal delirium

F19232

Other psychoactive substance dependence with withdrawal with perceptual disturbance
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F19239

F1929

Other psychoactive substance dependence with withdrawal, unspecified
Other psychoactive substance dependence with psychoactive substance-induced mood
disorder
Other psychoactive substance dependence with psychoactive substance-induced psychotic
disorder with delusions
Other psychoactive substance dependence with psychoactive substance-induced psychotic
disorder with hallucinations
Other psychoactive substance dependence with psychoactive substance-induced psychotic
disorder, unspecified
Other psychoactive substance dependence with psychoactive substance-induced persisting
amnestic disorder
Other psychoactive substance dependence with psychoactive substance-induced persisting
dementia
Other psychoactive substance dependence with psychoactive substance-induced anxiety
disorder
Other psychoactive substance dependence with psychoactive substance-induced sexual
dysfunction
Other psychoactive substance dependence with psychoactive substance-induced sleep
disorder
Other psychoactive substance dependence with other psychoactive substance-induced
disorder
Other psychoactive substance dependence with unspecified psychoactive substanceinduced disorder

F1990

Other psychoactive substance use, unspecified, uncomplicated

F19920

Other psychoactive substance use, unspecified with intoxication, uncomplicated

F19921
F19922

Other psychoactive substance use, unspecified with intoxication with delirium
Other psychoactive substance use, unspecified with intoxication with perceptual
disturbance

F19929

Other psychoactive substance use, unspecified with intoxication, unspecified

F19930

Other psychoactive substance use, unspecified with withdrawal, uncomplicated

F19931

Other psychoactive substance use, unspecified with withdrawal delirium

F19932

Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance

F19939

Other psychoactive substance use, unspecified with withdrawal, unspecified
Other psychoactive substance use, unspecified with psychoactive substance-induced mood
disorder
Other psychoactive substance use, unspecified with psychoactive substance-induced
psychotic disorder with delusions
Other psychoactive substance use, unspecified with psychoactive substance-induced
psychotic disorder with hallucinations
Other psychoactive substance use, unspecified with psychoactive substance-induced
psychotic disorder, unspecified
Other psychoactive substance use, unspecified with psychoactive substance-induced
persisting amnestic disorder
Other psychoactive substance use, unspecified with psychoactive substance-induced
persisting dementia
Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety
disorder
Other psychoactive substance use, unspecified with psychoactive substance-induced sexual
dysfunction

F1924
F19250
F19251
F19259
F1926
F1927
F19280
F19281
F19282
F19288

F1994
F19950
F19951
F19959
F1996
F1997
F19980
F19981
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F1999

Other psychoactive substance use, unspecified with psychoactive substance-induced sleep
disorder
Other psychoactive substance use, unspecified with other psychoactive substance-induced
disorder
Other psychoactive substance use, unspecified with unspecified psychoactive substanceinduced disorder

F1510

Other stimulant abuse, uncomplicated

F15120

Other stimulant abuse with intoxication, uncomplicated

F15121

Other stimulant abuse with intoxication delirium

F15122

Other stimulant abuse with intoxication with perceptual disturbance

F15129

Other stimulant abuse with intoxication, unspecified

F1514

Other stimulant abuse with stimulant-induced mood disorder

F15150

Other stimulant abuse with stimulant-induced psychotic disorder with delusions

F15151

Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations

F15159

Other stimulant abuse with stimulant-induced psychotic disorder, unspecified

F15180

Other stimulant abuse with stimulant-induced anxiety disorder

F15181

Other stimulant abuse with stimulant-induced sexual dysfunction

F15182

Other stimulant abuse with stimulant-induced sleep disorder

F15188

Other stimulant abuse with other stimulant-induced disorder

F1519

Other stimulant abuse with unspecified stimulant-induced disorder

F1520

Other stimulant dependence, uncomplicated

F1521

Other stimulant dependence, in remission

F15220

Other stimulant dependence with intoxication, uncomplicated

F15221

Other stimulant dependence with intoxication delirium

F15222

Other stimulant dependence with intoxication with perceptual disturbance

F15229

Other stimulant dependence with intoxication, unspecified

F1523

Other stimulant dependence with withdrawal

F1524

Other stimulant dependence with stimulant-induced mood disorder

F15250

Other stimulant dependence with stimulant-induced psychotic disorder with delusions

F15251

Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations

F15259

Other stimulant dependence with stimulant-induced psychotic disorder, unspecified

F15280

Other stimulant dependence with stimulant-induced anxiety disorder

F15281

Other stimulant dependence with stimulant-induced sexual dysfunction

F15282

Other stimulant dependence with stimulant-induced sleep disorder

F15288

Other stimulant dependence with other stimulant-induced disorder

F1529

Other stimulant dependence with unspecified stimulant-induced disorder

F1590

Other stimulant use, unspecified, uncomplicated

F15920

Other stimulant use, unspecified with intoxication, uncomplicated

F15921

Other stimulant use, unspecified with intoxication delirium

F15922

Other stimulant use, unspecified with intoxication with perceptual disturbance

F15929

Other stimulant use, unspecified with intoxication, unspecified

F19982
F19988
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F1593

Other stimulant use, unspecified with withdrawal

F1594

Other stimulant use, unspecified with stimulant-induced mood disorder

F15950
F15951

Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions
Other stimulant use, unspecified with stimulant-induced psychotic disorder with
hallucinations

F15959

Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified

F15980

Other stimulant use, unspecified with stimulant-induced anxiety disorder

F15981

Other stimulant use, unspecified with stimulant-induced sexual dysfunction

F15982

Other stimulant use, unspecified with stimulant-induced sleep disorder

F15988

Other stimulant use, unspecified with other stimulant-induced disorder

F1599

Other stimulant use, unspecified with unspecified stimulant-induced disorder

F550

Abuse of antacids

F551

Abuse of herbal or folk remedies

F552

Abuse of laxatives

F553
F554

Abuse of steroids or hormones
Abuse of vitamins

F558

Abuse of other non-psychoactive substances

O99320

Drug use complicating pregnancy, unspecified trimester

O99321

Drug use complicating pregnancy, first trimester

O99322

Drug use complicating pregnancy, second trimester

O99323

Drug use complicating pregnancy, third trimester

O99324

Drug use complicating childbirth

O99325

Drug use complicating the puerperium

F4310

Post-traumatic stress disorder, unspecified

F4311

Post-traumatic stress disorder, acute

F4312

Post-traumatic stress disorder, chronic

F13121

Sedative, hypnotic or anxiolytic abuse with intoxication delirium

F13129

Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood
disorder
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced
psychotic disorder with delusions
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced
psychotic disorder with hallucinations
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced
psychotic disorder, unspecified
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety
disorder
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual
dysfunction
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep
disorder
Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced
disorder

F1314
F13150
F13151
F13159
F13180
F13181
F13182
F13188
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F1319

Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolyticinduced disorder

F13220

Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated

F13221

Sedative, hypnotic or anxiolytic dependence with intoxication delirium

F13229

Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified

F13230

Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated

F13231

Sedative, hypnotic or anxiolytic dependence with withdrawal delirium

F13232

Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance

F13239

F1329

Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
mood disorder
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
psychotic disorder with delusions
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
psychotic disorder with hallucinations
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
psychotic disorder, unspecified
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
persisting amnestic disorder
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
persisting dementia
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
anxiety disorder
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
sexual dysfunction
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced
sleep disorder
Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolyticinduced disorder
Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or
anxiolytic-induced disorder

F13920

Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated

F13921

Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium

F13929

Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified

F13930

Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated

F13931

Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual
disturbances

F1324
F13250
F13251
F13259
F1326
F1327
F13280
F13281
F13282
F13288

F13932
F13939
F1394
F13950
F13951
F13959

Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced mood disorder
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced psychotic disorder with delusions
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced psychotic disorder with hallucinations
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced psychotic disorder, unspecified
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F1399

Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced persisting amnestic disorder
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced persisting dementia
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced anxiety disorder
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced sexual dysfunction
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolyticinduced sleep disorder
Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolyticinduced disorder
Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or
anxiolytic-induced disorder

T1491

Suicide attempt

T1491XA

Suicide attempt, initial encounter

T1491XD

Suicide attempt, subsequent encounter

T1491XS

Suicide attempt, sequelae

T39012A

Poisoning by aspirin, intentional self-harm, initial encounter

T39012D

Poisoning by aspirin, intentional self-harm, subsequent encounter

T39012S

Poisoning by aspirin, intentional self-harm, sequelae

T39092A

Poisoning by salicylates, intentional self-harm, initial encounter

T39092D

Poisoning by salicylates, intentional self-harm, subsequent encounter

T39092S

Poisoning by salicylates, intentional self-harm, sequelae

T391X2A

Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter

T391X2D

Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter

T391X2S

Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequelae

T392X2A

Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter

T392X2D

Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter

T392X2S

Poisoning by pyrazolone derivatives, intentional self-harm, sequelae

T39312A

Poisoning by propionic acid derivatives, intentional self-harm, initial encounter

T39312D

Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter

T39312S

T394X2D

Poisoning by propionic acid derivatives, intentional self-harm, sequelae
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm,
initial encounter
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm,
subsequent encounter
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm,
sequelae
Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial
encounter
Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent
encounter

T394X2S

Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequelae

F1396
F1397
F13980
F13981
F13982
F13988

T39392A
T39392D
T39392S
T394X2A
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T3992XS

Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified,
intentional self-harm, initial encounter
Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified,
intentional self-harm, subsequent encounter
Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified,
intentional self-harm, sequelae
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional
self-harm, initial encounter
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional
self-harm, subsequent encounter
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional
self-harm, sequelae

T400X2A

Poisoning by opium, intentional self-harm, initial encounter

T400X2D

Poisoning by opium, intentional self-harm, subsequent encounter

T400X2S

Poisoning by opium, intentional self-harm, sequelae

T401X2A

Poisoning by heroin, intentional self-harm, initial encounter

T401X2D

Poisoning by heroin, intentional self-harm, subsequent encounter

T401X2S

Poisoning by heroin, intentional self-harm, sequelae

T402X2A

Poisoning by other opioids, intentional self-harm, initial encounter

T402X2D

Poisoning by other opioids, intentional self-harm, subsequent encounter

T402X2S

Poisoning by other opioids, intentional self-harm, sequelae

T403X2A

Poisoning by methadone, intentional self-harm, initial encounter

T403X2D

Poisoning by methadone, intentional self-harm, subsequent encounter

T403X2S

Poisoning by methadone, intentional self-harm, sequelae

T404X2A

Poisoning by other synthetic narcotics, intentional self-harm, initial encounter

T404X2D

Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter

T404X2S

Poisoning by other synthetic narcotics, intentional self-harm, sequelae

T405X2A

Poisoning by cocaine, intentional self-harm, initial encounter

T405X2D

Poisoning by cocaine, intentional self-harm, subsequent encounter

T405X2S

Poisoning by cocaine, intentional self-harm, sequelae

T40602A

Poisoning by unspecified narcotics, intentional self-harm, initial encounter

T40602D

Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter

T40602S

Poisoning by unspecified narcotics, intentional self-harm, sequelae

T40692A

Poisoning by other narcotics, intentional self-harm, initial encounter

T40692D

Poisoning by other narcotics, intentional self-harm, subsequent encounter

T40692S

Poisoning by other narcotics, intentional self-harm, sequelae

T407X2A

Poisoning by cannabis (derivatives), intentional self-harm, initial encounter

T407X2D

Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter

T407X2S

Poisoning by cannabis (derivatives), intentional self-harm, sequelae

T408X2A

Poisoning by lysergide [LSD], intentional self-harm, initial encounter

T408X2D

Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter

T408X2S

Poisoning by lysergide [LSD], intentional self-harm, sequelae

T398X2A
T398X2D
T398X2S
T3992XA
T3992XD
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T40902D

Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial
encounter
Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm,
subsequent encounter

T40902S

Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequelae

T40992A
T40992D

Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter
Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent
encounter

T40992S

Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequelae

T423X2A

Poisoning by barbiturates, intentional self-harm, initial encounter

T423X2D

Poisoning by barbiturates, intentional self-harm, subsequent encounter

T423X2S

Poisoning by barbiturates, intentional self-harm, sequelae

T424X2A

Poisoning by benzodiazepines, intentional self-harm, initial encounter

T424X2D

Poisoning by benzodiazepines, intentional self-harm, subsequent encounter

T424X2S

T4272XS

Poisoning by benzodiazepines, intentional self-harm, sequelae
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm,
initial encounter
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm,
subsequent encounter
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm,
sequela

T43012A

Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter

T43012D

Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter

T43012S

Poisoning by tricyclic antidepressants, intentional self-harm, sequelae

T43022A

Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter

T43022D

Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter

T43022S

T431X2D

Poisoning by tetracyclic antidepressants, intentional self-harm, sequelae
Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial
encounter
Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm,
subsequent encounter

T431X2S

Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela

T43202A

Poisoning by unspecified antidepressants, intentional self-harm, initial encounter

T43202D

Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter

T43202S

Poisoning by unspecified antidepressants, intentional self-harm, sequelae
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional selfharm, initial encounter
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional selfharm, subsequent encounter
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional selfharm, sequela

T40902A

T4272XA
T4272XD

T431X2A

T43212A
T43212D
T43212S
T43222A
T43222D

Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter
Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent
encounter

T43222S

Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequelae
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T43292A

Poisoning by other antidepressants, intentional self-harm, initial encounter

T43292D

Poisoning by other antidepressants, intentional self-harm, subsequent encounter

T43292S

Poisoning by other antidepressants, intentional self-harm, sequelae
Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial
encounter
Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm,
subsequent encounter

T433X2A
T433X2D
T433X2S
T434X2A
T434X2D
T434X2S

Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequelae
Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial
encounter
Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm,
subsequent encounter

T43502D

Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequelae
Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial
encounter
Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent
encounter

T43502S

Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequelae

T43592A
T43592D

Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter
Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent
encounter

T43592S

Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequelae

T43602A

Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter

T43602D

Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter

T43602S

Poisoning by unspecified psychostimulants, intentional self-harm, sequelae

T43612A

Poisoning by caffeine, intentional self-harm, initial encounter

T43612D

Poisoning by caffeine, intentional self-harm, subsequent encounter

T43612S

Poisoning by caffeine, intentional self-harm, sequelae

T43622A

Poisoning by amphetamines, intentional self-harm, initial encounter

T43622D

Poisoning by amphetamines, intentional self-harm, subsequent encounter

T43622S

Poisoning by amphetamines, intentional self-harm, sequelae

T43632A

Poisoning by methylphenidate, intentional self-harm, initial encounter

T43632D

Poisoning by methylphenidate, intentional self-harm, subsequent encounter

T43632S

Poisoning by methylphenidate, intentional self-harm, sequelae

T43692A

Poisoning by other psychostimulants, intentional self-harm, initial encounter

T43692D

Poisoning by other psychostimulants, intentional self-harm, subsequent encounter

T43692S

Poisoning by other psychostimulants, intentional self-harm, sequelae

T438X2A

Poisoning by other psychotropic drugs, intentional self-harm, initial encounter

T438X2D

Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter

T438X2S

Poisoning by other psychotropic drugs, intentional self-harm, sequelae

T4392XA

Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter

T4392XD

Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter

T4392XS

Poisoning by unspecified psychotropic drug, intentional self-harm, sequelae

T43502A
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T50902A
T50902D
T50902S
T50992A
T50992D
T50992S
T5802XA
T5802XD
T5802XS
T5812XA
T5812XD
T5812XS
T582X2A
T582X2D
T582X2S
T588X2A
T588X2D
T588X2S

Poisoning by unspecified drugs, medicaments and biological substances, intentional selfharm, initial encounter
Poisoning by unspecified drugs, medicaments and biological substances, intentional selfharm, subsequent encounter
Poisoning by unspecified drugs, medicaments and biological substances, intentional selfharm, sequelae
Poisoning by other drugs, medicaments and biological substances, intentional self-harm,
initial encounter
Poisoning by other drugs, medicaments and biological substances, intentional self-harm,
subsequent encounter
Poisoning by other drugs, medicaments and biological substances, intentional self-harm,
sequelae
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial
encounter
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm,
subsequent encounter
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm,
sequelae
Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter
Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent
encounter
Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequelae
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels,
intentional self-harm, initial encounter
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels,
intentional self-harm, subsequent encounter
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels,
intentional self-harm, sequelae
Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter
Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent
encounter

T5892XD

Toxic effect of carbon monoxide from other source, intentional self-harm, sequelae
Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial
encounter
Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent
encounter

T5892XS

Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequelae

X710XXA

Intentional self-harm by drowning and submersion while in bathtub, initial encounter

X710XXD

Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter

X710XXS

Intentional self-harm by drowning and submersion while in bathtub, sequelae

X711XXA

Intentional self-harm by drowning and submersion while in swimming pool, initial encounter
Intentional self-harm by drowning and submersion while in swimming pool, subsequent
encounter

T5892XA

X711XXD
X711XXS
X712XXA
X712XXD

Intentional self-harm by drowning and submersion while in swimming pool, sequelae
Intentional self-harm by drowning and submersion after jump into swimming pool, initial
encounter
Intentional self-harm by drowning and submersion after jump into swimming pool,
subsequent encounter
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X712XXS

Intentional self-harm by drowning and submersion after jump into swimming pool, sequela

X713XXA

Intentional self-harm by drowning and submersion in natural water, initial encounter

X713XXD

Intentional self-harm by drowning and submersion in natural water, subsequent encounter

X713XXS

Intentional self-harm by drowning and submersion in natural water, sequelae

X718XXA

Other intentional self-harm by drowning and submersion, initial encounter

X718XXD

Other intentional self-harm by drowning and submersion, subsequent encounter

X718XXS

Other intentional self-harm by drowning and submersion, sequelae

X719XXA

Intentional self-harm by drowning and submersion, unspecified, initial encounter

X719XXD

Intentional self-harm by drowning and submersion, unspecified, subsequent encounter

X719XXS

Intentional self-harm by drowning and submersion, unspecified, sequelae

X72XXXA

Intentional self-harm by handgun discharge, initial encounter

X72XXXD

Intentional self-harm by handgun discharge, subsequent encounter

X72XXXS

Intentional self-harm by handgun discharge, sequelae

X730XXA

Intentional self-harm by shotgun discharge, initial encounter

X730XXD

Intentional self-harm by shotgun discharge, subsequent encounter

X730XXS

Intentional self-harm by shotgun discharge, sequelae

X731XXA

Intentional self-harm by hunting rifle discharge, initial encounter

X731XXD

Intentional self-harm by hunting rifle discharge, subsequent encounter

X731XXS

Intentional self-harm by hunting rifle discharge, sequelae

X732XXA

Intentional self-harm by machine gun discharge, initial encounter

X732XXD

Intentional self-harm by machine gun discharge, subsequent encounter

X732XXS

Intentional self-harm by machine gun discharge, sequelae

X738XXA
X738XXD

Intentional self-harm by other larger firearm discharge, initial encounter
Intentional self-harm by other larger firearm discharge, subsequent encounter

X738XXS

Intentional self-harm by other larger firearm discharge, sequelae

X739XXA

Intentional self-harm by unspecified larger firearm discharge, initial encounter

X739XXD

Intentional self-harm by unspecified larger firearm discharge, subsequent encounter

X739XXS

Intentional self-harm by unspecified larger firearm discharge, sequelae

X7401XA

Intentional self-harm by airgun, initial encounter

X7401XD

Intentional self-harm by airgun, subsequent encounter

X7401XS

Intentional self-harm by airgun, sequelae

X7402XA

Intentional self-harm by paintball gun, initial encounter

X7402XD

Intentional self-harm by paintball gun, subsequent encounter

X7402XS

Intentional self-harm by paintball gun, sequelae

X7409XA

Intentional self-harm by other gas, air or spring-operated gun, initial encounter

X7409XD

Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter

X7409XS

Intentional self-harm by other gas, air or spring-operated gun, sequelae

X748XXA

Intentional self-harm by other firearm discharge, initial encounter

X748XXD

Intentional self-harm by other firearm discharge, subsequent encounter

X748XXS

Intentional self-harm by other firearm discharge, sequelae
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X749XXA

Intentional self-harm by unspecified firearm discharge, initial encounter

X749XXD

Intentional self-harm by unspecified firearm discharge, subsequent encounter

X749XXS

Intentional self-harm by unspecified firearm discharge, sequelae

X75XXXA

Intentional self-harm by explosive material, initial encounter

X75XXXD

Intentional self-harm by explosive material, subsequent encounter

X75XXXS

Intentional self-harm by explosive material, sequelae

X76XXXA

Intentional self-harm by smoke, fire and flames, initial encounter

X76XXXD

Intentional self-harm by smoke, fire and flames, subsequent encounter

X76XXXS

Intentional self-harm by smoke, fire and flames, sequelae

X770XXA

Intentional self-harm by steam or hot vapors, initial encounter

X770XXD

Intentional self-harm by steam or hot vapors, subsequent encounter

X770XXS

Intentional self-harm by steam or hot vapors, sequelae

X771XXA

Intentional self-harm by hot tap water, initial encounter

X771XXD

Intentional self-harm by hot tap water, subsequent encounter

X771XXS

Intentional self-harm by hot tap water, sequelae

X772XXA

Intentional self-harm by other hot fluids, initial encounter

X772XXD

Intentional self-harm by other hot fluids, subsequent encounter

X772XXS

Intentional self-harm by other hot fluids, sequelae

X773XXA

Intentional self-harm by hot household appliances, initial encounter

X773XXD

Intentional self-harm by hot household appliances, subsequent encounter

X773XXS

Intentional self-harm by hot household appliances, sequelae

X778XXA

Intentional self-harm by other hot objects, initial encounter

X778XXD

Intentional self-harm by other hot objects, subsequent encounter

X778XXS

Intentional self-harm by other hot objects, sequelae

X779XXA

Intentional self-harm by unspecified hot objects, initial encounter

X779XXD

Intentional self-harm by unspecified hot objects, subsequent encounter

X779XXS

Intentional self-harm by unspecified hot objects, sequelae

X780XXA

Intentional self-harm by sharp glass, initial encounter

X780XXD

Intentional self-harm by sharp glass, subsequent encounter

X780XXS

Intentional self-harm by sharp glass, sequelae

X781XXA

Intentional self-harm by knife, initial encounter

X781XXD

Intentional self-harm by knife, subsequent encounter

X781XXS

Intentional self-harm by knife, sequelae

X782XXA

Intentional self-harm by sword or dagger, initial encounter

X782XXD

Intentional self-harm by sword or dagger, subsequent encounter

X782XXS

Intentional self-harm by sword or dagger, sequelae

X788XXA

Intentional self-harm by other sharp object, initial encounter

X788XXD

Intentional self-harm by other sharp object, subsequent encounter

X788XXS

Intentional self-harm by other sharp object, sequelae
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X789XXA

Intentional self-harm by unspecified sharp object, initial encounter

X789XXD

Intentional self-harm by unspecified sharp object, subsequent encounter

X789XXS

Intentional self-harm by unspecified sharp object, sequelae

X79XXXA

Intentional self-harm by blunt object, initial encounter

X79XXXD

Intentional self-harm by blunt object, subsequent encounter

X79XXXS

Intentional self-harm by blunt object, sequelae

X80XXXA
X80XXXD
X80XXXS
X810XXA

Intentional self-harm by jumping from a high place, initial encounter
Intentional self-harm by jumping from a high place, subsequent encounter
Intentional self-harm by jumping from a high place, sequelae
Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter

X810XXD
X810XXS

Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter
Intentional self-harm by jumping or lying in front of motor vehicle, sequelae

X811XXA
X811XXD

Intentional self-harm by jumping or lying in front of (subway) train, initial encounter
Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter

X811XXS

Intentional self-harm by jumping or lying in front of (subway) train, sequelae

X818XXA
X818XXD
X818XXS

Intentional self-harm by jumping or lying in front of other moving object, initial encounter
Intentional self-harm by jumping or lying in front of other moving object, subsequent
encounter
Intentional self-harm by jumping or lying in front of other moving object, sequelae

X820XXA
X820XXD

Intentional collision of motor vehicle with other motor vehicle, initial encounter
Intentional collision of motor vehicle with other motor vehicle, subsequent encounter

X820XXS

Intentional collision of motor vehicle with other motor vehicle, sequelae

X821XXA

Intentional collision of motor vehicle with train, initial encounter

X821XXD

Intentional collision of motor vehicle with train, subsequent encounter

X821XXS

Intentional collision of motor vehicle with train, sequelae

X822XXA
X822XXD
X822XXS

Intentional collision of motor vehicle with tree, initial encounter
Intentional collision of motor vehicle with tree, subsequent encounter
Intentional collision of motor vehicle with tree, sequelae

X828XXA

Other intentional self-harm by crashing of motor vehicle, initial encounter

X828XXD

Other intentional self-harm by crashing of motor vehicle, subsequent encounter

X828XXS
X830XXA
X830XXD
X830XXS
X831XXA
X831XXD
X831XXS
X832XXA
X832XXD
X832XXS
X838XXA

Other intentional self-harm by crashing of motor vehicle, sequelae
Intentional self-harm by crashing of aircraft, initial encounter
Intentional self-harm by crashing of aircraft, subsequent encounter
Intentional self-harm by crashing of aircraft, sequelae
Intentional self-harm by electrocution, initial encounter
Intentional self-harm by electrocution, subsequent encounter
Intentional self-harm by electrocution, sequelae
Intentional self-harm by exposure to extremes of cold, initial encounter
Intentional self-harm by exposure to extremes of cold, subsequent encounter
Intentional self-harm by exposure to extremes of cold, sequelae
Intentional self-harm by other specified means, initial encounter

X838XXD
X838XXS

Intentional self-harm by other specified means, subsequent encounter
Intentional self-harm by other specified means, sequelae
(ICD10Data.com, 2018)

372

Appendix M: OUD-Related Infection Codes Queried
Infection Related to
Intravenous Drug Use
Endocarditis
Candida endocarditis
Osteomyelitis
Bacteremia
Epidural Abscess/ Discitis
Septic Arthritis
Brain Abscess
Prosthetic Joint Infection
Necrotizing fasciitis
Empyema
Lung Abscess

ICD-10
I33.x
b37.6
m86.x
R78.81
m46.4; m51.9; m50.x; m51.8
m00.
g06.x
t84.5x
m72.6
j86
j85

Retrieved from: H. Englander, personal communication, January 25, 2018
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Appendix N: Non-OAT Pharmacotherapy Definitions
Acronyms
OAT = opioid agonist therapy; HCPCS = Healthcare Common Procedure Coding System.
Pre-Admission
Pre-Opioid
All formularies and routes of administration were included as present in the dataset. The preopioid variable included the presence of one of these medications: acetaminophen/codeine,
acetaminophen/hydrocodone, acetaminophen/oxycodone, belladonna/opium,
chlorpheniramine/hydrocodone, codeine, fentanyl, hydromorphone, meperidine, morphine,
oxycodone, oxymorphone, tapentadol, and tramadol.
Pre-Benzodiazepine
All formularies and routes of administration were included as present in the dataset. The prebenzodiazepine variable included the presence of one of these medications: alprazolam,
clonazepam, diazepam, temazepam, and lorazepam.
Pre-Gabapentin/Pregabalin
All formularies and routes of administration were included as present in the dataset. The
variable included the presence of one of these medications: gabapentin or pregabalin.
Pre-Naltrexone
All formularies and routes of administration were included as present in the dataset. The
variable included the presence of the tablet or injectable or HCPCS code J2315.
Pre-Concurrent Opioid and Benzodiazepine
Cases with both an opioid and benzodiazepine fill in the time period.
Pre-Naloxone
All formularies and routes of administration were included as present in the dataset (i.e.,
injection solution, kit, solution nasal spray).
Admission
Admission Pharmacotherapy
The majority of inpatient medications reported in this study came from the “Bar Code
Medication Administration” table. Outpatient appointments are possible during admission; thus,
resulting in an outpatient pharmacy prescription. In this cohort less than 1% (5,861 of 715,277)
of medications received during hospitalization were recorded as outpatient prescriptions rather
than medication administered.
Admission-Opioid
All formularies and routes of administration were included as present in the dataset (e.g., tablet,
oral solution, injection, suppository, nasal spray). The admission opioid variable included the
presence of one of these medications: acetaminophen/codeine, acetaminophen/hydrocodone,
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acetaminophen/oxycodone, belladonna/opium, butorphanol, bupivacaine/fentanyl, codeine,
fentanyl, hydromorphone, meperidine, morphine, oxycodone, oxymorphone, tapentadol, and
tramadol.
Any Adjuvant Therapy
The presence of a first line withdrawal management adjuvant or a second-line adjuvant as
defined below.
First-Line Adjuvant: Clonidine
The first-line variable included the presence of clonidine. Patch or tablet formularies were
included in the query for the dataset.
Second-Line Adjuvant
The second-line adjuvant was defined using the VHA recommendations for withdrawal
management for OUD (U.S. Department of Veterans Affairs, 2016b). All formularies and routes
of administration were included as present in the dataset. The variable included the presence of
one of these medications: baclofen, gabapentin, pregabalin, and tizanidine.
Admission-Gabapentin/Pregabalin
All formularies and routes of administration were included as present in the dataset. The
variable included the presence of one of these medications: gabapentin or pregabalin.
Admission-Benzodiazepine
All formularies and routes of administration were included as present in the dataset. The
admission-benzodiazepine variable included the presence of one of these medications:
alprazolam, clonazepam, diazepam, midazolam, temazepam, and lorazepam.
Admission-Naltrexone
All formularies and routes of administration (tablet and injectable) were included as present in
the dataset. HCPCS code J2315 was queried but not present in dataset.
Admission-No Opioid and No OAT
Cases without an opioid present or OAT present during admission.
Post-Admission
Post-Opioids
All formularies and routes of administration (e.g., suppository vs. oral) were included as present
in the dataset. The post-opioid variable included the presence of one of these medications:
belladonna/opium, chlorpheniramine/hydrocodone, codeine, fentanyl, hydromorphone,
meperidine, morphine, oxycodone, oxymorphone, tapentadol, and tramadol.
Post-Gabapentin/Pregabalin
All formularies and routes of administration were included as present in the dataset. The
variable included the presence of one of these medications: gabapentin or pregabalin.
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Post-Benzodiazepine
All formularies and routes of administration were included as present in the dataset. The postbenzodiazepine variable included the presence of one of these medications: alprazolam,
clonazepam, diazepam, midazolam, temazepam, and lorazepam.
Post-Naltrexone
All formularies and routes of administration were included as present in the dataset. The
variable included the presence of the tablet or injectable or HCPCS code J2315.
Post-Naloxone
All formularies and routes of administration were included as present in the dataset (i.e.,
injection solution, kit, solution nasal spray).
Post-Concurrent Opioid and Benzodiazepine
Cases with both an opioid AND benzodiazepine fill in the time period.
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Appendix O: OAT Pharmacotherapy Definitions
Pre-Admission OAT
Pre-admission OAT included a visit to an VHA OTP (counted by VHA stop code) or Healthcare
Common Procedure Coding System (HCPCS) codes (H0033: non-specific oral medication direct
observation; J0574: buprenorphine/naloxone 6.1-10 mg; J0575: buprenorphine/naloxone >
10mg; J0571: oral buprenorphine 1 mg; S0109: methadone oral 5 mg) or outpatient
buprenorphine filled prescriptions (only FDA-approved OAT formularies and routes of
administration were included: buprenorphine film buccal; buprenorphine sublingual tablet;
buprenorphine/naloxone film sublingual; buprenorphine/naloxone sublingual tablet).
Admission OAT
Admission OAT was defined as a visit to an VHA OTP (counted by VHA stop code) or HCPCS
codes (H0033: non-specific oral medication direct observation; J0571: oral buprenorphine 1 mg ;
S0109: methadone oral 5 mg) or any formulation of buprenorphine or methadone administered
during admission: buprenorphine sublingual tablet; buprenorphine/naloxone sublingual film;
buprenorphine/naloxone sublingual tablet; buprenorphine injection; buprenorphine patch;
methadone injection; methadone solution concentrate; methadone solution oral; methadone
tablet; methadone tablet effervescent; and methadone unknown formulation.
Post-Admission OAT
Post-admission OAT included a visit to an VHA OTP (counted by VHA stop code) or HCPCS codes
(H0033: non-specific oral medication direct observation; J0574: buprenorphine/naloxone 6.1-10
mg; J0575: buprenorphine/naloxone > 10 mg; J0571: oral buprenorphine 1 mg; S0109:
methadone oral 5 mg) or outpatient buprenorphine filled prescriptions (only FDA-approved OAT
formularies and routes of administration were included: buprenorphine film buccal;
buprenorphine sublingual tablet; buprenorphine/naloxone film sublingual; and
buprenorphine/naloxone sublingual tablet).
Specific Admission OAT Scenarios
Using the definitions in this appendix for pre, admission, and post OAT.
•

OAT Continuation: OAT delivery in the 30-days prior to and during admission, but not
after.

•

OAT Initiation & Linkage to Care: OAT delivery during admission and post-admission,
but not prior to admission.

•

OAT Sustained: OAT delivery before admission, during admission, and post-admission.

•

OAT Withdrawal: OAT delivery during admission, but not prior to admission and after
admission.
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Appendix P: Patient Health & Utilization Definitions
In-Hospital Mortality
In-hospital mortality was constructed using the VHA disposition variables (#6 and #7): death
with autopsy or death without autopsy during index hospitalization.
Left Against Medical Advice
Left against medical advice was constructed from VHA disposition variables (#2 and #4):
irregular or NBC or While ASIH (Absent Sick in Hospital).
30-Day Death
30-day death from index hospitalization discharge was captured from the VHA death data
sources: died during care provided by the VHA, BIRLS (i.e., national cemetery database), CMS,
Social Security Administration, VHA Benefits Division, and FEE Basis Care. This does not include
cases that were registered as having a death but health care resources were utilized post-death.
30-Day Hospital Readmission
30-day hospital readmission was captured when a patient was re-admitted to a VHA facility for
acute care within 30 days after the index hospitalization.
30-Day Emergency Department Visit
30-day emergency department visit was captured when a patient was seen in a VHA Emergency
Department (stop code 130) within 30 days after the index hospitalization.
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Appendix Q: Hospital Characteristic Definitions
Admission Volume
The number of admissions in that facility with the study cohort population.
Acute OUD Diagnosis Volume
The percentage of admissions out of all admissions in that facility with an acute OUD diagnosis.
As defined in Appendix M as either an OUD-related infection or any OUD diagnosis in the
primary or secondary admission diagnosis spot.
Hospital Census Region
Using the hospital state location hospitals were labeled as existing in one of the four U.S.
Geographic Census Regions (U.S. Census Bureau, 2015): Northeast; Midwest; South; and West.
Hospital Size
Bed counts for “acute care hospitals” (an additional report produced internally at the VHA)
included hospitals that had at least 500 acute bed days of care during the year. Bed size was
collapsed from four categories (1 to 49 beds; 50 to 99 beds; 100 to 199 beds; ³ 200 beds) to
three for analyses: 1) Small: 1 to 49 beds; 2) Medium: 50 to 99 beds; and 3) Large: ³ 100.
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Appendix R: Sensitivity Analysis: OAT Definition
The models were re-run using a narrower OAT definition for admission delivery; specifically,
excluding any non-FDA approved versions of OAT (i.e., injectable formulations of methadone
and buprenorphine). There were no differences in OAT quartile cut-offs during data preparation.
Model 1: The Variance Component Model. Meaningful differences were not observed for the
narrower OAT definition. The coefficient was the same (and same direction), as were the
random effects (ICC: 0.13 vs. 0.13).
Model 2: The Intermediate Model with Level 1 Covariates. There were no differences in the
intermediate model (Model 2) with regards to covariate direction or statistically significant
associations; except for the surgical variable. Which was statistically significant in the model
with the broader OAT definition. There was no difference in the ICC between the two models
(0.10 vs. 0.10).
Model 3: The Full Model with Level 1 and Level 2 Covariates. There were no differences in the
final model (Model 3) with regards to covariate direction or statistically significant associations;
except for, the surgical variable. Which was statistically significant in the model with the broader
OAT definition. The ICCs were the same (0.062).

Output:
Narrow OAT Definition
admit_age
male_dum
racecollapse_nonwhite_dum
racecollapse_unk2_dum
ethnicity_hisp_dum
ethnicity_unk_dum
_Ioud_dxinf_1
_Icosud_all_1
_Icomentalh_1
_Iunintent__1
_Iwd_codes_1
index_los
_Iicu_flag_1
_Isurgery_f_1
admitsource_other_dum
admitsource_direct_dum
_Ianyopioid_1
_Ianyadj_co_1
_Ibenzo_1
_Inaltrexon_1
_Ipre_anyoa_1
_Ipre_anyop_1
_Ipre_benzo_1
_Ipre_naltr_1
_Ipre_gaba_1
oud_dxinf_rel_vol_percent
bed_cat_collapse_med_dum

Model Output
OR
1.000299
1.503346
0.9459724
0.8397542
0.9842062
1.201423
2.298961
0.7782597
0.9536874
0.2717729
1.50842
1.043432
0.8893198
0.766244
0.8804784
0.9829147
0.5408422
1.51515
0.9098837
0.3129734
15.04093
0.482209
0.9870739
0.2692671
0.8937247
0.9824978
1.89009

SE
0.002539
0.2121659
0.0738042
0.149254
0.1419715
0.24997
0.1720454
0.0543631
0.0677582
0.0836167
0.206946
0.0045775
0.0745036
0.1058284
0.1260072
0.0771065
0.0376208
0.1087461
0.06681
0.1215771
1.143896
0.0418063
0.1243564
0.1035082
0.0687118
0.0069802
0.3410116

Z

0.12
2.89
-0.71
-0.98
-0.11
0.88
11.12
-3.59
-0.67
-4.23
3
9.69
-1.4
-1.93
-0.89
-0.22
-8.84
5.79
-1.29
-2.99
35.64
-8.41
-0.1
-3.41
-1.46
-2.49
3.53

P
0.9060
0.0040
0.4770
0.3260
0.9120
0.3780
0.0000
0.0000
0.5050
0.0000
0.0030
0.0000
0.1610
0.0540
0.3740
0.8260
0.0000
0.0000
0.1980
0.0030
0.0000
0.0000
0.9180
0.0010
0.1440
0.0130
0.0000

95% CI
1.00
1.14
0.81
0.59
0.74
0.80
1.99
0.68
0.83
0.15
1.15
1.03
0.75
0.58
0.67
0.84
0.47
1.32
0.79
0.15
12.96
0.41
0.77
0.13
0.77
0.97
1.33

1.01
1.98
1.10
1.19
1.31
1.81
2.66
0.89
1.10
0.50
1.97
1.05
1.05
1.00
1.17
1.15
0.62
1.74
1.05
0.67
17.46
0.57
1.26
0.57
1.04
1.00
2.69
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bed_cat_collapse_large_dum
census_reg_mw_dum
census_reg_ne_dum
census_reg_w_dum
admissions
_cons
fac_study_id: var (cons)

Output:
Broader OAT Definition
admit_age
male_dum
racecollapse_nonwhite_dum
racecollapse_unk2_dum
ethnicity_hisp_dum
ethnicity_unk_dum
_Ioud_dxinf_1
_Icosud_all_1
_Icomentalh_1
_Iunintent__1
_Iwd_codes_1
index_los
_Iicu_flag_1
_Isurgery_f_1
admitsource_other_dum
admitsource_direct_dum
_Ianyopioid_1
_Ianyadj_co_1
_Ibenzo_1
_Inaltrexon_1
_Ipre_anyoa_1
_Ipre_anyop_1
_Ipre_benzo_1
_Ipre_naltr_1
_Ipre_gaba_1
oud_dxinf_rel_vol_percent
bed_cat_collapse_med_dum
bed_cat_collapse_large_dum
census_reg_mw_dum
census_reg_ne_dum
census_reg_w_dum
admissions
_cons
fac_study_id: var (cons)

1.905646
1.25838
1.600228
1.626464
0.9989553
0.0599586
0.2176029

OR
1.00
1.52
0.95
0.84
1.02
1.20
2.30
0.77
0.97
0.29
1.47
1.04
0.88
0.75
0.88
0.99
0.53
1.52
0.92
0.31
15.26
0.49
1.03
0.26
0.89
0.98
1.90
2.04
1.27
1.80
1.62
1.00
0.06
0.22

0.3767839
0.1970601
0.2682119
0.2603606
0.0010102
0.0234484
0.0507659

SE
0.0025329
0.2151393
0.0738871
0.1484017
0.1444581
0.250349
0.1719125
0.0537238
0.0684419
0.0871154
0.2013285
0.0045693
0.0732433
0.1041471
0.1255941
0.0773472
0.0367234
0.1089526
0.0672824
0.120364
1.164097
0.0420021
0.1280635
0.1017697
0.0683887
0.0069608
0.3416866
0.4020263
0.1978938
0.2990432
0.259615
0.0010067
0.0243274
0.05

3.26
1.47
2.81
3.04
-1.03
-7.2
-

0.0010
0.1420
0.0050
0.0020
0.3010
0.0000
-

Z

P
0.86800
0.00300
0.51600
0.31700
0.89700
0.37700
0.00000
0.00000
0.62100
0.00000
0.00500
0.00000
0.11500
0.04000
0.36000
0.87600
0.00000
0.00000
0.24900
0.00300
0.00000
0.00000
0.80400
0.00100
0.13300
0.00700
0.00000
0.00000
0.13300
0.00000
0.00200
0.14300
0.00000
--

0.17
2.98
-0.65
-1
0.13
0.88
11.170
-3.730
-0.49
-4.120
2.79
9.760
-1.58
-2.06
-0.92
-0.16
-9.1700
5.8600
-1.15
-3.02
35.720
-8.350
0.25
-3.46
-1.5
-2.7
3.560000
3.62
1.5
3.52
3.03
-1.47
-7.11000
--

1.29
0.93
1.15
1.19
1.00
0.03
1.00

2.81
1.71
2.22
2.23
1.00
0.13
1.01

95% CI
1.00
1.01
1.16
2.01
0.82
1.11
0.59
1.19
0.77
1.34
0.80
1.81
1.99
2.66
0.67
0.88
0.84
1.11
0.16
0.52
1.12
1.92
1.03
1.05
0.74
1.03
0.57
0.99
0.66
1.16
0.85
1.15
0.46
0.61
1.32
1.75
0.80
1.06
0.14
0.66
13.14 17.72
0.41
0.58
0.81
1.32
0.12
0.56
0.77
1.04
0.97
0.99
1.33
2.70
1.39
3.00
0.93
1.72
1.30
2.49
1.19
2.22
1.00
1.00
0.03
0.13
0.14
0.34
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